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“There is at bottom only one genuine treatment for all diseases,… to stimulate the 
phagocytes.  Drugs are a delusion. … (when) the phagocytes are stimulated; they 
devour the disease…”    
 
George Bernard Shaw 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  
ACKNOWLEDGEMENTS 
 
This work wouldn’t be possible without the help and support of the following persons. I 
would like to thank: 
 
Professor Doutor Leonard Amaral, my supervisor, for the opportunity to realise my 
aspiration to learn more about that dreadful infection of pulmonary tuberculosis and to 
contribute to the manner by which extensively-drug resistant Mycobacterium 
tuberculosis and multi-drug resistance M. tuberculosis may be successfully treated. 
Thank you for all the scientific discussions, daily stimulus and support and for all the 
help in making me a more conscientious scientist; 
 
Professor Doutor Miguel Viveiros, for all the support, encouragement, scientific 
discussions, advice and critical review of my work; also for the constant good-humour, 
patience during all these years and especially, for your friendship, life is so much better 
when we have good friends like you; 
 
Professora Doutora Isabel Couto, my friend, for always being there and never forgetting 
that despite all, we are human; and for all the scientific discussions, valuable critique, 
infinite patience, and good advice. Thank you for the “post-office journeys” and all the 
small things that made a big difference every day; 
 
Mestre Clara Leandro, for all the good-times spent and much needed assistance during 
the initial period of my PhD. Thank you for your friendship and for teaching me that we 
should always pursue our dreams: the proof is Mariana and Gonçalo, a big kiss to you 
all; 
 
All my colleagues of the Unit of Mycobacteriology for that environment which 
facilitated my studies and assistance given during these years; special thanks to graduate 
students Liliana Rodrigues, Diana Machado and Ana Martins for all the patience, 
support and for listening. Sofia, Catarina, Laura, Jorge and Nadia thank you for keeping 
me updated in the news from the (un)real world!  
 
  
D. Josefina and D. Rosário, for all the knowledge and technical assistance given, 
especially in animal studies. Thank you for continuing to believe in the young; 
 
D. Mariana for the precious help in the laboratory and for making my days so much 
easier. D. Catarina and D. Cidália for all the technical support along these years;  
 
Zsuzsanna Schelz, my Hungarian friend, thank you for all the help and for the lovely 
times spent in Szeged. You are truly a very special person, Köszönöm; 
 
My colleagues, Sofia Martins and Pedro Fernandes; Sofia for always being there and 
making me laugh during difficult times and continuing to believe in my skills and 
Pedro, thank you for all the support and ideas; 
 
All the Marta’s in my life: Marta Costa (Martinha), Marta Agostinho and Marta 
Pingarilho. Thank you for all the support and strength. Martinha, thank you for your 
shoulder during those difficult moments; i hope that Maria brings you a whole sea of 
happiness; 
 
Professores Doutores João Piedade, Ricardo Parreira and Aida Esteves, from the Unit of 
Virology of IHMT, for all the help and the precious coffee moments, so vital for  
maintaining sanity during times of stress. Thank you for all the support and advice. To 
D. Teresa Veneno for all the technical support and Daniela, for all the conversations and 
good mude; 
  
The Sexually Transmitted Diseases Unit from IHMT for all the help. Special thanks to 
Professora Doutora Filomena Pereira for the revisions of my reports and to Filipa for 
the support, long conversations and availability when needed;  
 
Drª. Teresa Pacheco and colleagues from the Laboratório de Microbiologia, Hospital 
Egas Moniz, Lisboa, for the valuable contributions to this work; 
 
Professora Doutora Hermínia de Lencastre from the Instituto de Tecnologia Química e 
Biológica, Universidade Nova de Lisboa, for the gently donation of the MRSA COL 
and HPV107 strains;  
  
The President of the CC of IHMT Professora Doutora Amélia Grácio and all the 
members of the CC who created the environment much needed for the development of a 
graduate student who must compete with others in Europe; 
 
Fundação para a Ciência e a Tecnologia (FCT) for providing me the PhD grant 
SFRH/BD/14319/2003 that allowed me to develope this work and also for the project 
grants EU-FSE/FEDER-POCTI-37579/FCB/2001 and EU-FSE/FEDER-POCI/SAU-
MMO/59370/2004; 
 
To the following colleagues from Europe and the USA: 
 
Doutora Diane Ordway, for bringing me to the Immunology world and giving me the 
opportunity to work at the Unit of Mycobacteriology with such wonderful colleagues, 
who are now friends;   
 
Professor Wilfrid Bleiss and his team from the Department of Molecular Parasitology, 
Institut für Biologie, Humboldt-Universität zu Berlin, Berlin, Germany, for all the 
electron microscopy work that was so important for helping us to “see” inside the 
macrophage; 
 
Professor Sujata G. Dastidar from the Division of Microbiology, Department of 
Pharmaceutical Technology, Jadavpur University, Calcutta, India for all the cooperation 
with our team in the studies involving antibiotic resistance and novel non-antibiotics; 
 
Professor Seamus Fanning from the Centre for Food Safety, School of Agriculture, 
Food Science and Veterinary Medicine, University College Dublin, Belfield, Dublin, 
Ireland; for the wonderful lectures and discussions and the interest demonstrated in all 
of our work; 
 
Professor George Hajös from the Institute of Chemistry, Chemical Research Center, 
Budapest, Hungary; for the synthesis of the thioridazine derivatives; 
 
 
  
Professor Peter Henderson from the Astbury Centre for Structural Molecular Biology, 
Faculty of Biological Sciences, University of Leeds, for his gracious hosting during my 
visit to this University, UK and for his wonderful sense of humor during the 7th ECC in 
Budapest; 
 
Professor Winfried V. Kern and his team from the Center for Infectious Diseases and 
Travel Medicine, University Hospital, Freiburg, Germany; for cooperating with our 
team;  
 
Doctor Jette E. Kristiansen from the Department of Clinical Microbiology, Sønderborg, 
Southern Danish University, Sønderborg, Denmark; for all the work developed with 
thioridazine; 
 
Professor Joseph Molnar, and his team, from the Institute of Medical Microbiology, 
Albert-Szent Gyorgyi School of Medicine, Szeged, Hungary; for all the scientific 
discussions and the special moments spent in Hungary. Thank you for the concerts, the 
strudel and the palacsintas (I will never forget those days);  
 
Professor Jean-Marie Pagès from the Département EA2197 - Enveloppe Bactérienne, 
Perméabilité et Antibiotiques, Université de la Méditerranée, UFR/ Institut Faculté de 
Médecine; Marseille, France; for the fruitful discussions and suggestions and the 
constant enthusiasm demonstrated in science;  
 
Doctor Andras Varga from the Institute of Molecular Parasitology, Humboldt 
University, Berlin, Germany for the synthesis of SILA compounds that have huge 
potential for the therapy of MDR-TB/XDR-TB; 
 
Professor Mattias Winterhalter from Jacobs University, Bremen, Germany, for his 
gracious invitation to spend a valuable week at his workshop that defined the “State of 
the Art” of research in the field of efflux mediated MDR of bacteria;  
 
My friends, the best in the all world; special thanks to Perpétua, Rita and Susana for 
always being there during the good but especially in the less good moments of my life; 
 
  
Paula, my big sister for all the support and for remind me that life is just three days and 
we should enjoy it as much as we can. And for Ema, the new love of my life; 
 
All of my family, for the laughs, support and the big lunches! To my grand-father and 
especially to my grand-mother, Maria; despite the fact that you don’t recognize me 
anymore, thank you for your sweet eyes and for continuing to give me your smile every 
day; 
 
My parents, the anchors of my life; words cannot express what you both have given me 
other than life itself. Thank you for being the underpinnings of my existence, the 
support and for believing in me when at times I did not. I am really blessed for having 
such a wonderful parents like you. I love you both. 
 
 
 
To all who have contributed to these studies, thank you for your generosity and for the 
help in revealing the secrets of the microcosm in which the macrophage lives and 
protects us from infectious disease. 
 
 
 
From the bottom of my heart, I wish you all a wonderful life. 
 
 
 
 
 
 
 
 
 

  xvii
ABSTRACT  
 
The main objective of this Thesis was to evaluate thioridazine (TZ) and chemically 
derived derivatives for anti-Mycobacterium tuberculosis activity in particular against 
multi-drug resistant (MDR) M. tuberculosis. Twenty-two TZ derivatives were obtained 
and screened for toxicity and mutagenicity by the trypan blue exclusion assay in human 
lymphocytes and the Ames test, respectively. The derivatives that were devoid of any 
toxicity and mutagenicity were then tested against Methicillin-resistant Staphylococcus 
aureus (MRSA) used as a model during the entire work, and against antibiotic resistant 
M. tuberculosis (MDR-TB) strains in vitro and subsequently in the macrophage that has 
phagocytosed the organism. Since tuberculosis is an infection of the alveolar 
macrophage it is important to evaluate the activity of these compounds inside the 
phagocytic cell where the mycobacteria are to be found. Thioridazine was also tested for 
its ability to cure the mouse of infection by M. tuberculosis. Therefore, animal studies 
using Balb/C mice infected with M. tuberculosis H37Rv ATCC27294 strain were 
initiated to parameterize the route of infection, dose of compound to be administered, 
among others. The results obtained showed that from the twenty-two TZ derivates none 
was toxic or mutagenic under the conditions tested. Therefore, all the twenty-two 
derivatives were selected for in vitro evaluation against S. aureus and M. tuberculosis 
strains. From the in vitro results six derivatives showed greater activity than TZ and 
were selected for ex vivo studies. Three of these derivatives were shown to enhance the 
macrophage killing activity and one of the derivatives was even more active than TZ. 
From the animal studies it was possible to select the conditions to apply in further 
studies with the most active derivatives. From all the data obtained during this Thesis it 
was possible to develop a model based on the macrophage interaction with the bacteria 
and the subsequent action of the compounds. The macrophage model can elucidate what 
takes place inside the human macrophage when these compounds are added to the 
medium.  
 
Due to the uniqueness of the approaches developed during the Thesis research, other 
potential sources of anti-tubercular compounds were explored: plants and organosilicon 
compounds (SILA). These studies demonstrated that extracts from the nuisance plant 
Carpobrotus edulis could enhance the killing of intracellular bacteria such as MDR-TB 
and MRSA. In addition, the extract was shown to modulate the immune system thereby 
  xviii
indicating its potential use for cellular immune deficient disorder as well as render 
MDR mouse lymphoma cells carrying the human mdr1 gene completely susceptible to 
cytotoxic drugs to which they were initially resistant.  The results of this component of 
my research have resulted in the design of new experiments which are now being 
carried out by another Ph.D. student in our Unit and at the Medical University of 
Szeged, Hungary.  
 
In conclusion, the results obtrained from my Thesis research has paved the way for 
clinical trial consideration of the many compounds studied shown to have significant 
intracellular activity against XDR-TB/MDR-TB at concentrations that are non-toxic and 
that can be readily achieved in the infected human. 
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RESUMO 
 
O objectivo principal desta tese foi o de avaliar a acção da tioridazina (TZ), bem como 
de compostos derivados desta, obtidos por manipulação química, como agentes com 
actividade contra Mycobacterium tuberculosis, em particular contra M. tuberculosis 
multi-resistente (MDR-TB). Desta forma foram obtidos vinte e dois derivados e 
efectuados testes de toxicidade e mutagenicidade pelo método de exclusão com azul de 
trypan (realizado em linfócitos humanos) e o teste de Ames, respectivamente. Todos os 
derivados não tóxicos e não mutagénicos foram testados in vitro contra estirpes de 
Staphylococcus aureus resistente à meticilina (MRSA), que foi o microrganismo 
modelo utilizado durante todo o trabalho, e estirpes de MDR-TB. Visto que a 
tuberculose é uma infecção do macrófago alveolar, estes estudos foram 
subsequentemente aplicados a macrófagos infectados. Desta forma, é importante 
analisar a actividade que estes compostos apresentam dentro do macrófago, local onde 
normalmente a micobactéria se encontra. Iniciaram-se estudos animais com a TZ, de 
forma a verificar a eficácia deste composto em curar murganhos Balb/C infectados com 
M. tuberculosis H37Rv ATCC27294. Desta forma foi possível optimizar parâmetros, 
tais como, a via de infecção, a concentração de composto a administrar, entre outros. Os 
resultados obtidos demonstraram que dos vinte e dois derivados nenhum apresentava 
toxicidade ou efeitos mutagénicos, nas condições testadas. Desta forma, os vinte e dois 
derivados foram seleccionados para estudos in vitro contra estirpes de S. aureus e de M. 
tuberculosis. Dos estudos in vitro foi possível verificar que seis derivados apresentaram 
uma maior actividade do que a TZ e desta forma foram seleccionados para os estudos ex 
vivo. Quando testados em macrófagos infectados três derivados demonstraram um efeito 
marcado na activação das células fagocitárias (“enhancement of the killing activity”), 
sendo um dos derivados ainda mais activo do que a TZ. Dos estudos em animais, foi 
possível seleccionar as condições a serem implementadas em estudos futuros com os 
derivados mais activos. De todos os resultados obtidos durante esta tese foi possível 
desenvolver um modelo baseado na interacção do macrófago com a bactéria e a 
subsequente acção destes compostos. O modelo desenvolvido (“macrophage model”) 
pode assim contribuir para clarificar o que ocorre a nível intracelular aquando da adição 
dos compostos ao meio de cultura.  
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Devido à inovação das abordagens desenvolvidas durante esta tese, outras potenciais 
fontes de compostos tuberculostáticos foram exploradas, tais como, plantas e compostos 
SILA. Os estudos desenvolvidos demonstraram que extractos da planta Carpobrotus 
edulis podem apresentar actividade antibacteriana contra bactérias intracelulares, tais 
como, MDR-TB e MRSA. Adicionalmente, foi demonstrado que este extracto é um 
imuno-modulador do sistema imunitário, o que reflecte a sua potencial utilização em 
disfunções imunes verificadas a nível celular. Outra das potenciais aplicações é a sua 
utilização em linhas celulares murinas de linfoma multi-resistentes (que apresentam o 
gene mdr1), tornando-as completamente susceptíveis a compostos citotóxicos, aos quais 
estas células eram inicialmente resistentes. Os resultados desta componente da minha 
tese contribuíram para o “desenho” de novas experiências que se encontram de 
moemento a ser desenvolvidas por outra aluna de doutoramento, na Unidade de 
Micobacterias e na Universidade Médica de Szeged, Hungria.  
 
Em conclusão, o trabalho desenvolvido durante esta tese veio abrir caminho para a 
aplicação dos vários compostos analisados em ensaios clínicos, dado que estes 
demonstraram ter actividade intracelular contra estirpes de XDR-TB/MDR-TB a 
concentrações não tóxicas e que podem ser facilmente atingidas num indivíduo 
infectado. 
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3 
THESIS OUTLINE AND OBJECTIVES 
 
This Thesis includes the in vitro, ex vivo and in vivo studies of TZ against M. 
tuberculosis strains resistant to antibiotics. It is the intent to provide data about new 
anti-tubercular compounds and novel approaches that could be used for the treatment of 
MDR-TB and XDR-TB infections. The general aims of this thesis are: 
 
• Screening of thioridazine derivatives obtained by chemical manipulation for 
toxicity and mutagenicity; 
 
• Determination of the activity of the selected derivatives on antibiotic resistant 
and susceptible M. tuberculosis in vitro; 
 
• Determination of the activity of derivatives against M. tuberculosis that has been 
phagocytosed by the human macrophage, the amount of derivative that is 
concentrated by the phagocytic cell and if it is altered by the human 
macrophage; 
 
• Determination of selected thioridazine derivatives to clear the mouse pulmonary 
tree from MDR-TB infection and to prevent the infection of the mouse by MDR-
TB.  
 
 
The organization of this Thesis is in accordance to the Bologna Agreement Guidelines 
which employs as a basis the publications that have resulted from the Thesis research. 
 The sections of the Thesis have been organized so that each one can stand on its own as 
a full report that refers to the methods used in that section, the results, its discussion and 
conclusions as well as all references cited.  The sequence of Result sections has been 
designed so that the reader can be led from discovery to discovery in a developmental 
manner.  However, this sequence does not reflect the chronological order of the work 
done since many of the experiments were conducted while some other experiments were 
“cooking” (mycobacteria do grow rather slowly).  
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This thesis is divided into 11 chapters, as follows: 
 
Chapter I.  State of the Art. This section provides a review of the current knowledge on 
Tuberculosis and the emergence of MDR and XDR resistance. The issues focused on 
this Thesis were put into context to highlight the relevance of the studies presented. 
 
Chapter II. Materials and Methods. This section describes all the methodology used 
during the work performed in these studies.  
 
Chapter III. The in vitro and ex vivo effects of clinical concentrations of TZ against 
Methicillin-resistant Staphylococcus aureus are described.  In vitro, ex vivo and electron 
microscopy studies were conducted. 
 
Chapter IV. This section presents all the results obtained from the in vitro and ex vivo 
activity of TZ and its derivatives against Mycobacterium tuberculosis. It also describes 
the in vitro effects of several phenothiazines tested against M. avium. 
 
Chapter V. Describes the results of the curative activity of TZ on mice infected with 
Mycobacterium tuberculosis. Animal studies were conducted using TZ for the treatment 
of the infection. 
 
Chapter VI. This chapter focuses on the effect that other efflux pumps inhibitors such 
as, the methanolic extract of Carpobrotus edulis, reserpine, ouabain and verapamil have 
on the growth of phagocytosed multidrug-resistant M. tuberculosis and methicillin-
resistant S. aureus. 
 
Chapter VII. This chapter provides data on new patented and synthesized SILA 
compounds and their effect on infected human monocyte-derived macrophage, as a 
special example relationship between efflux inhibitors and its effect on macrophage 
infected with MDR M. tuberculosis strain. In this chapter a new and innovative method 
used to screen efflux pump activity and efflux pumps inhibitors is also described. 
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Chapter VIII. The future of chemotherapy is the main subject presented. The discovery 
of new anti-microbial agents that can be used in the therapy of MDR bacteria as well as 
a new approach that uses these agents in conjunction with the classical antibiotics will 
be analysed and discussed.  
 
Chapter IX. The Tuberculosis laboratory of the Future. In this section it will be 
discussed the role of the macrophage in the selection of agents that can be employed in 
the therapy of an MDR infection.  
 
Chapter X. From all the studies performed a hypothetical model (macrophage model) 
was developed in order to explain the enhancement of the killing activity of the infected 
macrophages when TZ, its derivatives or other inhibitors of Ca2+ and K+ transport are 
added to the cell cultures. The Macrophage Model will be described in detail to clarify 
the intracellular processes that take place inside the infected and treated macrophage. 
 
Chapter XI. Concluding Remarks and Future Perspectives. This section highlights the 
main conclusions obtained in each of the previous chapters as well as future 
recommendations and guidelines to be developed and implemented in order to treat 
MDR- and XDR-TB.  
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I.1 History and Epidemiology of Tuberculosis (TB)  
 
Tuberculosis (TB) continues to be considered the major cause for worldwide morbidity 
and mortality caused by an infective organism. This disease is caused by the steadfast 
human pathogen Mycobacterium tuberculosis, the bacterium known to infect the man 
since the birth of civilization (Gernaey et al., 2001; Morell, 1994). The M. tuberculosis 
complex presently includes: M. tuberculosis, M. africanum, M. bovis, M. microti, M. 
pinnipedii, M. caprae, and M. canettii (Ernst et al., 2007). However, in some studies, M. 
canettii is not considered in this complex (Gutierrez et al., 2005). This difference is due 
to the molecular approaches employed in the strains identification (difference in the 
number of genes analysed, etc.). The development of new molecular genetics tools and 
the sequencing of the genome of several M. tuberculosis strains allow a more accurate 
estimation of the time of origin of mycobacteria (Gutierrez et al., 2005). It is expected 
that all the members of the M. tuberculosis complex had a common African ancestor 
about 35,000-15,000 years ago (Daniel, 2006), since an early progenitor of M. 
tuberculosis was discovered to be present in East Africa as early as 3 million years ago 
(Gutierrez MC et al., 2005).  
 
M. tuberculosis infections can involve any organ or tissue of the human body 
(Hopewell, 1995; Lillebaek et al., 2002). Because of this extensive involvement, it has 
been possible to determine that this infection has been with man since the dawn of 
civilisation (Zink et al., 2003) as evident from typical skeletal abnormalities produced 
by TB that have been found in Egyptian mummies. The frequency of skeletons with 
apparent tubercular deformities and use of DNA amplification of M. tuberculosis 
obtained from tissues suggests that the disease was common among that population 
(Nerlich et al., 1997). In recorded history, Assyrian clay tablets describe patients 
coughing blood in the 7th century B.C. In classical Greece, Hippocrates writes of 
patients with phthisis (the Greek term for TB), which means consumption, i.e., wasting 
away associated with chest pain and coughing, frequently with blood in the sputum. 
Hippocrates thought the disease was largely inherited, while Aristotle (4th century B.C.) 
stressed its contagious nature, as did Galen, in the 2nd century A.D. (Sakula, 1983). By 
this time, the frequency of descriptions of patients with TB-like symptoms indicates that 
the disease was already well entrenched. Figure 1 describes some of the more 
representative events that took place during the history of TB.  
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Figure 1. Time-line of TB. Some of the most important events that occurred in the history of TB 
until the present time (sources: Daniel, 2006; Di Perri and Bonora, 2004; Dietrich et al., 2006; Murray, 
2004; Myers, 1967; Nerlich et al., 1997; Sakula, 1983) . 
 
In the 19th century TB was well established in East Africa by the time Europeans 
reached that area. Analysis of human phenotypes, like lactose tolerance, that is 
associated with the raising of cattle and selection for the ability to utilize milk, as well 
as the resulting exposure to M. tuberculosis suggests that Indo-Europeans cattle herders 
that entered East Africa spread the disease to Europe and Asia during their migrations 
into these regions (Smith, 2003). In studies recently published (Ernst et al., 2007), this 
theory is not supported and the transmission of the disease from cattle to human is 
considered to be impossible. However, this is not a consensual subject since some 
studies based on genetic analysis of the strains refute this belief. The actual 
representatives of the common ancestor of the M. tuberculosis complex include the 
ancestral and modern strains of M. tuberculosis. The latter are characterized by the 
deletion of a 2.1-kb fragment termed TbD1, account for most current TB cases, and 
include the Beijing family of strains that are prevalent in Asia and have caused 
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outbreaks worldwide. A separate lineage, marked by deletion of region of difference 9 
(RD9), diverged from an ancestral M. tuberculosis and sequentially gave rise to M. 
africanum, M. microti, M. pinnipedii, M. caprae, and M. bovis. It is thought that M. 
bovis, which has the greatest number of deletions, is the most recent member of this 
lineage. Based on these results the popular belief that M. tuberculosis evolved from M. 
bovis through the adaptation of a bovine strain to the human host is clearly refuted. 
Since M. tuberculosis contains chromosomal segments that have been deleted from M. 
bovis, M. tuberculosis could not have evolved from M. bovis (Ernst et al., 2007). Based 
on these new studies and genetic approaches the manner of transmission between 
humans and cattle is still not completely clarified. 
 
I.1.1 Evolution of TB in Europe and diagnosis of infection   
 
As Europe entered the middle ages, the written record of TB is almost non-existent. 
However, this does not mean that the disease was not present. In modern times, TB 
reached epidemic proportions in Europe and North America during the 18th and 19th 
centuries. The understanding of the pathogenesis of TB began with the work of 
Theóphile Laennec in the 19th century. He clearly elucidated the pathogenesis of TB and 
unified the concept of this disease. At that time, TB surged across Europe with death 
rates in London, Stockholm and Hamburg that approached 800-1000 cases/100,000 
inhabitants/year (Daniel, 2006). The demonstration of the transmissibility of M. 
tuberculosis infection was accomplished by Jean-Antoine Villemin in 1865. He 
inoculated a rabbit with a purulent liquid obtained from an individual who had died of 
TB (Murray, 2004). Although the animal remained healthy, it was found to have 
extensive TB when sacrificed and autopsied (Daniel, 2006). This was an important 
achievement; however, the history of TB was markedly changed in 1882, with Robert 
Koch's discovery of the tubercle bacillus. In his presentation “Die Aetiologie der 
Tuberculose”, Koch identified the tubercle bacillus as the etiologic agent and presented 
his famous postulates, which continue to set the standard for the demonstration of 
infectious etiology (Kaufmann and Schaible, 2005). In 1890, Koch started the isolation 
of tuberculin (Myers, 1967). The tuberculin skin test was developed in 1907 by 
Clemens von Pirquet and 3 years later used to demonstrate latent infection in 
asymptomatic children. Charles Mantoux introduced the use of a cannulated needle and 
syringe to inject tuberculin intra-cutaneously in 1908, and Florence Seibert developed 
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purified protein derivative (PPD) during the 1930s. With the availability of well-
standardized PPD, several studies of tuberculin reaction sizes were conducted. In 1952 
Carroll Palmer and Leroy Bates published a large study of reactions to one test unit of 
PPD-S (equivalent to 0.4 units of PPD-RT23) (Daniel, 2006). Three years later, a World 
Health Organization (WHO) study group published a report that expanded these skin 
testing studies to school children in various populations. This report showed that in high 
TB prevalence countries, a substantial number of healthy school children reacted with 
reaction sizes similar to those in TB patients (Daniel, 2006). These children had latent 
TB infections. In some populations, reaction sizes in these children were skewed 
towards smaller reactions. Edwards and Palmer using guinea pigs demonstrated that 
these smaller reactions were due to cross reacting hypersensitivity to the antigens of 
environmental mycobacteria (Daniel, 2006). They also established conclusively that 
latent TB infection is common in the United States (US) and presumably in other low 
TB prevalence countries; that latent infection could be recognized by tuberculin testing; 
and that non-specific tuberculin reactivity was common in certain geographic regions. 
During the early to mid-19th century the number of new cases of TB in Europe and 
North America and its associated mortality rates began to decline. The improved social 
and living conditions, as well as the improved nutrition status, contributed to the 
strengthening of immunity resulting from natural selection of humans resistant to TB. 
However, this postulated cause of the decrease, doesn’t explain the rapid decline in TB 
rates. This decrease was accompanied by an apparent shift of disease occurrence to 
older individuals (Davies et al., 1999; Frost, 1939).  
 
I.1.2 Approaches developed for treating TB, its control and prevention 
 
In the late 19th and early 20th centuries sanatoria were developed for the treatment of 
patients with TB. Pulmonary collapse therapy became popular, especially for cavity 
closure (Daniel, 2006). A more direct approach to the public health challenges of TB 
was taken by Albert Calmette and Camille Guérin. They developed the Bacille 
Calmette-Guérin (BCG) vaccine, by attenuating an M. bovis strain and the vaccine was 
ready to be tested in 1921 (Dietrich et al., 2006). Over the next few years, the vaccine 
was readily accepted in much of Europe and more than 100,000 children were 
immunized. TB rates fell rapidly in Europe during the first half of the 20th century, but 
the ravages of World War I led to a resurgence of the disease. During World War I, both 
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the allies and Germans screened their military recruits for TB using chest radiographs. 
After the war, TB detection in the population was accomplished by mass radiographic 
screening (Myers, 1967). In 1948, a campaign to control TB sponsorship by United 
Nations Children's Fund (UNICEF) and the Danish Red Cross was based on tuberculin 
testing followed by BCG vaccination of non reactors. During the next 3 years, nearly 30 
million persons were tuberculin tested and nearly 14 million vaccinated with BCG. The 
program was the first disease control program undertaken by an agency of the WHO. In 
1974 the WHO Expert Committee on TB provided policy guidelines for TB control for 
the next 2 decades (Daniel, 2006). It discouraged both radiographic screening and 
tuberculin testing and promoted sputum microscopy of symptomatic individuals and 
those at risk. It advocated ambulatory therapy and recommended against hospitalization 
of TB patients, strongly encouraging BCG vaccination. Today, the WHO continues to 
mount programs for TB control, but it no longer recommends BCG vaccination except 
for newborns. In the US, where BCG has not been widely used, TB control programs 
emphasize treatment of latently infected individuals (WHO, 2006d).  
 
I.1.3 Evolution of the Therapy of TB 
 
The discovery of para-amino salicylic acid (PAS) by Jorgen Lehmann in 1943 and of 
thiosemicarbazone by Gerhard Domagk yielded the first therapeutic agents with 
efficacy in the treatment of TB (Di Perri and Bonora, 2004). In 1944 Albert Schatz, 
Elizabeth Bugie, and Selman Waksman reported the isolation of streptomycin (STR), 
the first antibiotic and first bactericidal agent effective against M. tuberculosis (Daniel, 
2006). Isoniazid (INH), the first oral mycobactericidal drug, followed in 1952 and this 
agent was soon followed by rifamycins in 1957. A new era of TB treatment started 
allowing effective public health measures. Treatment was increasingly expanded to 
include those with latent TB infections. The history of TB control entered a new 
chapter. However, the underdeveloped world is still suffering from TB. It is estimated 
that over one-third of the World's population is currently infected; thirty million new 
cases were reported for 2003; TB infections caused three million deaths 
(WHO/IUATLD, 2004). Due to these facts, TB has been declared by the WHO a Global 
Emergency. The annual number of global cases is expected to continue to escalate.  In 
the third world countries, the rates of new cases of TB are extremely worrisome. The 
number of infected persons continues to increase due to famine, war, over-crowding, as 
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well as to the cost of anti-tubercular drugs which for many countries, is beyond their 
affordability (Amaral et al., 2001b). In order to stop and control this infection, there is 
the need to understand the pathogenesis of TB, develop rapid methods for the detection 
of infection and active disease, identify the areas in which the disease continues 
unabated, develop controls that will prevent the dissemination of the disease and 
develop new treatments which are affordable to the affected population. In short-
eliminate the global presence of TB.  
 
I.1.4 BCG vaccination 
 
M. tuberculosis infects only man and because it cannot survive in the environment it is 
considered a steadfast human pathogen. Therefore, all pulmonary infections of TB 
emanate from human sources. In order to prevent the rate of infection, the vaccination 
policy was applied and still persists. In some countries, such as is the case for Portugal, 
newborns are vaccinated with the BCG. This vaccine has been the subject of intensive 
research during the past decades. However, from the numerous studies performed and 
published it is evident that the efficacy of BCG vaccination is highly variable, ranging 
from 0% to 80% (Infuso et al., 2006). It is more likely that BCG vaccine prevents 
against disseminated forms of TB in children and is less effective for pulmonary TB in 
adolescents or adults. BCG vaccination is recommended in asymptomatic children with 
or at risk for Human Immunodeficiency Virus (HIV) infection, but it should not be used 
in persons with symptomatic HIV infection or Acquired Immune Deficiency Syndrome 
(AIDS) (WHO, 2001). In healthcare workers exposed to M. tuberculosis, including 
Multi-Drug Resistant TB (MDR-TB), BCG vaccination generally is not recommended 
(Cohn, 1997). Re-vaccination with BCG does not confer more benefit than initial 
vaccination and in the opinion of some experts the repeated vaccinations should be 
discontinued (Cohn, 1997). The recent advances in technology and the better 
understanding of the immunopathogenesis of TB lead to continuous efforts to develop a 
more potent and specific vaccine. However, vaccination has become an obstacle in the 
detection of new cases of infection. The fact that BCG vaccination “masks” the results 
implies that new infections cannot be detected and therefore all the new cases that are 
reported correspond to an active disease state. This feature should be the subject of 
attention and there is the urgent need for every one to understand two simple, but very 
important concepts: infection versus active disease.  
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I.1.5 Infection: processes and sites 
 
A TB infection is acquired via airborne microdroplets of sputum that contain the 
organism M. tuberculosis and which are generated when a person that has progressed to 
active disease, coughs, sneezes or yells. The inhaling of these microdroplets brings the 
organism in contact with pneumocyte type II cells of the alveolar sac, also known as 
pulmonary macrophages (Tomioka, 2003). These cells are efficient in the phagocytosis 
of the bacteria; however, they are unable to destroy them. It is important to note that 
90% of all such infections are resolved without any noticeable pathology and are 
therefore sub-clinical (Cardona, 2007). However, the remaining 10% of TB infections 
progress to active disease. In this state of the disease there is the release of the 
bacterium from the macrophage, concomitantly with the destruction of the lung 
parenchyma (Russell, 2007). By this manner, while pulmonary TB is considered an 
intracellular infection, active disease is an extracellular one. Active disease is therefore 
the means by which the infective organism is transmitted from individual to individual 
and because a new infection cannot be readily distinguished by skin tests or radiological 
procedures, all the new cases of infection that are reported correspond to active disease.  
 
I.1.6 Global TB today 
 
The global distribution of new cases of TB per 100,000 inhabitants is illustrated by 
Figure 2. The incidence of TB ranges from less than 10 per 100,000 inhabitants in North 
America to 100 to 300 per 100,000 inhabitants in Asia and Western Russia to over 300 
per 100,000 inhabitants in Southern and Central Africa. There is one death from TB 
every 15 seconds (over two million per year), and eight million people develop TB 
every year (Chakrabarti and Davies, 2007). Without treatment, up to 60% of people 
with the disease will die. Essentially all these cases are in the third world countries, 
reflecting the poverty and the lack of healthy living conditions and adequate medical 
care. This global crisis is compounded by the emergence of multi-drug resistance 
(MDR) in countries like the former Soviet Union, South Africa, and India, where some 
antibiotics are available but are of inferior quality or are not used for a sufficient time to 
control the disease according to the recommended regimens (Dorman and Chaisson, 
2007). 
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Figure 2. TB notification rates (2005). The 199 countries reporting to WHO notified 5.1 million 
new and relapsed cases, of which 2.4 million (47%) were new smear-positive cases (reproduced from 
WHO, 2007a). 
 
I.2 Multi-Drug Resistance (MDR) 
 
Due to the increasing number of individuals infected with HIV and the problems 
associated with the current regimens of antimicrobial therapies, the appearance of 
MDR-TB strains, i.e., strains resistant to at least INH and rifampin (RIF) took place 
wherever HIV/AIDS was frequent (Di Perri and Bonora, 2004; Munsiff et al., 2002). 
The development of MDR-TB was due to incompetent therapy and patient non-
compliance (Mitchison, 2004; Ormerod, 2005; Zhang, 2007) and took place as follows; 
initially susceptible strains to antibiotics that became resistant to one antibiotic by 
spontaneous mutation were selected as a consequence of ineffective therapy and these in 
turn could infect patients who would also be managed poorly with these agents thereby 
favouring a second spontaneous mutation that caused resistance to the second antibiotic 
(Rao, 1998). These MDR-TB strains that emerged during the 1990s posed a threat to the 
control of TB, both in the US (Dooley et al., 1992) and worldwide (WHO/IUATLD, 
2004). The therapy of MDR-TB regardless of whether all five first line drugs of defence 
(INH, RIF, STR, ethambutol (EMB), pyrazinamide (PZA)) or in combination with 
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second line of defence compounds is extremely problematic (Amaral et al., 2004). 
Because the use of these therapeutic modalities produce significant morbidity, hence the 
problem of non-compliance (Drobniewski and Balabanova, 2002), new cases of MDR-
TB have continued to increase in many of the urban centres of western and third world 
countries (WHO, 2005). Nevertheless, recommended treatment of MDR-TB infections 
requires second-line drugs (WHO, 2006c). These drugs in general are less effective, 
more toxic, and costlier than first-line INH- and RIF-based regimens (Di Perri and 
Bonora, 2004; Gupta et al., 2001; Shah et al., 2007). Furthermore, individual resistance 
to these agents is many fold greater than resistance to INH and RIF (Johnson et al., 
2006; Shi et al., 2007). In 2000, the Stop TB Partnership's Green Light Committee was 
created to increase access to second-line drugs worldwide while ensuring their proper 
use to prevent increased drug resistance. MDR-TB also requires a two- to four-fold 
longer period of treatment compared with drug-susceptible TB (Di Perri and Bonora, 
2004). In the treatment of MDR-TB there are three major issues that should be 
addressed: rapid diagnosis, selection of drugs to which the strain is susceptible and 
adherence of the patient to therapy. The starting point should be the access to good 
diagnostic services. Rapid methods to reduce time of diagnosis of MDR-TB and of 
susceptibility testing are important measures to adopt. The radiometric BACTEC 460 
technique has been proved to be reliable for second-line drug-susceptibility testing 
compared with the standard proportional method with solid media. Other improved 
automated non-radiometric systems, such as the MGIT 960 or the MB/BACT, however, 
have been only evaluated for the first-line of anti-tuberculous drugs. Among tools for 
rapid detection, the reverse hybridization-based probe assay and other amplification 
methods are available for the rapid detection of mutations to RIF (Di Perri and Bonora, 
2004). These methods are discussed in the next section. The choice of an anti-MDR-TB 
regimen should give preference to the first-line drugs shown to still be active, such as 
pyrazinamide, STR and EMB. Depending on local resources, parenterally administered 
drug such as amikacin, capreomycin or kanamycin could eventually be included in 
association with second-line oral agents such as fluoroquinolones, ethionamide, PAS, 
cycloserine, clarithromycin, linezolid, etc. The duration of the treatment should be 
determined on an individual basis and should be prolonged for at least 18 months after 
sputum conversion (sputum free of acid fast mycobacteria). Hospital-based treatment 
should be performed at least until sputum conversion occurs. Because adherence of the 
patient to treatment continues to be a major issue due to the morbidity produced by the 
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combination of first line and second line of defence drugs, directly observed treatment 
(DOT) must be provided, particularly when there is prior evidence of patient non-
compliance. The prevention of the development of further drug resistance and 
epidemics in high prevalence regions must remain a major concern (Di Perri and 
Bonora, 2004). Furthermore, as formulated by the programmes of the WHO for the 
control and prevention of TB and MDR-TB, surveillance is an absolute necessity. 
Therefore, data describing the global distribution of MDR-TB on an annual basis and its 
comparison to that obtained for previous years as shown by Figure 3 provide an 
understanding of where the MDR-TB problem continues and where, as a consequence 
of effective recently introduced TB control programs, the MDR-TB problem is seen to 
abate.  As can be seen by the data provided by Figure 3 resistance to anti-TB drugs is 
present worldwide. The global number of MDR-TB cases reported between 1994 and 
2002 showed enormous gaps in many areas, especially in countries with a large TB 
burden or where available data strongly suggest that there may be a much larger 
problem, particularly in Asia and countries of the former Soviet Union. From 1994-
1997 particularly high prevalence of MDR-TB were found in the Baltic republics of 
Estonia and Latvia, parts of Russia, China, Iran, the Dominican Republic, Argentina, 
Nepal, Gujarat, India, New York City, Bolivia and Korea (Figure 3A) (Cohn et al., 
1997; Pablos-Méndez et al., 1998). The increased case rates in Sub-Saharan Africa were 
largely due to the HIV epidemic and in the former Soviet republics, mostly due to the 
social-economic crisis that followed the collapse of the Soviet Union (Raviglione et al., 
1993). This increased number of MDR-TB cases led the WHO and the International 
Union Against Tuberculosis and Lung Disease (IUATLD) to establish a global project 
of drug resistance surveillance based on standard epidemiological methods and quality 
control through an extensive network of reference laboratories. From 1994-2002 until 
2004 it is notorious the increase in the number of MDR-TB cases reported especially, in 
Russia. Analysing the data reported by the WHO in 2006, the 3 areas with significantly 
different proportions of MDR-TB cases among new cases were the Central Europe, 
Latin America and Africa (both with low and high HIV prevalence, respectively), 
Eastern Europe and the Eastern Mediterranean region, Southeast Asia and the Western 
Pacific region (Figure 3B). The regions with the highest burden of MDR-TB were 
found to be Eastern Europe, Southeast Asia, and the Western Pacific region. 
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Figure 3. Global distribution of MDR-TB rates. Prevalence among new TB cases 
(1994-2002) (A); (2004) (B) (reproduced and adapted from WHO/IUATLD, 2004; Zignol et al., 
2006).  
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The vast majority of patients with MDR-TB in low-resource countries do not have 
access to proper diagnostic services and to the quality-assured second-line drugs needed 
to treat these infections. By this manner, plans to expand appropriate diagnostic and 
treatment services for patients with MDR-TB are urgently needed, especially in 
countries where the burden of MDR-TB is greatest, such as the case of China, India and 
the Russian Federation and in areas with the highest MDR-TB rates (such as Eastern 
Europe) (Zignol et al., 2006). 
 
I.2.1 Extensively Drug Resistance TB (XDR-TB) 
 
The term Extensively Drug Resistance TB (XDR-TB) was used for the first time in 
March of 2006, in a report jointly published by the US Centers for Disease Control and 
Prevention (CDC) (CDC, 2006) and the WHO (WHO, 2006b). In that report, XDR-TB 
was defined as a disease caused by M. tuberculosis resistant to INH and RIF (MDR-TB) 
and to at least three of the six classes of second-line anti-TB drugs (aminoglycosides, 
polypeptides, fluoroquinolones, thioamides, cycloserine and PAS). However, due to 
difficulties in performing drug susceptibility testing for “second line of defence” drugs 
and also because some forms of drug resistance are less treatable than others, this 
definition was revised at a meeting of the WHO XDR-TB Task Force that occurred in 
Geneva (Switzerland) in 2006. Thus, currently XDR-TB is defined as: M. tuberculosis 
strains resistant to at least INH and RIF, in addition to any fluoroquinolone, and to at 
least one of the three injectable drugs used in anti-TB treatment: capreomycin, 
kanamycin and amikacin (WHO, 2006b). Re-evaluating the definition of XDR-TB led 
to incomplete information about the actual number of cases of the disease (Migliori et 
al., 2007). The results presented by the CDC (CDC, 2006) revealed that XDR-TB 
strains had been reported in all continents prior to 2000 with the highest known rates in 
Eastern Europe and Asia. The first study on the prevalence of XDR-TB was reported on 
2006 in Tugela Ferry, a rural town in the South African province of KwaZulu-Natal 
(Gandhi et al., 2006), the epicentre of South Africa’s HIV/AIDS epidemic (Singh et al., 
2007). This area which presents a very high number of cases of HIV was assessed for 
prevalence of XDR-TB by Gandhi and co-workers from January of 2005 to March of 
2006. The results showed that from the 1539 patients monitored, 221 had MDR-TB and 
from these, 53 were infected with XDR-TB (Gandhi et al., 2006). After the initial cases 
reported in South Africa other countries also started to report at least one case of XDR-
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TB. Among those countries are: Argentina, Armenia, Bangladesh, Brazil, Chile, Czech 
Republic, Ecuador, France (one case imported), Georgia, Germany, Italy, Republic of 
Korea, Latvia, Mexico, Peru, Portugal, Russian Federation, South Africa, Spain, 
Thailand, United Kingdom and the United States of America (Figure 4). Indeed, in the 
1997 WHO Report on Global MDR-TB, the frequency of strains resistant to 4 or more 
first line of defence drugs were identified as a global problem. Admittedly, these strains 
do not satisfy the current definition of XDR-TB; it does suggest that these XDR-TB 
strains have been present much earlier than recognised.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Global distribution of MDR-TB among new cases and countries that 
reported XDR-TB. The countries with red circles reported at least one case of XDR-TB (reproduced 
from Migliori et al., 2007). 
 
At least 10 of the countries that reported XDR-TB are in, or bordering, Europe. 
Preliminary anecdotal evidence suggests that some XDR-TB strains in Europe (from 
Italy, for example) may, in fact, be “XXDR-TB” or “extremely drug-resistant”, i.e. 
resistant to all first- and second-line drugs available. This increased resistance to 
second-line drugs implies losing the fluoroquinolones and the injectable agents that are 
the last resource measures available at the present. It also means losing the most potent 
and least toxic options for second-line drug therapy. Fluoroquinolones are some of the 
few potent antibiotics still active against most MDR-TB strains and their use has been 
identified as a favourable prognostic factor in cases of MDR-TB, with very few cases of 
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fluoroquinolones resistance reported (Veziris et al., 2007). Unfortunately, a significant 
number of XDR-TB strains go beyond the definition of XDR-TB and are essentially 
untreatable, being resistant to numerous other second-line drugs (Hamilton et al., 2007). 
This constitutes a big concern since the number of cases is almost for sure higher than 
the ones reported. In that manner, some strategies should be developed to control or 
prevent the spread of the disease. The WHO Global Task Force on XDR-TB developed 
several main recommendations to prevent and control XDR-TB (WHO, 2007b). These 
recommendations consist in the prevention of XDR-TB through basic strengthening of 
TB and HIV control. These are priority interventions which main guidelines are based 
on the new Stop TB Strategy and the Global Plan to Stop TB. Other important 
recommendation requires the improvement in the management of patients suspected to 
have XDR-TB. These interventions have to consider accelerating the access to the 
laboratory facilities. However, this could be difficult to implement since in most 
resource-limited settings TB laboratory services are inadequate and laboratory-based 
diagnosis of TB typically relies on microscopy of stained sputum. This method has poor 
sensitivity (missing more than 50% of cases), especially in HIV-positive individuals, 
and does not provide information about drug susceptibility. Culture is more sensitive 
than microscopy and can be used for drug susceptibility testing, but M. tuberculosis 
takes several weeks to grow. New diagnostic modalities that could improve TB 
detection and the identification of drug resistance include: nucleic acid amplification 
tests to detect M. tuberculosis in sputum; phage-based methods to detect M. 
tuberculosis and drug resistance in sputum; and rapid molecular genetic tests to detect 
RIF resistance in sputum or in cultured bacteria (see next section for more detailed 
information). These tests, however, have generally been regarded as too costly for 
widespread use in most TB endemic settings (Dorman and Chaisson, 2007). Besides 
these rapid tests of drug susceptibility one should consider the improvement on the 
detection of cases suspected of presenting MDR-TB strains in HIV infected individuals 
and the strengthened management of XDR-TB and treatment design in HIV negative 
and positive individuals. The basis of this intervention is the correct application of the 
new WHO guidelines for programmatic management of drug-resistant TB using 
second-line drugs properly. Also a new approach centred on the patient in order to 
establish adequate support and supervision. One most important recommendation is the 
standardization of the definition of XDR-TB. It is important that all the countries adopt 
the new definition to allow the comparability of data obtained through ongoing 
Chapter I 
 
 
23 
surveillance in low and high TB incidence countries. One main area of concern is the 
health care workers. There is the need for an increased control and protection of all the 
health care workers; the main goal should be the reduction of the transmission of MDR 
strains especially among HIV positive individuals in congregate care settings presenting 
high HIV prevalence. Therefore, there is the need to implement immediate XDR-TB 
surveillance programs that should be coordinated by the Supranational and National 
Reference Laboratories and should be focused on the complete assessment of the XDR 
prevalence worldwide. One important aspect that should never be forgotten is the 
initiation of advocacy, communication and social mobilization activities. It continues to 
be extremely important to inform the general community and raise awareness about TB 
and XDR-TB (Migliori et al., 2007). In order to achieve control of MDR or XDR-TB, 
basic research has to be conducted to develop new diagnostics, new drugs, treatments 
and prevention tools. Exactly 125 years have passed since Robert Koch’s discovery of 
M. tuberculosis (the milestone of modern control of TB) and the ‘‘white plague’’ is still 
affecting mankind.  Lastly, consideration must be given to the use of all methods that 
provide the means for control of TB, MDR-TB and XDR-TB. The argument that it is 
costly does not stand up in the face of the costs that are incurred in terms of human 
suffering and economics such as loss of wages, increased dependence of patient and 
family on governmental assistance, and not to say the least, the cost of treating (cost of 
drugs) and maintaining a patient within hospital grounds (Muniyandi et al., 2006). If TB 
can be obviated, the costs required for this task are infinitely less than the incurring of 
costs due to increasing frequency of TB, MDR-TB and XDR-TB.  
 
I.3 TB in Portugal 
 
Portugal presents a very peculiar situation since it has an incidence of TB that is   
approximately 10 times greater than the countries of Western Europe (DGS, 2006). The 
understanding of the global evolution of TB and the new tools of epidemiologic analysis 
is forcing responsible specialists to develop more ambitious goals for the control of TB 
in the next decades. This attention is now centred on the DOT strategy and in the 
detection of latent cases. With the appearance of the HIV and the development of MDR, 
the strategy has to suffer a rearrangement in order to solve this continuous case of 
infection. Portugal has an incidence of 33 cases/100,000 inhabitants (new cases in 2005) 
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(DGS, 2006). However, the data reported to the WHO is relative to the year of 2005 and 
since there is no available data for 2006 the situation cannot be accurately discussed. 
The actual incidence of TB means that the risk of being infected with TB suffered a 
reduction to half in the last 17 years. In terms of notified number of cases, only the three 
Baltic countries have higher numbers, namely, Lithuania (63), Latvia (63) and Estonia 
(43) (WHO, 2007a). In a global context the highest incidences of cases in the EU are 
considered intermediates (between 20 and 80 cases/100,000 inhabitants). In this group 
are included Poland (26) and Hungary (22) (WHO, 2007a). However, if we consider the 
differences in the detection rates to this calculus of estimated cases, Spain will also be 
included in this group with an estimated rate of 27/100,000 inhabitants. In Portugal the 
distribution of TB cases is very different. According to the number of cases reported by 
the Direcção Geral de Saúde (DGS) in 2006 (relative to the year of 2005), the areas that 
have higher number of cases reported are Porto (696), Lisboa (569), followed by 
Setúbal (276), Braga (182), Faro (132) and Aveiro (129) (DGS, 2006). As can be seen, 
the big metropolitan areas of Lisboa and Porto have the highest rates of incidence 
(Figure 5) (DGS, 2006). In the opposite, areas like Alto Alentejo, a big part of the 
centre of the country and Bragança district have a very few number of cases notified. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Rate of new cases of TB per district of Portugal. The islands account for 17.6 
and 14.1 for Madeira and Açores respectively (reproduced and adapted from DGS, 2006). 
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One important aspect is the immigration. In Portugal, the proportion of cases in 
immigrants is of 12%, much lower than the one in the EU (28% in 2004) (DGS, 2006). 
The proportion of TB cases in immigrants is small compared to other EU countries like 
Belgium, Cyprus, Denmark, Malta, Holland, Sweden and United Kingdom, were there 
is an incidence of more than 50% of cases in immigrants. The incidence rates of TB in 
immigrants in the EU are 12 times higher in the foreign population (WHO, 2006b). In 
Portugal, this rate is 3 times higher relatively to the incidence in the national citizens 
(DGS 2006). These differences are also due to the origin of the immigrants. In the EU 
the majority of cases are from citizens from Africa (32%), Asia (30%) and Central and 
East Europe (25%) (WHO, 2006b). In Portugal, the vast majority is from the Sub-
Saharan Africa (70%). From Asia and East Europe there is the notification of 6 and 9% 
of the cases, respectively (DGS 2006). One of the most important factors is undoubtedly 
the number of HIV cases. The HIV infection contributes to the risk of reactivation of 
TB, being an important demographic factor to consider (WHO, 2006a). In comparison 
with the EU, Portugal is the country with more cases of TB/HIV (15% in 2005), what it 
is correlated with the highest incidence of AIDS (9.9/100,000 inhabitants in 2004) 
(DGS 2006). In general, in the other countries of the EU the number of cases of 
TB/HIV has been stable with the exception of Estonia and Latvia (WHO, 2006b). In 
Portugal, the absolute number of cases has been reduced to 30% in the last years. 
However, in the population infected with HIV the estimated risk of TB is 15 times 
higher. In 2004, in 11.6% of all TB cases, this was the disease considered has initial 
indicative of AIDS (against 2.9% in the EU) (DGS 2006). Despite the progress recorded 
in the last years, the HIV testing in the TB cases is still a poor marker of performance 
(around 50%) (Post and Emerson, 2008). The co-infection with TB/HIV is very high in 
the foreign populations (26%) and in the district areas of Lisbon (23%) and Setúbal 
(24%) (DGS, 2006). However, other demographic factors contribute to this 
epidemiology, such as the numbers of individuals that are in prisons (estimated risk of 
26 times) (Marques et al., 2006), the drug addicts (estimated risk of 15 times) (March et 
al., 2007), the health care workers (estimated risk of 1.5 times) (Banhart et al., 1997) 
and the homeless (no estimated risk available) (DGS 2006). The individuals that are in 
prisons constitute a group with a very increased risk, because of the dynamic of the 
transmission (Post and Emerson, 2008). This population infected with TB constitute 
3.2% of the total of notified cases in 2005 with medium ages of 30 years and presenting 
a high incidence of MDR-TB (12%), high percentage of foreigners (20%), a big 
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proportion of co-infection with HIV (55%) and consumers of injectable drugs (61%) 
(DGS, 2006). The proportion of pulmonary TB in Portugal is 73% and similar to the 
EU, that is 77%. In terms of distribution of TB the extrapulmonary form more notified 
is the pleural TB (13%), followed by the lymph node TB (7%) (Marques et al., 2006). 
The meningeal (1.3%) and disseminated (3%) forms are concentrated mainly in the 
group of 25 to 44 years and they are associated with the HIV infection in 50 and 65% of 
the cases, respectively. The proportion of cases of pulmonary TB with positive 
microscopy in the sputum is much higher in Portugal than in the other countries of the 
EU (65% against 43%) (DGS, 2006; WHO, 2006b). The confirmation of pulmonary 
cases by culture, is in the total of the EU (60%), slightly lower than in Portugal (64%). 
The major difference is the extrapulmonary forms with 18% (against 37% in the EU). 
Relatively to the identification of the M. tuberculosis complex, this is just known in 
42.4% of the cases in our country, against 74% in the EU (DGS, 2006). 
 
I.4 TB diagnosis 
 
Rapid and accurate diagnosis of symptomatic patients is a major goal for the TB control 
strategies (Perkins, 2000). To help control the spread of TB, rapid diagnostic is 
desirable (Bergmann and Woods, 1996). Therefore, the clinical laboratory has a major 
role in the control of TB, inasmuch as an effective management of TB patients from 
areas that have high rates of MDR-TB is dependent on the rapid identification of M. 
tuberculosis complex strains as well as their antibiotic susceptibility profiles (Ridderhof 
et al., 2007). Deficiencies in current case-findings tools in disease endemic countries 
have made it difficult to ensure access to good diagnostics at all health service levels, 
leaving many patients undiagnosed. Additionally, in well-established TB control 
programs where diagnostic access has been ensured, efforts to interrupt disease 
transmission have been hampered by the insensitivity and late detection of smear 
microscopy (Perkins, 2000). Some methods are being developed and others remain in 
usage and will be described in the following sections. 
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I.4.1 Smear microscopy 
 
The primary laboratory tool supporting case detection in the vast majority of cases in 
disease endemic countries is still the microscopic examination of the stained sputum 
smear (Perkins, 2000). The advantages of the acid-fast staining of smears are well 
known. It is relatively inexpensive to perform; is a rapid technique; and detects the most 
infectious subset of patients (Perkins, 2000). However, it has a low sensitivity since it 
needs approximately 104 bacteria/mL of specimen for a positive result. Other 
disadvantage is the fact that it does not differentiate between species of Mycobacterium 
(Bergmann and Woods, 1996). The differentiation of M. tuberculosis from other 
mycobacteria represents an important health issue, since only TB is transmissible from 
individual to individual (Heifets and Good, 1994). It also requires equipment that is 
difficult to maintain in field settings and yields results that depend upon a trained 
technician. An additional problem aroused with the increase in the number of cases of 
smear-negative disease in patients infected with HIV (Perkins, 2000). 
 
I.4.2 Culture 
 
Culture remains the gold standard for the diagnosis of TB (Tortolli and Marcelli, 2007). 
The growth of the organism on solid or liquid media can take up to 6 to 8 weeks, 
depending on the method used (Bergmann and Woods, 1996). Radiometric liquid 
culture systems have been currently used in level II or III Mycobacteriology laboratories 
for more than a decade due to their speed and sensitivity (Perkins, 2000), being 
BACTEC 460 TB system one of the best known successful examples. However, the 
difficulty in working with radioactive materials, the necessity of expensive apparatus for 
the detection of radioactive gas and the cost of materials constitute primary obstacles 
(Perkins, 2000). Alternative growth detection methods for liquid culture employing 
oxygen quenching and redox reagents have been commercialized and demonstrated 
performances comparable to BACTEC 460 TB, such as the case of BACTEC MGIT 
960 system (Gumber and Whittington, 2007; Perkins, 2000; Piersimoni et al., 2006). It 
is unquestionable the importance of the routine culture of acid-fast bacilli since it is still 
necessary for its higher sensitivity and ability to identify mycobacterial species other 
than M. tuberculosis complex and for the recovery of isolates for antimicrobial 
susceptibility testing (Zheng et al., 2001). However and despite all the improvements 
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made in recent years it still requires, on average, 2 to 3 weeks for positive samples to be 
detected (Tortolli and Marcelli, 2007). Amplification techniques can therefore, be used 
in order to support and accelerate an earlier diagnostic, enabling rapid implementation 
of treatment and minimizing the risk of contagion (Tortolli and Marcelli, 2007).  
 
I.4.3 Biochemical methods 
 
Biochemical methods were, for many years, the only available tool to identify 
Mycobacterium species after isolation in culture. The development of these methods 
was focused on the identification of the M. tuberculosis complex. When the 
determination of Mycobacterium species is required after a preliminary report of M. 
tuberculosis complex, a few tests are necessary for differentiation from other species in 
the complex. A combination of biochemical tests may be used to identify and 
differentiate mycobacteria within the M. tuberculosis complex. These include: the 
niacin test, the nitrate reduction test, the pyrazinamidase test, the thiophene-2-
carboxylic acid hidrazide (TCH) and the heat-stable catalase test (Heifets and Good, 
1994). The niacin test is based on the detection of niacin in the medium, not in the 
bacteria. The niacin in the medium is extracted and subsequently detected by the use of 
a commercial strip used to detect this compound. After an incubation period the 
development of colour is obtained. The test is considered positive if the liquid turns 
yellow. Formerly the niacin test was developed for identification of M. tuberculosis but 
it can be positive with other mycobacterial species such as M. simiae and some BCG 
strains among others (Burgos et al., 2004). Other biochemical test that can be used is 
the nitrate reduction test. This test is based on the identification of the enzyme nitrate 
reductase that is produced by a variety of species like M. tuberculosis, M. kansasii, M. 
fortuitum, among others. This is useful after the initial identification of the M. 
tuberculosis complex. The test is based on the addition of several reagents with the 
main goal of colour development with the addition of N-napthylethylenediamine that 
can be compared to a series of colour tube standards and reactions from 3 quality 
controls. The pyrazinamidase test detects the presence of the enzyme that converts PZA 
to pyrazinoic acid. Pyrazinamidase can be found in cultures of M. tuberculosis strains 
susceptible to PZA but PZA-resistant M. tuberculosis strains do not possess detectable 
amounts of this enzyme. M. bovis strains including BCG are resistant to PZA as well as 
other non-tuberculous mycobacteria. The principle is the addition of biochemical 
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reagents in order to observe the development of coloured reactions, indicatives of a 
positive result. Only M. bovis strains (including BCG) are susceptible to TCH. This test 
is performed in the same way as an indirect susceptibility test and all mycobacterial 
species other than M. bovis produce growth in the presence of TCH (Heifets and Good, 
1994). The heat-stable catalase test identifies strains of the M. tuberculosis complex but 
it has no role in differentiating M. tuberculosis from M. bovis since both species 
produce negative results. This test is useful to differentiate between M. gastri and M. 
malmoense from other slowly growing non-chromogenic mycobacteria. When the 
primary isolate is identified as M. tuberculosis complex by one of the rapid methods, 
the differentiation between members of the complex can be limited to the other four 
biochemical tests described. Although these are simple and rapid tests, in fact they are 
not accurate and sometimes present false-positive results or crossed results with other 
mycobacterial species. This has contributed to the replacement of these tests by other 
identification methods (Burgos et al., 2004; Hazbón 2004; Millar et al., 2007). 
 
I.4.4 Chromatographic methods 
 
Chromatographic analysis of cell wall lipids of M. tuberculosis can be performed by 
High Performance Liquid Chromatography (HPLC), Gas Liquid Chromatography 
(GLC) or Thin-Layer Chromatography (TLC). These methods are able to differentiate 
between M. tuberculosis and other mycobacteria and also expedite determination of the 
species of the non-tuberculous mycobacteria (Burgos et al., 2004). HPLC uses a liquid 
mobile phase at high pressure to carry a sample through a column packed with 
particulate material or stationary phase, where the separation into components take 
place (Heifets and Good, 1994). Mycolic acids extracted from saponified mycobacterial 
cells are converted to the p-bromophenacyl esters, and the unique mycolic acid pattern 
associated with each species is detected by chromatographic separation of the esters. 
The method has been used for accurate identification of eight slowly growing 
mycobacterial species: M. tuberculosis, M. bovis, M. kansasii, M. szulgai, M. gordonae, 
M. asiaticum, M. marinum and M. gastri (Heifets and Good, 1994). The analysis is 
based on a comparison of retention time of the peaks and of their height ratios. Despite 
all the simplifications of the method to examine a large number of cultures in one 
working day, approximately 106 colony forming units (CFU) are required to perform the 
test. BACTEC cultures cannot be used directly in HPLC, since that the usual harvest of 
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M. tuberculosis from 12B broth cultures may not be sufficient for this procedure 
(Siddiqi et al., 1981). In comparison with other detection systems like the nucleic acid 
probe systems it requires specialized instrumentation and technicians as well as a longer 
period of time. GLC uses hydrogen in the mobile phase and liquid in the stationary 
phase. The analysis of the microbial short-chain fatty acids (methyl esters) is based on 
the comparison of the retention time of the tested sample to the retention times of 
known standards. GLC analysis of the cell wall lipids for mycobacterial identification 
has been successfully used in several laboratories by employing a commercially 
available chromatograph and a computer (Heifets and Good, 1994). The library of 
aerobic bacteria includes the cell wall lipid patterns of 26 or more mycobacterial 
species. Profiles of the tested cultures are compared with those in the library, and the 
results are presented by a computer-generated report giving the actual parameters of the 
chromatogram as well as percentages of probability that the isolate belongs to a certain 
species. The main disadvantages of these methods are that usually they require a 
substantial bacterial harvest from solid media. To have a positive identification usually 
takes 3 weeks or longer (Heifets and Good, 1994) and it is demanding the use of 
specialized instrumentation and skilled technician, most of which conditions are not 
available in a Mycobacteriology laboratory. 
 
I.4.5 Phage systems 
 
Clinical diagnostic applications have been spawned by basic mycobacteriophage 
research. One is a phage replication system that detects live mycobacteria in clinical 
samples or in fresh liquid cultures using phages that infect and replicate in 
mycobacterial cells, as indicators. However, the technical skills requirement of such 
tests, which can be used both for case detection and drug susceptibility testing are likely 
to be at least as high as those for conventional culture, which will limit the number of 
laboratories in which this might be applied. Luciferase reporter phages have also been 
engineered which may be pressed into service for rapid drug susceptibility testing 
(Perkins, 2000). 
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I.4.6 Nucleic acid – based methods  
 
I.4.6.1 Probe hybridization and Polymerase Chain Reaction (PCR) 
 
One of the most important technical advances for TB laboratories in industrialized 
countries has been the development of nucleic acid – based identification assays. Most 
of these assays use hybridization and/or amplification procedures. The fist one is based 
on the hybridization between a particular region of the mycobacterial DNA or RNA and 
a single-stranded probe, which targets specific region(s) of the genome (Heifets and 
Good, 1994). The principle of this reaction - the complementarities between the 
nucleotide sequences of nucleic acids - is the same behind the annealing of primers to 
target regions needed for nucleic acid amplification by the polymerase chain reaction 
(PCR). While the hybridization procedures introduced speed, but most important, high 
reliability to the identification methods by identifying accurately mycobacteria present 
in the culture, the PCR procedure, which exponentially amplifies the amount of targeted 
DNA, further allowed detecting mycobacteria directly from specimens. PCR as a 
diagnostic tool for identification of mycobacteria is being developed in various 
technological modifications. The major advantage of this technique is that PCR can 
detect just a few bacterial cells in a raw specimen, which means that a molecular 
diagnosis of TB can be completed in a few days or even hours after the arrival of the 
specimen to the laboratory instead of the period required currently. Another advantage 
is the possibility of diagnosis with specimens having a number of bacteria below the 
levels of sensitivity of culture methods. 
 
I.4.6.2 Commercial available tests 
 
Until the present date, US Food and Drug Administration (FDA) have approved two 
tests for the direct detection of M. tuberculosis in respiratory specimens: the Gen-Probe 
AMPLIFIEDTM Mycobacterium tuberculosis Direct (MTD; Gen-Probe Inc., San Diego 
California) Test and the Roche AMPLICOR® Mycobacterium tuberculosis 
(AMPLICOR MTB) test (Roche Molecular Systems Inc.; Branchburg, N.J.). In 1998, a 
modified version of the MTD test that is faster and more sensitive than the previous 
version was approved by the FDA. The MTD test utilizes transcription-mediated 
amplification to detect M. tuberculosis complex rRNA directly in respiratory specimens 
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(Zheng et al., 2001). According to the manufacturer’s it can detect M. tuberculosis 
complex rRNA at a concentration equivalent to 5 CFU per test and does not react with 
150 species of microorganisms (including respiratory flora) at the level of 5×107 
organisms per reaction. It is intended for use with specimens from patients that show 
signs and symptoms consistent with active pulmonary TB. The test should be used in 
addition to acid-fast bacillus smear and culture but it can provide results in 2.5 to 3.5 
hours. The AMPLICOR MTB test is also based in nucleic acid amplification, allowing 
the evaluation of respiratory specimens (Bergmann and Woods, 1996). It identifies the 
presence of genetic information unique to M. tuberculosis complex directly in pre-
processed clinical samples. The nucleic acid amplification technique is used to obtain 
sufficient nucleic acid so that, within a few hours, these tests can distinguish between 
M. tuberculosis complex and non-tuberculous mycobacteria in an acid-fast bacilli 
positive specimen. These tests are recommended only for respiratory specimens, smear 
positive for acid-fast bacilli, from persons who have never received anti-TB treatment 
or have received less than 7 days of anti-TB treatment during the past year (ATS, 2003). 
A positive direct amplified test in conjunction with an acid-fast bacilli positive smear is 
highly predictive of TB disease. However, the results of the nucleic acid amplification 
tests are preliminary, since the mycobacterial culture is still needed for species 
identification and confirmation as well as for drug-susceptibility testing. Negative 
nucleic acid amplification with an acid-fast bacilli positive smear indicates that the acid-
fast bacilli are probably non-tuberculous mycobacteria. However, they present some 
limitations. The MTD and MTB tests are highly sensitive and specific for M. 
tuberculosis on specimens that are smearing positive for acid-fast bacilli. Occasionally 
they can give false negative or false positive results. The result can be falsely negative if 
there are substances in the specimen itself inhibiting the amplification so that the test 
does not detect the M. tuberculosis complex. The falsely positive result can occur in 
case of contamination. In addition, because the nucleic acid amplification test can 
amplify DNA from both viable and non-viable organisms, a positive result may be 
misleading. For example, the test may detect non-viable tubercle bacilli that are 
coughed up by individuals who have been receiving anti-TB treatment; the test result 
may be positive even though the treatment has decreased the likelihood that the TB is 
infectious. By this manner, the test should be interpreted in a clinical context and the 
final decision as to the use and interpretation of the MTD should be defined by the 
physician.  
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The test most widely used for identification of the M. tuberculosis complex is the 
commercially available Accuprobe (Gen-Probe, San Diego, California) system, which is 
based on hybridization with nucleic acid probes. This test is based on the ability of 
complementary nucleic acid strands to align and associate with bacterial rRNA to form 
a stable, specific, double-stranded complex. The chemiluminescent acridinium ester-
labelled single-stranded DNA probe is complementary to the rRNA of the target 
species, so that the association of the two strands forms a stable hybrid. 
Chemiluminescence is developed by the addition of hydrogen peroxide, and the 
response is measured in a luminometer (Heifets and Good, 1994). Regarding 
identification of cultures, other probes are also available for identification of M. avium, 
M. intracellulare, M. kansasii and M. gordonae (Heifets and Good, 1994). 
 
I.4.6.3 Genotype® Mycobacterium CM and Genotype® Mycobacterium AS 
 
Within the genus Mycobacterium it can be distinguished between M. tuberculosis 
complex and Non-Tuberculous Mycobacteria (NTM or MOTT – Mycobacteria Other 
Than Tuberculosis) (Falkinham III, 1996). In view of the varying pathogenicity of some 
species a fast and certain differentiation is extremely important. From a medical point of 
view it is indispensable to make a clear and safe distinction between the M. tuberculosis 
complex and NTM and to apply adequate therapies. A late diagnosis and hence a delay 
in the beginning of appropriate treatment is detrimental to the successful of the 
treatment and facilitates transmission of the disease. Non-tuberculous mycobacteria can 
cause chronic mycobacterioses. Infectiousness and symptoms vary in a broad range and 
depend both on the pathogen as well as on the immunocompetence of the affected 
individuals. If the immune system is weakened, such as in the case of HIV infection or 
patients presenting cancer, mycobacteria can spread into the organism and lead to 
infections. This is a serious threat and requires rapid and appropriate treatment of 
atypical mycobacterioses. Consequently, the clinical significance of the NTM group 
members also has to be differentiated in order to avoid under- or over-treatment. On the 
basis of a positive solid or liquid culture the combination of two test systems 
Genotype® Mycobacterium CM (Common Mycobacteria) (Hain Lifescience GmbH) 
and Genotype® Mycobacterium AS (Additional Species) (Hain Lifescience GmbH) 
allow a safe and fast differentiation of more than 30 clinically relevant mycobacteria 
species. Both tests are based on the DNA•STRIP® Technology including an 
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amplification step and a subsequent reverse hybridization. The high sensitivity achieved 
by this combination enables the detection of even weak-positive cultures and the 
identification of mixed cultures from fast- and slow-growing mycobacteria. The 
Genotype® Mycobacterium CM allows the detection and discrimination of 13 non-
tuberculous mycobacteria species and of the M. tuberculosis complex as a whole. In 
addition, a genus-specific probe identifies the presence of other mycobacterial species. 
In this case, the Genotype® Mycobacterium AS offers a further differentiation. Some 
examples of species identified other than the ones belonging to the M. tuberculosis 
complex are: M. avium, M. chelonae, M. fortuitum, M. intracellulare, M. kansasii, etc. 
When applying the Genotype® Mycobacterium AS, another 16 non-tuberculous species 
can be distinguished. The use of this test system is particularly advantageous when only 
the genus-specific probe is developed in the Genotype® Mycobacterium CM. The 
amplicon generated in the Genotype® Mycobacterium CM may also be used for the 
Genotype® Mycobacterium AS; it is thus not necessary to perform a second PCR. Some 
species that can be detected by this test are M. simiae, M. smegmatis, M. lentiflavum, M. 
phlei, M. szulgai, etc. 
 
I.4.6.4 INNO-LIPA Rif. TB 
 
A variety of diagnostics have capitalized on the recent elucidation of molecular 
mechanisms of drug resistance, especially to RIF, which in most settings is a good 
marker for MDR-TB detection and which is almost always caused by a limited number 
of mutations in a single gene, the rpoB (Perkins, 2000). Ninety-five percent of M. 
tuberculosis strains with resistance to RIF contain distinct mutations located within an 
81-pb (27 codon) region of the beta (β) sub-unit of the RNA polymerase (rpoB) gene 
(Somoskovi et al., 2001; Telenti et al., 1993). Several methods can rapidly detect these 
specific mutations and thereby identify RIF-resistant M. tuberculosis complex strains 
(Kapur et al., 1994; Piatek et al., 1998; Telenti et al., 1993; Victor et al., 1999). INNO-
LIPA Rif. TB (Innogenetics, Zwijndrecht, Belgium) is one of these methods. This 
commercial kit has not yet been approved by the US FDA, however, it has been on the 
market since 1997 (Rossau et al., 1997). The assay is simple, convenient, cost-effective, 
and highly reliable when run in parallel with a conventional TB laboratory diagnostic 
algorithm. It can provide an answer between 24 to 48 hours after the arrival of the 
specimens, when adapted to direct detection from clinical samples. It is based in a 
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reverse-phase DNA probe system that identifies M. tuberculosis complex strains, 
detecting RIF resistance within a very short period of culture time (Rossau et al., 1997). 
It has ten probes, from which: one probe is specific for M. tuberculosis complex strains, 
five-partially overlapping probes hybridize exclusively with the rpoB gene wild-type 
sequence and four probes hybridize with amplicons carrying the mutations R2:D616V, 
R4a:H526Y, R4b:H526D and R5:S531L (Rossau et al., 1997; Viveiros et al., 2005b). 
The absence of hybridization of one or more of the wild-type probes indicates a 
mutation that can be identified by hybridization with one of the mutation probes. When 
adapted to the direct amplification of M. tuberculosis complex from clinical specimens 
is a useful adjunct to microscopy and culture and is used worldwide with the goal of 
reaching an earlier diagnosis of active TB (Tortolli and Marcelli, 2007). The availability 
of a system that combines the direct detection of M. tuberculosis complex in clinical 
specimens with the prediction of RIF resistance is therefore very useful, particularly 
because RIF resistance is, in the large majority of cases, accompanied by INH resistance 
(Tortolli and Marcelli, 2007). However, the major limitations found in this system are 
the false-negative results due to the inhibition of amplification, the absence of an 
internal amplification control and the fact that this assay, as well as other nucleic acid 
amplification assays, identifies DNA from dead mycobacteria from patients undergoing 
therapy (Viveiros et al., 2005b). The possible presence of PCR inhibitors may explain 
the failure of the system to amplify a number of M. tuberculosis complex-positive 
isolates, but, since INNO-LIPA Rif. TB does not include any system for monitoring 
inhibitors, no quantification is possible. Although the INNO-LIPA Rif. TB does not 
seem sufficiently sensitive to be used solely as a diagnostic tool on unselected 
specimens it may represent, thanks to the added value of prediction of RIF 
susceptibility, a valid alternative to other amplification methods on smear-positive 
samples (Tortolli and Marcelli, 2007).  
 
I.4.7 The TB-Task Force – The Lisbon experience 
 
One of the WHO recommendations for the control of TB is the rapid diagnosis of the 
disease, namely of MDR cases (WHO, 2006a). Following these guidelines, the “TB 
Fast-Track Program” for the rapid diagnosis of TB was implemented at the laboratory 
of the Unit of Mycobacteriology (IHMT/UNL) in Lisbon. This program was modelled 
after that of the New York State Department of Health (Frieden et al., 1993; Hale et al., 
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2000; Salfinger, 1977) and is under the supervision of the TB Task Force of Greater 
Lisbon. The TB Task Force of Greater Lisbon is a cooperative joint venture involving a 
structured net of 12 hospitals of the Greater Lisbon area and it was further extended to a 
second phase (now named “Faster-Track Program”), being employed with success to 
perform the rapid detection of the MDR cases (Watterson et al., 1998). In Portugal, as is 
the case worldwide, the vast majority of M. tuberculosis complex strains with resistance 
to RIF are also resistant to INH and although monoresistance to INH is common 
(Ridzon et al., 1998) monoresistance to RIF is rare (CDC, 1993, 2005b, 2005c; DGS, 
2004; Mitchison, 1998; Portugal et al., 1999; Somoskovi et al., 2001). Thus, RIF 
resistance can be used for the identification of MDR-TB infections (Hale et al., 2000; 
Somoskovi et al., 2001). This makes possible the aggressive treatment of MDR-TB 
patients (with four or five drugs) while sparing non MDR-TB patients from areas with 
high MDR-TB frequencies from said therapy (CDC, 1993; Hale et al., 2000; Parsons et 
al., 2004); a marked reduction in the frequency of non-compliance would consequently 
be expected (CDC, 1993; Hale et al., 2000; Mitchison 1998; Parsons et al., 2004). At 
the laboratory of the Unit of Mycobacteriology the line probe assay INNO-LiPA Rif.TB 
was evaluated for the identification of M. tuberculosis complex strains and the detection 
of mutations in the rpoB gene linked to RIF resistance directly from acid-fast smear 
positive respiratory specimens obtained from patients who presented with active TB 
(clinical symptoms and radiological evidence). The assays were performed in parallel 
with conventional isolation, identification and susceptibility testing procedures routinely 
used in the Mycobacteriology clinical laboratory. From September 2002 to September 
2003, a total of 360 acid-fast positive respiratory specimens consisting of sputa (n=318), 
bronchoalveolar lavage fluids (n=23), and bronchial secretions (n=19) from patients 
presenting with presumptive active TB were received at the laboratory; each specimen 
was accompanied by a physician-completed questionnaire that included pertinent 
patient demographics, clinical history, and MDR-TB risk factors. The patients, all from 
the Greater Lisbon area, ranged in age from 14 to 89 years (average, 42 years) and were 
mainly male (73.8%). The three major MDR-TB risk factors reported were, in order of 
importance, prior anti-TB treatment, contact with other MDR-TB patients, and origin 
from an area with a known high incidence of MDR-TB. The HIV status was determined 
for only 150 patients (41.7%), and of these, 82 patients were co-infected with HIV. The 
identification of M. tuberculosis and M. avium complex strains present in full-grown 
cultures in the BACTEC MGIT 960 culture system was conducted with the Accuprobe 
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system. A positive identification of M. tuberculosis was followed by susceptibility 
assays for RIF, INH, EMB, STR, and PZA afforded by the BACTEC MGIT 960 
system. The ability to rapidly identify an MDR-TB-type infection afforded the effective 
management of MDR-TB, reduced the frequency of non-compliance since patients that 
do not have MDR-TB were treated less aggressively, and therefore contributed to the 
control of TB. 
 
I.4.7.1 The contribution of the Unit of Mycobacteriology to the control of TB in the 
Greater Lisbon Area 
 
As of this writing the Unit of Mycobacteriology of the IHMT via its Faster TB Track 
Programme has processed more than 100 MDR-TB specimen (since 2002) most of 
which are reported within one day of receiving the specimen. The ability to reduce the 
turn-around time of reporting and identifying an MDR-TB patient to one day has, in my 
opinion, been the main reason as to why the rates of new cases of MDR-TB have 
decreased from an excess of 28% in 2003 to less than 8% in  2006. Further reductions in 
the rate of new cases of MDR-TB are expected in the years to come. Unfortunately, 
because Porto does not use the system that has been developed in Lisbon, its rate of new 
cases of MDR-TB continues to escalate at an alarming rate (DGS, 2006). 
 
I.4.8 Tests to detect latent infection 
 
I.4.8.1 Tuberculin skin test (TST) 
 
Tuberculin (also known as “old tuberculin”) was discovered by Robert Koch in 1890. 
The original tuberculin was a glycerine extract of the tubercle bacilli and was initially 
developed as a treatment for TB. However, the fact of being an unrefined product, 
contributed to its lack of sensitivity in the diagnosis of infection with M. tuberculosis. 
By this manner, it was considered ineffective in the treatment of TB. Clemens von 
Pirquet discovered that patients who had previously received injections of horse serum 
or smallpox vaccine had quicker and more severe reactions to a second injection. Soon 
thereafter von Pirquet discovered that the same type of reaction took place in 
individuals infected with TB, and he thus found the utility of what would become the 
tuberculin skin test (TST), also referred, in some countries, as the Mantoux test. The 
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TST continues to be used as the standard method for detecting latent infection with M. 
tuberculosis. It is widely used to support clinical and radiological findings in the 
evaluation of patients with suspected TB. A positive TST result can help in the decision 
to start treatment while bacteriological confirmation is awaited or lacking (Cardona, 
2007). However, the greatest utility of a test of M. tuberculosis infection lies in its 
potential to exclude a diagnosis of TB when other tests are negative. This requires a test 
with high diagnostic sensitivity to minimise the possibility of falsely ruling out TB. The 
poor sensitivity of TST in young children and immunosuppressed people makes it 
impossible to interpret negative TST results in these groups. Moreover, up to 25% of 
immunocompetent adults with active TB may have a negative or ambiguous result 
(Gooding et al., 2007). Multiple puncture tests should not be used to determine whether 
a person is infected, as this test is unreliable (because the amount of tuberculin injected 
intradermally cannot be precisely controlled) (WHO 2006d). The Mantoux test is now 
standardised by the WHO and uses purified protein derivative (PPD). PPD was obtained 
from the refinements of the “old tuberculin” preparation and is a combination of 
mycobacterial antigens obtained from M. tuberculosis culture and that share a large 
number of antigens both with BCG and with environmental mycobacteria. The test is 
based on the intradermal injection of 0.1 mL of tuberculin (100 Units/mL). This 
combination, elicits delayed-type hypersensitivity (DTH) response or type IV 
hypersensitivity reaction that is mediated by specific T lymphocytes. This denomination 
is due to the fact that these responses, caused by pre-existing T lymphocytes, take hours 
or days to develop. Such effectors cells function in essentially the same way as during a 
response to an infectious agent. When small amounts of PPD are injected, a T cell 
mediated local inflammatory reaction evolves in individuals who have previously 
responded to M. tuberculosis. This indicates the presence of antibodies or lymphocytes 
that are specific for PPD. This cell-mediated immunity can then be detected as a local 
response when the individual’s skin is injected with a small amount of PPD. The 
response typically appears a day or two after the injection and consists of a raised, red 
and hard (or indurated) area. This induration can be measured two to seven days 
afterwards and disappears as the PPD is degraded (Janeway et al., 1999). Since 
hypersensitivity responses are relatively non-specific, PPD skin testing is plagued by 
errors due to reader interpretation and by the need for return patient visits (Perkins, 
2000). Due to all the problems involving the TST other alternative tests have been 
pursued and are discussed below. 
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I.4.8.2 Interferon-gamma (IFN-γ) detection assays  
 
Individuals infected with M. tuberculosis complex strains have lymphocytes in their 
blood that recognize mycobacterial antigens. This recognition process involves the 
production of interferon-gamma (IFN-γ), a specific cytokine for cell mediated immune 
response (Smith et al., 2002). The QuantiFERON®-TB test (QFT) (Cellestis Limited, 
Carnegie, Victoria, Australia) was developed to measure the IFN-γ produced by T 
lymphocytes in whole blood after stimulation with PPD (Cellestis, 2005). This test was 
approved in 2001, by the US FDA, as an aid for diagnosing latent TB infection. This 
test is no longer commercially available (CDC, 2005a). Tests using the same 
methodology that the one employed for PPD hypersensitivity are problematic, since that 
tuberculin reactivity is such an imperfect marker, as already seen with the TST (Perkins, 
2000). In 2005, the US FDA approved a new test: the QuantiFERON®-TB Gold Test 
(QFT-G, Cellestis Limited, Carnegie, Victoria, Australia). This test was developed to 
aid in the diagnosis of M. tuberculosis infection, whether latent or active. However, it 
does not distinguish between latent TB infection and active disease (CDC, 2005a). 
QFT-G was based on a new design for the replacement of the first-generation version of 
QFT tests. This enzyme-linked immunosorbent assay (ELISA) test detects the release of 
IFN-γ in fresh heparinized whole blood from sensitized persons. Whereas the TST and 
QFT measure the response to PPD, QFT-G measures the response to a mixture of 
synthetic peptides simulating two specific antigenic proteins that are present in M. 
tuberculosis: the early secretory antigenic target-6 (ESAT-6) and the culture filtrate 
protein-10 (CFP-10) (CDC, 2005a). ESAT-6 and CFP-10 are secreted by all M. 
tuberculosis and pathogenic M. bovis strains (Brodin et al., 2004). Because these 
proteins are absent from all BCG vaccine strains and from commonly encountered non-
tuberculous mycobacteria, except M. kansasii, M. szulgai, and M. marinum, QFT-G is 
expected to be more specific for M. tuberculosis than tests that use PPD as the antigen 
(CDC, 2005a). QFT-G results can be available in less than 24 hours after testing 
without the need for a second visit. As a laboratory-based assay, QFT-G is not subject 
to biases and errors of TST placement and reading. However, errors in collecting or 
transporting blood specimens or in running and interpreting the assay can decrease its 
accuracy (Cellestis, 2005). Each of the three tests (TST, QFT, and QFT-G) relies on a 
different immune response and differs in its relative measures of sensitivity and 
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specificity. The TST assesses in vivo DTH (Type IV), whereas QFT and QFT-G 
measure in vitro release of IFN-γ. QFT-G is not affected by prior BCG vaccination and 
is expected to be less influenced by previous infection with non-tuberculous 
mycobacteria. In the opposite, TST are variably affected by these factors. QFT-G does 
not trigger an anamnestic response (i.e., boosting) because it does not expose persons to 
antigen. Injection of PPD for the TST can boost subsequent TST responses, primarily in 
persons who have been infected with non-tuberculous mycobacteria or vaccinated with 
BCG. Compared with the TST, QFT-G might be less affected by boosting from a 
previous TST. QFT-G represents one type of IFN-γ release assay (CDC, 2005a). Other 
type is the enzyme-linked immunospot assay (ELISpot) that enumerates cells releasing 
IFN-γ after mononuclear cells recovered from whole blood are incubated with similar 
antigens. The commercially available ELISpot assay, T-SPOT.TB (Oxford Immunotec 
Ltd, Abingdon, UK) have been approved by the National Institute for Clinical 
Excellence (NICE) for diagnosis of latent TB infection and as adjunctive tests for the 
evaluation of patients with active TB (de Joncheere et al., 2006). The assay detects T 
cells specific for antigens in M. tuberculosis, which are absent from BCG and most 
environmental bacteria. It is therefore not confounded by prior BCG vaccination and is 
more specific than TST. ELISpot was found to have a sensitivity of 96% in HIV-
negative adults with culture confirmed active TB, and 92% in HIV-positive patients 
with pulmonary TB (Meyer et al., 2005). These attributes suggest that this test could 
improve and accelerate the diagnostic evaluation of patients with suspected TB. 
However, clinical data on the performance of this test in TB patients and how they will 
impact on clinical decision-making is limited. The most relevant target population is 
that in which the test will actually be used in practice: patients presenting with 
suspected TB whose diagnoses are unknown at the time of testing (Gooding et al., 
2007). Despite all the evidences there is still the need for more information about these 
tests and time will dictate if they are sensitive and contributing to the rapid detection of 
TB. Consideration of the role of new diagnostics should start with the recognition that 
more than one diagnostic test type is needed. 
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I.4.8.3 Antibody detection tests 
 
Despite all the research conducted on the humoral response to TB, serologic tests 
haven’t demonstrated sufficient performance to be implemented in the routine of a 
Mycobacteriology laboratory. The accomplished knowledge about the humoral response 
in the last few years has been threatened by the HIV epidemic and its impact on 
immunity. The existing tests use well-described antigens to detect immunoglobulin G 
(IgG) or other Ig classes, usually in an ELISA assay format (Abebe et al., 2007). 
However, the data available sustains that none of the commercial tests evaluated 
perform well enough to replace sputum smear microscopy. Thus, these tests have little 
or no role in the diagnosis of pulmonary TB. Lack of methodological rigor in these 
studies was identified as a concern. The co-infection with HIV makes most of these 
assays perform very poorly, detecting less than 1/3 of patients with active disease 
(Steingart et al., 2007). Promising research developments should include the availability 
of highly purified and recombinant antigens, improved understanding of the heterotypic 
nature of the humoral response to TB and the development of multi-antigen tests that 
maintain high specificity; novel M. tuberculosis proteins identified and characterized 
with the assistance of the newly available genome sequence; the characterization of a 
number of non-protein antigens, some of which appear promising in HIV-infected 
patients and the development of improved and simplified test formats, including those 
accepting whole-blood or non-invasively collected specimens (Abebe et al., 2007; 
Perkins, 2000). 
 
I.5 Antimycobacterial agents 
 
The overall goals for treatment of TB are to cure the patient and to minimize the 
transmission of M. tuberculosis to other persons. Thus, successful treatment of TB has 
benefits both for the individual as also to the community in which the patient resides 
(ATS, 1993, 2003). The emergence of strains of M. tuberculosis resistant to existing 
drugs has focused attention on the urgent need for development of new anti-
mycobacterial agents. Such agents have not been perceived as a high priority by 
pharmaceutical companies over the last thirty years and a coordinated effort to screen 
general antimicrobial compound developed during this time for activity against M. 
tuberculosis may well prove worthwhile. However, as long as spontaneous resistance by 
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mutation to new compounds results as a consequence of selection due to faulty therapy, 
etc., the problem will remain unless the mechanism of action of new drugs bypasses 
mutational events leading to resistance (Di Perri and Bonora, 2004). The recent 
development of genetic tools for monitoring the viability of M. tuberculosis provides a 
rapid approach for this type of screening. From a broader perspective, molecular genetic 
tools for study and manipulation of mycobacteria provide access to a vast amount of 
new information about the biochemistry and metabolism of M. tuberculosis, and 
exploitation of this information has important potential in the rational development of a 
new generation of anti-mycobacterial agents. To avoid disruption of normal microbial 
flora during the prolonged course of TB therapy and to limit possible transfer of 
resistance factors from other bacterial genera, it is preferable that new drug targets be 
specific for mycobacteria. Drugs must act on a target that is essential for bacterial 
survival, and ideally, they should be effective against bacteria throughout their growth 
cycle both inside and outside mammalian cells during infection. 
 
I.5.1 First-line and second-line anti-TB drugs 
 
Currently, there are 10 drugs approved by the US FDA for treating TB 
(http://www.fda.gov/). These include the first-line drugs, INH, RIF, Rifapentine, EMB, 
PZA and the second-line drugs, cycloserine, ethionamide, PAS, STR and capreomycin. 
In addition, the fluoroquinolones, although not approved by the FDA for TB, are used 
relatively commonly to treat TB caused by drug-resistant organisms or for patients who 
are intolerant to some of the first-line drugs. The same happens with amikacin and 
kanamycin (WHO, 2003). Of the approved drugs, INH, RIF, EMB and PZA are 
considered first-line anti-TB agents and form the core of initial treatment regimens (Di 
Perri and Bonora, 2004). Rifabutin and rifapentine may also be considered first-line 
agents under specific situations. STR was formerly considered to be a first-line agent 
and in some instances, is still used in initial treatment. However, an increasing 
prevalence of resistance to STR in many parts of the world has decreased its overall 
usefulness (ATS, 2003). The other drugs are reserved for special situations such as drug 
intolerance or resistance. INH is used for treatment of all forms of TB caused by 
organisms known or presumed to be susceptible to the drug. It has profound early 
bactericidal activity against rapidly dividing cells. RIF is used for treatment of all forms 
of TB and it has activity against organisms that are dividing rapidly (early bactericidal 
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activity) and against semi-dormant bacterial populations, thus accounting for its 
sterilizing activity (WHO, 2003). RIF is an essential component of all short-course 
regimens. Rifabutin is used as a substitute for RIF in the treatment of all forms of TB. 
The drug is generally reserved for patients who are receiving any medication having 
unacceptable interactions with RIF or have experienced intolerance to RIF. Rifapentine 
may be used once weekly with INH in the continuation phase of treatment for HIV-
seronegative patients with non-cavitary disease and/or drug susceptible pulmonary TB 
patients who have negative sputum smears at completion of the initial phase of the 
treatment. EMB is used to treat all forms of TB. It is included in the initial treatment 
regimens primarily to prevent emergence of RIF resistance when primary resistance to 
INH may be present. PZA is a nicotinamide analog prodrug which is converted into the 
active bactericidal form, pyrazinoic acid, by the bacterial enzyme pyrazinamidase. Its 
mode of action and mechanism of resistance is still not completely understood, since 
PZA does not appear to have a specific cellular target. Instead, exerts its bactericidal 
effect by disrupting the membrane energetic and acidification of the cytoplasm. 
However, its sterilizing activity against semi-dormant tubercle bacilli makes it one of 
the most important front line anti-TB drugs. And when used in combination with RIF 
and INH, it has a remarkable role in shortening the treatment duration from 9 months to 
6 months (Singh et al., 2006; Hu et al., 2006). Relatively to the second-line drugs, 
cycloserine is used to treat patients with drug-resistant TB caused by organisms with 
known or presumed susceptibility to the agent. Ethionamide is used for patients with 
drug-resistant TB disease caused by organisms that have demonstrated or presumed 
susceptibility to the drug (WHO, 2003). STR and EMB have been shown to be 
approximately equivalent when used in the initial phase of the treatment with 6-month 
regimens. However, among patients likely to have acquired M. tuberculosis in a high-
incidence country, the likely high rate of resistance to STR limits is usefulness (ATS, 
2003; WHO 2003). Amikacin and kanamycin are two closely-injectable second-line 
drugs that are used for patients with drug-resistant TB whose isolate has demonstrated 
or presumed susceptibility to the agents. There is nearly always complete cross-
resistance between the two drugs, but most STR-resistant strains are susceptible to both 
(WHO, 2006a). Because it is used to treat a number of other types of infections 
amikacin may be more easily obtained, and serum drug concentration measurements are 
easily available. Capreomycin is a second-line injectable drug that is used for patients 
with drug-resistant TB caused by organisms that have known or presumed susceptibility 
Chapter I 
 44 
to the drug. PAS is an oral agent used in the treatment of drug-resistant TB caused by 
organisms that are susceptible to the drug. Of the fluoroquinolones, levofloxacin, 
moxifloxacin, and gatifloxacin are the most active against M. tuberculosis. On the basis 
of cumulative experience suggesting a good safety profile with long-term use of 
levofloxacin, this drug is the preferred oral agent for treating drug-resistant TB caused 
by organisms known or presumed to be sensitive to this class of drugs, or when first-
line agents cannot be used because of intolerance. Cross-resistance has been 
demonstrated among ciprofloxacin, ofloxacin, and levofloxacin and presumably is a 
class effect. Fluoroquinolones should not be considered first-line agents for the 
treatment of drug-susceptible TB except in patients who are intolerant to first-line drugs 
(ATS, 2003). 
 
I.5.2. Phenothiazines  
 
The antimicrobial activity of phenothiazines has been known for over a century. At the 
end of the 19th century, Paul Ehrlich described the properties of methylene blue 
(Kristiansen and Amaral, 1997). This tricyclic compound would later become the 
nucleus of a group of derived compounds that constitute the phenothiazines (Figure 6). 
The application of this dye at dilute concentrations was described by Ehrlich to render 
motile bacteria and protozoa immobile as well as inhibit the in vitro growth of some 
Gram-positive bacteria (Kristiansen and Amaral, 1997). The antimicrobial properties of 
this dye were not immediately exploited because of Ehrlich's formula for the treatment 
of syphilis and the use of sulphur-containing compounds for the management of 
bacterial infections. But interest in the antimicrobial properties of methylene blue 
remained and the compound was used to manage urinary tract infections and parasitic 
infections of sheep (De Eds et al., 1939). However, the antimicrobial properties were 
overshadowed by its neuroleptic properties after the demonstration that the dye caused 
cats to become lethargic (McMahon and Kadowitz, 1992). The effects that methylene 
blue presented on the central nervous system stimulated a large number of studies. 
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Figure 6. Molecular structures of phenothiazines (adapted from 
http://apropos.mcw.edu/kegg_pathways/show/267, consulted in January, 2008). 
 
In 1952, Charpentier et al. associated to the French pharmaceutical company Rhone-
Poulenc, developed the first antipsychotic drug obtained from a phenothiazine-derived 
methylene blue, chlorpromazine (CPZ). The availability of CPZ in 1957 resulted in its 
widespread use for the therapy of psychoses and severe neuroses. Its use in patients 
presenting a variety of infections was confirmed by numerous studies, sporadically 
reported on literature. Simultaneously, the number of antimicrobial agents grew almost 
exponentially. Soon became clear that CPZ had antibacterial properties, including 
activity against M. tuberculosis (Bourdon, 1961; Levaditi et al., 1951; Molnar et al., 
1977). However, that time was the “Golden Age of Antibiotics” and other effective anti-
TB compounds such as STR and INH were available (Amaral and Kristiansen, 2000). 
The extensive use of antibiotics however made the problem of resistance to emerge 
(Amaral et al., 2001b). The number of cases was so significantly increased that for 
many bacterial infections treatment became problematic (Amaral et al., 2006; Nielsen 
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and Black, 1999; Viveiros and Amaral, 2001). The pharmaceutical companies initially 
responded by making available new antibiotics. However, this was a short-time solution 
since that soon it started to appear strains resistant to these newly introduced antibiotics. 
The failure of conventional anti-tubercular therapy experienced early in the 1990s 
contributed to the search for new anti-tubercular drugs. This search however, didn’t 
result in new effective compounds. Because the problem of MDR-TB primarily took 
place in countries that were economically disadvantaged (Loddenkemper et al., 2002; 
Raviglione et al., 1993) the required incentive was not present for the creation of new 
and effective compounds, given the high cost of drug development and the poor market 
conditions present in the affected countries. This brought attention to new compounds 
that could be used to manage these infections and phenothiazines were again the subject 
of interest.  
 
I.5.2.1 Antimicrobial activity 
 
Phenothiazines were shown to be active against a wide range of microorganisms such 
as: Gram-negative, Gram-positive bacteria (Kristiansen and Mortensen, 1987) and 
mycobacteria regardless of their antibiotic susceptibility status (Amaral et al., 1996; 
Crowle et al., 1992; Gadre and Talwar, 1999; Kristiansen and Vergmann, 1986; Molnár 
et al., 1977). A wide gamut of parasitic organisms such as amoeba (Josefsson et al., 
1975; Ockert, 1984; Schuster and Mandel, 1984; Schuster and Visvesvara, 1998), 
plasmodia (Chen and Hu, 1993; Kristiansen and Jepsen, 1985; Miki et al., 1992; Oduola 
et al., 1998; Ohnishi et al., 1989; Satayavivad et al., 1987; Tanabe et al., 1989), 
Leishmania (Banerjee et al., 1999; Benaim and Romero, 1990; Berman and Gallalee, 
1985; Berman and Lee, 1983; Chan et al., 1998), chlamydamona (Detmers and 
Condeelis, 1986; Hirschberg and Hutchinson, 1980; Schuring et al., 1990), trichinella 
(Stewart et al., 1985), trypanosomes (Chan et al., 1998; Chang and Pechère, 1989; 
Loiseau et al., 1996; Paglini-Oliva et al., 1998), toxoplasma (Pezzella et al., 1997) and 
many other parasites was also reported. It has also been shown that phenothiazines 
reduce the adherence of Gram-negative bacteria to epithelial cells (Molnar et al., 1983, 
1987). The phenothiazine promethazine prevents the recurrence of pylonephritis caused 
by Escherichia coli in pediatric patients (Molnar et al., 1990). Because the 
concentration of this phenothiazine required to inhibit the growth of bacteria is well 
beyond that clinically relevant, the success of the therapy is probably due to the effect of 
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promethazine on the adherence of E. coli to the epithelium of the urinary bladder. The 
in vitro as well as ex vivo antibacterial activities of phenothiazines most probably 
account for cures of bacterial infections treated with phenothiazines. Mice infected with 
Salmonella enterica serovar Typhimurium can be cured with trifluoperazine (Jeyaseeli 
et al., 2006; Mazumder et al., 2001) or fluphenazine (Dastidar et al., 1995), by a 
combination of trimethoprim and trimeprazine (Guha et al., 2000). It has been shown by 
Komatsu et al. that pre-treatment with 10-[n-(phthalimido)alkyl]-2-substituted-10H-
phenothiazines or 1-(2-chloroethyl)-3-(2-substituted-10H-phenothiazines-10-yl)alkyl-1-
ureas protected the animals from lethal infection of E. coli to various extents (Komatsu 
et al., 1997) and mice infected with mycobacteria could be cured with methdilazine 
(Chakrabarty et al., 1993). It was also demonstrated that when exposed to light, 
phenothiazines yield a variety of derivatives that have greater activity against bacterial 
infectious agents than the parent molecule (Wainwright, 1998; Wainwright et al., 1998).  
 
I.5.2.2 Mode of action in prokaryotic and eukaryotic cells 
 
 Until the present date the mechanism by which phenothiazines exert their antimicrobial 
activity is not completely understood. However, some studies show that phenothiazines 
inhibit bacterial growth by inhibiting calcium transport or by interfering with the influx 
and efflux of potassium into bacterial cells (Kristiansen et al., 1982; Molnar et al., 
1992a, 1997; Ren et al., 1993; Sinha and Dick, 2004). Phenothiazines may also increase 
the permeability of the cell wall envelope (Amaral and Kristiansen, 2000; Amaral and 
Lorian, 1991; Amaral et al., 1992; Chattopadhyay et al., 1998) and interfere with DNA 
synthesis/transcription by intercalating with DNA (de Mol and Busker, 1984; Guth et 
al., 1964; Hagmar et al., 1992; Izbirak, 1989; Kelder et al., 1991; Kochevar et al., 1998; 
Lalwani et al., 1995). Although this may be the case for microorganisms that do not 
have a cell wall, it is doubtful that these molecules can reach beyond the cell envelope 
of the affected cells. In bacteria, the morphological responses of phenothiazine-affected 
cells are remarkably similar to those produced when such bacteria are exposed to 
concentrations of β-lactams below their minimum inhibitory concentration (MIC). This 
suggests that they inhibit one or more of the penicillin-binding proteins of the plasma 
membrane of the bacteria (Amaral and Lorian, 1991; Kristiansen and Amaral, 1997). In 
mycobacteria, it was proposed that the mechanism by which phenothiazines exert their 
anti-tubercular activity is by inhibiting the activity of Type-II nicotinamide adenine 
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dinucleotide (reduced form) (NADH)-menaquinone oxidoreductase, which is an 
essential respiratory enzyme of M. tuberculosis (Yano et al., 2006). Although the 
majority of the studies reported have been primarily in vitro, there are a number of 
reports describing the antimicrobial activity of phenothiazines in humans and animals. It 
is documented that phenothiazines and their derivatives bind to calmodulin (CaM), the 
Ca2+-binding protein, to prevent the influx of Ca2+ into eukaryotic cells (Hidaka and 
Naito, 1998; Ishikawa and Hidaka, 1993; Motohashi, 1991; Roufogalis et al., 1983). 
Soon after CPZ was widely used, psychotic patients presenting with cavitary infections 
of M. tuberculosis were cleared of this infection (Kaminska, 1967). The phenothiazine 
methdilazine was also shown to cure mice of experimental infections of TB 
(Chakrabarty et al., 1993).  
 
I.5.2.3 Secondary side-effects 
 
The resistance to clinical use of phenothiazines is mainly due to the side-effects 
associated with the long-term use of some earlier phenothiazines, such as CPZ. Severe 
side-effects such as hepatotoxicity and cardiac dysrhythmia do occur in some patients 
(Chitturi and George, 2002; Moore, 2002). Because the chronic administration of CPZ 
is known to produce a wide range of mild-to-severe side-effects, the use of this 
compound for the therapy of TB was not seriously considered (Amaral et al., 2007c). 
Long-term use of CPZ inhibits the in vitro phagocytosis of infectious agents (Elferink, 
1979) by preventing Ca2+ transport (Kodovanti et al., 1990). The toxicity associated 
with CPZ further discouraged its use for antimicrobial purposes (Kaplowitz et al., 1986; 
Kodovanti et al., 1990). However, toxic side-effects occur infrequently with new 
phenothiazine neuroleptics. Thioridazine (TZ), a specific derivative of CPZ that is 
milder and less toxic, is also used for the treatment of psychosis. In fact, the major side 
effect is somnia although it is now known to produce Torsades de Pointes (Vieweg and 
Wood, 2004), albeit, at a very low frequency (1 sudden death over 10,000) man years of 
use (Glassman and Bigger, 2001).  
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I.5.2.4 The use of phenothiazines to treat intracellular infections 
 
TZ has in vitro antimycobacterial properties, being as effective as CPZ against all 
encountered clinical strains of M. tuberculosis regardless of their antibiotic 
susceptibility status (Amaral et al., 1996). Nevertheless, the concentrations required for 
in vitro inhibition of mycobacterial growth are well beyond those achievable in the 
patient (Amaral et al., 2007c). In vitro activity of these compounds takes place at 
concentrations higher than 1 mg/L (Amaral et al., 1996; Courmont and Derries, 1951; 
Crowle et al., 1992). However, because phenothiazines are concentrated by tissues and 
organs containing large populations of macrophages (Daniel and Wojcikowski, 1999a, 
b, 1997b; Daniel et al., 2001), Crowle et al. demonstrated that physiological 
concentrations of CPZ present in the medium could enhance the killing of phagocytosed 
M. tuberculosis (Crowle et al., 1992). Macrophages that have phagocytosed M. 
tuberculosis can concentrate phenothiazines more than 10-fold (Daniel and 
Wojcikowski, 1999a, 1999b). Thus, clinically acceptable dosing of a TB patient might 
result in an inhibitory effect in situ at the intracellular level similar to that observed in 
vitro (Viveiros and Amaral, 2001). This is of great importance because a TB infection is 
essentially an intracellular infection of the macrophage. As the effective in vivo 
concentration against M. tuberculosis is the result of the drug being concentrated by the 
macrophage, levels of the drug employed for the management of TB would be much 
lower than those clinically employed for the management of psychosis, and hence no 
significant toxicity would be anticipated. Other problem that should be considered is the 
development of resistance by the bacterial strains. Because CPZ and TZ lack specificity 
and thus affect a large number of targets lethal to M. tuberculosis (Gadre et al., 1998; 
Ratnakar and Murthy, 1993; Ratnakar et al., 1995; Salih et al., 1991), the problem of 
resistance to these compounds may be quite small. By this manner, TZ might be useful 
as an adjuvant to current regimens used for the management of freshly diagnosed TB as 
its in vitro activity is equal to that of CPZ against M. tuberculosis (Viveiros and Amaral, 
2001). Although TZ may serve a useful anti-tubercular function, its use should be 
limited to specific situations that limit the effectiveness of current front-line anti-
tubercular drugs. For example, if a patient is newly diagnosed with a recent TB 
infection, and hence cavitary disease would be nominal or moderate and if the patient is 
most likely to be infected with a strain of M. tuberculosis that is MDR, and if antibiotic 
susceptibility data is not forthcoming within 3 or 4 weeks, then the use of this 
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compound is justifiable. However, although the case for the use of TZ is quite strong, 
and in light of the fact that it may cause no harm, it must not be used indiscriminately. 
Studies to provide a definition of the compound and recommendations for its use in 
human patients are urgently needed. Alternative strategies such as TZ derivatives should 
be considered. Often the chemical manipulation of the parent phenothiazine yields a 
molecule that is more active than the parent compound (Csiszar and Molnar, 1992; 
Molnar et al., 1991). This could constitute a good approach to obtain more efficient 
compounds that lack the problems initially stated for the parent molecule.  
 
I.5.3 Other inhibitors of efflux pumps  
 
Mycobacteria display marked intrinsic resistance to a variety of antimicrobial agents 
(Piddock, 2006). This property is caused by their unique cell wall structure, since the 
mycobacterial cell wall functions as an efficient protective barrier and limits the access 
of drugs to their cellular targets (Nikaido, 1994; 1998; Piddock, 2006; Poole, 2007). 
However, the cell wall barrier alone is not sufficient to explain the intrinsic drug 
resistance of these bacteria. Drug efflux is also known to contribute to intrinsic or 
acquired resistance (Li and Nikaido, 2004; Li et al., 2004; Nikaido and Zgurskaya, 
1999; Piddock, 2006; Poole, 2005). In this manner, assessment of efflux pumps of a 
clinical isolate has been for the last few years the subject of intense research. The main 
goal has been the discovery and/or creation of new agents which have the capacity to 
inhibit MDR efflux pumps and hence, render the organism susceptible to the antibiotics 
to which it was once resistant (Lomovskaya and Bostian, 2006; Zgurskaya and Nikaido, 
2000). Given the significance of multi-drug efflux mechanisms, as regards antimicrobial 
resistance in important human pathogens, such as M. tuberculosis, there is a need to 
search for new and active efflux pump inhibitors (EPIs).  
 
EPIs isolated from plant extracts are one important source of compounds with 
antimycobacterial activity (Marquez, 2005). One of these examples is reserpine. This 
indole alkaloid was first isolated in 1952 from the dried root of Rauwolfia serpentine 
(Ruyter et al., 1991), which had been used for centuries in India for the treatment of 
insanity, as well as fever and snakebites (Mashour et al., 1998). Due to its antipsychotic 
and antihypertensive properties, reserpine has also been used for the control of high 
blood pressure. However, because of the development of better drugs for these purposes 
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and due to its toxicity, it is rarely used today (Michalet et al., 2007). The 
antihypertensive properties are a result of its ability to deplete catecholamines from 
peripheral sympathetic nerve endings. It almost irreversibly blocks the uptake and 
storage of norepinephrine, serotonin, and dopamine, normally involved in controlling 
heart rate, force of cardiac contraction and peripheral resistance (Buu, 1989; Verheij and 
Cools, 2007). When used as an EPI, reserpine potentiates the activity of 
fluoroquinolones on MDR Gram-positive bacteria and of tetracycline (TET) on MRSA 
strains (Piddock, 2006). It also decreases the emergence of MDR S. aureus and S. 
pneumoniae strains in vitro (Marquez, 2005). Unfortunately, it cannot be used in 
combination with antibiotics for the treatment of staphylococcal infections, since the 
concentrations required for the treatment are neurotoxic (Michalet et al., 2007). Other 
important feature is the known inhibition of the P-glycoprotein (Piddock, 2006).  
 
Members of the plant family Aizoaceae, considered as one of southern Africa’s most 
diverse and abundant plant families but also the least studied in terms of its medicinal 
potential (van der Watt and Pretorius, 2001) also contain alkaloids known to have 
narcotic-anxiolytic properties and strong synergism with psychomimetics (Smith MT et 
al., 1996). These properties are consistent with those presented by other neuro-active 
compounds whose activities reside primarily at the level of the plasma membrane 
(Williams JT et al., 2001). Although some of these alkaloids have been reported to have 
anticancer properties as well (Smith et al., 1996), they have received little attention, 
perhaps due to their reported toxicity. One such member of the Aizoaceae family is 
Carpobrotus edulis a plant that besides been found in southern Africa (van der Watt and 
Pretorius, 2001) is also found along the coast of Portugal and that is so prolific that it is 
considered a nuisance (Ordway et al., 2003a). Due to the antimicrobial activity of this 
family, C. edulis has also become the subject of research for antimicrobial activity 
(Ordway et al., 2003a; van der Watt and Pretorius, 2001).  
 
Other compound usually found in the ripe seeds of the African plants Strophanthus 
gratus and Acokanthera ouabaio, is ouabain. It is used worldwide extensively for in 
vitro studies to block the Na+ pump (Na+/K+-ATPase) (Clausen, 2003). The blockage of 
this pump is associated with high concentrations of the compound that are attainable in 
vitro. In the opposite, low concentrations stimulate the Na+/K+-ATPase (Gao et al., 
2004). Interestingly, this compound was also identified in the human, as an endogenous 
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hormone (Schoner and Scheiner-Bobis, 2005), being probably an isomer of the ouabain 
found in plants (Gao et al., 2004). In the human, it is synthesized in the adrenal gland 
and in the hypothalamus, being augmented in conditions of oxygen deficiency. 
However, its exact mode of action and physiological significance is not yet determined 
(Schoner and Scheiner-Bobis, 2007). In France and Germany, ouabain has a long 
history in the treatment of heart failure, and some continue to advocate its use in angina 
pectoris and myocardial infarction (Gao et al., 2004).  
 
Some phenols, present in green tea extracts, also possess numerous biological activities, 
including antimicrobial activity (Bandyopadhyay et al., 2005; Marquez, 2005), reversal 
of methicillin resistance in MRSA strains (Michalet et al., 2007) or inhibition of P-
glycoprotein (Marquez, 2005; Michalet et al., 2007). Natural products isolated from 
Berberis plants have also been identified as inhibitors of bacterial efflux pump 
(Michalet et al., 2007). Interestingly, they potentiate the antibacterial activity of 
berberine, an alkaloid produced by the same plant, suggesting that plants may have 
evolved to produce weak antibacterial compounds associated with EPIs, to enhance 
their activity (Marquez, 2005; Michalet et al., 2007).  
 
The calcium channel antagonist, verapamil, is a voltage-dependent Ca2+ channel blocker 
that inhibits several bacterial efflux pumps (Marquez, 2005). It has been used in the 
treatment of hypertension, angina pectoris, cardiac arrhythmia, headaches, being also 
used as a vasodilator during cryopreservation of blood vessels (Yedinak, 1993). It was 
approved by the FDA as an antiarrhythmic, being very effective in controlling the 
ventricular rate (Grossman and Messerli. 2004). Calcium channels are present in the 
smooth muscle that lines blood vessels. By relaxing the tone of this smooth muscle, 
Ca2+-channel blockers dilate these vessels what has led to their use in treating 
hypertension and angina pectoris (Yedinak, 1993). Verapamil is also used as an 
inhibitor of drug efflux pump proteins, such as P-glycoprotein. This is useful as many 
tumour cell lines over-express drug efflux pumps, limiting the effectiveness of cytotoxic 
drugs (Nobili et al., 2006).  
 
Disiloxanes are synthetic resistance modifiers that inhibit MDR efflux pumps in various 
cancer cell lines, as well as reverting MDR of E. coli strains. Among these, SILA 
compounds, showed a remarkable anti-proliferative effect and markedly inhibited the P-
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glycoprotein-mediated efflux mechanism in vitro (Zalatnai and Molnár, 2006). Due to 
the activity of these compounds on the inhibition of Ca2+ and K+ flux, they could 
constitute a good basis for the synthesis of new agents. These new agents could be 
important in the activation of infected macrophages and the subsequent destruction of 
the internalized bacteria. 
 
I.5.4 Limitations of drugs 
 
The last effective anti-TB drug was RIF and this drug came into use in the early 1960’s. 
Since TB has remained a serious medical problem in Africa, South-East Asia and South 
America (WHO, 2005) the need for new anti-TB drugs became more and more 
prominent. Although each year hundreds of compounds are reported that have activity 
against TB, with few exceptions, activities are restricted to in vitro. Other aspect is that 
the infection is most frequent in countries that are economically disadvantaged (Amaral 
et al., 2004) posing a problem in terms of monetary incentive. However, the resurgence 
of TB in Western urban centres, and more importantly, the appearance and escalation of 
MDR-TB and XDR-TB worldwide has caused sufficient concern. This was the basis for 
the development of several international programs, to make funds available for the 
development of new anti-TB drugs (TB Alliance, 2006). These programs may in time 
alleviate the problem but we must consider that creating effective anti-TB drugs is far 
more difficult than that for the therapy of other bacterial infections. To obtain an 
effective anti-TB drug two important criteria must be satisfied: i) it must penetrate the 
cell housing the trapped mycobacterium, and ii) it must be active at the intracellular 
level, when non-toxic concentrations of the drug are administered to the patient. This 
poses several problems, since that although thousands of compounds can inhibit the 
replication of mycobacteria in vitro, very few are effective at the intracellular site. All of 
these questions should contribute to a novel approach in drug design. Perhaps it would 
be wiser to develop drugs that enhance the killing activity of the phagocytic cells 
instead of the traditional approach that has been implemented. This new strategy is also 
important since that if we create drugs that act in the phagocytic cell instead of acting in 
the bacteria itself then, the problem of resistance, as is the case for conventional 
antibiotics, could be prevented.                 
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I.6 Immunology of TB 
 
I.6.1 Mycobacterial interaction with the macrophage 
 
One of the most known associations in TB is the relationship established between the 
macrophage and M. tuberculosis. These mycobacteria exhibit specific cellular tropism 
for mononuclear phagocytes, i.e., macrophages, monocytes and dendritic cells (Kusner, 
2005).  However, the success of this infection is due to the ability of M. tuberculosis to 
persist inside the host cells, namely the macrophages (Mueller and Pieters, 2006; Zhang, 
2005). The alveolar macrophage is a phagocytic cell that as compared to neutrophils 
presents little killing activity of its own (Ordway et al., 2003b). This ability to survive 
and replicate in its hostile environment as well as the route of entry of M. tuberculosis 
into the alveolar macrophage constitute key components of the pathogenesis of TB 
(DesJardin et al., 2002; Fenton, 1998; Gomes et al., 1999; Schlesinger, 1996). During 
primary infection with the mycobacteria, aerosol-droplet nuclei containing small 
numbers of M. tuberculosis are deposited in the lungs alveoli and subsequently 
phagocytosed by the alveolar macrophages. Once in the alveoli environment M. 
tuberculosis can enter the macrophage by binding to a different number of receptors.  
 
I.6.1.1 Macrophage receptors for M. tuberculosis 
 
M. tuberculosis can infect macrophages via receptor mediated phagocytosis, a process 
that involves complement receptors (CR) (CR1, CR3 and CR4) (Vergne et al., 2004). 
The mechanism and consequences may be determined by features of the individual 
bacterial strain (complement dependent or independent), the environment of the 
macrophage (such as the availability of complement proteins), and the state of 
differentiation or activation of the macrophage (Ernst, 1998). Human monocyte-derived 
macrophages are also able to internalize virulent M. tuberculosis by binding of the 
ligand of M. tuberculosis, lipoarabinomannan (LAM) to the mannose receptors of the 
macrophages (Kang et al., 2005; Shimada et al., 2006). The expression of these 
receptors is down regulated by IFN-γ (Ernst, 1998); therefore, their role in ingestion of 
M. tuberculosis early in infection or in individuals with compromised cellular immunity 
may be more important than in established granulomas. The mannose receptors can also 
mediate the delivery of LAM to endocytic compartments that contain CD1b, thereby 
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facilitating presentation of mycolic acid and lipoglycan antigens to T cells (Prigozy et 
al., 1997). Other receptors involved in the phagocytosis process are the scavenger 
receptors. These receptors bind polyanionic macromolecules and particles, including 
lipopolysaccharides (LPS) of Gram-negative bacteria and lipoteichoic acid of Gram-
positive bacteria (Ernst, 1998; Hirsch et al., 1994; Schlesinger, 1993; Stokes et al., 
1993; Zimmerli et al., 1996). Some infected individuals have circulating antibodies to 
M. tuberculosis (Sousa et al., 2000) and one study has demonstrated that the 
intracellular trafficking of M. tuberculosis H37Rv opsonized with immune serum is 
distinct from that of non opsonized bacteria. The entry through Fcγ (Fragment, 
crystallisable) receptors (proteins found on the surface of certain cells, including 
macrophages) may have implications in distinct intracellular trafficking pathways for 
virulent M. tuberculosis. However, it does not affect the intracellular growth of the 
bacteria. Other route of entry into the macrophage is the direct binding of M. 
tuberculosis to the surfactant protein A (SP-A). This protein is the most abundant 
protein present in the surfactant monolayer of the lung, being a member of the collectin 
family of proteins, which includes serum mannose binding protein (MBP) and 
complement component C1q (Gold et al., 2004). This response is mediated through a 
direct interaction between SP-A and the macrophage (Beharka, 2002; Gaynor, 1995). It 
is suggested that SP-A can operate as an opsonin and modulate the activity of one or 
more receptors that are responsible for directly binding M. tuberculosis (Khubchandani 
and Snyder, 2001). A phosphatidylinositol glycan-linked membrane protein, CD14, is a 
high affinity receptor for LPS of Gram-negative bacteria. However, CD14 can also bind 
LAM of M. tuberculosis (H37Ra), and this binding induces macrophages to secrete 
interleukin-8 (IL-8) (Ernst, 1998). Toll-like receptors (TLRs) play a central role in 
activation of the cells of the innate immune system. They recognize conserved motifs in 
microorganisms, activating several signal cascades in order to destroy the internalized 
pathogens (Tjärnlund et al., 2006). Mycobacteria trigger different TLRs through 
different mycobacterial components. These components can activate cells through 
TLR1, TLR2, TLR4 and TLR6. TLR-activating compounds include mycobacterial 
lipoproteins that are thought to have an important role in the activation of immunity 
(Houben et al., 2006). LPS acts through TLR4, and the lipoprotein 19 kDa of M. 
tuberculosis act through TLR2. TLR2 is not only present on the surface of 
macrophages, but also within the phagosome. This suggests that chronic infection of 
macrophages could continuously down-regulate Major Histocompatibility Complex 
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(MHC) class II expression by stimulation of intraphagosomal TLR2 (Flynn and Chany, 
2003). A particulate target such as M. tuberculosis that displays numerous and diverse 
ligands on its surface are likely to engage several receptors of multiple types 
simultaneously. Therefore, in vivo, M. tuberculosis is probably not internalized by 
macrophages using a single receptor-mediated pathway.  
 
I.6.1.2 Mycobacterial phagosome 
 
One of the main reasons why M. tuberculosis is successful as a pathogen is because of 
its ability to persist in an immunocompetent host. This pathogenic mycobacterium does 
not avoid capture by macrophages or tolerate the lysosomal environment. Instead, it 
survives the bactericidal milieu of the macrophage by blocking fusion of their 
intracellular niche, the phagosome, with late endosomes and lysosomes (Nguyen and 
Pieters, 2005). After sealing of the plasma membrane, the phagosome undergoes a 
sequence of changes in its composition. These alterations are triggered by a series of 
membrane fusion and fission events (Griffiths, 2004; Hackam et al., 1997; Mueller and 
Pieters, 2006; Yates et al., 2005). Incomplete luminal acidification, absence of mature 
lysosomal hydrolases and aberrations in trafficking of plasma membrane markers are 
the most prominent characteristics on the M. tuberculosis phagosome (Anes et al., 2003; 
Chua et al., 2004). In fact, pathogenic mycobacteria employ eukaryotic-like signal 
transduction mechanisms to modulate the host cell trafficking pathways (De Chastellier 
and Thillo, 2006; Kuehnel et al., 2001; Warner and Mizrahi, 2007). The intracellular 
survival of M. tuberculosis is due to its ability to inhibit the fusion of the phagosome 
with lysosomes, avoid direct bactericidal mechanisms and block efficient antigen 
processing and presentation (Deretic et al., 2006).  
 
I.6.1.3 Modulation of the macrophage trafficking events by M. tuberculosis 
 
Hosts infected with M. tuberculosis mount a strong immune response. This response is 
usually sufficient to prevent progression to active disease. The strong immune response 
can control, but not eliminate the bacilli, indicating that M. tuberculosis has evolved 
mechanisms to modulate or avoid detection by the host immune response. Recent 
advances have improved our understanding of how M. tuberculosis evades two major 
antimicrobial mechanisms of macrophages: phagolysosome fusion and the production 
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of toxic reactive nitrogen intermediates (RNI). Once the bacteria are phagocytosed, the 
macrophage activates a cascade of cellular and biochemical processes in order to 
destroy the internalized bacteria. The most studied antimycobacterial mechanism of 
activated macrophages is the nitric oxide synthase 2 (NOS2)-dependent pathway, which 
generates toxic RNI (Flynn and Chany, 2003). However, M. tuberculosis has evolved 
various mechanisms to evade RNI toxicity. M. tuberculosis ahpC encodes the 
peroxiredoxin alkyl hydroperoxide reductase subunit C (AhpC) protein. This 
peroxiredoxin has the ability to catalytically catabolize peroxynitrite anion (ONOO-), a 
potent oxidant formed via the reaction between nitric oxide (NO) and superoxide anion 
(O2-), two products of activated macrophages. Other studies revealed that M. 
tuberculosis peptide methionine sulfoxide reductase catalyses the reduction of 
methionine sulfoxide (which is formed via the reaction of ONOO- and methionine 
residues of proteins). This might play a significant role in resistance against the toxic 
effect of this potent oxidant (Flynn and Chany, 2003). The pathogen-containing 
phagosomes undergo a series of fusion and fission events that modify the composition 
of their limiting membrane and of their contents. This process of phagosome maturation 
culminates in the formation of the phagolysosome (Vieira et al, 2002). Subsequently 
there will be acidification of the phagolysosome with the decrease in the internal pH of 
the cellular compartment, inducing the activation of hydrolases which in turn, afford the 
complete destruction of the bacterium (Anes et al., 2006; Jordao et al., 2008; Pillay et 
al., 2002; Vieira et al., 2002). However, in order to escape this killing process, 
mycobacteria have evolved strategies that control the ability of the macrophage to kill 
the bacterium. By this manner, to persist in the host, M. tuberculosis arrests the 
maturation of bacilli-containing phagosomes into phagolysosomes, thereby evading the 
antimicrobial effects of the lysosome. In addition, M. tuberculosis maintains an 
intraphagosomal environment that allows its persistence. It is thought that this is 
accomplished by the exclusion of vacuolar H+-ATPases (acquired from endosomes) 
from bacilli-containing phagosomes that by this manner avoid an acidic environment 
(Hestvik et al., 2005; Nishi and Forgac, 2002;). Studies on the molecular basis for the 
trafficking of intracellular vesicles have identified the soluble N-ethylmaleimide-
sensitive factor-attachment protein receptor (SNARE) proteins and the small 
Guanosine-5'-triphosphate (GTP)-binding protein of the Rab family capable of 
regulating membrane fusogenicity, involved in phagolysosomal biogenesis (Flynn and 
Chany, 2003). Mannosylated LAM from M. tuberculosis attenuates the activity of 
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hVPS34, a phosphatidylinositol 3(OH) kinase and inhibits the recruitment of early 
endosome autoantigen 1 (EEA1), a molecule that interacts with SNARE and is 
implicated in endosome–endosome fusion. Another means by which mycobacteria can 
affect phagosome maturation is through interaction with tryptophan aspartate rich coat 
protein (TACO). This molecule is specific for phagosomes containing live bacilli and 
the sequestration of the molecule by M. tuberculosis prevents the fusion with lysosomes 
(Flynn and Chany, 2003). Other mechanisms proposed for the intracellular survival of 
the mycobacteria are the production of high amounts of ammonia and the interference 
with presentation of MHC class II-restricted antigens (Flynn and Chany, 2003). 
 
I.6.1.4 Mycobacterial components modulation of the phagosome maturation  
 
Both host cell and mycobacterial lipids are known to modulate the intracellular fate of 
pathogenic mycobacteria. The lipid-rich cell wall of M. tuberculosis has been 
recognized as providing the bacilli with an effective innate immune defence against 
lysosomal degradation (Nguyen and Pieters, 2005). Mycobacteria produce copious 
amounts of complex lipids, which constitute approximately 60% of the cell wall 
(Vergne et al., 2004). Several classes of mycobacterial lipid products have been 
considered as potential modulator of membrane trafficking in the host cell. The acyl 
trehalose family includes the sulphatides and the cord factor. Sulfolipid plays a very 
little if any, role in mycobacterial survival in macrophages. However, a characteristic 
product of M. tuberculosis, called cord factor, which is chemically a trehalose 
dimycolate has been reported to inhibit Ca2+-induced fusion between liposomes in vitro, 
although its mechanism of action is not known. Another mycobacterial lipid family is 
represented by the phosphatidylinositol derivatives that include phosphatidylinositol 
mannoside (PIM) and LAM. The cell wall gycolipid LAM, activates the host tyrosine 
phosphatase, SHP-1, in human monocytic cells. Stimulation of SHP-1 is coupled to 
inhibition of mitogen-activated protein (MAP) kinases and may be linked to other 
inhibitory functions of LAM, including reductions in levels of tumour necrosis factor-
alpha (TNF-α), IL-12, and MHC class II molecules (Kusner, 2005; Roach et al., 2005). 
LAM inhibits the recruitment of EEA1 to the phagosome and subsequently its 
maturation. The mycobacterial Phosphatidylinositol 3-phosphate (PI3P) analog, 
glycosylated phosphatidylinositol LAM (ManLAM) probably blocks the PI 3-kinase 
dependent pathway involved in the transport of cargo between the trans-Golgi network 
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and the phagosome, a transport step required for phagolysosome biogenesis (Kusner, 
2005; Mueller and Pieters, 2006; Nguyen and Pieters, 2005). ManLAM also inhibits the 
recruitment of EEA1 to phagosomes by inhibiting a cytosolic Ca2+ rise. This inhibitory 
effect of LAM on membrane fusion raises the question of how mycobacteria maintain 
interactions with early endosomes. Since this pathway is postulated to deliver 
transferrin loaded with iron, an essential nutrient to the mycobacteria that is located in 
the phagosomes, there must be an alternative pathway for the iron acquisition. It has 
been reported that PIM specifically stimulates early endosomal fusion in an adenosine 
triphosphate (ATP) and cytosol dependent manner. The PIM stimulated fusion shows an 
absolute requirement for Rabs proteins. These are small GTPases that play an important 
role in phagosome maturation process by recruiting and facilitating fusion events 
between early and late organelles of the endocytic pathway. Fusion with early 
endosomes is required for mycobacterial retention in early phagosomal compartments 
and an inadequate supply of iron is one factor in mycobacterium’s inability to prevent 
the normal maturation process in macrophages expressing inactive Rab5 (Hestvik et al., 
2005). The stimulator effect of PIM is insensitive to PI3K inhibition. Thus, PIM does 
not simply counteract LAM, but it compensates for LAM inhibition of PI3K-dependent 
trafficking pathways by generating a bypass membrane fusion neo-pathway independent 
of PI3P generation (Vergne et al., 2004). Additionally, there are three mycobacterial 
proteins that have been shown to play an important role in the survival of intracellular 
bacteria: i) the secreted acid phosphatase of M. tuberculosis, SapM; ii) the isocitrate 
lyase (ICL) and iii) protein kinase G (PknG). SapM could be responsible for the 
depletion of PI3P at the mycobacteria phagosomes. ICL is upregulated following uptake 
of mycobacteria and catalyzes an essential reaction of the glyoxylate shunt pathway, 
which is mobilized when bacteria are grown in fatty acids as the limiting carbon source 
(Ehrt and Schnappinger, 2007; Mueller and Pieters, 2006). PknG is a mycobacterial 
virulence factor that is delivered into the cytosol of host cells and might interfere with 
the regulation of phagosome-lysosome transfer. In the absence of this enzyme 
pathogenic mycobacteria are readily delivered to lysosomes and degraded. This could 
be considered for the development of future drugs (Nguyen and Pieters, 2005).    
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I.6.2 The role of Ca2+ signalling in the macrophage  
 
Upon ingestion of complement or antibody opsonized organisms, macrophages respond 
with a significant increase in cytosolic Ca2+ (Kusner, 2005). This signal is necessary for 
subsequent events, including the respiratory burst that generates reactive oxygen species 
and the maturation of phagosomes to phagolysosomes. However, live, virulent M. 
tuberculosis infect human macrophages without triggering an increase in cytosolic Ca2+. 
This block in macrophage Ca2+ signalling requires mycobacterial viability since virulent 
M. tuberculosis that have been killed by heat treatment or gamma irradiation induce 
normal elevations in the level of cytosolic Ca2+ and their encompassing phagosomes 
mature to phagolysosomes (Kusner, 2005). Usually, the phagosome maturation is 
determined by acidification and acquisition of lysosomal protein markers (Pillay et al., 
2002). Cytosolic Ca2+ signalling has a causative role in the pathogenesis of TB. 
Addition of extracellular ATP results in the maturation of phagosomes to 
phagolysosomes and decreased viability of intracellular mycobacteria (Stober et al., 
2001). Characterization of the biochemical mechanisms responsible for this 
enhancement of macrophage immunity to M. tuberculosis revealed an absolute 
requirement for increases in the cytosolic Ca2+ triggered by stimulation of plasma 
membrane P2X7 receptors for ATP. Since this class of ATP receptors is largely 
restricted to macrophages and dendritic cells it may be possible to physiologically 
enhance the host immune response either alone or in conjunction with antibiotic therapy 
(Kusner, 2005). Killed M. tuberculosis triggers a complement receptor-dependent rise in 
cytosolic Ca2+ via activation of the macrophage enzyme, shingosine kinase. Through 
catalyzing the conversion of shingosine to the bioactive lipid, shingosine kinase 
functions to increase levels of cytosolic Ca2+ stimulating its release from the 
endoplasmic reticulum, where it is usually stored. This stimulation is accompanied by 
translocation of the enzyme from the cytosol to the region of the nascent phagosome. 
Live virulent M. tuberculosis inhibits macrophage shingosine kinase in human 
macrophages, ex vivo. This inhibition of shingosine kinase activity is accompanied by 
failure of the enzyme to be recruited to phagosomes containing live tubercle bacilli 
(Thompson et al., 2005). By this manner, sphingosine kinase could be considered as a 
novel molecular target of pathogenesis in TB, whose inhibition by live virulent M. 
tuberculosis results in evasion of Ca2+-dependent phagosomal maturation and 
bactericidal activity. Increases in the level of macrophage cytosolic Ca2+ during 
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phagocytosis of complement-opsonized particles, including killed M. tuberculosis, 
results in activation of the major Ca2+ effectors protein, CaM. This activated Ca2+-CaM 
complex translocates from the cytosol to the membrane of the nascent phagosome. CaM 
is a necessary component of Ca2+ dependent antimicrobial activity in human 
macrophages. The Ca2+-dependent increase in phagosomal CaM is coupled to localized 
activation of Ca2+-CaM-dependent protein kinase II (CaMKII) on the phagosome 
surface. Similar to blockade of CaM, specific inhibition of CaMKII activation results in 
decreased phagosome maturation. In fact, inhibition of either CaM or CaMKII blocks 
phagosome maturation despite physiologic or pharmacologic increases in cytosolic 
Ca2+, demonstrating that the CaM/CaMKII pathway is a major regulator of phagosome-
lysosome fusion. In the case of live M. tuberculosis, inhibition of macrophage Ca2+ 
signalling results in a lack of activation of cytosolic CaM and impairment of its 
recruitment to the phagosome membrane. In the absence of the activated Ca2+-CaM 
complex, there is a lack of conversion of CaMKII from its inactive, non phosphorylated 
state to the activated, phosphorylated form of the enzyme that is required for subsequent 
phagosome maturation. This implicate specific inhibition of a phagosome localized 
Ca2+-CaM-CaMKII signalling complex in the pathogenesis of TB leading to promotion 
of the intracellular survival of M. tuberculosis within human macrophages. The 
mechanism by which the Ca2+-CaM-CaMKII pathway regulates the maturation of 
phagosomes to phagolysosomes is by linking it to components of the phosphoinositide-
dependent signalling cascades. A phosphatidylinositol (PI)-specific PI 3-kinase, 
hVPS34, is recruited to the membrane of nascent phagosomes. This kinase catalyzes the 
production of the lipid second messenger, PI 3-phosphate, on the early endosomal and 
phagosomal membrane (Nguyen and Pieters, 2005). PI 3-phosphate is required for the 
recruitment of proteins, including EEA 1 that regulate fusion of phagosomes with 
vesicles of the endosomal-lysosomal pathway. Inhibitors of PI 3-kinase, which block 
the generation of phagosomal PI 3-phosphatase and the recruitment of EEA1, inhibit 
phagosome maturation. Normal functioning of the Ca2+-CaM-CaMKII pathway is 
required for the hVPS34/PI 3-P/EEA1 cascade since inhibitors of CaM or CaMKII 
cause loss of phagosomal PI 3-P and EEA1. The phagosomes containing the 
mycobacterial vaccine strain BCG, or latex beads coated with LAM from M. 
tuberculosis, do not accumulate EEA1. Since M. tuberculosis infection modulates the 
macrophage transcriptome, it can be hypothesized that mycobacterial-induced 
alterations in Ca2+-mediated signal transduction contribute to these effects on gene 
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regulation. A second physiologic process in which Ca2+ normally plays a major 
regulatory role, and which is modulated in infected macrophages by M. tuberculosis is 
apoptosis. Thus mycobacterial-induced deregulation of cytosolic Ca2+ signalling may 
contribute to the bacilli’s inhibition of macrophage apoptosis, which promotes the 
intracellular survival that is characteristic of M. tuberculosis-macrophage interactions. 
Finally, inhibition of host Ca2+ responses may impair macrophage anti-tuberculous 
mechanisms that operate synergistically with phagosomal maturation, including the 
generation of reactive oxygen and nitrogen intermediates (Kusner, 2005; Nguyen and 
Pieters, 2005). 
 
I.6.3 Cellular immune responses to M. tuberculosis 
 
The interaction of M. tuberculosis with the cells of the immune system is a complex 
process. However, the sequence of events that follows the infection is relatively well 
defined. It all starts with the inhalation of droplets containing the infectious bacilli. 
Once in the pulmonary milieu, alveolar macrophages ingest the bacilli and often destroy 
them. However, this destruction usually depends on two factors: the intrinsic 
microbicidal capacity of host phagocytes and the virulence factors of the ingested 
mycobacteria (van Crevel et al., 2002). If this process is not controlled, mycobacteria 
will replicate inside the alveolar macrophages. The subsequent spread of bacilli to 
regional lymph nodes in the lungs and presentation of antigens to the host immune 
system cells will occur. How this develops still remains understood, but it may involve 
the migration of macrophages containing M. tuberculosis across the alveoli to lymph 
nodes (Saunders and Cooper, 2000). This induces the attraction of blood monocytes and 
other inflammatory cells to the lung. These monocytes will differentiate into 
macrophages which again readily will ingest but not destroy the mycobacteria. In this 
stage, mycobacteria grow logarithmically and blood-derived macrophages accumulate, 
but little tissue damage occurs (van Crevel et al., 2002). In the majority of cases, the 
host develops a protective response to M. tuberculosis infection that involves 
containment of the tubercle bacilli by the formation of granulomas that contain 
aggregated and fused (giant cells), apoptotic, infected macrophages (Saunders and 
Cooper, 2000). Two to three weeks after infection, T-cell immunity develops, with 
antigen-specific T lymphocytes arriving and proliferating within the early lesions or 
tubercles. Posterior activation of macrophages to kill the intracellular mycobacteria will 
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occur and as a consequence of that the early logarithmic bacillary growth stops. Central 
solid necrosis in these primary lesions inhibits extracellular growth of mycobacteria. As 
a result, infection may become stationary or latent. In most cases the individual is 
asymptomatic and non-infectious. This latency often extends for the lifetime of the 
individual. In latent infections, mycobacteria could be in a dormant non-replicating 
state, actively replicating but killed off by the immune response or metabolically altered 
with limited or infrequent replicative cycles (Flynn and Chan, 2001). However, 
perturbations of the immune system such as infection with HIV, poor nutrition, 
treatment with corticosteroids, aging, stress, alcohol and drug abuse, increase the 
potential for reactivation of latent TB (Flynn and Chan, 2001; Russell, 2007). More 
mature-phase granulomas show marked neovascularization and develop an extensive 
fibrotic capsule that delineates the margin between macrophages, granulocytes, foamy 
macrophages and giant cells, and the lymphocytic infiltrate. In the last stage, the centre 
of the granuloma loses its vascular appearance and becomes necrotic. Disease may 
progress and haematogenous dissemination may take place after primary infection, as 
well as months or years afterwards, as defined as post-primary TB, under conditions of 
failing immune surveillance. In a progressive lesion, the necrosis precedes and probably 
facilitates caseation (Russell, 2007). Both host and mycobacterial factors contribute to 
caseation. Under intense cytokine and direct cell-cell activation, macrophages and 
epithelioid cells undergo necrosis and/or apoptosis to form this material (Saunders and 
Britton, 2007). Liquefied caseous foci provide excellent conditions for extracellular 
growth of M. tuberculosis. Cavity formation may lead to rupture of nearby bronchi, 
allowing the bacilli to spread through the airways to other parts of the lung and the 
outside environment.  
 
I.6.3.1 Experimental models of TB infection 
 
Animal infectious disease models are fundamental to provide insight into the 
pathogenesis of TB. The animal model allows the identification of active drugs, access 
the effectiveness of drug combinations, and demonstrate the prevention of the selection 
of resistant mutants as well as to define the duration of the treatments (Lounis et al., 
2003). Other important application is the analysis of the cytokine profile in 
inflammatory cell populations as well as the evaluation of antimicrobial agents 
relatively to their prophylactic or therapeutic efficiency. Testing of antimicrobials using 
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animal models is essential to establish the link between in vitro studies and clinical 
application. In experimental pulmonary infections, a variety of animal’s species can be 
used. Examples are: mice, rats, rabbits, guinea pigs, hamsters and ferrets (Bakker-
Wounderberg, 2003). The choice of animal species is an important determinant in the 
experimental studies conducted. Rabbits provide the closest facsimile of human TB in 
terms of tissue pathology and disease progression (Gomez and McKinney, 2004). 
However, this is not a model widely used probably due to its economic and logistical 
demanding. Other example, the guinea pigs, is important to mimic the acute disease that 
is obtained in TB, since these animals develop a granulomatous, extensive caseous 
necrosis or cavitation and death (Bakker-Wounderberg, 2003), processes that dot not 
occur in mice. However and despite all the advantages mentioned above, the most 
popular model, the inbred mouse, has a long history of research focused on the 
immunology and chemotherapy of infectious diseases (Gomez and McKinney, 2004). 
This intense research is due mainly to the cost of the animals that are relatively low, and 
their relatively easy maintenance. In addition, there is also a large knowledge available 
about mouse genetics and immunology. Reagents, such as antibodies, are also widely 
available (Bakker-Wounderberg, 2003). All of this has provided a large amount of 
information in terms of predicting mechanisms of immunity subsequently shown to be 
operative in humans (Orme, 2003). However, it should be highlighted that a good 
animal model of infection should mimic the infectious process that occurs in man. 
Sometimes this is not possible, since the primarily portal of entry of the infectious 
microorganisms are most of the times artificial and cannot be correlated with the 
infectious route that is observed in the human. Additionally, animals and humans differ 
substantially in many aspects such as the susceptibility to infectious agents, 
immunological status and antibiotic pharmacokinetics (Bakker-Wounderberg, 2003). 
Despite all the mentioned factors one of the major difference in the mouse model is a 
consequence of its size. The bronchial tree is far less complex in mice and there are 
marked differences in the vasculature. As example, mice do not present a second 
circulatory supply to bronchial associated lymphoid tissue. Also, the lymphatics are less 
complex with limited drainage into the alveolar regions (Orme, 2003). However, the 
mouse is a useful tool for understanding and revealing the bacterial factors that are 
essential in the infectious process and for probing the antigenic and cellular basis of a 
protective immune response (Russell, 2007). 
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I.6.4 Cytokines and chemokines in M. tuberculosis infection  
 
One of the major problems in the persistence of infection with TB is that once inside the 
macrophage M. tuberculosis is protected from the responses induced by the immune 
system. Nevertheless, in order to destroy the bacteria, the infected macrophage initiates 
a cascade of biochemical and cellular events all of which lead to the recruitment of 
other cells involved in cellular immunity. The initial event subsequent to the 
phagocytosis of bacteria by the macrophage is the release of cytokines. This cytokine 
network plays a crucial role in the inflammatory response and in the outcome of 
mycobacterial infections (Flynn and Chan, 2001). Some examples are IL-6 and IL-12 
that attract T helper (Th) lymphocytes to the site of infection. When arriving to the site 
of infection Th lymphocytes release cytokines, namely, IFN-γ, one of the most potent 
macrophage-activators. Although IFN-γ production alone is insufficient to control M. 
tuberculosis infection, it is required for the protective response to this pathogen. The 
main contributors to this non-specific production of IFN-γ are mainly natural killer 
(NK) and CD4+ and CD8+ T cells. Before adaptive T-cell immunity has fully 
developed, NK cells may be the main producers of IFN-γ, either in response to IL-12 
and IL-18 or directly by exposure to mycobacterial products. T cells expressing γδ T-
cell receptors (γδ T cells) and CD1-restricted T cells may also produce IFN-γ during 
early infection. γδ T cells may directly recognize small mycobacterial proteins and non-
protein ligands in the absence of antigen-presenting molecules (Flynn and Chan, 2001). 
CD1-restricted T cells do not react with mycobacterial protein antigens in the context of 
MHC class I or class II molecules. Instead, these cells react with mycobacterial lipid 
and glycolipid bound to CD1 on antigen-presenting cells. CD1-restricted T cells display 
cytotoxic activity and are able to produce IFN-γ (van Crevel et al., 2002). This 
mycobacterial antigen-specific IFN-γ production in vitro has lead to several attempts to 
use this cytokine as a surrogate marker of infection with M. tuberculosis (CDC, 2005a; 
Gooding et al., 2007). However, this cytokine may be unreliable as an immune correlate 
of protection, since some studies have demonstrated that M. tuberculosis can prevent 
macrophages from responding to IFN-γ. The infection of monocytes, macrophages and 
dendritic cells with M. tuberculosis or mycobacterial products also induces the 
production of TNF-α. This pro-inflammatory cytokine plays a key role in granuloma 
formation, induces macrophage activation, and has immunoregulatory properties 
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(Russell, 2007). The requirement for TNF-α to control an M. tuberculosis infection is 
complex maybe due to its role as a mediator of macrophage activation. TNF-α acts 
synergistically with IFN-γ to induce the production of NOS2 expression. However, 
systemic production of TNF-α may account for unwanted inflammatory effects like 
fever and wasting. Clinical deterioration early in treatment is associated with a selective 
increase of this cytokine in the plasma of the patients (Saunders and Britton, 2007). 
Other pro-inflammatory cytokine involved in the host response to M. tuberculosis is IL-
1β. In TB patients, it is expressed in excess and at the site of disease (van Crevel et al., 
2002). IL-6 is a cytokine that presents both pro- and anti-inflammatory properties. It is 
produced early during mycobacterial infection at the site of infection (Flynn and Chan, 
2001). However, its role may be controversial since that in mycobacterial infections it 
inhibits the production of TNF-α and IL-1β. One key player in host defence against M. 
tuberculosis is IL-12. IL-12 is produced following phagocytosis of M. tuberculosis by 
macrophages and dendritic cells inducing a Th1 response, with production of IFN-γ 
(Flynn and Chan, 2001). In TB patients, IL-12 has been detected in lung infiltrates, 
pleurisy, granulomas and in lymphadenitis. In humans suffering from recurrent non-
tuberculous mycobacterial infections, genetic mutations in the genes encoding IL-12p40 
and IL-12R have been identified. These patients display a reduced capacity to produce 
IFN-γ (Sahiratmadjaa et al., 2007). Apparently, IL-12 is a regulatory cytokine which 
connects the innate and adaptive host response to mycobacteria and which exerts its 
protective effects mainly through the induction of IFN-γ (van Crevel et al., 2002). In 
addition to IL-12, two cytokines are also important in the IFN-γ production. IL-18, a 
pro-inflammatory cytokine was initially discovered as an IFN-γ-inducing factor, 
synergistic with IL-12. It also stimulates the production of other pro-inflammatory 
cytokines, chemokines, and transcription factors (van Crevel et al., 2002). IL-15 is a 
pleiotropic pro-inflammatory cytokine primarily synthesized by monocytes and 
macrophages (Abebe et al., 2005). The pro-inflammatory response which is initiated by 
M. tuberculosis is antagonized by anti-inflammatory mechanisms. Soluble cytokine 
receptors prevent binding of cytokines to cellular receptors, thereby blocking further 
signalling. Three anti-inflammatory cytokines, IL-4, IL-10, and transforming growth 
factor beta (TGFβ), may inhibit the production or the effects of pro-inflammatory 
cytokines in TB. IL-10 is produced by macrophages after phagocytosis of M. 
tuberculosis and after binding of mycobacterial LAM. Release of IL-10 induces the 
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survival of M. tuberculosis in the host cells, down regulating a Th1 response (Majumder 
et al., 2006). By this manner, IL-10 antagonizes the pro-inflammatory cytokine 
response because it down regulates the production of IFN-γ, TNF-α, and IL-12. 
Mycobacterial products such as LAM induce production of TGFβ by monocytes and 
dendritic cells (Flynn and Chan, 2001). Like IL-10, TGFβ is produced in excess during 
TB and is expressed at the site of disease. In addition, TGFβ may be involved in tissue 
damage and fibrosis during TB, as it promotes the production and deposition of 
macrophage collagenases and collagen matrix (Flynn and Chan, 2001). TGFβ may also 
interact with IL-4 but in the presence of both cytokines, T cells may be directed to a 
protective Th1-type profile. The deleterious effects of IL-4 in TB have been attributed 
to this cytokine suppression of IFN-γ production and macrophage activation (van Crevel 
et al., 2002). In mice infected with M. tuberculosis, progressive disease and reactivation 
of latent infection are both associated with increased production of IL-4. Similarly, 
over-expression of IL-4 intensified tissue damage in experimental infection (Flynn and 
Chan, 2001). Chemokines are chemotactic cytokines responsible for the recruitment of 
inflammatory cells to the site of infection. Several studies have addressed the role of IL-
8, which attracts neutrophils, T lymphocytes, and possibly monocytes. In TB patients, 
IL-8 has been found in bronchoalveolar lavage fluid, lymph nodes, and plasma and high 
levels of this chemokine was found in patients who died from TB. M. tuberculosis 
preferentially induces production of monocyte chemoattractant protein 1 (MCP-1). In 
murine models, deficiency of MCP-1 inhibited granuloma formation. In murine models, 
expression of Regulated upon Activation, Normal T-cell Expressed, and Secreted 
(RANTES) (now called CCL5) was associated with development of M. bovis induced 
pulmonary granulomas. In human patients, RANTES has been detected in alveolar 
lavage fluid. Apart from IL-8, MCP-1, and RANTES, other chemokines may be 
involved in cell trafficking in TB (van Crevel et al., 2002). Inhibition of chemokine 
production may lead to an insufficient local tissue response. However, due to the 
complexity of the chemokine system, the contribution of individual chemokines is 
difficult to evaluate.  
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I.6.4.1 The immune system as the means for predicting who is to progress to active 
disease 
 
The vast majority of countries with high burdens of TB are poorer countries in which 
health care facilities lack biosafety containment and implementation of obligatory 
preventive therapy for TB infection. In these countries, health care workers are at risk 
for nosocomially acquiring TB due to the repeatedly exposition to aerosolized M. 
tuberculosis (Ordway et al., 2005b; Raviglione et al., 1993). Because TB can readily 
result from the inhalation of few bacilli (Bloom and Murray, 1992) these health care 
workers besides being at proven risk (ATS, 2000), constitute sources for new infections 
in the community and within the hospital settings. Due to factors such as the: i) repeated 
exposure to M. tuberculosis, that most probably will result in a large number of TB 
infections; ii) progression of these infections to active TB disease; and iii) increased 
numbers of TB cases on open hospital wards and minimal or absent TB infection 
control, these individuals constitute a good group to study the development and 
progression of TB and its relationship to a variety of markers of immunity involved in 
the infectious process. The vast majority of studies that evaluate the immune responses 
in TB disease are derived from clinically diagnosed patients with active TB (Ordway et 
al., 2004). Therefore, immune responses associated with initial inhalation of tubercle 
bacilli, development and progression of disease are largely unknown. Studies 
addressing the susceptibility of individuals to TB have been conducted by several 
groups (Smith et al., 2002; van Crevel et al., 2000). Individuals with multiple exposures 
to M. tuberculosis develop a Th1 response (IFN-γ) associated to an early expression of a 
Th2 response (IL-4) and subsequently to active disease. A Th2 response confined to 
TCD8+ and γδ phenotype can result in reduced bactericidal function of mycobacterial 
infected cells. However, the components of the immune response responsible for the 
failure of elimination of intracellular M. tuberculosis that leads to active disease are not 
completely understood. In countries with a low incidence of TB, the results show 
reduced levels of IFN-γ production without an increase in IL-4 response in patients with 
TB (Johnson and McMurray, 1994; Sanchez et al., 1994). In the case of countries where 
TB is endemic the results show that reduced levels of IFN-γ are correlated with an 
increase in the IL-4 response (Bhattacharyya et al., 1999; Smith et al., 2002; van Crevel 
et al., 2000). Some of these studies have being carried out by our team at the Unit of 
Mycobacteriology (IHMT/UNL) in order to clarify if multiple TB exposure would lead 
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to induction of Th2 responses and by this manner contribute to active disease (Ordway 
et al., 2004; Ordway et al. 2005a, b). To address this question, we collected blood from 
10 health care workers that worked with TB patients under conditions that afforded little 
protection to repeated exposure to air-borne M. tuberculosis and 10 non- health care 
workers with no evidence of contact with M. tuberculosis (Ordway et al., 2005a). 
Peripheral blood mononuclear cells obtained from these individuals were stimulated 
with M. tuberculosis and the cell proliferation and production of IFN-γ, IL-5 and IL-4 
using ELISA and Flow Cytometry was evaluated. The results obtained were compared 
with the results from the DTH responses. This group of individuals was studied 
longitudinally for 5 years after the assays were completed. During this time, 6 health 
care workers developed active TB (Ordway et al., 2005a). The analysis of its cellular 
phenotype and cytokine production revealed an early expression of a Th1 response with 
increased levels of IL-4 within the CD8+ and γδ+ T cells (Ordway et al., 2004; Ordway 
et al., 2005a, b). These results suggest that antigen persistence from repeated M. 
tuberculosis exposure leads to early expression of an immune profile that consists of the 
presence of a declining Th1 response with concomitant expression of a Th2 response. 
This presence of a Th2 response results in reduced DTH Mantoux indurations and lack 
of an early clinical diagnosis. In this early phase, failing Th1 immunity, persistence of 
antigen and the early expression of Th2 (IL-4), leads to the eventual development of 
TB. The immune profile associated with these individuals was detected years prior to 
the onset of active disease and therefore may serve as a predictor of progression to TB 
disease. Health care workers that did not developed active disease showed a higher 
percentage of CD8+ T cells expressing IFN-γ; a higher percentage of γδ+ T cells 
expressing IFN-γ and low levels of IL-4 in CD8+ and γδ+ T cells (Ordway et al., 2005a, 
b). The early presence of IL-4 in T cells leads to the progression of the infection to 
active disease. These results are extremely important since they suggest an early 
immune profile that can be used to predict increased susceptibility of the human host to 
TB. 
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II.1. Determination of Toxicity of compounds to be evaluated for activity against 
bacteria under study 
 
II.1.1 Materials. 
 
RPMI medium, Ficoll-Hypaque, Hank’s Balanced Salt Solution (HBSS) and Trypan 
blue were purchased from Sigma-Aldrich Química SA (Madrid, Spain). 50 mL Falcon 
tubes and microwell tissue culture plates were purchased from Nalgene (Nunc, Thermo 
Scientific; Rochester, NY, USA). 
 
Thioridazine (TZ) was purchased from Sigma-Aldrich Química SA (Madrid, Spain). 
Stock solutions of the phenothiazine were freshly prepared in the days of the experiment 
in sterile distilled water and protected from light.  
 
Modifications of the TZ molecule to a clinically more active one were achieved by 
chemical manipulations and according to the mechanism of action of these neuroleptic 
drugs. In order to accomplish this, twenty-two TZ derivatives were synthesised by 
Professor György Hajós from the Institute of Chemistry, Budapest, Hungary. These 
derivatives were produced by chemical manipulations (new TZ derivatives attached to 
alkyl, aryl or hetaryl groups), the derivatives isolated (micro and semi-preparative scale; 
thin layer chromatography, column chromatography by normal and medium pressure, 
vacuum distillation), characterized (by 400 and 200 MHz Nuclear magnetic resonance 
(NMR) (1H and 13C), Fourier transfer Infra red and Raman Spectroscopy, Ultraviolet 
(UV) Spectroscopy, Mass Spectroscopy, X-Ray structure determination), synthesized 
(by ring closure and ring opening reactions, Pd(0) catalysis such as cross-coupling 
reactions; cyclo-additions, etc.) in 100 milligram quantities and then sent to Portugal. 
The mentioned derivatives were identified as follows: #1550, #1470, #1686, #1687, 
#1532-2, #1688, #1689, #1819, #1820, #1821, #1867, #1868, #1869, #1870, #1871, 
#1872, #1873, #1874, #1875, #1876, #1926 and #1929. The structures of these 
compounds are presented in Table 1. 
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Table 1. Structure of TZ derivatives. 
 
Compound Structure 
#1470  
 
 
 
#1550 Non available 
#1689 (R = CF3, X = Cl)    
#1686 (R = H, X = OCH3)       
#1687 (R = CF3, X = OCH3)      
#1688 (R = Cl, X = OCH3)     
#1550 (R = H, X = C(NH2)=N-OH) 
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Compound Structure 
#1872 
 
 
 
 
 
#1873 
 
 
 
 
 
#1874 
 
 
 
 
#1876  
 
 
 
#1875 (X = NO2) 
#1926 (X = F)    
#1867 (X = H) 
#1870 (X = Cl) 
#1868 (X = CH3) 
#1869 (X = Br)    
 
 
#1929 
 
 
 
 
 
 
Other compounds such as reserpine, ouabain and verapamil were purchased from 
Sigma-Aldrich Química SA (Madrid, Spain). Patented compounds 1,3-Dimethyl-1,3-
bis(4-fluorophenyl)-1,3-bis(3-morpholino-propyl)-disiloxan-dihydrochlorid (SILA 409) 
and 1,3-Dimethyl-1,3-bis(4-fluorophenyl)-1,3-bis{3-[1(4-buthyl-piperazinyl)]-propyl}-
disiloxan-tetrahydrochlorid (SILA 421) were synthesised by Hegyes et al (Hegyes et 
al., 2000) and have received patents, Brevet Europeen nº 0099150.6, PCT/DE00/04110. 
Their structures are indicated in Table 2. 
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Table 2. Structures of other efflux pump inhibitors. 
Compound Structure 
Reserpine  
 
 
Ouabain 
 
 
 
 
 
 
 
 
Verapamil  
SILA 409  
 
 
 
 
 
 
SILA 421  
 
 
 
 
 
 
 
 
 
 
2HCl
 
4HCl
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II.1.2 Carpobrotus edulis 
 
Carpobrotus edulis (L.) N. E. Br. (Aizoaceae) leaves were collected in December of 
2003 from the cliffs of Cabo da Roca (Sintra, Lisbon, Portugal) and authenticated by 
Prof. António Viveiros (Professor Emeritus of Botany, Plant Biology Department, 
Faculdade de Ciências, Universidade de Lisboa). The plant extract was prepared as 
described: two hundred grams (g) of leaves were homogenised in 50 mL of water and 
methanol (MeOH) was added yielding a final 70% MeOH concentration (v/v). The 
preparation was mixed for 3 hours at room temperature and centrifuged at 10,000 
rotations pre minute (r.p.m.). The residues were pooled and weighed and the supernatant 
filtered through a 3-mm Whatmann paper. The paper and its contents were dried and 
weighed, and its weight added to the pooled weight of the pellets. Total wet solids 
weigh approximately 194 g. Methanol was removed from the supernatant in vacuum at 
55ºC to yield the aqueous solution that would be tested for its antibacterial activity. The 
final volume representing the aqueous phase was approximately 150 mL and this 
material was used at various dilutions for intracellular activity against phagocytosed 
bacteria. A 50 mL aliquot of the aqueous phase was further concentrated to a volume of 
10 mL and used for assaying its in vitro activity against bacteria (Martins et al., 2005). 
 
II.1.3 Instrumentation  
 
Analytic Balance (Explorer; Ohaus) 
Vortex (Snijders Model No. 34524) 
-20ºC Freezers (30L and 80L; Bosch) 
Microscope (Lietz Biomed) 
Neubauer chamber (Hirschmann) 
Refrigerated centrifuge (Rotanta 46R; Hettich Zentrifugen) 
Micropipettes (Gilson) 
Laminar Flow Cabinets (NU-425-600E; Nuaire) 
CO2 Water Jacketed Incubator (Nuaire NU-4500/E)  
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II.1.4 Quality control 
 
The optical microscope was adjusted for Kohler illumination (Bohnhoff, 1979) in order 
to certify that the optimum conditions required for sensitivity were present. Microscopy 
is an essential component of the laboratory work and the means by which the cells are 
evaluated for toxicity of compounds is an important feature since the criteria define 
toxicity are dependent on initial observations of the cells. It is important to ensure that 
the detection of stain is not due to dirt; the adjustment of the microscope was performed 
on a scheduled basis. All the instruments referred above are periodically checked and 
calibrated according to the Good Laboratory Practices employed in the Unit of 
Mycobacteriology (IHMT/UNL). 
 
II.1.5 Method 
 
Human peripheral blood (20 mL) was collected from voluntary healthy donors to a 
heparinized tube (300 µL, Monoparin; CP Pharmaceuticals, 1,000 Units) and the 
purified human mononuclear cells obtained by the Ficoll differential centrifugation 
method (Ordway et al., 2003b), as follows: total blood was diluted in Roswell Park 
Memorial Institute (RPMI) 1640 medium (Sigma-Aldrich, Madrid, Spain) 1:2 (40 mL 
of final volume). From this dilution, 2 sets of 20 mL were layered on the top of 12 mL 
of histopaque 1.077 (Sigma-Aldrich Química, S.A., Madrid, Spain) (5/3) (v/v) 
contained in 50 mL tubes and the tubes centrifuged at 800×G for 30 minutes. After this 
centrifugation 4 phases were obtained: plasma, buffy-coat containing the mononuclear 
cells (layer of interest), ficoll-hypaque phase and in the bottom the red blood cells, 
platelets and granulocytes. The plasma was carefully aspirated with a sterile Pasteur 
pipette to a new 50 mL tube and kept for posterior addition to RPMI medium in a 10% 
ratio (complete medium). The white layer (between saline and histopaque phases) was 
carefully aspirated, with a sterile Pasteur pipette, pooled to a new 50 mL tube and HBSS 
(Sigma-Aldrich, Madrid, Spain) added to the cells until a final volume of 50 mL. Cells 
were then washed at 800×G for 10 minutes, the supernatant discarded, 50 mL of HBSS 
added and a new centrifugation performed (in the same conditions mentioned above). 
After this, a third wash was performed. The supernatant was discarded and the pellets 
re-suspended in 5 mL of RPMI 1640 medium. From this, an aliquot of 10 µL of the 
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cellular pellet was added to 90 µL solution of trypan blue/phosphate buffered saline 
(PBS) for determination of cellular viability. When cells are damaged trypan blue enters 
the cells and stains the cytoplasm (Fong and Kissmeyer-Nielsen, 1972). Counting of 
viable cells was performed using a Neubauer chamber (Ordway et al., 2003b). The 
concentration of cells was adjusted with RPMI medium plus 10% autologous human 
serum to yield 1×107 cells/mL. From this adjusted cellular suspension, 180 µL were 
transferred to the wells of a 96-well microplate. The cells dispersed to a 96-well 
microplate (1×107 cells/mL) were then pulsed with 20 µL aliquots of TZ and its 
derivatives, added in triplicate, at concentrations ranging from 0 to 0.5 mg/L. The plates 
were then incubated at 37ºC with 5% of CO2 for a period of 3 days subsequent to the 
addition of the compounds and each day an aliquot of 10 µL was retrieved from the 
wells, added to 90 µL of a trypan blue solution and viability of the cells assessed. By 
this manner, it was possible to determine the optimum concentration of the compounds 
that did not present any toxicity for the human lymphocyte and select the concentrations 
to be used in the ex vivo assays.  
 
II.1.5.1 QC for method 
 
Human purified lymphocytes were obtained by the Ficoll differential centrifugation 
method as previously described (see method description). After the adjustment of cell 
number, lymphocytes were split into two parts. One part of the cells was killed using 
potassium cyanide (positive control) and the other received no compound (control). The 
two parts (dead and live cells) were then mixed to yield dead cells on final percentages 
of 10, 25, 50, 75 and 100%. Aliquots of these cell suspensions were retrieved, mixed 
with a 0.9% of trypan blue solution and counted in a Newbauer chamber to perform a 
calibration curve. By this manner, it was possible to obtain a correlation (coefficient of 
correlation >0.99) between the concentrations that presented toxicity to the lymphocytes 
and the percentage of dead cells. This assured that the percentage of stained cells (dead) 
after the treatment with the compounds was due to toxicity of the compounds tested. 
 
 
 
 
Chapter II 
 80 
II.2. Mutagenicity of compounds 
 
The mutagenic effects of TZ and each of its derivatives was assessed by the modified 
Ames procedure (Ames et al., 1975). This method allows us to directly assay potential 
carcinogens by testing their ability to revert mutation in Salmonella enterica serotype 
Typhimurium. The most effective way to detect carcinogenic compounds is to inoculate 
a sample into animals and monitor for tumours development. However, this is difficult, 
time consuming, expensive and cumbersome (Knight and Breheny, 2002). In addition, 
most of the compounds that cause tumours in animal cells (carcinogens) are mutagens. 
Based upon this insight, Bruce Ames and colleagues developed a simple, indirect assay 
for potential carcinogens (Ames et al., 1975). The assay is based upon the reversion of 
mutations in the histidine (his) operon in the bacteria Salmonella enterica serotype 
Typhimurium. The operon encodes enzymes required for the biosynthesis of that amino 
acid. Strains with mutations in the operon are designated his auxotrophs and are unable 
to grow in media without addition of his. Revertants that restore his phenotype (his+) 
will grow on minimal medium plates without the amino acid. This provides a simple 
and sensitive selection for revertants of his mutants. His mutants are mixed with the 
potential mutagen and then plated on minimal medium with a very small amount of his. 
The concentration of his used is limiting, so after the cells go through several cell 
divisions his is used up and the auxotrophs stop growing. This is essential because many 
mutagens work only on replicating DNA. If the potential mutagen induces his+ 
revertants during the initial few cell divisions, then each of the resulting revertants will 
continue to divide and form a colony. The number of colonies produced is proportional 
to how efficiently the mutagen revert the original mutation. If these agents are shown to 
be mutagenic for bacteria they may also alter the DNA of eukaryotic cells. 
 
II.2.1 Bacteria 
 
Salmonella enterica Serotype Typhimurium TA1538 auxotrophic for histidine (his-). 
 
II.2.2 Materials 
 
Glucose minimal-salts agar, histidine, biotin, sodium azide and Tryptic Soy Broth 
(TSB) were purchased from Oxoid (Basingstoke, England).  
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II.2.3 Instrumentation  
 
37ºC Incubator (Model 600; Memmert) 
 
II.2.4 Quality control 
 
In order to ensure that the temperature presented by the instrument is the exact 
temperature inside the incubator, periodic temperature quality control was performed 
according to the Good Laboratory Practices implemented in the laboratories of the Unit 
of Mycobacteriology (IHMT/UNL). 
 
II.2.5 Method 
 
The experimental procedure was followed as described: glucose minimal-salts agar 
plates were prepared (test and control plates). After this an inoculum of S. enterica 
serotype Typhimurium (his-), was prepared in soft agar and uniformly spread over the 
surface of the plates. The agar was allowed to harden for a few minutes and using sterile 
forceps, prepared discs were dipped into tubes containing the compounds to be tested. 
The excess of the liquid in the discs was removed by gently pressing the discs against 
the walls of the tubes. The discs were placed in the agar plates and plates were 
incubated at 37ºC for 48 hours. After this incubation period CFU were counted. 
 
II.2.5.1 QC for method  
 
In order to ensure the correct performance of the protocol, two controls were conducted 
in parallel. A negative control was performed using a saline solution instead of the 
tested compounds and the disc was placed on one half of the control plate. A positive 
control was also conducted using a disc emerged in a sodium azide (known mutagen) 
solution and the disc placed on the other half of the control plate. 
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II.3. Evaluation of in vitro activity of compounds studied against S. aureus strains 
  
In vitro activity of TZ and its derivatives was initially conducted with S. aureus strains 
(ATCC25923 strain and Methicillin-resistant clinical strains) by the microplate 
microdilution method (CLSI, 2006) in order to determine which derivatives presented 
higher activity than the parental molecule (TZ). The minimum inhibitory concentration 
(MIC) is defined as the minimal concentration of an agent that inhibits the replication of 
the bacterium. The MIC of an agent against a specific bacterial strain contributes to the 
characterisation of that strain as well as provides the means by which the in vitro 
activity of a series of agents against the same bacterial strain can be compared and 
therefore, ranked (CLSI, 2006). We have found that the in vitro response of S. aureus is 
usually similar to that of M. tuberculosis (Ordway et al., 2003b) and defined within one 
day as opposed to three or more weeks for the latter species, and is far less costly. As an 
example of this cost differential, the cost for medium and reagents for the evaluation of 
in vitro activity against one staphylococcus strain is approximately 14 euros (for testing 
22 TZ derivatives) whereas that for similar evaluation for one mycobacterial strain 
would be 1.237 euros (for the same 22 compounds). Therefore, we have employed the 
staphylococcal strains as a model for predicting which of the derivatives will be 
effective against M. tuberculosis (Ordway et al., 2002a, b). Derivatives which yielded 
MICs against staphylococcal strains that were equal or lower than that of the parental 
TZ compound were then selected for the evaluation of in vitro activity against M. 
tuberculosis strains. 
 
II.3.1 Microplate Microdilution Method 
 
II.3.1.1 Bacteria 
 
S. aureus ATCC25923 (control strain) and Methicillin-Resistant S. aureus (MRSA) 
strains were selected as the experimental model for screening of compounds that will 
work on MDR-TB strains. 
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II.3.1.2 Materials  
 
Mueller-Hinton (MH) broth and Mueller-Hinton agar (MHA) were purchased from 
Oxoid (Basingstoke, England). PBS was purchased from Sigma-Aldrich Química SA 
(Madrid, Spain). Microwell tissue culture plates were purchased from Nalgene (Nunc, 
Thermo Scientific; Rochester, NY, USA). 
 
II.3.1.3 Instrumentation  
 
37ºC Incubator (Model 600; Memmert) 
 
II.3.1.4 Quality control 
 
Temperature quality control was performed in a periodically basis following the Good 
Laboratory Practices Guidelines (UNDP/World Bank/WHO Special Programme for 
Research and Training in Tropical Diseases (TDR), 2001) implemented in the 
laboratory of the Unit of Mycobacteriology (IHMT/UNL).  
 
II.3.1.5 Method by MIC and its principle  
 
The method used with S. aureus strains is briefly described: MH media was prepared 
and aliquots of 150 µl distributed to the wells of 96-well microplates. After this, fresh 
stock solutions of the tested compounds were prepared and added to the wells of the 
microplates. A serial two-fold dilution of each compound was performed in order to test 
compounds in concentrations ranging from 0 to 400 mg/L. An overnight culture of S. 
aureus prepared in MH broth was diluted in a saline solution and its concentration 
adjusted to 0.5 of McFarland scale (according to the CLSI guidelines). Wells containing 
the dilutions of the compounds were inoculated with 50 µL of the adjusted bacterial 
suspension. In parallel, two controls were also conducted: a negative control, containing 
just MH broth and a positive control presenting the inoculum (no compound). The 
plates were incubated at 37ºC and after 16 and 18 hours the results were recorded and 
confirmed. The results were compared with the two controls and processed as growth 
(turbidity in the wells) or no growth (absence of turbidity). The MIC was defined as the 
lowest concentration where no growth was observed (in comparison with the absolute 
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control). Aliquots of 100 µL from the wells with no growth were plated in MHA plates. 
The plates were incubated overnight and the minimum concentration showing no 
colonies was considered the minimum bactericidal concentration (MBC). All the assays 
were conducted in triplicate and the data obtained did not vary. 
 
II.3.1.5.1 QC for method 
 
All the procedures were conducted according to the Performance Standards for 
Antimicrobial Susceptibility Testing; Sixteen Informational Supplement (CLSI, 2006). 
 
II.3.2 Kirby-Bauer 
 
II.3.2.1 Bacteria  
 
S. aureus ATCC25923 (control strain) and Methicillin-Resistant S. aureus (MRSA) 
strains were selected as experimental model for screening of compounds. 
 
II.3.2.2 Materials  
 
MHA was purchased from Oxoid (Basingstoke, England). Phosphate buffered solution 
was purchased from Sigma-Aldrich Química SA (Madrid, Spain). Sterilized Petri dishes 
were purchased from Nalgene (Nunc, Thermo Scientific; Rochester, NY, USA). 
Sterilized swabs were purchased from Omnilabor (Omnilabor, Lisbon, Portugal). 
 
II.3.2.3 Instrumentation  
 
37ºC Incubator (Model 600; Memmert) 
 
II.3.2.4 Quality control 
 
Plate drying, method of storage and storage time was previously determined by the 
laboratory of the Unit of Mycobacteriology (IHMT/UNL) as part of the Quality 
Assurance Programme. Plates were storage at 4-8°C in sealed plastic bags. Tests were 
made in a schedule basis in order to confirm that excess moisture was not produced in a 
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sealed environment or that plates were not over-dried in an unsealed environment. 
Temperature quality control was performed periodically for all incubators used during 
the protocol and followed the guidelines of Good Laboratory Practices (UNDP/World 
Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), 
2001).  
 
II.3.2.5 Method and its principle  
 
The susceptibility profile of each strain employed in this study was conducted in 
accordance to the Kirby-Bauer method (CLSI, 2006). Briefly, each strain was grown in 
MH media for 2-3 hours of culture. After this period, the strains were diluted in PBS 
and the inoculums adjusted to 0.5 of McFarland scale (as recommended by the Clinical 
Laboratory Standard Institute (CLSI)). The adjusted suspension was used to inoculate 
MHA plates by dipping a sterile cotton-wool swab into the suspension and remove the 
excess by turning the swab against the side of the tube. The inoculum was swabbed in 
the surface of the plate in three directions and left stand for 3-4 minutes. After this, 
antibiotics disks, representative of each class, were placed on the surface of the agar 
containing the inoculums. Ninety mm plates were used since they can accommodate six 
discs without unacceptable overlapping of zones. The plates were left to stand for a few 
minutes and then incubated at 37ºC for 16 and 18 hours. After these periods, the 
diameters of the inhibition zones were measured (edge was taken as the point of 
inhibition judged by the naked eye) with a ruler.  The zone of inhibition for the control 
strain was confirmed to fall within the acceptable ranges before interpreting the test. 
After the validation of the result obtained for the control strain, the tested strains were 
characterized for their antibiotic susceptibility profile as susceptible, resistant or 
intermediate according to the CLSI Standards (CLSI, 2006). 
 
II.3.2.5.1 QC for method 
 
The control organism selected was the S. aureus ATCC25923 as recommended by the 
CLSI guidelines (CLSI, 2006). To minimise the risk of mutations, the control strain was 
stored at -70°C, in 15% of glycerol. Two vials of the control were stored, one as an “in 
use” supply and the other for archiving. Every week an aliquot of the “in use” vial was 
sub-cultured on MH broth and checked for purity. From this pure culture, subcultures 
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for each of the following 7 days were prepared. The method was performed with an 
inoculum giving semi-confluent growth of colonies after an overnight incubation. This 
is important since an inoculum that yields semi-confluent growth has the advantage 
over that resulting in isolated colonies in that a uniform appearance is more easily be 
observed. Larger or a smaller inoculae will yield reduced or augmented zones of 
inhibition, respectively. To obtain a semi-confluent inoculum the adjustment of the cell 
concentration was performed accordingly with the McFarland standard. A commercial 
vial of 0.5 of the McFarland scale (McFarland, 1907) was used. This scale is constituted 
by a barium chloride (BaCl2) solution with standardized turbidity. The McFarland 
standard was taken from the refrigerator and left to stand for a few minutes at room 
temperature. After this, the vial was mixed to ensure that it was evenly suspended. The 
commercial standard is periodically checked by measuring the absorbance in a 
spectrophotometer at a wavelength of 625 nm. For a 0.5 McFarland standard the 
acceptable range for the absorbance is between 0.08 and 0.13 (McFarland, 1907). The 
inoculum preparation was performed according to the CLSI guidelines. At least four 
morphologically similar colonies were removed with a sterile loop, transferred to MH 
broth and incubated with shaking at 37°C until the visible turbidity was equal to or 
greater than the 0.5 McFarland standard. Adjustment of the suspension was conducted 
by adding an aliquot of saline solution. The comparison between the test and the 
standard was conducted against a white background with a contrasting black line and 
the suspension was used within 15 minutes of preparation. 
 
II.4. Ethidium bromide (EB)-agar method for the demonstration of efflux pump 
activity of bacteria 
 
II.4.1.1 Bacteria 
 
Escherichia coli K12 (AG100-main efflux pump acrAB intact), E. coli (AG100A-main 
efflux pump acrAB deleted-∆acrAB) and the progeny of the AG100 strain induced to 
high level resistance to TET (AG100 acrABTET). This last strain was produced in our 
laboratory by serial culture in increasing concentrations of the antibiotic (Viveiros et al., 
2005a). S. aureus strain ATCC25923 and MRSA strains COL (Kornblum et al., 1986) 
and HPV107 (Sanches et al., 1995) were generously provided by Prof. Dr. Hermínia de 
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Lencastre. Enterobacter aerogenes EA27 resistant to chloramphenicol has been 
maintained and characterized by our colleague, J.M. Pagès (Ghisalberti et al., 2005).  
 
II.4.1.2 Materials  
 
Luria Bertani (LB) and Tryptic Soy Broth (TSB) media employed for broth and agar 
based cultures for Gram-negative bacteria and S. aureus strains, respectively, were 
purchased from Difco (Madrid, Spain). Antibiotics (as powder or as Kirby-Bauer disks) 
were purchased from Sigma-Aldrich Química SA (Madrid, Spain). EB was purchased 
from Sigma-Aldrich Química SA (Madrid, Spain).  
 
II.4.1.3 Instrumentation  
 
37ºC Incubator (Model 600; Memmert) 
Eagle Eye (Strategene, USA)   
 
II.4.1.4 Quality control 
 
Temperature quality control was performed in a periodically basis following the Good 
Laboratory Practices Guidelines (UNDP/World Bank/WHO Special Programme for 
Research and Training in Tropical Diseases (TDR), 2001) implemented at the 
laboratory of the Unit of Mycobacteriology (IHMT/UNL).  
 
II.4.1.5 Method and its principle  
 
The EB-agar method is an instrument-free method that was developed at our Unit for 
the demonstration of efflux pump activity of bacteria. Conventional evaluation of efflux 
pumps by the use of the substrate ethidium bromide (EB) or by the retention of 
radioactive antibiotics requires specialized instrumentation not normally found in 
clinical laboratories. Therefore, at the Unit of Mycobacteriology we have developed a 
simple, instrument free, agar based method that utilizes EB, to identify clinical isolates 
that have an over-expressed efflux pump activity. The assay is also shown to afford the 
evaluation of agents that may inhibit efflux pumps activity. This method can provide 
additional important information that defines the cause of MDR of the clinical isolates. 
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The effect of the temperature on the efflux pump system was also considered. Briefly, 
two sets of agar plates containing EB concentrations ranging from 0.05 to 1.5 mg/L 
were swabbed with the bacterial strain and incubated overnight at 37ºC. After this 
period, the results were recorded and one set re-incubated at 37ºC, whereas the 
duplicate set was transferred to 4ºC. At the end of an additional 24 hours period, the 
minimal concentration of EB that produced fluorescence at each temperature was 
compared to that evident after the first incubation (at 37ºC). To determine whether the 
method could distinguish a mixed culture that consisted of strains of E. coli or S. aureus 
that differed from each with respect to the degree of efflux pump activity, from each 
separate culture, 0.1 mL were transferred to a single tube containing 10 mL of saline, 
mixed, and from this 0.010 mL were transferred to another tube containing 10 mL of 
saline. These two dilutions, each containing a mixture of both strains, were plated onto a 
replicate series of agar plates containing concentrations of EB ranging from 0.2 to 2.2 
mg/L. Evaluation of fluorescence from the excitation of EB by UV light was first made 
with the use of a UV transilluminator and the plates photographed with the use of the 
Eagle Eye system (Strategene, USA).   
 
II.4.1.5.1 QC for method 
 
E. coli K12 and E. coli AG100 acrABTET strains were used as controls, due to the 
expression of the efflux pumps system. In the case of S. aureus strains, the controls used 
were S. aureus ATCC25923 and the MRSA COL strains, for the same reasons stated 
previously for E. coli strains (differences observed in the expression of the efflux pumps 
system). 
 
II.5. Evaluation of in vitro activity of compounds studied against Mycobacterium 
tuberculosis strains 
 
In 1969, Deland and Wagner (DeLand and Wagner, 1969) developed a technique for 
automated detection of the metabolism of bacteria by measuring the 14CO2 released 
during the decarboxylation of 14C labelled substrates present in the medium. This 
technique was applied successfully for the evaluation of growth of Neisseria sp. under 
different nutrient conditions and for the determination of the effects of antibiotics on 
said growth. Cummings and co-workers in 1975 carried out preliminary work that 
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showed that the same principle could be applied to detect growth of M. tuberculosis 
(Cummings et al., 1975). Middlebrook and his team further developed the technique 
and introduced 7H12 liquid medium containing a 14C labelled substrate specific for 
mycobacterial growth (Siddiqi et al., 1981). He reported a significant time saving in the 
primary isolation of mycobacteria from clinical specimens using this improved 
radiometric medium. The BACTEC TB medium (12B) is an enriched Middlebrook 7H9 
broth base. Mycobacteria utilize a 14C labelled substrate (14C palmitic acid) present in 
the medium and release 14CO2 into the atmosphere above the medium. When the 7H12 
medium vials with growth are tested on the BACTEC 460 instrument, the 14CO2 is 
aspirated from the vial and its radioactivity is determined quantitatively in terms of 
numbers on a scale from 0 to 999. These numbers are designated as the Growth Index 
(G.I.). The G.I. numbers are displayed by the BACTEC 460 instrument and are also 
printed out along with identifying rack and bottle numbers. The daily increase in the 
G.I. output is considered to be directly proportional to the rate and amount of growth in 
the medium. The BACTEC instrument also introduces fresh 5% CO2 in air into the 
medium head space every time a vial is tested. This enhances the growth of 
mycobacteria. The instrument can automatically test 60 vials at the rate of 
approximately one vial per minute and stops at the end of the run. If an inhibitory agent 
is introduced into the medium, inhibition of the metabolism is indicated by reduced 
production of 14CO2 when compared to a control having no inhibitory agent. This basic 
principle is applied for drug susceptibility testing and also in differentiating M. 
tuberculosis from other mycobacteria. The development of 7H12 medium (BACTEC 
12A) led to several studies which reported excellent recovery of mycobacteria from 
sputum as well as extra-pulmonary specimens (Kirihara et al., 1985; Morgan et al., 
1983; Siddiqi et al., 1985; Takahashi and Foster, 1983). Since the BACTEC system 
utilizes a liquid medium, it is important to add an antimicrobial supplement to suppress 
growth of contaminating microorganisms which may survive the decontamination 
process (in the case of clinical samples processing). Siddiq et al. reported an 
antimicrobial mixture (PANTA) that contains polymyxin B, amphotericin B, nalidixic 
acid, trimethropim and azlocillin (Siddiqi and Rüsch-Gerdes, 2006). Although 
BACTEC TB medium supports rapid growth of most mycobacteria, occasional strains 
of M. tuberculosis, such as isolates from treated chronic cases, may grow poorly. By 
this manner, a growth promoting substance, polyoxyethylene stearate (POES) was 
reported by Siddiq et al. (Siddiqi and Rüsch-Gerdes, 2006; Siddiqi et al., 1981, 1985). 
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When added to the BACTEC TB medium, this substance enhanced growth of those 
strains which grew slowly or poorly. This growth-promoting substance was 
incorporated in the reconstitution fluid, which should be used to reconstitute lyophilized 
PANTA supplement. The BACTEC TB system offers a simple automated technique 
with significant convenience and time saving being extremely accurate for MIC 
determination.  However, it should be stated that the results only show that the cells are 
respiring and that conditions which inhibit growth may not affect respiration. Hence 
care must be taken in interpreting the results in terms of effects of agents on the 
replication of the organism (Duarte et al., 2007). However, because of external and 
internal controls maintained by the Unit of Mycobacteriology, an understanding of the 
effects of an agent on the replication of the organism can be readily inferred. Lastly, 
evaluation of the BACTEC TB system involved a comparison of 14C generated in the 
absence and presence of an agent to colony forming units obtained from the cultures 
themselves.  This data showed without ambiguity, that in the hands of the staff of the 
Unit of Mycobacteriology the results obtained from the BACTEC TB system could 
indeed be interpreted in terms of growth and its inhibition by a given agent. 
 
II.5.1 BACTEC 460-TB method 
 
II.5.1.1 Bacteria 
 
Mycobacterium tuberculosis H37Rv ATCC27294 (control strain) and Multi-drug 
resistant (MDR-TB) strains (resistant to INH, RIF and STR) were the strains selected 
for conduct studies with TZ and its derivatives. 
 
II.5.1.2 Materials  
 
12B BACTEC 460 vials were purchased from Quilaban (Portugal). Insulin syringes 
were purchased from Omnilabor (Omnilabor, Lisbon, Portugal). 
 
II.5.1.3 Instrumentation  
 
BACTEC 460-TB instrument (Becton-Dickinson Diagnostic Instrument Systems, 
Towson, Md., USA). 
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II.5.1.4 Quality control 
 
A daily performance test was performed as recommended (BACTEC 460 TB SIRE 
method (1985) Becton Dickinson Microbiology Systems) and is described as follows. 
Using 1 mL syringe, 0.2 mL of a standard 14C solution (provided in the kit) were 
injected into one of the three acid vials (provided). The vial was vigorously shaken for 
ten seconds to release a known amount of 14CO2. The acid vial was then tested in the 
BACTEC instrument; a G.I. of 50-60 should be obtained. If the result was outside this 
range, a repetition was made with the same vial (as recommended by the manufacturer). 
Low readings usually indicate probable needle blockage requiring replacement of the 
needle set. High readings may indicate over-inoculation of the test vials or instrument 
malfunction. The maintenance schedule of the BACTEC 460 instrument was strictly 
followed. Good maintenance of the needle heater, filter, media trap and U.V. light was 
also performed. At least once a month proper disinfection of the equipment was 
performed as recommended by the manufacturer. Maintenance of the instrument 
needles was specially conducted. Needles were changed every day and used needles 
were placed in a larger container with proper disinfectant and autoclaved. The needles 
points were carefully checked and all the needles were autoclaved in individual syringe 
paper bags. The CO2 supply was carefully checked in order to maintain CO2 in 5-10% 
with the balance air. CO2 pressure in the cylinder was daily checked and also the 
“aerobic switch” button. All the BACTEC vials were tested before the inoculation 
protocol, to establish the recommended 5% CO2 atmosphere. Non inoculated vials that 
showed G.I. of 20 or more were discarded. The BACTEC 460 instrument contains a 
special TB hood (as recommended by the manufacturer). The TB hood exhaustion is 
made through HEPA filters and negative pressure in the test area. In addition, the TB 
hood is also equipped with an ultraviolet light source. The unit performs automatic 
testing of vials and is not used for inoculation or sub-culturing; those procedures were 
performed on a biological cabinet type II. BACTEC 460-TB instrument was checked 
and calibrated according to the annual maintenance recommended by the certified 
manufacturer (Quilaban, Lisbon, Portugal). Weekly performance tests were also 
conducted according with Becton-Dickinson Diagnostic Instrument Systems (Towson, 
Md., USA) recommendations. 
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II.5.1.5 Method 
 
The MIC and MBC of TZ and its derivatives were determined individually by the 
BACTEC 460-TB method (BACTEC 460 TB SIRE method (1985) Becton Dickinson 
Microbiology Systems). M. tuberculosis strains were grown as a primary culture in 
Middlebrook 7H12 broth in 12B BACTEC 460 vials (Becton-Dickinson Diagnostic 
Instrument Systems, Towson, Md., USA), until they reach an optical density (O.D.) 
equal to 1 of McFarland standard (McFarland, 1907). From these cultures, aliquots were 
transferred to new 12B BACTEC vials and the O.D. adjusted to a 0.5 McFarland scale. 
Each vial received 0.1 ml of 12B BACTEC 460 medium containing an adjusted 
concentration of mycobacteria corresponding to approximately 105 to 106 CFU. These 
vials served as the source for the inoculation of triplicate BACTEC 12B vials containing 
the phenothiazines. A separate 1:100 dilution of the adjusted inoculum was made and 
transferred to one BACTEC 12B vial that contained no drug; this served as the 
proportional control as defined by the recommended BACTEC proportional method for 
M. tuberculosis (BACTEC 460 TB SIRE method (1985) Becton Dickinson 
Microbiology Systems). Inoculation of each strain into control and experimental 
BACTEC vials were in accordance with the BACTEC 460 proportional method 
procedure (BACTEC 460 TB SIRE method (1985) Becton Dickinson Microbiology 
Systems). Stock solutions containing each derivative were freshly prepared in water and 
protected from light at all times and 0.1 mL aliquots inoculated into 12B BACTEC 460 
vials prior to use. The final concentrations of TZ and its derivatives in the 12B 
BACTEC 460 vials were 0, 0.3125, 0.625, 1.25, 2.5, 5, 10, and 20 mg/L. The vials were 
incubated at 37ºC and the contents daily assessed by the BACTEC 460-TB instrument 
(Becton-Dickinson Diagnostic Instrument Systems, Towson, Md., USA) for 14CO2 
generated from the metabolism of 14C palmitic acid. Terminations of a set of cultures 
were in accordance to G.I. parameters to which the controls were subjected. When the 
absolute control reached a G.I. of 999 the vials were removed and the MIC determined. 
According to this method the MIC is defined as the minimum concentration where no 
growth is observed. The MBC of TZ and its derivatives were determined by extending 
the MIC curves well beyond each MIC, and 100 µl aliquots of the BACTEC 12B 
cultures at zero time and those after 30 days that showed no evidence of growth in the 
BACTEC 12B vials were subjected to determination of the numbers of CFU (Ordway et 
al., 2002a). The MBC is defined as the minimum concentration where no growth is 
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observed when the diluted control (1/100; vial containing 100 times less bacteria) 
presents a G.I. of 999 (defined as maximum growth). The MIC and MBC 
determinations were repeated three times, and the values obtained did not differ 
significantly. Derivatives that had significant activity over that exhibited by their parent 
compound were selected for ex vivo studies on antibiotic resistant M. tuberculosis 
phagocytosed by human macrophages.  
 
II.5.1.5.1 QC for method  
 
According to the BACTEC proportional method for M. tuberculosis (BACTEC 460 TB 
SIRE method (1985) Becton Dickinson Microbiology Systems) the diluted control 
(1:100) serves as the proportional control. This allows us to determine the 1% 
proportion of growth. The rate of increase in the G.I. or the amount of change over that 
of the previous day, called delta (∆) G.I., is compared to the control vial and the vials 
containing the compounds. If the daily increase in the vial containing the compound is 
equal or greater than that in the control vial, the test organisms are considered resistant 
to the drug. For a susceptible population, the daily G.I. increase for the control would be 
higher than that of the drug vial. For example, if 1% of the mycobacterial population is 
resistant to INH, then 99% of the organisms would be inhibited by INH and only 1% 
would grow in the vial containing the antibiotic. The growth rate in the vial containing 
INH would be similar to the growth rate in the control vial in which the original 
bacterial inoculum was only 1/100 of that in the drug vial. Thus, instead of counting 
colonies in the control and the drug medium, the G.I. values are utilized to determine 
susceptibility results. The G.I. readings of a susceptibility test require more 
interpretation than do the primary isolation vials. For the first two to three days, the G.I. 
in the control vial will be low but then it will start increasing by a factor of two to three. 
Since the vials containing drugs were inoculated with a 1/100-fold larger inoculum, the 
G.I. readings are usually higher than the control for the first day or two. If the strain is 
susceptible to the test drug, the G.I. output levels off or decreases on the subsequent 
days. However, the G.I. value continues to increase for resistant strains and is much 
higher than the control. This is the reason that a resistant strain can be detected and 
reported earlier than a susceptible strain. The difference in the G.I. values from the 
previous day is designated ∆G.I. Negative ∆G.I. values indicate a decrease while 
positive ∆G.I. values indicate an increase in growth and G.I. output. When the control 
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vials reach a G.I. of 30 or more, the results should be interpreted as follows: if the ∆G.I. 
is less in the drug vial than the control, the population is susceptible; if more, it is 
resistant. The definition of the susceptibility profile of the strains could be summarized 
as follows: 
∆G.I. (Control) > ∆G.I. (drug) – “susceptible” 
∆G.I. (Control) < ∆G.I. (drug) – “resistant” 
∆G.I. (Control) = ∆G.I. (drug) – “borderline” 
  
In all the experiments conducted this control was performed in order to assure the 
correct interpretation and liability of the results. 
 
The same approach was employed to test the in vitro activity of phenothiazines, CPZ, 
TZ, PMZ, PMTZ and DSP against Mycobacterium avium strains CIP 14 031 002-S4 
(Pasteur Institute, Paris, France) and a clinical isolated obtained from an AIDS patient. 
The in vitro effect of SILA compounds 409 and 421 against M. tuberculosis strain was 
also the same described above. 
 
II.6. Electron microscopy (in vitro) 
 
II.6.1 Bacteria 
 
Methicillin-Resistant S. aureus (MRSA) and Multi-drug resistant (MDR-TB) (resistant 
to INH, RIF and STR) strains. 
 
II.6.2 Materials  
 
Thioridazine (TZ), oxacillin (OXA) paraformaldehyde, sodium dodecylsulphate (SDS), 
glutaraldehyde and osmium tetroxide were purchased from Sigma Aldrich Química SA 
(Madrid, Spain). PBS was purchased from Gibco (Paisley, United Kingdom). TSB and 
Trypticase Soy Agar (TSA) were purchased from Difco Laboratories (Detroit, MI, 
USA). TZ solutions were prepared in distilled sterile water on the day of the experiment 
and protect from light. 
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II.6.3 Instrumentation  
 
Zeiss EM 900 electron microscope (Carl Zeiss, Oberkochen, Germany). 
Ultracut S (Microtome, Leica, Vienna, Austria) 
 
II.6.4 Quality control  
 
The quality control was performed by Prof. Dr. W. Bleiss at his laboratory in the 
Institute of Molecular Parasitology of the Humboldt University, Berlin, Germany.  The 
evaluation of the ultra-structure of bacteria and macrophages with the aid of the electron 
microscope was conducted jointly by Prof. Dr. Bleiss and Prof. Dr. L. Amaral.  
 
II.6.5 Method 
 
In order to determine the effects that TZ induced on the ultra-structure of MRSA and 
MDR-TB in vitro, bacterial cultures were prepared and TZ added at a concentration of 
20 mg/L. A control with no TZ was also conducted in parallel. In the case of MRSA, 18 
hours cultures were performed and in the case of M. tuberculosis, cultures for 24 hours. 
The products of in vitro cultures-containing or lacking TZ were centrifuged at 800×G 
for 30 minutes. The pellets were washed with PBS (pH 7.4), centrifuged and re-
suspended in 2.5% glutaraldehyde. After being maintained for 2 hours at 4ºC, the pellets 
were centrifuged, washed twice with PBS, re-suspended in 2% osmium tetroxide and 
maintained at 4ºC for 2 hours. After this time cells were centrifuged, washed with PBS, 
mixed with a small volume of melted 2.5% agarose and immediately chilled on ice. The 
solidified agarose was cut into blocks (about 1 mm3), stained en bloc for 1 hour with 1% 
uranyl acetate in 0.05 M sodium maleate buffer pH 5.2 at 4ºC, dehydrated in a graded 
ethanol series, infiltrated and embedded in Spurr's epoxy resin and polymerised for 24 
hours at 70ºC. For transmission electron microscopy (TEM), ultra-thin sections of 80 
nm were obtained with the aid of an Ultracut S (Microtome, Leica, Vienna, Austria) 
using a diamond knife. The sections were post-stained with uranyl acetate and 
Reynold's lead citrate and viewed by Prof. Dr. Amaral and Prof. Dr. Bleiss with the aid 
of a Zeiss EM 900 electron microscope (Carl Zeiss, Oberkochen, Germany). 
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II.7. Evaluation of ex vivo activity of compounds studied against S. aureus 
  
II.7.1 Bacteria 
 
S. aureus ATCC25923 (control strain) and Methicillin-Resistant S. aureus (MRSA) 
strains were selected as experimental model for screening of compounds that will work 
on MDR-TB. The MRSA strains were clinical isolates gently provided by Drª. Teresa 
Pacheco (Laboratório de Microbiologia, Hospital Egas Moniz; Lisboa, Portugal). 
 
II.7.2 Materials  
 
RPMI medium, Ficoll-Hypaque, HBSS and Trypan blue were purchased from Sigma-
Aldrich Química SA (Madrid, Spain). 50 mL Falcon tubes and tissue culture plates were 
purchased from Nalgene (Nunc, Thermo Scientific; Rochester, NY, USA). TSA was 
purchased from Oxoid (Basingstoke, England). 
 
II.7.3 Instrumentation  
 
Refrigerated centrifuge (Rotanta 46R; Hettich Zentrifugen) 
CO2 Water Jacketed Incubator (Nuaire NU-4500/E)  
 
II.7.4 Quality control 
 
The incubator was periodically checked and calibrated with a certified thermometer 
(Omnilabor, Lisboa, Portugal). Weekly performance tests related to temperature and 
percent of CO2 inside the incubator chamber were conducted according to manufacturer 
recommendation. 
 
II.7.5 Method 
 
II.7.5.1 Isolation of Human monocyte-derived macrophages 
 
Twenty-millilitres of blood from healthy voluntary donors was collected and transferred 
into tubes containing 50 U of preservative-free sodium heparin (Monoparin, CP 
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Pharmaceuticals Ltd, Wrexham, UK). The blood sample was processed on the same day 
of the collection. A 1:2 dilution was performed with RPMI 1640 medium and 20 mL 
were layered onto 12 mL of Ficoll (Sigma, Madrid, Spain). Blood was centrifuge at 
800×G for 30 minutes. Plasma was collected to a new Falcon tube and kept for 
subsequent complete media preparation (RPMI medium supplemented with 10% of 
autologous serum). The mononuclear cells obtained from the buffy coats were 
transferred to new 50 mL Falcon tubes. Cells were washed with HBSS at 800×G for 30 
minutes and then 2 more times at 800×G for 10 minutes. The pellet obtained was re-
suspended in 5 mL of RPMI 1640 medium and an aliquot of 10 µL was retrieved and 
added to 90 µL of a trypan-blue solution. Viable cells were counted and the cellular 
concentration adjusted to 1×106 cells/mL in RPMI 1640 medium containing 2 mM L-
glutamine (Sigma; Madrid, Spain) and supplemented with 10% of autologous serum. 
From this cellular suspension aliquots of 1 mL were distributed to the wells of a 24-well 
plate (Nalgene, Nunc, Thermo Scientific; Rochester, NY, USA). Cellular cultures were 
incubated at 37ºC with 5% CO2 for 3 days. After this period, medium was retrieved 
from each wells and aliquots kept at -80ºC for posterior cytokines analysis. A cycle of 
three washes were performed with RPMI 1640 medium to remove all the non adhered 
cells (lymphocytes). 10% of the total cells that adhere to the wells of the plate are 
monocyte-derived macrophages. Aliquots of complete medium (1 mL) are added to 
each well and the plate incubated at 37ºC with 5% of CO2 for 2 more additional days. 
After this incubation period, monocyte-derived macrophages were ready for infection 
with S. aureus strains.  
 
II.7.5.2 Phagocytosis assay 
 
On the day the cells were to be infected with S. aureus, the wells were previously 
washed three times with RPMI 1640 medium and new fresh medium was distributed to 
each well. The monocyte-derived macrophages were then infected with 0.010 mL of a 
bacterial suspension of 1.0 ×106 bacteria/mL and the cells incubated at 37°C, 5% CO2 
for 30 minutes. This ratio of 10:1 (bacteria:macrophage) was previously optimized and 
was found to result in optimum phagocytosis (Ordway et al., 2003b). After this period, 
all the supernatants were removed and three consecutive washes with RPMI were 
performed to remove all the non-phagocytosed bacteria. The supernatants of the last 
wash was pooled, plated in TSA and subjected to counting of the numbers of CFU in 
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order to determine if all the non-phagocytosed bacteria had been removed by the 
washings. The TZ and its derivatives in concentrations of 0.01 and 0.1 mg/L were added 
to the wells. Control wells (no compounds) were conducted in parallel. The plates were 
incubated at 37°C for 0, 1 minute, 2, 4 and 6 hours. 1.0 mL of 0.01% SDS was added to 
each well at the determined period of incubation and the wells scrapped to release all 
the phagocytosed bacteria. Aliquots of 0.1 ml of the lysed supernatants were serially 
diluted with saline to 10-4 and plated onto TSA plates. The plates were incubated 
overnight at 37°C and the CFU counted for determination of bacterial concentration 
(Ordway et al., 2002a). All the procedures were conducted in triplicate and repeated at 
least two times. 
 
II.7.5.3 QC for method 
 
All the procedures were conducted in triplicate and TZ was used in all the experiments 
as an internal control. The killing activity of the macrophages was also assessed by the 
plating of the supernatants at 0 and 1 minute of phagocytosis. 
 
The same methodology was applied to test the effect of the methanolic extract of C. 
edulis and of the K+ flux inhibitors, reserpine, ouabain and verapamil. 
 
II.8. Evaluation of ex vivo activity of compounds studied against M. tuberculosis 
strains 
  
II.8.1 Bacteria 
 
M. tuberculosis H37Rv ATCC27294, which is susceptible to RIF, INH, STR, and EMB, 
served as the absolute control and MDR-TB strain (resistant to IHN, RIF and STR) was 
the strain selected for conduct studies with TZ and its derivatives. The MDR strain was 
isolated from a patient involved in an outbreak caused by a highly virulent MDR M. 
tuberculosis strain (cluster A or cluster Lisbon) in a Lisbon Prison Hospital in 1997 and 
has been typed by IS6110-based restriction fragment length polymorphism analysis as a 
member of this cluster (Ordway et al., 2003b; Portugal et al., 1999). This strain has 
been maintained in the Unit of Mycobacteriology (IHMT/UNL; Lisboa, Portugal) and 
characterized for their susceptibility and resistance to the antibiotics listed above with 
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the BACTEC 460-TB system (BACTEC 460 TB SIRE method (1985) Becton 
Dickinson Microbiology Systems).  
 
II.8.2 Materials  
 
PBS, HBSS, RPMI 1640 medium, Ficoll, and L-glutamine were purchased from Gibco 
(Paisley, United Kingdom). TZ, SDS and trypan blue were purchased from Sigma 
Aldrich Química SA (Madrid, Spain). Middlebrook 7H11 solid medium was purchased 
from Difco (Detroit, Mich). Microwell tissue culture plates were purchased from 
Nalgene (Nunc, Thermo Scientific; Rochester, NY, USA). All solutions were prepared 
in distilled, sterile water on the day of the experiment. 
 
II.8.3 Instrumentation  
 
Refrigerated centrifuge (Rotanta 46R; Hettich Zentrifugen) 
CO2 Water Jacketed Incubator (Nuaire NU-4500/E)  
 
II.8.4 Quality control 
 
Weekly performance tests of temperature and CO2 were conducted at the Unit of 
Mycobacteriology according to the manufacturer recommendations. The incubator was 
also periodically checked and calibrated by a certified manufacturer (LaboControle, 
Lisbon, Portugal).  
 
II.8.5 Method 
 
II.8.5.1 Isolation of Human monocyte-derived macrophages 
 
Twenty millilitres of intravenous blood from healthy voluntary donors was collected 
and transferred into tubes containing 50 U of preservative-free sodium heparin 
(Monoparin, CP Pharmaceuticals Ltd, Wrexham, UK). The collected blood was diluted 
1:2 in RPMI 1640 medium and 20 mL was layered onto 12 mL of Ficoll (Sigma, 
Madrid, Spain). Blood was centrifuge at 800×G for 30 minutes and after this period 
monocytes were obtained from formed buffy coats and transferred to new 50 mL Falcon 
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tubes. HBSS was added and three washes were performed, as described: three cycles of 
centrifugations at 800×G for 30 minutes. The pellet obtained was re-suspended in 5 mL 
of RPMI medium and from these an aliquot of 10 µL was retrieved and added to 90 µL 
of a trypan-blue solution and displaced in a Neubauer chamber to perform a viability 
assay. After the cell counting, the concentration was adjusted to 1×106 cells/mL in 
RPMI 1640 medium containing 2 mM L-glutamine (Sigma; Madrid, Spain) and 
supplemented with 10% of autologous serum. Aliquots of 1 mL of this cellular 
suspension were disposed in the wells of a 24-well plate (Nalgene, Nunc, Thermo 
Scientific; Rochester, NY, USA), and the cultures incubated at 37ºC, 5% CO2 for 5 
days. On the third day of incubation, medium was retrieved from the wells and a cycle 
of three washes was performed with RPMI medium in order to remove all the non 
adhered cells. After 5 days of culture, monocyte-derived macrophages were then ready 
for infection with M. tuberculosis. It is important to note that all blood samples were 
processed on the same day of the collection. 
 
II.8.5.2 Phagocytosis and killing activities of M. tuberculosis strains by peripheral 
blood monocyte-derived macrophages (PBMDMs)  
 
After 18 hours of culture of PBMDMs (1.0 × 106 cells/ml) in RPMI medium containing 
2 mM L-glutamine and autologous human serum, approximately 10% of the PBMDMs 
that adhere to the bottom of the wells are monocytes (Ordway et al., 2002a). A bacterial 
suspension of 1.0 ×106 bacteria/mL in 0.010 mL, which had previously been found to 
result in optimum phagocytosis (ratio of 10 CFU:1 macrophage) (Ordway et al., 2003b) 
was added to the monolayer cultures and the cultures were incubated at 37°C, 5% CO2 
for 1 hour (phagocytosis). Two consecutive washes with RPMI were performed to 
remove the extracellular bacteria. These washings were pooled and subjected to 
counting of the numbers of CFU in order to determine the efficiency of phagocytosis. A 
third wash was performed and subjected to plating and counting of the numbers of CFU 
for verification of the complete absence of non phagocytosed bacteria. New RPMI 1640 
media supplemented with 10% of autologous serum was disposed in the wells of the 
plate. The infected macrophages were then pulsed with either TZ or its derivatives at 
non-toxic concentrations of 0.1 and 0.01 mg/L. The cultures were incubated at 37°C, 
5% CO2 for 0, 1, 2 and 3 days. After these periods, cells were lysed with 1.0 mL of 
0.01% SDS and from these lysed supernatant, 0.1 mL aliquots were serially diluted with 
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saline to 10-4. Aliquots (0.1 mL) from each dilution were plated onto 7H11 
Mycobacteria medium and the plates incubated at 37°C for 3 to 4 weeks. After this 
period, CFU were counted and the bacterial concentration determined (Ordway et al., 
2002a).  
 
II.8.5.3 QC for method 
 
Thioridazine was used in all the experiments as an internal control since it had been 
already established by us that this phenothiazine enhanced the killing activity of the 
macrophage in a highly reproducible manner (Ordway et al., 2002a; Ordway et al., 
2003b). The killing activity of the M. tuberculosis infected macrophages was also 
assessed by periodically plating aliquots of supernatants from zero time, 1, 2 and 3 days 
after infection (phagocytosis of M. tuberculosis). All the procedures were conducted in 
triplicate and repeated at least two times.  
 
The methanolic extract of C. edulis, SILA compounds, 409 and 421 and the EPIs, 
reserpine, ouabain and verapamil, were also tested for the enhancement of the 
macrophage killing activity, applying the same methodology described above. 
 
II.9. Electron microscopy (ex vivo) 
  
II.9.1 Bacteria 
 
MRSA strains and MDR-TB strains were selected for studies with TZ and its 
derivatives. These strains have been maintained in the Unit of Mycobacteriology 
(IHMT/UNL; Lisboa, Portugal) and characterized for their susceptibility and resistance 
with the aid of BACTEC 460-TB system to the antibiotics and antimicrobial agents 
listed above (BACTEC 460 TB SIRE method (1985) Becton Dickinson Microbiology 
Systems).  
 
II.9.2 Materials  
 
TZ, OXA, paraformaldehyde, SDS, trypan blue, glutaraldehyde and osmium tetroxide 
were purchased from Sigma Aldrich Química SA (Madrid, Spain). PBS, HBSS, RPMI 
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medium, Ficoll and L-glutamine were purchased from Gibco (Paisley, United 
Kingdom). Microwell tissue culture plates were purchased from Nalgene (Nunc, 
Thermo Scientific; Rochester, NY, USA). TZ was prepared in distilled sterile water on 
the day of the experiment and protected from light. 
 
II.9.3 Instrumentation 
 
Refrigerated centrifuge (Rotanta 46R; Hettich Zentrifugen) 
Zeiss EM 900 electron microscope (Carl Zeiss, Oberkochen, Germany) 
Ultracut S (Microtome, Leica, Vienna, Austria) 
 
II.9.4 Method 
 
In order to determine if the effects that TZ induced on the ultra-structure of MRSA and 
MDR-TB in vitro, could also be seen ex vivo, macrophages cultures were prepared as 
previously described (see II.6. Evaluation of ex vivo activity of compounds studied 
against Staphylococcus aureus). Infection of the monocyte-derived macrophages was 
also performed in accordance with the protocols described (see sections II.6 and II.7 for 
S. aureus and M. tuberculosis cultures, respectively). A control with no TZ was 
conducted in parallel. The protocol described was conducted in the same manner for 
MRSA and MDR-TB strains and is described as follows: after the incubation period, 
cells were lysed with 0.01% of SDS and the products of ex vivo cultures-containing or 
lacking TZ, were centrifuged at 800×G for 30 minutes. The pellets were washed with 
PBS (pH 7.4), centrifuged and re-suspended in 2.5% glutaraldehyde. After being 
maintained for 2 hours at 4ºC, the pellets were centrifuged, washed twice with PBS, re-
suspended in 2% osmium tetroxide and maintained at 4ºC for 2 hours. After this time, 
pellets were centrifuged, washed with PBS and mixed with a small volume of melted 
2.5% agarose and immediately chilled on ice. The solidified agarose was cut into blocks 
(about 1 mm3), stained en bloc for 1 hour with 1% uranyl acetate in 0.05 M sodium 
maleate buffer pH 5.2 at 4ºC, dehydrated in a graded ethanol series, infiltrated and 
embedded in Spurr's epoxy resin and polymerised for 24 hours at 70ºC. For TEM, ultra-
thin sections of 80 nm were obtained with the aid of an Ultracut S (Microtome, Leica, 
Vienna, Austria) using a diamond knife. The sections were post-stained with uranyl 
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acetate and Reynold's lead citrate and viewed with a Zeiss EM 900 electron microscope 
(Carl Zeiss, Oberkochen, Germany).  
 
II.10. Evaluation of in vivo activity of TZ against Balb/C mice infected with M. 
tuberculosis 
  
The main goal of this thesis was to evaluate the toxicity effect of TZ and its selected 
derivatives as well and the effectiveness of these phenothiazines for curing Balb/C mice 
infected with M. tuberculosis H37Rv ATCC27294. This study was conducted with the 
parent molecule (TZ) since the parameters (toxicity, optimization of compound dosage, 
concentration, injection schedule, etc.) to be established are extremely important. The 
animals selected were Balb/C mice since they present an increased susceptibility to 
infection and progression to active disease and by this manner, can mimic the process 
that occur in the human exposed to M. tuberculosis.  
 
II.10.1 Bacteria 
 
Because we had already demonstrated that the response of MDR-TB is identical to that 
of antibiotic susceptible M. tuberculosis H37Rv ATCC27294 (Ordway et al., 2003b) 
the latter strain was selected for infecting the mouse. Moreover, the selection of this 
strain provided more safety to the Ph.D. candidate since the therapy of an infection with 
antibiotic susceptible M. tuberculosis is readily possible whereas an infection with 
MDR-TB can be lethal. M. tuberculosis ATCC H37Rv was cultured in MGIT 960 
medium (Difco, Madrid, Spain) containing Tween 80 (Difco, Madrid, Spain) until an 
O.D. of approximately 0.6 was reached. After this, aliquots were prepared and the 
inoculums adjusted to 1×106 bacteria/mL in PBS (Sigma-Aldrich Química SA, Madrid, 
Spain). 
 
II.10.2 Animals 
 
Thirty female Balb/C mice age 2-3 weeks (approximately 30 g) were purchased to 
Harlan Iberica (Madrid, Spain).  
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II.10.2.1 Animal and Human Safety conditions 
 
During and after the quarantine period that the animals were subjected after being 
delivered to the IHMT, during infection and during treatment with TZ, that is, for the 
duration of the experiment, mice were housed in a Class II BioSafety Cabinet 
maintained within a fully certifiable P3 facility (Office of Health and Safety (OHS) 
USA-Section VI, Recommended biosafety levels for infectious agents) at the Unit of 
Mycobacteriology. Licensing and certification of the Ph.D. candidate for laboratory 
animal handling an experimental infection of small animals was obtained after the 
attending of the Course in Laboratory Animal Science, FELASA, Category C, held at 
the IHMT/UNL (Lisboa, Portugal) and subsequent examination. The License and 
researcher certificate was granted by the Direcção Geral de Veterinária (DGV, 
Portugal).  
 
II.10.3 Materials  
 
Insulin syringes (Terumo) were purchased from Omnilabor (Lisbon, Portugal) 
Microisolator cages (E1CCBAC056) with HEPA filters on the top (E4FVCOU926) 
(Charles River Laboratories, Massachusetts, USA) 
 
II.10.4 Instrumentation  
 
Analytic Balance (Explorer; Ohaus) 
Laminar Flow Cabinets (NU-425-600E; Nuaire) 
Microcentrifuges (Labofuge 200; Heraeus) 
Wallthrough double door Autoclave (AMARO 2000; A. J. Costa)  
37ºC Incubator (Model 600; Memmert) 
 
II.10.5 Quality control 
 
The described study requires important security measures that were strictly followed 
since the work performed involved infection of the animals with M. tuberculosis. In this 
manner, the state of the art biosafety level 3 conditions of the Unit of 
Mycobacteriology-P3-Safety Laboratory were maintained, by replacing the HEPA 
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filters (P3 Safety Laboratory Air Control Devices; Tecniclima, 1999) every 6 months by 
a certified company (Tecniclima, Portugal). Also, additional annual maintenance was 
conducted for the wall-through autoclave.  
 
II.10.6 Method 
 
II.10.6.1 Quarantine 
 
Before toxicity assays were initiated the animals were kept in quarantine for 3 weeks. 
Mice were divided in groups of 5 animals each with water and food ad libitum. Every 
day the animals were observed for any alterations in behaviour, indicative of stress or 
disease. The illumination of the laboratory safety facility was daily checked. During the 
quarantine period none of the animals developed any visible scar or signal of disease. 
By this manner, all the animals were considered for toxicity testing. 
 
II.10.6.2 Toxicity assays 
 
Mice were divided in 6 groups of 5 animals each. From these, 5 groups were daily 
injected with 0.1 mL of a TZ solution in concentrations of 0.01, 0.02, 0.05, 0.10, 0.2 
and 0.5 mg/day. These doses are equivalent to 25, 50, 100, 200, 400 and 1200 mg 
TZ/kg/day in the human. The remaining group (control) was submitted to the same 
protocol however, it was injected with a saline solution. Daily monitoring was 
performed recording all the alterations in behaviour or in weight. 
 
II.10.6.3 Infection studies 
 
All the animals were intraperitoneally (i.p.) infected with M. tuberculosis H37Rv 
ATCC27294 with 1×106 bacteria in 0.1 ml of sterile saline, strictly following all the 
safety and security measures recommended for experiments involving animals and 
handling of infectious agents (CDC, 1999; Hau and Van Hoosier, 2003; NIH, 1996). 
After the infection, mice were divided into groups of 5 animals each. After three days 
post-infection, treatment with TZ (Sigma-Aldrich Química SA, Madrid, Spain) was 
initiated, except for the control group. Each day, four groups of mice (to be treated) 
were injected i.p. with 0.1 mL of TZ in the concentrations of 0.05, 0.10, 0.2 and 0.5 
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mg/day, respectively. These doses are equivalent in the human to 100, 200, 400 and 
1200 mg TZ/kg/day, considering an average weight of 70 Kg for an adult. The 
maximum dose of 0.5 mg/day is equivalent, on a kg basis, to approximately twice the 
maximum dose a chronically treated psychotic patient receives per day. The control 
group received no treatment however, in order to be submitted to the same stress than 
the animals of the other groups, was injected with a saline solution (PBS, Sigma-
Aldrich Química SA, Madrid, Spain) with the same volume used to administrate the 
agent to the mice. The animals were observed daily in order to monitor alterations of 
behaviour and were weighed daily before the administration of TZ. At the end of 30 
days, and thereafter at monthly intervals, mice from each group were sacrificed by 
cervical dislocation and their lungs, liver and spleen removed and weighed. One lung, a 
lobe of the liver and a portion of the spleen were kept for histological studies. The 
remaining portions of these organs were weighed, diced and transferred to 
homogenizing conical tubes containing 1 mL of 0.1N NaOH. The organs were manually 
homogenised and aliquots of 0.1 mL transferred in triplicate to 1.0 mL of saline (PBS, 
Sigma-Aldrich Química SA). From these, aliquots of 0.1 mL were serially transferred to 
1.0 mL of saline and 0.1 mL of the resulting solution plated onto 7H11 agar plates 
(Mycobacteria 7H11 Agar; Difco, Madrid, Spain). The plates were incubated at 37ºC 
and after 3 to 4 weeks of incubation the CFU were counted and extrapolated to CFU/kg 
of tissue.    
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
CHAPTER III. 
 
Clinical Concentrations of Thioridazine Enhance the Killing of 
Intracellular Methicillin-resistant Staphylococcus aureus: an In Vivo, 
Ex Vivo and Electron Microscopy Study 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter contains data published in: 
 
Martins, M., W. Bleiss, A. Marko, D. Ordway, M. Viveiros, C. Leandro, J. Molnar, J. E. 
Kristiansen, J. Wecke, and L. Amaral. 2004. Clinical concentrations of thioridazine enhance the killing 
of intracellular methicillin-resistant Staphylococcus aureus: an in vivo, ex vivo and electron microscopy 
study. In Vivo 18:787–794. 
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To reduce the global burden of TB by 2015, the WHO in line with the Millennium 
Development Goals and the Stop TB Partnership, has defined 4 main objectives, 
namely: the achievement of universal access to high-quality diagnosis and patient-
centred treatment; the reduction of the human suffering and socioeconomic burden 
associated with TB; the protection of poor and vulnerable populations from TB, 
TB/HIV and MDR-TB and finally to support the development of new tools and enable 
their timely and effective use. In order to accomplish these objectives the targets 
considered were endorsed by the Stop TB Partnership and by 2005 detected at least 
70% of new sputum smear-positive TB cases and cure of at least 85% of these cases. By 
2015, these targets are expected to reduce prevalence of and deaths due to TB by 50% 
relative to 1990 and, by 2050 eliminate TB as a public health problem (<1 case per 
million population). In order for this strategy to succeed, 6 main components were 
established, namely: 
 
1) Pursue high-quality DOTS expansion and enhancement through the political 
commitment with increased and sustained financing; the case detection through 
quality-assured bacteriology; standardized treatment with supervision and patient 
support; an effective drug supply and management system and the monitoring and 
evaluation system, and impact measurement;  
 
2) Address TB/HIV, MDR-TB and other challenges by implementing collaborative 
TB/HIV activities; prevent and control MDR-TB and address prisoners, refugees and 
other high-risk groups and special situations; 
 
3) Contribute to health system strengthening by actively participate in efforts to 
improve system-wide policy, human resources, financing, management, service 
delivery, and information systems and share innovations that strengthen systems, 
including the Practical Approach to Lung Health, as well as to adapt innovations from 
other fields; 
 
4) Engage all health care providers: Public-Public, and Public-Private Mix approaches 
and defining International Standards for TB Care; 
 
Chapter III 
 110
5) Empower people with TB, and communities by advocacy, communication and social 
mobilization; community participation in TB care and patients’ Charter for Tuberculosis 
Care; 
 
6) Enable and promote a Programme-based operational research to develop new 
diagnostics, drugs and vaccines. 
 
At the Unit of Mycobacteriology (IHMT/UNL) we have focused on objectives 1 and 6 
which have, with the implementation of the TB Task Force (previously described in the 
introduction of this thesis) yielded reduction of new cases of MDR-TB from an excess 
of 28% to less than 8% (DGS, 2006) and developed new drugs which have activity 
against XDR-TB/MDR-TB.  
 
The main objective of my thesis research is the development of new drugs that have 
activity against XDR-TB/MDR-TB. Because phenothiazines have been shown by our 
group to have activity against these antibiotic resistant strains of M. tuberculosis, I have 
selected thioridazine, a derivative of chlorpromazine but which produces far milder side 
effects, for assessment of its in vitro, ex vivo and in vivo activity against M. 
tuberculosis; have examined the mechanism by which it produces its anti-TB effects; 
and as a consequence have provided this information for the synthesis of derivatives of     
TZ derivatives by a colleague of our laboratory (Professor György Hajós, Hungarian 
Academy of Science, Budapest, Hungary). The results presented in the next series of 
sections will describe the studies conducted that define in vitro, ex vivo and in vivo 
activity of TZ derivatives against M. tuberculosis strains, the mechanism by which these 
agents produce their anti-TB effects as well as the methods that have been developed for 
the characterisation of a specific form of resistance which render bacteria resistance to 
two or more unrelated antibiotics. Each chapter will present an initial outline and the 
most important results obtained as well as a general discussion. Whenever relevant, the 
publication itself or aspects of that publication that resulted from this component of the 
thesis will be presented. 
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CHAPTER OUTLINE 
 
This chapter is focused on the in vitro and ex vivo effects of TZ on Methicillin-resistant 
S. aureus (MRSA) strains. MRSA has been used as a model that evaluates the effects of 
the phenothiazine since these are essentially the same as those produced with strains of 
M. tuberculosis and are produced and evaluated within a day as opposed to three or 
more weeks when M. tuberculosis is used. The data obtained from the MRSA model is 
then used for the planning of experiments with M. tuberculosis. The minimum 
inhibitory and minimum bactericidal concentrations of CPZ and TZ against MRSA 
strains were determined and the intracellular killing activity of these phenothiazines on 
MRSA strains evaluated. Electron microscopy studies were also performed to determine 
the effects of TZ on the ultrastructure of MRSA strains in vitro and on MRSA that has 
been phagocytosed by macrophages. The results obtained with Methicillin-resistant S. 
aureus strains establish the parameters to be applied in subsequent work involving M. 
tuberculosis strains.   
 
SUMMARY  
 
Chlorpromazine (CPZ) is concentrated by human macrophages where it kills 
intracellular mycobacteria when the concentration outside the macrophage is sub-
clinical. We have previously demonstrated that thioridazine (TZ), a much milder 
phenothiazine, has similar activity and kills intracellular methicillin-susceptible S. 
aureus at sub-clinical concentrations (Ordway et al., 2002a). We have extended this 
latter study to include methicillin-resistant S. aureus (MRSA) and show that TZ kills 
intracellular MRSA at clinically relevant concentrations. The ultrastructure of MRSA 
exposed to in vitro concentrations of TZ just below its MIC and that of MRSA 
phagocytosed by macrophages previously exposed to a clinically relevant concentration 
of TZ was also studied. TZ inhibits the replication of phagocytosed MRSA, affecting 
the structure of the cell envelope resulting in lysis of the bacterium 6 hours post-
phagocytosis. These ultrastructural changes are identical to those produced in vitro by a 
TZ concentration that is near the MIC. Because macrophage intracellular MRSA is not 
killed by the macrophage and its intracellular location protects it from antibiotics that 
are unable to reach that site, recurrent infections which result may be successfully 
managed with the use of TZ. 
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The materials and methods employed for this study are described in Chapter II,                                     
(sections II.3 and II.7) as well as by publication #1 listed in the Appendix. Nevertheless, 
the legends of the tables and figures contain sufficient information relevant to the 
methods employed. 
 
RESULTS 
 
The minimum inhibitory concentration (MIC) and minimum bactericidal 
concentration (MBC) of CPZ and TZ against MRSA strains. The in vitro activity of 
CPZ and TZ against MRSA strains is summarised in Table 1. Briefly, although CPZ 
and TZ have similar MICs against either strain of S. aureus, the activity of TZ is greater 
than that exhibited by CPZ. The MICs for CPZ and TZ against these S. aureus are 
consistent with those previously reported (Amaral et al., 1992; Ordway et al., 2002a; 
Radhakrishnan et al., 1999). The bactericidal activity of each of these compounds is 
expressed at a higher concentration of each compound and, again, the activity of TZ, as 
expressed by the MBC, is higher than that of CPZ although the difference is not 
statistically significant. 
 
Table 1. MIC and MBC of CPZ and TZ against methicillin-resistant S. aureus 
(MRSA) strainsa. 
  
MIC and MBC of compounds 
(mg/L) 
  MRSA1 MRSA2 MRSA3 
MIC 40 40 40 
CPZ 
MBC 80 70 80 
MIC 20 20 30 
TZ 
MBC 60 40 50 
 
a100,000 CFU were incubated at 37°C with increasing concentrations of each compound in 10 mL TSB 
for 18 hours. The MIC of each compound-strain was determined from visible examination of cultures that 
contained no evidence of growth. The MBC of each compound-strain was determined by plating the 
cultures beyond each MIC on TSB agar plates and counting CFUs. CPZ (chlorpromazine), TZ 
(thioridazine). 
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The intracellular killing activity of CPZ and TZ on MRSA strains. A minimal 
concentration of CPZ or TZ of 0.1 mg/L, as shown by Figure 1, after a slow initial 
effect (2 hours), consistently reduced the number of viable MRSA cells by the end of 4 
hours after phagocytosis by human PBMDM. Enhanced intracellular killing activity 
continued to increase with time such that, by the end of 6 hours, killing was almost 
complete. Similar results were obtained with the use of the THP-1 cell line (data not 
shown). The lower concentration of 0.01 mg/L of either of these two phenothiazines had 
a marginal effect on the number of viable bacteria recovered 6 hours subsequent to 
phagocytosis. The concentration of 0.1 mg/L was confirmed in this study, and in 
previous studies, to be non-toxic to the macrophage and not to affect the phagocytic 
processes of this cell (Ordway et al., 2002a). 
 
Figure 1. The average effect of chlorpromazine (CPZ) and thioridazine (TZ) on 
intracellular growth of the 3 MRSA strains tested. The THP-1 and human PBMDM were 
infected for 30 minutes with the methicillin-resistant clinical strains of S. aureus (MRSA), at 
concentrations of 10 CFU per macrophage (10:1). CPZ and TZ were then separately added to the cultures 
at concentrations of 0.01 and 0.1 mg/L. Control cultures received no drug. Results are expressed as the 
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mean CFU of the 3 MRSA strains tested in 3 independent experiments. Data presented was obtained with 
the use of human PBMDM and is similar to that obtained from the use of THP-1 cells. 
 
The effects of TZ on the ultrastructure of MRSA strains in vitro. The in vitro 
presence of a concentration of 20 mg/L of TZ that is below that which totally eliminates 
the replication of MRSA produced the typical ultrastructure of MRSA is shown by 
Figure 2. Briefly, major alterations noted were: blebbing of the cell wall (a); thickening 
of the cell wall and cross-walls (b); partial separation of the internal portion of the cell 
wall (c); continued production of cross-walls without subsequent separation of the 
replicated cells (d); asymmetrical cross-wall formation (e); partial loss of cell wall (f) 
and lysis of the cell (g). Only (f) and (g) alterations are expected to ultimately, result in 
cell death, inasmuch as even the most severe changes (a-e) are reversible when the 
organism is transferred to TZ-free medium (data not shown). All of the alterations noted 
have been previously reported for methicillin-susceptible S. aureus exposed in vitro to 
sub-inhibitory concentrations of chlorpromazine (Kristiansen and Amaral, 1997). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The in vitro effect of TZ on the ultrastructure of MRSA after 18 hours of 
culture. Blebbing of cell wall (a), thickened cell wall and cross-walls (b), partial partitioning of the 
internal portion of the cell wall (c), continued production of cross-walls without separation of the 
replicated cells (d), asymmetrical cross-wall formation (e), partial loss of cell wall (f), evidence of lysis 
(g). It is important to note that this concentration of TZ does not kill the majority of cells and that, with 
the exception of (f) and (g), the alterations noted are reversible. The strain selected for the electron 
microscopy studies was the MRSA3. 
 
a
b
c
d
e
f
g
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The ultrastructure of MRSA that has been phagocytosed by macrophages 
previously exposed to a concentration of TZ of 0.1 mg/L. The typical ultrastructure 
of phagocytosed MRSA of a 6-hour culture control is presented in Figure 3 and is quite 
normal and identical to that previously shown for in vitro controls (Kristiansen and 
Amaral, 1997). There is ample evidence that cell division is taking place within the 
phagosome, as noted by the presence of cross-walls in different degrees of completion 
and almost complete separation of the two replicated cells from each other. It should be 
noted that, because the thickness of the section was very small (80 nm), many of the 
cells present in Figure 3 show only portions of the cell that are distal to the cross-wall. 
In contrast to the ultrastructure of the 6-hour control population of intracellular MRSA, 
phagocytosis of the MRSA followed by exposure to 0.1 mg/L of TZ results in the 
alteration of the ultrastructure of MRSA as early as 4 hours post-phagocytosis (Figure 
4). Evidence of replication was scarce as noted by the absence of cross-walls in the 
majority of phagocytosed MRSA and, when cross-walls are present, they are thickened 
(Figure 4a). The periphery of the cell wall appeared eroded (Figure 4b). Further 
alteration of the ultrastructure of S. aureus was evident after 6 hours (Figure 5). It 
should be noted that phagocytosed MRSA showed an incomplete cell wall and in some 
cases, an incomplete plasma membrane that allowed the spilling of the cytoplasm out of 
the bacterium. The presence of cross-walls in this population of intracellular MRSA was 
then quite rare suggesting that replication had been essentially inhibited. 
 
 
 
 
 
 
 
 
 
 
Figure 3. The ultrastructure of MRSA 6 hours after it has been phagocytosed by 
the human macrophage (Controls). Presence of normal morphology, evidence of cross-wall 
formation at different stages.  
 
0.15 µm0.25 µm
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Figure 4. The ultrastructure of MRSA 4 hours after it has been phagocytosed by 
the human macrophage that had been subsequently exposed to a concentration of 
TZ of 0.1 mg/L. Cross-walls are scarce and when present are bizarre (a); periphery of cell wall is 
eroded (b). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. The ultrastructure of MRSA 6 hours after it has been phagocytosed by 
the human macrophage that had been subsequently exposed to a concentration of 
TZ of 0.1 mg/L. The same effect was observed in all TZ exposed cells. Note: Incomplete cell wall, 
incomplete plasma membrane, evidence of lysis. Compare with Figure 2. 
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DISCUSSION 
 
The main objections raised for the use of chlorpromazine as an antibacterial agent are: 
(i) its known toxicity when chronically employed and, (ii) its in vitro antibacterial 
activity which takes place at concentrations which are well beyond those achievable in 
the human. The results obtained in this study suggest that, as previously shown (Amaral 
and Kristiansen, 2000; Amaral and Kristiansen, 2001; Amaral et al., 1996; Amaral et 
al., 2001a; Amaral et al., 2001b; Bettencourt et al., 2000; Ordway et al., 2002b; 
Viveiros and Amaral, 2001), thioridazine has in vitro antibacterial activity equal to that 
of chlorpromazine. Furthermore, the current study also showed that a concentration of 
either phenothiazine corresponding to one easily achieved in patient plasma kills 
intracellular staphylococci regardless of their antibiotic susceptibility. Because the in 
vitro concentration of either phenothiazine needed to kill MRSA is of the order of 60 
mg/L, and since both of these compounds are known to be concentrated by 
macrophages/tissues rich in macrophages (Ordway et al., 2002a), we hypothesise that 
the concentration of either drug needed to kill intracellular Staphylococcus is reached as 
a result of the macrophage's ability to concentrate these compounds. This belief is 
further supported by the demonstration that  whereas a concentration of TZ near its MIC 
is needed to alter the morphology of  MRSA in vitro, the altered morphology are 
reproduced in phagocytosed MRSA by a concentration of TZ in the cell culture medium 
that is 200 to 300 times lower. Phenothiazines intercalate between nucleic bases of 
DNA (Stolze and Mazon, 1991) and result in inhibition of all DNA-based processes 
(Hawtrey et al., 2002; Kruglova and Zinenko, 1993; Webb and Hass, 1984). The in 
vitro concentration needed for sufficient TZ to traverse the cell envelop of MRSA and 
reach DNA for its intercalation must be exceedingly greater than that present in the 
medium to which the macrophage-phagocytosed MRSA is exposed. We believe that the 
killing of intracellular staphylococci by TZ is the result of the macrophage achieving the 
sufficiently high concentrations of drug needed for the penetration of the drug and its 
subsequent intercalation into the bacterium DNA. However, because of the killing 
activity of the macrophage, at least with respect to methicillin-resistant S. aureus, it may 
well be that the initial process of killing might first involve the action of macrophage-
lysosomal enzymes on the cell wall of the bacterium making it more permeable to the 
phenothiazine. Thus the concentrations achieved within the macrophage need not be 
equal to those corresponding to the in vitro MBC. Because the partial loss of the cell 
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wall and plasma membrane produced in vitro is identical to that present in MRSA that 
have been phagocytosed by the macrophage and subsequently treated with TZ, we 
conclude that the TZ-concentrating effect inside the macrophage is the primary cause 
for the killing of MRSA. MRSA strains account for a large number of deaths that result 
from nosocomial infections (Hiramatsu et al., 2001; Metlay, 2002; Noskin, 2001). The 
use of fluoroquinolones rapidly resulted in resistance of S. aureus (Appelbaum and 
Hunter, 2000). Furthermore, some of these quinolones were found to be toxic and 
subsequently removed from use (Appelbaum and Hunter, 2000). Vancomycin is the 
only really effective drug that remains and resistance to this compound is already taking 
place (Boyle-Vavra et al., 2001; Ward et al., 2001). We believe that TZ has potential for 
the therapy of persistent and recurrent MRSA infections that result from the inability of 
the antibiotics to reach the bacterium after it has been phagocytosed (Talon et al., 2002). 
Because TZ has been in safe use for many decades and its use as an anti-bacterial agent 
is anticipated to be, for a shorter period of time than that employed for the psychotic 
disorder therapy, safe and effective for the management of persistent and recurrent 
intracellular infections. Because the number of lethal bacterial targets affected by the 
phenothiazine is large, resistance to thioridazine is anticipated to be low, if not, 
improbable (Amaral et al., 2001a, b; Kristiansen and Amaral, 1997). Nevertheless, 
clinical trials are strongly recommended. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER IV. 
 
In vitro and ex vivo activity of TZ and its derivatives against 
Mycobacterium tuberculosis and M. avium 
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CHAPTER OUTLINE 
 
This chapter is focused on the in vitro and ex vivo activity of TZ against mycobacteria.  
 
The main headings addressed in this chapter are: 
 
• The effect that clinical concentrations of TZ have on intracellular multidrug-
resistant Mycobacterium tuberculosis. Ex vivo studies were conducted on 
monocyte derived macrophages infected with multidrug-resistant M. tuberculosis. 
From the results obtained with the parental compound (TZ), parameters such as 
concentration, time of incubation, ratio of infection, etc.,  were selected; 
 
• The in vitro and ex vivo activity of TZ derivatives against M. tuberculosis. The 
in vitro activity of twenty-two TZ derivatives was evaluated against M. 
tuberculosis strains and further extended to the infected monocyte derived 
macrophages; 
 
• The in vitro activity of TZ, as well as other phenothiazines against M. avium. 
M. avium shows resistance to most of the compounds available to treat 
mycobacterial infections. However, in patients presenting with AIDS these 
infections are more difficult to treat and therefore, the need for new non-toxic 
compounds is obvious. Because phenothiazines, especially TZ, have significant 
activity against M. tuberculosis, the in vitro activity of CPZ, TZ, promazine, 
promethazine and desipramine against M. avium strains was evaluated. 
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IV.1 Clinical concentrations of thioridazine kill intracellular multidrug-resistant 
Mycobacterium tuberculosis 
 
SUMMARY 
 
The phenothiazines chlorpromazine (CPZ) and thioridazine (TZ) have equal in vitro 
activities against antibiotic-sensitive and -resistant Mycobacterium tuberculosis. These 
compounds have not been used as anti-M. tuberculosis agents because their in vitro 
activities take place at concentrations which are beyond those that are clinically 
achievable. In addition, chronic administration of CPZ produces frequent severe side 
effects. Because CPZ has been shown to enhance the killing of intracellular M. 
tuberculosis at concentrations in the medium that are clinically relevant, we have 
investigated whether TZ, a phenothiazine whose negative side effects are less frequent 
and serious than those associated with CPZ, kills M. tuberculosis organisms that have 
been phagocytosed by human macrophages, which have nominal killing activities 
against these bacteria. Both CPZ and TZ killed intracellular antibiotic-sensitive and       
-resistant M. tuberculosis organisms when they were used at concentrations in the 
medium well below those present in the plasma of patients treated with these agents. 
These concentrations in vitro were not toxic to the macrophage, nor did they affect in 
vitro cellular immune processes. TZ thus appears to be a serious candidate for the 
management of a freshly diagnosed infection of pulmonary tuberculosis or as an adjunct 
to conventional anti-tuberculosis therapy if the patient originates from an area known to 
have a high prevalence of multidrug-resistant M. tuberculosis isolates. Nevertheless, we 
must await the outcomes of clinical trials to determine whether TZ itself may be safely 
and effectively used as an anti-tuberculosis agent. 
 
Materials and Methods employed in this study are described in publication #5 and in 
Chapter II (sections II.5 and II.8). 
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RESULTS 
 
MICs and MBCs of CPZ and TZ for antibiotic-susceptible and MDR M. 
tuberculosis strains. The average MICs and MBCs of CPZ and TZ for three antibiotic-
susceptible strains (including strain ATCC27294) and three antibiotic-resistant M. 
tuberculosis strains are summarized in Table 1. Briefly, the MBCs of CPZ and TZ were 
significantly greater than the respective MICs for antibiotic-susceptible and -resistant 
strains of M. tuberculosis. The activities of TZ against each of the strains were greater 
than those of CPZ. Lastly, MDR M. tuberculosis strains were significantly more 
resistant to the actions of CPZ and TZ than the antibiotic-susceptible strains were. It is 
noteworthy that because the MICs and MBCs were not determined by the broth dilution 
method and, indeed, were the precise concentrations used against a constant 
standardized inoculum, the differences noted above are deemed significant. 
 
Table 1. MICs and MBCs of CPZ and TZ for antibiotic-sensitive and MDR strains 
of M. tuberculosisa 
Susceptible strains  Resistant strains 
ATCC27294 / A / B  C  D  E  
Drug MIC 
(mg/L) 
MBC 
(mg/L) 
 MIC 
(mg/L) 
MBC 
(mg/L) 
 MIC 
(mg/L) 
MBC 
(mg/L) 
 MIC 
(mg/L) 
MBC 
(mg/L) 
CPZ 10 20  30 40  20 30  20 30 
TZ 15 30  30 50  20 30  20 30 
 
a
 The individual MICs of RIF, INH, STR, EMB, CPZ and TZ, were determined by the BACTEC 460-TB 
method, as described previously (Amaral and Kristiansen, 2000; Bettencourt et al., 2000; Viveiros et al., 
2002). Stock solutions containing various amounts of each compound were freshly prepared in BACTEC 
460 medium, and 0.1-mL aliquots of each solution were added to BACTEC 460 vials. The final 
concentrations of CPZ and TZ in the BACTEC 460 vials were 0, 1, 5, 10, 15, 20, 30, 40, 50, and 60 
mg/L. A total of 0.1 mL of BACTEC 460 medium containing an adjusted concentration of mycobacteria 
corresponding to approximately 105 to 106 CFU was added to each vial (Viveiros et al., 2002). The MBCs 
of CPZ and TZ were determined by extending the MIC curves well beyond each MIC and 10 µL aliquots 
of the 10 mL cultures at zero time and those after 30 days that showed no evidence of growth in the 
BACTEC 12B vials were subjected to counting of the numbers of CFU (Viveiros et al., 2002). The MIC 
and MBC determinations were repeated three times, and the values obtained did not differ significantly. 
Strains ATCC27294, A, and B are susceptible to INH, RIF, STR, and EMB. Strain C is resistant to all 
four drugs. Strains D and E, besides being resistant to INH and RIF, are also resistant to STR. 
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Toxicities of CPZ and TZ against THP-1 cells, PBMDMs, and subsets of the Ficoll 
preparation. The potential toxicities of CPZ or TZ against THP-1 cells and PBMDMs 
were evaluated by three distinct methods in a previous study, and 50% of the full 
toxicity was shown to take place at concentrations that exceeded 3.0 mg/L (Ordway et 
al., 2002a). Similar results were obtained in this study (data not shown). The toxicities 
of the phenothiazines at concentrations below those anticipated to be present in the 
plasma of a patient treated with 600 mg of either phenothiazine per day (Amaral et al., 
2001a) against subsets of the Ficoll monocyte preparation were examined in the present 
study. Briefly, as shown in Figure 1, the concentrations of CPZ and TZ that correspond 
to those readily evident during initial therapy of a patient, i.e., 0.1 mg/L, had a nominal 
effect on annexin V binding, determination of which is the method of choice for the 
demonstration of apoptosis (Ordway et al., 2002a). The percentage of annexin V 
binding indicative of early apoptosis is 10% for alpha-beta and gamma-delta T cells and 
CD14+ macrophages (Ordway et al., 2002a). The data presented in Figure 1 also show 
that the presence of live mycobacteria during a culture period of 3 days did not increase 
the percent annexin V binding by the various monocyte subsets evaluated.  
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Figure 1. Effects of CPZ and TZ on percent annexin V binding by monocyte 
subsets of Ficoll preparations of PBMCs. Subpopulations of the Ficoll preparation containing 
PBMCs from healthy donors were separately stimulated for 3 days with M. tuberculosis (H37Rv 
ATCC27294) or with concentrations of CPZ and TZ that ranged from 0 to 0.5 mg/L. After 3 days the 
cells were harvested and stained with fluorescent antibodies against alpha-beta TCR+, gamma-delta 
TCR+, and CD14+ macrophages in combination with annexin V. Cells were analyzed with an Ortho 
absolute flow cytometer. Results are expressed as the mean ± standard deviation percent annexin V 
binding in lymphocytes. Annexin V binding in excess of 10% is an indication of early apoptosis (Ordway 
et al., 2002a).  
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Effects of CPZ and TZ on killing of M. tuberculosis phagocytosed by PBMDMs or 
THP-1 macrophages. THP-1 macrophages and PBMDMs were selected for use in the 
assays of the phagocytosis of M. tuberculosis on the basis of the fact that these cells, 
unlike neutrophils, possess slight killing activities against bacteria (Hoidal et al., 1981; 
Ordway et al., 2002a). This provides an understanding of the killing activities of agents 
against intracellular bacteria. As shown in Figure 2, the phagocytosis of approximately 
105 mycobacterial cells by an equal number of PBMDMs does not result in any 
effective killing for 3 days post-infection, regardless of the organism’s susceptibility to 
INH, RIF, STR, and EMB (including strain H37Rv ATCC27294) or resistance to INH 
and RIF (MDR M. tuberculosis). In contrast to this lack of killing, when CPZ or TZ was 
added to the infected macrophage cultures at 0.1 mg/L, the killing of strain ATCC27294 
and the antibiotic-susceptible and MDR M. tuberculosis strains was enhanced within 1 
day post-infection (Figure 3A and B). Complete killing took place by the end of the 
third day post-infection (Figure 3A and B). Lower concentrations of these 
phenothiazines were ineffective, and the rates of survival of all intracellular 
mycobacterial strains were indistinguishable from those for their controls (Figure 3A 
and 3B). Although the results presented above were obtained by use of PBMDMs, 
similar results were obtained by use of the THP-1 macrophage cell line (data not 
shown). 
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Figure 2. Average killing activities of human PBMDMs against M. tuberculosis 
ATCC 27294 (ATCC), two antibiotic-susceptible strains (strains A and B [TB]), 
and three MDR M. tuberculosis strains (strains C, D, and E; resistant at least to 
RIF and INH [MDR-TB]). The killing activities against the strains used were not significantly 
different. 
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Figure 3. Average killing activities of human PBMDMs against three MDR M. 
tuberculosis strains (resistant to RIF and INH) (MDR-TB) and three antibiotic-
susceptible M. tuberculosis strains (TB) including strain ATCC27294 when either 
CPZ (A) or TZ (B) was present in the medium at concentrations of 0.01 and 0.1 
mg/L. The control value is the average numbers of CFU for cultures of all six strains to which no 
phenothiazine was added, inasmuch as the CFU did not differ appreciably between strains. 
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DISCUSSION 
 
The toxicity associated with the chronic use of CPZ is well known (Amaral et al., 
2001a; Kaplowitz et al., 1986; Kodovanti et al., 1990). In addition, CPZ has been 
shown to affect the activities of a variety of T lymphocytes in vitro (Ghezzi, 1991; 
Grabski et al., 2001; Hieronymus et al., 2000), although requiring concentrations of 
CPZ which are beyond those clinically relevant (i.e., in excess of 1 mg/L) or fairly close 
to the highest concentration of CPZ in plasma that might result from its aggressive use 
(≥0.5 mg/L). Our previous study (Ordway et al., 2002a) and the present study show that 
an in vitro concentration of 0.1 mg/L of either CPZ or TZ, which is equivalent to that 
anticipated to be present in the plasma of a patient treated with either phenothiazine, has 
no significant toxicity against macrophages or alpha-beta TCR+, gamma-delta TCR+, or 
CD14+ macrophages. Concentrations of CPZ or TZ that are well below their range for 
toxicity against human macrophages, THP-1 macrophages, or subsets of T lymphocytes 
in vitro, as shown in this and other studies (Ordway et al., 2002a), were shown in the 
present study to enhance the killing of M. tuberculosis strains that are phagocytosed by 
either PBMDMs or THP-1 cells. Complete killing is evident by the end of 3 days post-
infection at a minimum concentration of 0.1 mg/L, regardless of the antibiotic 
susceptibility of the strain. When similar M. tuberculosis strains are exposed to 
concentrations of CPZ or TZ in vitro, the minimum concentration of either CPZ or TZ 
required to completely inhibiting growth ranges from 8 to over 30 mg/L (Amaral et al., 
1996; Bettencourt et al., 2000; Crowle et al., 1992; Viveiros and Amaral, 2001). The 
minimum in vitro concentration of either phenothiazine required for complete killing 
(MBC), as shown in our study, ranges from 20 to 50 mg/L and is similar to that reported 
previously (Amaral et al., 1996). Because these phenothiazines are concentrated by 
macrophages (Amaral and Kristiansen, 2001), cells that have little killing actions of 
their own (Hoidal et al., 1981; Ordway et al., 2002a), it is likely that the concentration 
of either phenothiazine required to kill M. tuberculosis cells in vitro is achieved because 
the macrophage is able not only to concentrate the compounds but also to make these 
compounds available in an active form to the cytoplasmic structure of the macrophage 
that houses the entrapped phagocytosed bacterium (Amaral and Kristiansen, 2001). 
Nevertheless, it is also possible that the lytic action of the macrophage lysosomal 
apparatus, which is apparently weak, might be sufficiently effective to affect the 
integrity of the bacterium’s cell wall. This weakened cell wall might be more permeable 
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for the penetration of these compounds, which eventually intercalate between the 
nucleic acid base pairs of the bacterium’s DNA, where DNA-dependent functions may 
be affected (de Mol et al., 1983). Regardless of the cause of killing, in vitro resistance 
of MDR M. tuberculosis to either CPZ or TZ, as opposed to that of the antibiotic 
susceptible strains, is not evident after the MDR strain is phagocytosed by macrophages 
that have been treated with CPZ or TZ. The demonstration that clinically relevant 
concentrations of either CPZ or TZ that are neither toxic in vitro to the macrophage nor 
inhibitory of T-cell activity in vitro kill phagocytosed mycobacteria supports their use in 
the management of intracellular M. tuberculosis infections. TZ has significantly fewer 
serious side effects than CPZ (Amaral et al., 2001a), making the use of TZ as an anti-
TB agent far more attractive than the use of CPZ. However, its use is not without some 
risk, inasmuch as almost twice as many sudden deaths due to cardiac failure take place 
in patients managed with TZ compared to the number of deaths from such causes in the 
general population (Glassman and Bigger, 2001). Although TZ may induce episodes of 
torsade de pointes that result in sudden death, there are only 10 to 15 such events in 
10,000 person-years of observation (Glassman and Bigger, 2001). Regardless, careful 
monitoring of cardiac function during TZ management is strongly recommended. 
Admittedly, the use of TZ for the management of an active pulmonary TB infection 
caused by antibiotic-susceptible M. tuberculosis strains provides no advantage over the 
use of present therapies. Moreover, because the concentration of TZ needed to kill or 
even inhibit mycobacterial replication when the bacterium is outside the macrophage is 
far beyond that which can be achieved in the patient, it cannot be used for the 
management of a cavitary pulmonary M. tuberculosis infection of moderate to severe 
status. Nevertheless, even for patients with cavitary infections of moderate status whose 
origins are associated with a high prevalence of MDR M. tuberculosis, especially when 
there is a lack or absence of appropriate, effective clinical laboratory support, TZ could 
serve as an adjunct to conventional therapy during initial management of the patient, at 
least until the susceptibility data for the causative organism are made available 
(Viveiros and Amaral, 2001). Because the length of such management is anticipated to 
be weeks, side effects associated with chronic TZ therapy are not anticipated. Normally, 
such a recommendation would not be made until the effectiveness of TZ therapy was 
defined subsequent to clinical trials. However, given the severity of MDR M. 
tuberculosis in parts of the world where effective therapy is not possible, the use of TZ 
deserves consideration. 
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IV.2 In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium 
tuberculosis 
 
SUMMARY 
 
Thioridazine (TZ) has previously been shown by us to have in vitro and ex vivo activity 
against antibiotic-susceptible and multidrug-resistant Mycobacterium tuberculosis 
(MDR-TB). Because current therapy of MDR-TB is highly problematic even when all 
five ‘first line of defence’ drugs are employed, there is a need for effective 
antituberculosis drugs. New derivatives of TZ were synthesised and their in vitro 
activity against a reference strain of M. tuberculosis was evaluated with the aid of the 
BACTEC 460 system. Derivatives that presented significant activity were evaluated by 
ex vivo studies and were shown to enhance the killing of intracellular M. tuberculosis. 
 
Materials and Methods employed in this study are described in publication #3 and in 
Chapter II (sections II.5 and II.8). 
 
RESULTS AND DISCUSSION 
 
The results obtained in this study show that from the twenty-two TZ derivatives tested 
against M. tuberculosis H37Rv ATCC27294, in the BACTEC 460 system, six (#1867; 
#1875; #1926; #1470; # 1870; #1876) have higher activity (MIC=5-10 mg/L) than TZ 
(MIC=15 mg/L) (Table 1).  
 
Table 1. Minimum inbibitory concentration of TZ and its derivatives against 
Mycobacterium tuberculosis 
 Phenothiazines MIC (mg/L) 
Thioridazine TZ 15 
#1867; #1875; #1926 5 
#1470; # 1870; #1876 10 
#1687; #1688; #1689; #1868; #1532-2; #1686; #1872 20 TZ derivatives 
#1550; #1819; #1820; #1821; #1869; #1871; #1873; 
#1874; #1929 >20 
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The evaluation of TZ and active derivatives for potential toxicity was performed on 
lymphocytes cultured for up to 3 days and is summarised by Table 2. Briefly, TZ was 
cytotoxic at concentrations that exceed 0.5 mg/L (Ordway et al., 2002b; Ordway et al., 
2003b). However, at this same concentration no significant toxicity was detected for the TZ 
derivatives (trypan blue exclusion by over 90% of lymphocytes).  
 
Table 2. Percent toxicity of TZ and TZ derivatives on human lymphocytes 
 Toxicity (%) 
Phenothiazines 0.1 mg/L 3 mg/L 10 mg/L 
TZ 0 50 100 
#1867; #1875; #1926; #1470; #1870; #1876  0 1.6 5.3 
 
If a compound is to be useful as an antituberculosis agent it must have activity against 
intracellular M. tuberculosis. Because our previous studies demonstrated that TZ at a 
clinically relevant concentration of 0.1 mg/L enhanced the killing of phagocytosed M. 
tuberculosis (Ordway et al., 2003b), derivatives that had the greatest in vitro activity and 
were devoid of significant toxicity were selected for evaluation of similar killing activity. 
As shown by Figure 1, macrophages derived from human blood did not appreciably kill 
phagocytosed M. tuberculosis during a period of 3 days’ incubation. These results are 
consistent with those previously presented (Martins et al., 2007b; Ordway et al., 2003b). In 
contrast, cultures containing the phenothiazine TZ (used as a positive control) at a 
concentration of 0.1 mg/L yielded only a few live mycobacteria after 3 days of culture. 
When tested ex vivo for the enhancement of the macrophage killing activity, the non-toxic 
TZ derivatives (#1867, #1875, #1926, #1470, #1870, #1876), also demonstrated ex vivo 
activity against M. tuberculosis (see Figure 1). Derivatives #1875, #1926 and #1876 
enhanced the killing of mycobacteria at a concentration of 0.1 mg/L. When compared with 
the parental molecule (TZ), derivative #1875 was especially active and more effective than 
TZ, since after 2 days post-infection no colony forming units (CFU) were retrieved from the 
lysed cultures.  
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Figure 1. Effect of TZ and its derivatives in the killing activity of macrophages 
infected with M. tuberculosis H37Rv ATCC27294. Human macrophages (1×105 cells/mL) 
were infected with M. tuberculosis at a ratio of 1:10 (1 macrophage:10 bacteria). After 1 hour of 
phagocytosis, cells were washed to remove non-phagocytosed bacteria. Aliquots of the tested compounds 
were added to the corresponding wells and cells incubated for 0, 1, 2 and 3 days. After incubation, 
supernatants of the cells were removed and plated in order to determine whether the addition of the agents 
cause the lysis of the macrophage and subsequent release of the bacterium. Adhered cells were lysed with 
SDS 0.01% in order to release all the intracellular bacteria and aliquots of the lysed cells were plated in 
7H11 plates and incubated at 37ºC. After 3 to 4 weeks, CFU were counted and bacterial concentrations 
calculated. The data presented are averages from three independent experiments each of which was 
conducted in triplicate. 
 
The results obtained in this study demonstrate the in vitro and ex vivo potential of new 
non-toxic derivatives of TZ against M. tuberculosis. However, further evaluation of 
these new derivatives for in vivo toxicity and effectiveness in rendering the M. 
tuberculosis infected mouse free of this infection are absolutely necessary before these 
compounds can be seriously considered for the therapy of a pulmonary TB infection. 
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IV.3 The in vitro activity of phenothiazines against Mycobacterium avium: potential 
of thioridazine for therapy of the co-infected AIDS patient 
 
SUMMARY 
 
Patients presenting with Acquired Immune Deficiency Syndrome (AIDS) are 
predisposed to co-infection with Mycobacterium avium. The management of such 
patients is problematic due to underlying immuno-incompetence and the high resistance 
of M. avium to most non-toxic compounds. Therefore, the need for effective agents is 
obvious. Because phenothiazines, especially the relatively mild thioridazine, have 
significant activity against Mycobacterium tuberculosis, we investigated the in vitro 
activity of chlorpromazine, thioridazine, promazine, promethazine and desipramine 
against a reference and clinical strains of M. avium. The results obtained show that 
whereas all of the phenothiazines employed in this study had an minimum inhibitory 
concentration (MIC) against the strains studied that ranged from ca. 10 to >50 mg/L, as 
was previously shown for M. tuberculosis, thioridazine was the most active of the group 
against M. avium. 
 
Materials and Methods employed in this study are described in publication #4 and in 
Chapter II (section II.5). 
 
RESULTS 
 
The in vitro activity of the phenothiazines CPZ, TZ, PMZ, PMTZ and DSP are 
presented in Figure 1. Briefly, the ascending order of activity, as defined by the MIC 
(lowest concentration that produces 100% inhibition of growth assessed by the 
inhibition of the 14CO2 generated) in mg/L, was as follows: TZ (10), CPZ (25), PMZ 
(25-50), PMTZ (25-50) and DSP (>50). Because it has generally been assumed that the 
resistance of M. avium to drugs employed for the management of pulmonary 
tuberculosis produced by M. tuberculosis is due to the cell wall of the former, it was 
surprising to discover that M. avium is more sensitive to TZ than is M. tuberculosis, the 
latter being completly inhibited in its growth by concentrations of TZ that exceed 25 
mg/L. However, with respect to CPZ, PMZ, PMTZ and DSP, the sensitivity of M. 
avium to these agents is practically identical to that produced against M. tuberculosis 
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(Bettencourt et al., 2000). Because the assays were conducted in triplicate and the 
experiments repeated at least twice, the difference between the MICs of TZ for M. 
avium versus M. tuberculosis were considered to be significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The in vitro activity of chlorpromazine (CPZ), thioridazine (TZ), 
promazine (PMZ) and desipramine (DSP) against Mycobacterium avium. 
Mycobacterium avium strain CIP 14 031 002-S4 (Pasteur Institute, Paris, France) (A) and a 
Mycobacterium avium strain isolated from an AIDS patient (B) were incubated in BACTEC 12B vials 
that contained concentrations of each phenothiazine that ranged from 0.0 to 50 mg/L. The experiment was 
repeated twice and essentially the same quantitative data was obtained. The results represent the data 
obtained from one such experiment and describe the activity against both strains. 
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DISCUSSION 
 
Patients presenting with AIDS are at risk of acquiring a variety of opportunistic 
infections (Bellamy et al., 2004). Although each of these infections may cause death to 
any given AIDS patient, pulmonary infections caused by M. avium produce the highest 
mortality (Bellamy et al., 2004; Hoffmann and Brunner, 2004) since effective drugs are 
few and relatively ineffective against this organism (Hoffmann and Brunner, 2004). 
Currently, azithromycin and clarithromycin are the two most effective agents for the 
therapy of M. avium pulmonary non-tubercular infections (Hoffmann and Brunner, 
2004). However, there is now evidence that these agents produce ototoxicity (Uzun et 
al., 2001) and arrhythmia (Ohtani et al., 2000), respectively. The need for effective 
drugs for the management of this infection is obvious. The results obtained in our 
current study indicate that each of the phenothiazines studied had in vitro activity 
against the ATCC and clinical strains. The response of the reference and clinical strains 
was quantitatively very similar, thereby suggesting that other clinical strains will show 
similar responses. The order of increasing effectiveness against these strains was TZ, 
CPZ, PMZ, PMTZ and DSP. TZ was by far the most effective of the phenothiazines 
evaluated, presenting with an MIC of ca. 10 mg/L. Surprisingly, M. avium is far more 
sensitive to the phenothiazine TZ than are strains of M. tuberculosis (Amaral et al., 
2001a, 2001b). Nevertheless, the MIC of 10 mg/L for TZ is not clinically achievable. 
However, TZ does enhance the killing of intracellular M. tuberculosis (Ordway et al., 
2003b) when the concentration of this agent in the medium is of the order of 0.1 mg/L 
and, hence, within clinical range and below any associated with toxicity (Ordway et al., 
2002a, b; Ordway et al., 2003b). Killing is considered to be the result of the agent being 
concentrated by the macrophage to levels equivalent to those that produced in vitro 
killing (Ordway et al., 2002a, b; Ordway et al., 2003b) and, because phenothiazines are 
concentrated by lysosomes (Daniel et al., 2001; Wojcikowski and Daniel, 2002), the 
killing of the bacterium by macrophages that have little killing activity of their own 
(Ordway et al., 2003b) is probably due to the fusion of the phagosome with the 
lysosome containing the highly concentrated phenothiazine (Ordway et al., 2002a, 
2002b; Ordway et al., 2003b). The greater sensitivity of M. avium to TZ as opposed to 
that produced against M. tuberculosis is interesting. Although at this time we cannot 
provide an adequate explanation for this difference, we can confidently conclude that 
the cell wall of M. avium, generally considered being the cause for its resistance to anti-
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TB agents, does not lead to greater resistance to TZ. The results of the current study are 
not sufficient to recommend that TZ be used for the management of AIDS patients co-
infected with M. avium. Furthermore, even when the study that evaluated the killing 
activity of TZ against phagocytosed M. avium showed that the concentration required 
for such killing was comparable to that expected to be present in the plasma of patients 
chronically treated with this agent, the use of the mild TZ is not without risk, as shown 
by recent studies demonstrating that, for a very small number of patients, TZ is 
associated with serious arrhythmia such as “torsade de pointes” (Vieweg and Wood, 
2004). However, the relationship is now in question since the number of risk factors 
presented by the patient may be more significant for the arrhythmia than that produced 
by the agent itself (Titier et al., 2005). 
 
In the future, studies evaluating the ability of TZ, its derivatives and other 
phenothiazines to enhance the killing activity of the infected macrophage will be 
performed to determine if these compounds also demonstrate activity against 
phagocytosed M. avium. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  
 
 
 
 
 
 
 
 
 
 
 
CHAPTER V. 
 
The Curative Activity of Thioridazine on Mice Infected With 
Mycobacterium tuberculosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter contains data published in: 
 
Martins, M., M. Viveiros, J. E. Kristiansen, J. Molnar, and L, Amaral. 2007. The curative activity of 
thioridazine on mice infected with Mycobacterium tuberculosis. In Vivo 21:771–776. 
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CHAPTER OUTLINE 
 
This chapter describes all the studies conducted on Balb/C mice infected with M. 
tuberculosis. The effectiveness of TZ was evaluated. Infected animals were treated with 
different doses of TZ and the results are presented by CFU counts obtained from the 
infected organs.  
 
SUMMARY 
 
The aim of the study was to evaluate the effectiveness of thioridazine (TZ) at different 
dose levels on mice that had been infected intraperitoneally (i.p.) with a high dose of the 
M. tuberculosis ATCC H37Rv strain. Groups of five female Balb/C mice were infected 
i.p. with 106 CFU/mL. After thirty days, treatment with TZ was initiated, except for the 
control group. Mice were treated with TZ at equivalent concentrations to that used in 
the humans (1200 mg/day), ranging from 0.05 to 0.5 mg/day. The results demonstrated 
that a daily dose of 0.5 mg/day of TZ reduced the number of colony forming units 
retrieved from the lungs of infected mice within one month. By the end of 300 days of 
therapy, although mycobacteria were still retained, their presence, in comparison to that 
of the control was 8 orders of magnitude lower.  
 
Materials and Methods employed in this study are described in publication #5 and in 
Chapter II (section II.10). 
 
RESULTS 
 
The average absolute number of CFU retrieved from the lungs of mice after infection 
with approximately 106 M. tuberculosis ATCC H37Rv is shown in Figure 1A. Daily 
doses of TZ below 0.5 mg did not produce any significant change in the bacterial load 
as compared to the untreated control mouse group during the entire period of the study 
(data not shown). Thirty days after the mice were treated daily with 0.5 mg/day of TZ 
there was an excess of five log reduction in the CFU/kg retrieved from the lung as 
compared to the control group (Figure 1B). The effects of 0.5 mg/day on the bacterial 
load recovered from the lung of the animals becomes more prominent with each passing 
30 day interval, such that by the end of 300 days of treatment the difference between the 
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treated group and its control untreated group is approximately 8 orders of magnitude 
(Figure 1B). The bacterial load recovered from the liver or the spleen, unlike that 
recovered from the lung, continued to increase regardless of therapy with TZ and was 
similar to that recovered from the untreated infected control mouse group (data not 
shown). 
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Figure 1.  Effect of daily TZ treatment of mice infected with M. tuberculosis. Mice 
were infected i.p. with approximately 106 M. tuberculosis ATCC H37Rv. After thirty days of infection, 
mice were treated daily with a dose equivalent in the human to 1200 mg of TZ (0.5 mg/day). A, Average 
absolute number of colony forming units (CFU) per kg of mouse lung retrieved from the lungs of treated 
and non-treated (control) infected mice. B, Log reduction of M. tuberculosis per kg of mouse lung 
retrieved from the lung of the treated mice as compared to the control group (no treatment).   
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DISCUSSION 
 
Although TZ therapy appears to be very effective, after 300 days a few CFU per mg of 
lung tissue could still be recovered, hence the infection persisted, albeit at a very low 
level. The question of why mycobacteria could still be recovered 300 days after daily 
therapy, whereas experimental data obtained from human macrophages that had been 
infected ex vivo could be completely rid of M. tuberculosis subsequent to exposure to as 
little as 0.1 mg/L of TZ (Ordway et al., 2003b) can be answered from the data obtained 
from spleens and livers of both treated and untreated mice. Daily therapy with TZ did 
not reduce the number of CFU of mycobacteria retrieved from the liver or the spleen 
(data not shown) during the time of the experiment as opposed to the decrease of 
mycobacteria that was evident in the lungs. The single dose of mycobacteria (106 CFU) 
introduced i.p. is massive compared to that to which a human is exposed and 
subsequently infected with.  This massive dose was necessary inasmuch as mice, even 
though the strain used in this study is relatively more readily infected with mycobacteria 
than other strains (Ordway et al., 2005b), are relatively resistant to infection by M. 
tuberculosis. Taking this massive dose into account, as well as the possibility that the 
spleen and liver were sources of mycobacteria, it was surprising to note the 
effectiveness of TZ therapy. The experimental protocol employed in this study does not 
shed any light as to whether TZ is effective against mycobacteria that are trapped in the 
liver and spleen given the massive i.p. dose administered. Recent studies have provided 
evidence that phenothiazine derivatives can clear the lungs of mice that have been 
infected with only 200 CFU of M. tuberculosis (Weinstein et al., 2005; Yano et al., 
2006). In light of these latter studies, the significance of TZ therapy becomes even 
greater given its effectiveness against an infection that was 5,000 times greater. 
Nevertheless, we must remember that although TZ is effective for the therapy of 
pulmonary TB of the mouse, other than anecdotal evidence and laboratory studies that 
support the use of TZ (Amaral et al., 2004), its effectiveness for therapy of human 
pulmonary TB remains to be determined.       
 

  
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER VI. 
 
Effect of Carpobrotus edulis, reserpine, ouabain and verapamil on the 
growth of phagocytosed multidrug-resistant Mycobacterium 
tuberculosis and methicillin-resistant Staphylococcus aureus 
 
 
 
 
 
 
 
 
 
This chapter contains data published and accepted for publication in: 
 
Martins, M., D. Ordway, M. Kristiansen, M. Viveiros, C. Leandro, J. Molnar, and L. Amaral. 2005. 
Inhibition of the Carpobrotus edulis methanol extract on the growth of phagocytosed multidrug-resistant 
Mycobacterium tuberculosis and methicillin-resistant Staphylococcus aureus. Fitoterapia 76:96–99; 
Martins, M., M. Viveiros, D. Ordway, J. E. Kristiansen, J. Molnar, and L. Amaral. 2006. Reserpine, 
ouabain and the calcium channel blocker verapamil, cause intracellular killing of Staphylococcus aureus. 
Research J. Microbiology 1:203–209; Martins, M., M. Viveiros, and L. Amaral. 2008. Inhibitors of 
Ca2+ and K+ transport enhance intracellular killing of M. tuberculosis by non-killing macrophages. In 
Vivo 22: In press. 
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CHAPTER OUTLINE 
 
From all the data obtained several questions were posed relative to the mechanism of 
action of TZ as well as other phenothiazines, namely: 
 
• Is the effect of the enhancement of the macrophage killing activity due to a 
concentration of the compound inside the macrophage? 
 
• Or is this effect due to the inhibition of the Ca2+ and K+ pumps present in the 
membrane of the macrophage since the phenothiazines are known to inhibit 
efflux systems of bacteria (Amaral et al., 2001b; Amaral et al., 2007c; Martins 
et al., 2008)? 
 
In order to understand these questions, several studies were conducted. Inhibitors of 
efflux pumps systems were selected, namely, the methanol extract of C. edulis, ouabain, 
reserpine and verapamil. Plants extracts are a good source of compounds that inhibit the 
efflux pumps of bacteria as well as eukaryotic cells. Some alkaloids present in the plant 
extracts have been identified as inhibitors of bacteria, such as S. aureus, and also of 
efflux pumps of eukaryotic cells. Its mode of action is mainly based on the inhibition of 
K+ flux. Others inhibitors of the K+ transport such as ouabain, reserpine and verapamil 
(Contreras et al., 2004; Orlov et al., 2004), exert their action by direct or indirect 
inhibition of K+ transport by limiting access of Ca2+ to Ca2+-dependent ATPases (Gao et 
al., 2004).   
 
This chapter presents all the data obtained from the studies conducted with these 
inhibitors in macrophages infected with MDR M. tuberculosis and MRSA.  
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VI.1 Inhibition of the Carpobrotus edulis methanol extract on the growth of 
phagocytosed multidrug-resistant Mycobacterium tuberculosis and methicillin-
resistant Staphylococcus aureus 
 
SUMMARY 
 
The Carpobrotus edulis methanol extract, inactive in vitro against the methicillin-
resistant Staphylococcus aureus or the multidrug-resistant Mycobacterium tuberculosis, 
does inhibits the growth of these two bacteria once they are phagocytosed by monocyte 
derived human macrophages. 
 
Material and methods are described in chapter II (sections II.7 and II.8), as well as in 
publication #6 listed in the Appendix. 
 
RESULTS 
 
Concentrations of methanol extract that are five times higher than that which produce 
toxicity against monocyte derived macrophages do not inhibit the in vitro growth of 
methicillin-resistant S. aureus or multidrug-resistant M. tuberculosis (data not shown).  
 
In contrast to these results, the fivefold diluted methanol extract that is well below the 
level that is toxic to the macrophage effectively inhibits the growth of phagocytosed 
Methicillin resistant S. aureus within 6 h of culture (Table 1), and that of multidrug-
resistant M. tuberculosis within 3 days of culture (Table 2). 
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Table 1. Effects of C. edulis leaves methanolic extract (CELME) on phagocytosed 
S. aureusa 
CFUb×105 (hours)  
Bacteria 1 2 6 
S. aureus ATCC 25923 2.0 3.2 3.6 
S. aureus ATCC 25923+CELME 1.9 3 2.5 
S. aureus MRSAc 3.0 3.5 3.7 
S. aureus MRSAc+CELME 0.3 0.5 0.3 
 
a
 Approximately 0.5 to 1.0×105 CFU could be retrieved from 100,000 macrophages after the period 
employed for phagocytosis of approximately 105 CFU presented to the macrophages (zero time). CFU 
presented are calculated from colonies resulting from the plating of serial dilutions of 0.1 ml aliquots of 
cultures after the lysing of the macrophages. About 20 µl of undiluted aqueous methanol extract was 
added to 180 µl of medium and this total volume was added directly to the cultures containing the 
macrophage-phagocytosed MRSA (20 µl of water served as the blank added to controls). Final volume of 
the culture was 250 µl. b CFU: Colony Forming Units of bacteria. c Results are expressed as the mean of 
the two strains tested. 
 
Table 2. Effects of C. edulis leaves methanolic extract (CELME) on phagocytosed 
M. tuberculosisa 
CFUb×106 (days)  
Bacteria 1 2 3 
M. tuberculosis H37Rv ATCC 27294 0.8 2 1.9 
M. tuberculosis H37Rv ATCC 27294+CELME 0.5 1 0.6 
M. tuberculosis MDR-TBc 2.1 3 3.9 
M. tuberculosis MDR-TBc +CELME 1.1 1.3 1.2 
 
a
 Approximately 0.5×106 CFU could be retrieved from 100,000 macrophages after the period employed 
for phagocytosis of approximately 106 CFU presented to the macrophages (zero time). CFU presented are 
calculated from colonies resulting from the plating of serial dilutions of 0.1 ml aliquots of cultures after 
the lysing of the macrophages. Concentrations of extract, final volumes, etc., are identical to that 
described in legend of Table 1. b CFU: Colony Forming Units of bacteria. c Results are expressed as the 
mean of the two strains tested. 
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VI.2 Reserpine, ouabain and the calcium channel blocker verapamil, cause 
intracellular killing of Staphylococcus aureus 
 
SUMMARY 
 
Killing of bacteria by neutrophils is dependent upon the availability of potassium. 
Although macrophages derived from human peripheral blood monocytes have little 
killing activity of their own, they can be transformed into effective killers of 
Staphylococcus aureus and Mycobacterium tuberculosis by in vitro exposure of the 
macrophage to clinically relevant concentrations of phenothiazines, namely, 
thioridazine or chlorpromazine. Because transport mechanisms dependent upon the 
availability of calcium are inhibited by these agents, the possibility that other agents 
which have similar activity also have the ability to enhance the killing of bacteria by the 
macrophage derived from peripheral blood monocytes was investigated. In this study 
we show that the presence of increasing concentrations of ouabain, reserpine or 
verapamil in the medium enhances the killing of Staphylococcus aureus. Because these 
concentrations have no activity on the replication or killing of the bacterium, killing is 
deemed to be due to the macrophage itself. A model is presented which describes the 
mechanism by which these agents and phenothiazines indirectly activate lysosomal 
enzymes as a result of the inhibition of potassium efflux pumps that would normally 
pump the ion from the phagocytic vacuole to the cytoplasm of the macrophage. 
 
Materials and Methods employed in this study are described in publication #7 and in 
Chapter II (section II.7). 
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RESULTS 
 
Toxicity of reserpine, ouabain and verapamil on Monocyte Derived Macrophages 
and their in vitro activity against S. aureus 
 
The toxicity of reserpine, ouabain and verapamil on human monocyte derived 
macrophages (MDM) was determined, along the same guidelines and approaches 
followed for CPZ and TZ on Chapter IV (section IV.1) (Ordway et al., 2002a; Ordway 
et al., 2003b). Briefly, concentrations as high as 100 mg/L of reserpine, ouabain or 
verapamil did not produce any toxicity against MDM (data not shown).  
 
In vitro activity of reserpine, ouabain and verapamil against S. aureus 
 
The minimum inhibitory concentration (MIC) and minimum bactericidal concentration 
(MBC) for ouabain, reserpine and verapamil were determined by the broth 
microdilution method. These compounds at the highest concentrations employed for the 
determination of toxicity had no effect on the growth rate or final growth of S. aureus 
(MIC and MBC>100 mg/L). 
 
Effect of reserpine, ouabain and verapamil on the killing of S. aureus that have 
been phagocytosed by human monocyte derived macrophages 
 
The effects of ouabain, reserpine and verapamil on S. aureus that have been 
phagocytosed by human monocyte derived macrophages are summarised by in Figure 1. 
Reserpine, ouabain and verapamil enhanced the macrophage killing activity when added 
to the culture media (Figura 1A). The effects were similar to those obtained with CPZ 
and TZ although these latter agents produced an enhancement of the macrophage killing 
activity at concentrations in the medium that were far lower than the ones employed for 
reserpine, ouabain and verapamil (Fig. 1B). 
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Figure 1. The effect of reserpine, ouabain, verapamil (A), CPZ and TZ (B) on S. 
aureus that have been phagocytosed by human monocyte derived macrophages. 
Macrophages derived from peripheral blood monocytes (1×106 cells/mL) were suspended in 1 mL RPMI 
medium and distributed to the wells of a 24 microwell plate. After 6 days of incubation, wells were 
washed with RPMI medium to remove non-adherent cells (lymphocytes). The adherent monocyte derived 
macrophages (MDM) were counted and the yield per well was approximately 105 with less than 5% 
variation of each well from this number. 106 bacteria were added for 30 minutes and after this period the 
wells were washed to remove any non-phagocytosed bacteria and fresh RPMI medium (1 mL) added to 
each well. One hundred microliter of each compound was added to yield the concentration that ranged 
from 0.0 to the maxima identified in the Figure. The microplates were incubated for 0 to 6 h and the 
MDM lysed with SDS thereby releasing the bacteria which were then counted by the colony forming unit 
(CFU) method (Ordway et al., 2002a, 2003b). The data in Figure 1A was obtained from a number of 
repeat experiments involving different donations of derived MDM and due to the biological variation 
resulting from differences of donors, the data was normalised and the curves presented generated by 
regression analysis. The data presented by 1B is actual data obtained from a representative experiment. 
Figure 1A. The addition of each of these agents to the medium after the phagocytosis of the bacterium 
produced significant enhancement in the killing of S. aureus in a concentration dependent manner with a 
maximum effect on the killing of intracellular staphylococci at the highest concentration employed. 
0
500
1000
1500
2000
2500
0 20 40 60 80 100 120
Conce ntration (m g/L)
CF
U
Reserpine
Ouabain
V erapamil
A
0
5000
10000
15000
20000
25000
30000
0 0,1 0,2 0,3 0,4 0,5 0,6
Conce ntration (m g/L)
CF
U
TZ
CPZ
B
 
Chapter VI 
 
 
151 
DISCUSSION 
 
The results obtained in our current study show, for the first time that inhibitors of 
potassium transport have the capacity to enhance the killing of bacteria that have been 
phagocytosed by monocyte derived macrophages that have little killing action of their 
own. Our previous studies (Ordway et al., 2002a, 2003b) suggested that the killing 
activity of phenothiazines was due to the ability of the macrophage to concentrate the 
agent to levels comparable to those in vitro that had bactericidal activity. However, the 
results of the current study suggest that agents that have similar activity as 
phenothiazines with respect to effects on calcium binding also enhance the killing of 
intracellular bacteria. Because the agents reserpine, ouabain and verapamil, unlike the 
phenothiazines (Amaral et al., 2004), are shown in the current study to be devoid of any 
in vitro activity against S. aureus, we attribute their intracellular activity to their effects 
on the transport of potassium in as much as these agents inhibit this transport (Kanoh, 
1999; Galli, 1988). The results obtained in our current study coupled to those results 
recently obtained by others (Ahluwalia et al., 2004; Reeves et al., 2002), suggest the 
mechanisms presented by Figure 2 as those involved in the killing of intracellular 
bacteria. Firstly, the transport of potassium into the macrophage is dependent upon 
calcium dependent type pumps present in the plasma membrane of the macrophage. The 
process of phagocytosis involves the invagination of the plasma membrane to which the 
bacteria is first bound (Figure 2A). The relative position of the potassium pump would 
now be reversed in the phagosome and the transport of potassium would effectively be 
from the inside of the phagocytic vacuole to the cytoplasm of the macrophage (Figure 
2B). Normally, the activity of these pumps would be expected to reduce the potassium 
concentration of the phagosome and hence the latent hydrolases in the lysosome that 
now fuses with the phagosome remain inactive. These pumps would be subjected to 
being inhibited by agents that inhibit calcium dependent ATPase activity and hence the 
efflux of K+ from the phagosome-lysosome complex would be inhibited (Figures 2C to 
E). The availability of this ion for the activation of hydrolases present in the lysosome 
would be insured-hence killing would take place (Figure 2E). With respect to the 
activity of phenothiazines on intracellular bacteria, we should also consider that when 
bacteria are trapped in the phagosome-lysosome, there is also leakage of K+ from the 
bacteria that is promoted by the agent (Kristiansen et al., 1982). The killing activity of 
macrophages that is enhanced by inhibitors of the potassium pump that is present in the 
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membrane of the phagosome is a subject that is now under investigation and involves 
the isolation of the phagocytic vacuole and the evaluation of potassium efflux activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Model suggested for the killing of intracellular Staphylococcus aureus by 
ouabain, reserpine and verapamil. (A) Internalization of the bacteria by the macrophage, (B) 
Invagination of the macrophage membrane containing the bacteria, (C) Phagosome trapping with the 
bacteria, (D) Fusion of the phagosome with the lysosome and (E) Inhibition of the pumps by the 
compounds reserpine, ouabain and verapamil with the activation of the hydrolases and subsequent 
bacterial killing. 
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VI.3 Inhibitors of Ca2+ and K+ Transport Enhance Intracellular Killing of M. 
tuberculosis by Non-Killing Macrophages  
 
SUMMARY 
 
Human monocyte-derived macrophages that have little killing activity of their own kill 
intracellular Staphylococcus aureus when cultured in the presence of inhibitors of 
calcium and potassium efflux pumps. The aim of this study was to evaluate the effect of 
inhibitors such as ouabain, reserpine and verapamil in the killing activity of 
macrophages infected with Mycobacterium tuberculosis. Macrophages obtained from 
peripheral blood were infected with M. tuberculosis ATCC27294 H37Rv and treated 
with reserpine, ouabain and verapamil. After three days post-infection, macrophages 
treated with the inhibitors demonstrated an enhancement of the killing activity 
destroying the internalized bacteria. Whereas drugs that target the bacterium are 
predicted to lose effectiveness due to mutation of the bacterial target, drugs that enhance 
killing by macrophages that normally do not kill mycobacteria may yield a more 
effective form of therapy of infections caused by multidrug resistant M. tuberculosis.  
 
Materials and Methods employed in this study are described in publication #8 and in 
Chapter II (sections II.5 and II.8). 
 
RESULTS 
 
The evaluation of ouabain, reserpine and verapamil for direct in vitro activity against M. 
tuberculosis H37Rv ATCC27294, by the BACTEC 460-TB method, that identifies the 
minimum inhibitory concentration (MIC) for each agent, is summarised by Table 1. 
Briefly, whereas TZ (positive control) has an MIC of 15 mg/L, a concentration of 
ouabain, reserpine or verapamil as high as 80 mg/L had no significant effect on the 
replication of the mycobacterium.  
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Table 1. Minimum inhibitory concentration of TZ and other efflux pumps 
inhibitors against M. tuberculosis H37Rv ATCC27294 
 MIC (mg/L) 
Phenothiazine (positive control)  
TZ 15 
Other efflux pump inhibitors  
Reserpine 100 
Ouabain >200 
Verapamil 128 
 
The evaluation of toxicity of ouabain, reserpine and verapamil on lymphocytes cultured 
for up to 3 days is summarised by Table 2. Briefly, whereas TZ was cytotoxic at 
concentrations that exceed 0.5 mg/L, concentrations of ouabain, reserpine and 
verapamil as high as 100 mg/L did not produce significant toxicity, i.e., the percentage 
of lymphocytes that exhibited trypan blue staining of their cytoplasm did not exceed 
10%.  
 
Table 2. Percent toxicity of reserpine, ouabain and verapamil on human 
lymphocytes 
 Toxicity (%) 
Phenothiazine (positive control) 0.1 mg/L 3 mg/L 10 mg/L 
TZ 0 50 100 
Other efflux pump inhibitors 2 mg/L 50 mg/L 100 mg/L 
Reserpine 0 0.54 1.1 
Ouabain 0 5.5 10a 
Verapamil 0 2.4 4.8 
 
a Concentration of 100 mg/L of ouabain produces marginal toxicity.   
 
In order to determine whether the enhanced killing obtained with TZ and its derivatives 
(results presented in Chapter IV.2) could be due to the inhibition of transport of Ca2+ 
and K+, we examined whether common inhibitors of Ca2+ and K+ transport can enhance 
the killing of intracellular bacteria at concentrations of agents which are non-toxic. As 
can be seen in Figure 1, these efflux pump inhibitors enhanced the killing activity of 
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infected macrophages, however, at concentrations much higher (80 mg/L) than those 
used for TZ (0.1 mg/L). Verapamil demonstrated a greater activity than TZ. The 
maximum concentration of the K+ inhibitors examined for ability to enhance the killing 
of intracellular M. tuberculosis was 80 mg/L inasmuch as this concentration was devoid 
of any significant toxicity against human lymphocytes (see Table 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Effect of TZ and other efflux pumps in the killing activity of 
macrophages infected with M. tuberculosis. Cultures of isolated human macrophages (1×105 
cells/mL) were infected with M. tuberculosis at a ratio of 1:10 (1 macrophage:10 bacteria). After 1 hour 
of phagocytosis, cells were washed to remove non-phagocytosed bacteria. Aliquots of the tested 
compounds were added to the wells and cells incubated for 0, 1, 2 and 3 days. After incubation, 
supernatants of the wells were removed and kept for CFU study in order to determine whether the 
addition of the agents cause the lysis of the macrophage and subsequent release of the bacterium. Adhered 
cells were lysed with SDS 0.01% in order to release all the intracellular bacteria and aliquots of the lysed 
cells were plated on 7H11 medium. Plates were incubated at 37ºC for 3 to 4 weeks. After the incubation 
period, CFU were counted and bacterial concentrations calculated. The data presented are averages from 
three independent experiments each of which was conducted in triplicate. 
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DISCUSSION 
 
Phenothiazines inhibit the replication of S. aureus (Kristiansen et al., 2006; Martins et 
al., 2006b; Ordway et al., 2002b), and M. tuberculosis (Bettencourt et al., 2000; Martins 
et al., 2007b;Ordway et al., 2003b) and are bactericidal at concentrations that are 
multiples of their MIC (Amaral and Kristiansen, 2000). Because phenothiazines are 
concentrated as much as 100-fold by cells that are rich in lysosomes (Amaral and 
Kristiansen, 2000; Amaral et al., 2001a, 2006, 2007b; Daniel and Wojcikowski, 1997a, 
1999b), the enhanced intracellular killing produced by TZ and its derivatives could be 
the result of concentrations that are comparable to those that are bactericidal 
(Bettencourt et al., 2000; Ordway et al., 2003b;). Because previous studies have shown 
that concentrations of verapamil and reserpine that are considerably higher than those 
employed in our study do not significantly affect the growth of bacteria (Viveiros et al., 
2002; Kristiansen et al., 2006), enhanced killing is probably not due to any 
antimicrobial activity that results from their being concentrated by the macrophage. 
 
Recent studies have shown that the killing activity of the neutrophils is dependent upon 
the transport of Ca2+ (Ahluwalia et al., 2004), K+ and hydrolysis of ATP (Reeves et al., 
2002). Because these processes are inhibited by phenothiazines (Amaral et al., 2004, 
2007b; Ordway et al., 2002b) enhanced killing may be due to the effect that the 
phenothiazine has on the transport of Ca2+ and K+. This raises the question, of how 
these inhibitors of Ca2+ and K+ transport enhance the killing of intracellular 
mycobacteria. After phagocytosis, the bacterium is contained in a phagosome that was 
formed from the invagination of the plasma membrane of the macrophage. The plasma 
membrane is rich in pumps that transport Ca2+ and K+ into the cell, and due to 
invagination, would now pump these ions to the cytoplasm of the cell. When fusion of 
the phagosome with a lysosome takes place, the absence or low concentration of Ca2+ 
and K+ prevents the acidification of the phagolysosome and hence the bacterium is not 
killed. The unification of a vacuole that contains the inhibitor of Ca2+ and K+ transport 
with the phagolysosome inhibits the transport of these ions to the cytoplasm and they 
begin to accumulate within the phagolysosome. This would soon be followed by the 
activation of the V-ATPase system, which is probably ouabain insensitive (probably 
also phenothiazine insensitive); K+ is extruded and hydrogen ions flood into the 
phagolysosome resulting in the acidification of the phagolysosome and activation of 
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hydrolytic enzymes. The killing of the bacterium subsequently takes place. However, 
the possibility that a direct action of the agent on the phagosome-trapped bacterium due 
to the agent being concentrated to levels equivalent to those that kill the bacterium in 
vitro cannot be ruled out.  
 
The question of whether the results obtained in this study will further contribute to the 
therapy of MDR-TB is intriguing, because:  
 
Firstly, therapy of mice infected with M. tuberculosis with phenothiazines derivatives 
has proven successful (Amaral et al., 2007b; Weinstein et al., 2005; Yano et al., 2006). 
Secondly, these results are consistent with the predictions provided by ex vivo studies 
(Amaral et al., 2007b; Martins et al., 2006b, 2007b; Ordway et al., 2002b, 2003b), 
demonstrating the relevance of testing these compounds on infected macrophages. 
 
The results of the current study suggest an entirely different approach for the therapy of 
TB, and especially, MDR-TB. This approach involves the design of agents which target 
the macrophage and transform it into an effective bacterial killer. Whereas agents which 
target the bacterium are predicted to become ineffective due to mutations of the 
bacterial target, agents that enhance the killing activity of the macrophage will not 
suffer from this limitation. Moreover, this approach is also viable for the therapy of 
other intracellular infections such as malaria, leishmaniasis, trypanosomiasis inasmuch 
as phenothiazines have already been shown to be effective (Amaral et al., 2001b, 2006; 
Grácio et al., 2003; Happi et al., 2006; Wainwright and Amaral, 2005). Perhaps the 
search for effective agents for the therapy of intracellular infections should be extended 
to include all agents that are known to inhibit Ca2+ and K+ transport processes. 
 
 
 
 
 
 
 

  
 
 
 
 
 
 
 
 
 
 
 
CHAPTER VII. 
 
The effect of efflux pumps inhibitors, such as SILA compounds, on 
macrophages infected with MDR M. tuberculosis. New methods for the 
screening of efflux pump activity and efflux pump inhibitors 
 
 
 
 
 
 
 
 
 
 
This chapter contains data published and submitted for publication in: 
 
Martins, M., M. Viveiros, J. Ramos, I. Couto, J. Molnar, and L. Amaral. 2008. SILA compound 421, 
an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular MDR-TB. Submitted to 
J. Antimicrob. Chemother.; Martins, M., B. Santos, A. Martins, M. Viveiros, I. Couto, A. Cruz, J. M. 
Pagès, J. Molnar, S. Fanning, L. Amaral, and Management Committee Members of COST B16; 
European Commission/European Science Foundation. 2006. An instrument-free method for the 
demonstration of efflux pump activity of bacteria. In Vivo 20:657-664.  

Chapter VII 
 
 
161 
CHAPTER OUTLINE 
 
This chapter is focused on the effect of SILA compounds and infected macrophages as a 
special example relationship between efflux pumps inhibitors and the effect on infected 
macrophages. Human macrophages infected with MDR/XDR M. tuberculosis were 
treated with SILA compounds and the effect on the enhancement of the macrophage 
killing activity was assessed by colony forming units. These new and enthusiastic 
results provide evidence for a new compound that presents in vitro activity against 
XDR-TB and also enhance the macrophage killing activity. The fact that efflux 
inhibitors not only have activity against the bacteria itself but also ex vivo, lead us to 
develop methods for the rapid screening of new active compounds. 
  
The screening methods to be described, allow the rapid detection of efflux pumps 
inhibitors using an agar-based approach and a broth microplate system. These methods 
were developed at the Unit of Mycobacteriology (IHMT/UNL) and allow the rapid 
screening of efflux pump activity in large collection of clinical isolates, as well as efflux 
pump inhibitors (that reverse resistance or reduce antibiotic resistance) identification. 
These methods will be eventually adapted for the identification and screening of efflux 
activity of clinical isolates of M. tuberculosis and M. avium during my post-graduate 
work. 
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VII.1 SILA compound 421, an inhibitor of efflux pumps of cancer cells, enhances 
the killing of intracellular MDR-TB 
 
SUMMARY  
 
Multi-Drug Resistant Tuberculosis (MDR-TB) and Extensively-Drug Resistant 
Tuberculosis (XDR-TB) infections are problematic to manage, especially when the 
patient presents with AIDS.  There is a dire need for effective anti-TB agents and none 
as of now have been made available. We have previously shown that agents which have 
the ability to inhibit efflux pumps of multi-drug resistant (MDR) bacteria and cancer 
cells also enhance the killing of intracellular mycobacteria possibly by increasing the 
availability of K+ and Ca2+ needed for the activation of lysosomal enzymes of the 
phagolysosomal unit. In the herein study to be described, the newly synthesized and 
recently patented SILA compound 421, were tested for in vitro and ex vivo activity 
against an XDR-TB strain. Minimum inhibitory concentration of each agent was 
determined by the BACTEC 460 method. The effect of each compound on the killing 
activity of human monocyte-derived macrophages infected with the XDR-TB strain was 
determined by exposing the macrophage that had phagocytosed the bacterium to 
varying concentrations of each agent and the killing activity assessed by colony forming 
units counting. SILA compound 421 was shown to have in vitro activity against XDR-
TB (MIC < 3.5 mg/L) and transforms non-killing macrophages into effective killers of 
phagocytosed XDR-TB. Because this agent is devoid of any cytotoxic activity it has 
good potential as an anti-XDR-TB/MDR-TB drug.   
 
Materials and Methods employed in this study are described in publication #9 and in 
Chapter II (sections II.5 and II.8). 
 
RESULTS 
 
The in vitro activity of TZ and SILA compounds 409 and 421 is summarized by Table 
1.  Briefly, the MIC of TZ, SILA compounds 409 and 421 are 15, 12.5, and 3.125 mg/L, 
and 20, 12.5, and 3.125 mg/L, for M. tuberculosis ATCC H37RV and XDR-TB strains, 
respectively. These compounds were evaluated for cytotoxicity against human 
lymphocytes via the trypan blue exclusion method (Ordway et al., 2003b) and found not 
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to increase the retention of trypan blue at concentrations as high 100 mg/L as compared 
that of the drug-free controls (data not shown). These results are compatible with those 
of others who demonstrated that the compounds do not produce toxicity to the mouse 
(Fusi et al., 2008).  
 
Table 1. The in vitro activity of TZ and SILA compounds 409 and 421 against M. 
tuberculosis strains.    
MIC (mg/L) 
M. tuberculosis strains 
TZ SILA 409 SILA 421 
H37Rv ATCC 15 12.5 3.125 
XDR-TB 20 12.5 3.125 
 
The activity of TZ (positive control) and of SILA compounds 409 and 421 against 
phagocytosed XDR-TB was evaluated. As shown by Figure 1, whereas the lowest 
concentration of TZ and SILA compound 421 that enhances the killing of intracellular 
XDR-TB is 0.1 mg/L, at this concentration SILA compound 409 does not enhance 
killing.        
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Ex vivo effect of SILA compounds 421 and 409 in human macrophages 
infected with XDR-TB. Average killing activities of human monocyte-derived macrophages against 
XDR-TB (filled losanges), when either TZ (cross), SILA compounds 421 (filled squares) and 409 (filled 
triangles) were present in the medium at concentrations of 0.1 mg/L. The results are the average numbers 
of CFU for cultures obtained from three independent experiments. 
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DISCUSSION 
 
Global infections of antibiotic resistant M. tuberculosis continue to escalate especially 
in areas of the world that are poverty stricken and are laden with economic strife 
(Dorman and Chaisson, 2007). Although the problem of antibiotic resistance is not 
nearly as acute in Western European countries, there are some urban centres of Western 
Europe where the rates of new cases of MDR-TB and now, XDR-TB, are high (Migliori 
et al., 2007; WHO/IUATLD, 2004; Zignol et al., 2006;). Lisbon and Porto, the two 
major cities of Portugal are examples where the rates of MDR-TB are exceedingly high 
(DGS, 2006) although with respect to Lisbon, there has been a dramatic reduction of 
new cases of MDR-TB due to the implementation of the Faster TB Track Programme of 
the Institute of Hygiene and Tropical Medicine and the ability of its Mycobacteriology 
laboratory to identify within one day of receiving a positive acid fast stained sputum 
specimen, the patient that is infected with MDR-TB (Viveiros et al., 2005b). With 
respect to Porto, that as of this writing is not using the systems and programmes of the 
Institute of Hygiene and Tropical Medicine of Lisbon, the rates of new cases of MDR-
TB continue to escalate (DGS, 2006). With respect to XDR-TB, retrospective 
evaluation of MDR-TB strains isolated from patients during the past 8 years, clearly, a 
significant number are of an XDR-TB nature. The XDR-TB strain employed in the 
current study was isolated 3 years ago and is an example of this assumption.  
Undoubtedly, the pulmonary TB laboratory plays a major role in the control of TB 
(Bergmann and Woods, 1996; Ridderhof et al., 2007).  However, until the pulmonary 
TB is completely eliminated, effective therapy is an absolute requirement if the disease 
is to be controlled (WHO, 2007b). Although antibiotic susceptible TB infections are not 
difficult to manage effectively under conditions that optimize therapy (Ducati et al., 
2006), inexperience of the physician or non-compliance of the patient contribute to the 
selection of antibiotic resistant strains of M. tuberculosis (Drobniewski and Balabanova, 
2002; Rao, 1998;). When the patient is infected with MDR-TB, therapy is problematic 
and cure rates, although they can be as high as 85% in certain locales (Raviglione, 
2003), are very low wherever the frequency of MDR-TB is high (Vanacore et al., 2004). 
If the patient is co-infected with HIV or presents with AIDS, mortality is complete 
within one year of diagnosis regardless of therapy (Kawai et al., 2006).  Now with the 
advent of XDR-TB, therapeutic success is highly improbable with currently available 
drugs, and this includes the increasing number of agents that make up the “second line 
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of defence” drugs (Kim HR et al., 2007). And as of the time of this writing, no new 
drugs are on the horizon; and only two clinical trials of new agents are active with little 
success in evidence (Zhang, 2007). There is an obvious dire need for effective anti-
MDR-TB/XDR-TB compounds, and, this is where our studies have been directed 
during the past 8 years (Amaral and Kristiansen, 2000; Amaral et al., 1996, 2001a, 
2001b, 2004, 2006, 2007c; Bettencourt et al., 2000; Kristiansen and Amaral, 1997; 
Martins et al., 2005, 2007a, 2007b; Ordway et al., 2002b; Viveiros and Amaral, 2001; 
Wainwright and Amaral, 2005).   
 
We have recommended in our rprevious published studies (Amaral and Kristiansen, 
2000; Amaral et al., 2001a, 2001b, 2006, 2007b; Martins et al., 2008) that until 
effective anti-MDR-TB agents are made available, TZ be considered for the therapy of 
MDR-TB (Amaral and Kristiansen, 2000; Amaral et al., 2001b, 2006). Because TZ 
does cause prolongation of QTc when used at a considerably high dose (Amaral et al., 
2007b), there has been resistance to use this compound for therapy of MDR-TB even 
for compassionate reasons, i.e., after everything else has failed and the mortality is 
certain (Amaral et al., 2006, 2007b). Perhaps the derivatives of TZ which have been 
shown to be even more effective than the parent compound will receive serious 
attention (Martins et al., 2007b). In the meanwhile, SILA compound 421, a cancer cells 
efflux pump inhibitor, that has been studied and reported herein, has significant in vitro 
activity at a concentration acceptable for a potential anti-MDR-TB/XDR-TB drug (the 
MIC is quite low, namely, less than 3.5 mg/L). Although this concentration is free of 
any cytotoxicity, what is of far greater significance is that the enhancement of killing of 
intracellular XDR-TB by non-killing human macrophages takes place when the 
concentration of the agent in the medium is 0.1 mg/L. One would expect that a similar 
concentration of the agent in the interstitial fluids of the XDR-TB infected patient 
would also be effective and enhance the killing of XDR-TB at the site where this 
organism resides-namely, the pulmonary macrophage (Amaral et al., 2007b; Martins et 
al., 2008). Hence, barring any unforeseen negative aspects, SILA compound 421 is a 
very exciting anti-MDR-TB/XDR-TB agent and for this it deserves immediate attention 
from the pharmaceutical concern.  
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VII.2 An instrument-free method for the demonstration of efflux pump activity of 
bacteria  
 
SUMMARY 
 
The aim of the study was to develop a simple, inexpensive, reproducible ethidium 
bromide (EB)-agar based method that is independent of any specialized instrumentation, 
for the demonstration of efflux pump activity, which is responsible for antibiotic 
resistance of bacteria and therefore, can be the basis for the identification of new 
antimicrobial agents. A series of agar plates containing varying concentrations of EB 
were swabbed with strains of Escherichia coli or Staphylococcus aureus, which differed 
with respect to efflux pump activity. The plates were incubated at different temperatures 
and time periods and the measurements of fluorescence were used to evaluate the efflux 
activity of each culture. This simple assay allowed us to identify the efflux of EB in 
different bacteria following an overnight incubation. The minimal concentration of EB 
that produced fluorescence was significantly greater at 37ºC than at 4ºC, suggesting the 
presence of an energy-dependent pump. The method was shown to simultaneously 
identify strains of a mixed culture that differed from each other with respect to the 
activity of their efflux pumps. The method, in conjunction with the use of antibiotic-
containing disks, provides an additional advantage for the easy identification and 
selection of colonies that differ with respect to antibiotic susceptibility and degree of 
efflux pump activity. Because the method is very reproducible it may form the basis for 
inter-laboratory standardization of efflux pump activity of multi-drug resistant (MDR) 
clinical isolates, as well as the screening of compounds for the ability to inhibit efflux 
pumps of bacteria. 
 
Materials and Methods employed in this study are described in publication #9 and in 
Chapter II (section II.4). 
 
RESULTS 
 
The use of a system that is to contain an agent for the demonstration of an efflux pump 
or its activity must first be preceded by studies that determine the effect of that agent on 
the growth of the bacteria under study (Viveiros et al., 2002). As evident from Table 1, 
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EB, a common bacterial efflux pump substrate, has differential activity against the 
bacteria listed. This efflux pump substrate was chosen because of its fluorescent 
properties that make it easily trackable at low concentrations. 
 
Table 1. The minimum inhibitory concentration (MIC) of EB against bacteria. 
Bacterium MIC for EB (µg/ml) 
E. coli K-12 AG100 (acrAB) 150 
E. coli K-12 AG100 (acrAB TET) >200 
E. coli K-12 AG100A (∆acrAB) 5 
Enterobacter aerogenes EA27 >150 
S. aureus ATCC25923 5 
MRSA COL 10 
MRSA HPV107 >30 
 
The MIC for EB was determined by the use of the broth dilution method previously described (Viveiros 
et al., 2005a).  
 
Therefore, the concentrations of EB present in the agar that is to be streaked or swabbed 
with the bacterial inoculum must be well below those that have an effect on growth. 
Furthermore, because EB will fluoresce under UV light, the selection of the maximum 
concentration of EB in the agar must be one that is below the resolution of the UV 
detector employed. With these considerations in mind, the maximum concentration of 
EB in agar was below 7.5 µg/ml. Examples of the growth at 37ºC of streaked S. aureus 
ATCC25923 strain in agar containing concentrations of EB that ranged from 0.0 to 4.0 
µg/ml demonstrate that at a concentration of 0.4 µg/ml EB bacteria begin to exhibit 
fluorescence, whereas the agar-EB itself does not exhibit any detectable fluorescence at 
a concentration as high as 4.0 µg/ml of EB (Figure 1).  
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Figure 1. Fluorescence associated with isolated S. aureus colonies grown on agar 
containing increasing concentrations of EB. S. aureus ATCC25923 grown overnight in TSB 
was diluted with saline to yield approximately 100,000 cells per ml. This dilution was further diluted 100-
fold and from this a small loopful streaked onto TSB agar containing concentrations of EB ranging from 
0.0 to 4.0 µg/ml. Plates were incubated overnight and examined under UV illumination. Photographs 
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were obtained with the aid of the Eagle Eye (Stratagene, USA) instrument. Fluorescence of the colonies is 
associated with the minimal concentration of EB-agar of 0.4 µg/ml. Also note that concentrations of EB 
as high as 4.0 µg/ml do not produce any fluorescence from the agar itself.  
 
The use of swabbing affords certain advantages over the streaking method such as 
providing a more representative and perhaps uniform result if the strain employed is 
homogeneous with respect to the presentation of fluorescence at a given concentration 
of EB. As shown by Figure 2, swabbing of S. aureus ATCC25923 strain yields the same 
result — namely that the minimal concentration of EB that produces significant 
fluorescence is identical to that yielded by the streaking method (0.4 µg/ml). As the 
concentration of EB is increased, more fluorescence is associated with the confluent 
mass. Figure 2 also demonstrates that the minimal concentration of EB that produces 
fluorescence of the ATCC strain is markedly lower than that of two MRSA strains COL 
and HPV107, the latter of which has an MDR phenotype.  
 
 
 
COL ATCC COL ATCC 
COL ATCC 
0 µg/mL 0.2 µg/mL 
0.4 µg/mL 
HPV HPV 
HPV 
 
Figure 2. The minimal concentration of EB that produces fluorescence of S. aureus 
ATCC, MRSA COL and MRSA HPV107 MDR phenotype. Strains of S. aureus were 
grown overnight in TSB and 10 µl aliquots were diluted in 10 ml of saline. With the aid of a sterile swab, 
individuals sectors of each agar plate, which contained various concentrations of EB was swabbed with 
the ATCC, MRSA COL and MRSA HPV107 strains, respectively. The minimum concentration of EB 
producing fluorescence of the ATCC strain was 0.4 µg/ml whereas the MRSA COL and HPV107 strains 
did not fluoresce until a concentration above 1.8 µg/ml of EB was used.  
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The effect of temperature on the retention of EB is shown by Figure 3. The transfer of 
the EB plates that had been incubated at 37ºC to 4ºC resulted in fluorescence of the 
cultures at a concentration that produced no fluorescence at 37ºC. The set of duplicate 
plates returned to 37ºC maintained the same minimal concentration of EB that produced 
fluorescence after the first 24 hours at 37ºC (data not shown). 
 
 
 
 
 
 
 
 
 
 
Figure 3. The effect of temperature on the minimal concentration of EB that 
produced fluorescence of S. aureus ATCC, MRSA COL and MRSA HPV107. Agar 
plates containing EB were examined for concentrations that did not produced fluorescence of MRSA 
COL and HPV107 strains but that did produce ample fluorescence of the ATCC strain. These plates were 
transferred to 4ºC and examined after 24 h. The minimal concentration of EB that produced fluorescence 
was reduced from about 1.8 to < 0.5 µg/ml (example shown is for 0.6 µg/ml and shows highly evident 
fluorescence).    
 
The minimal concentration of EB that produced fluorescence by different bacteria 
cultured on EB-containing agar and which have different degrees of efflux pump 
activity is summarized by Table 2.  
 
 
 
 
 
 
 
 
COL ATCC 
HPV 107 
0.6 µg/mL 
37ºC 
 
HPV 107 
COL ATCC 
0.6 µg/mL 
4ºC 
Chapter VII 
 
 
171 
Table 2. Lowest concentration of EB that produced fluorescence associated with 
bacterial cell mass after 24 hours at 37ºC, after 48 hours at 37ºC and after transfer 
from 24 hours at 37ºC to 4ºC. 
Lowest EB concentration producing 
fluorescence (µg/ml) 
Bacterium 
After 24h at 
37ºC 
Transfer  
to: 4ºC 
After 48h at 
37ºC 
E. coli K-12 AG100 (acrAB) 0.4 0.1 0.4 
E. coli K-12 AG100 (acrAB TET) 2.0 0.1 2.0 
E. coli K-12 AG100A (∆acrAB) 0.1 <0.1 0.1 
Enterobacter aerogenes EA27 1.9 0.1 1.9 
S. aureus ATCC25923 0.4 0.05 0.4 
MRSA COL 1.6 0.5 1.6 
MRSA HPV107  2.2 0.5 2.2 
 
From overnight cultures in LB or TSB broth, 100 µl were transferred to 10 ml of saline, mixed, and one 
sterile cotton swab dipped into the mixture, dabbed onto the inside of the tube, and replicate LB or TSB 
agar plates containing concentrations of EB ranging from 0.0 to 2.2 µg/ml were extensively swabbed to 
yield a uniform distribution of cells. The plates were incubated for 24 h at 37ºC and then illuminated 
briefly by a fluorescent lamp and the lowest concentration of EB associated with uniform fluorescence of 
the colonies recorded. One set of replicate plates were returned to 37ºC and the other replicate transferred 
to 4ºC. The plates were examined periodically and the lowest concentration of EB that produced uniform 
fluorescence of the colonies present recorded.  
 
The demonstration of fluorescence associated with the bacterial mass takes place at 
different concentrations of EB for each of the bacteria studied - The transfer of these 
plates to 4ºC reduced the minimal concentration of EB that produced fluorescence 
(Table 2). These assays have been conducted on at least six separate occasions, each 
time in duplicate, and the data obtained has been consistent. Colonies from the 4ºC or 
37ºC plates that showed fluorescence at a minimal concentration of EB associated with 
the cell mass when transferred to the appropriate broth (TSB or LB) were as viable as 
their respective initial controls (data not shown). Therefore, the presence of EB 
associated with the bacterial cell mass does not result in any measurable lethality.  
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To determine whether the method allows the distinction between strains of one species 
that differ significantly from each other by the activity of efflux pumps, E. coli K-12 
AG100A (∆acrAB) and the AcrAB over-expressed strain (AG100 TET) were separately 
cultured in LB broth overnight. The AcrAB-TolC system in E. coli has been identified 
as the predominant drug efflux pump of this organism and is the major described MDR 
mechanism (Elkins and Nikaido, 2002). We have used an E. coli K-12 strain whose 
genes that code for this main efflux pump (AcrAB) have been deleted (E. coli AG100A) 
and also a strain that contains an over-expressed intact acrAB operon. This last strain 
(E. coli AG100TET) has a high level of resistance to TET due to its slow and gradual 
culture in media containing this antibiotic (Viveiros et al., 2005a). Since E. coli K-12 
AG100A (∆acrAB) and E. coli K-12 AG100 (acrAB intact) strains are resistant to 
kanamycin (KAN) and TET, respectively, separate disks containing these antibiotics 
were placed on each EB-agar plate.  As shown in Figure 4, the colonies of the KAN-
resistant strain, AG100A (∆acrAB), that grow up to the KAN disk exhibit heavy 
fluorescence, whereas those that grow around the TET disk, the AG100 (acrAB intact), 
strain do not fluoresce.  These results show that whereas the strain which has the main 
efflux pump deleted (∆acrAB), as expected, cannot extrude the EB at concentrations 
above 0.4 µg/ml, the strain that has the intact acrAB efflux pump readily extrudes EB.   
 
 
 
TET 
KAN 
37ºC 
0.6 µg/mL 
 
 
Figure 4. The use of the EB-agar method for the demonstration of different strains 
of E. coli that differ with respect to the absence and over-expressed AcrAB efflux 
pump. The EB-agar plate was swabbed with a mixture of acrAB deleted E. coli AG100A, resistant to 
KAN, and acrAB E. coli AG100, which has high level resistance to TET (Viveiros et al., 2005a). The 
plate was incubated at 37ºC, examined and photographed. Colonies around the TET disk that do not 
fluoresce are those that contain an over-expressed intact acrAB operon which is the cause of high level 
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resistance to this antibiotic whereas those that surround the KAN disk have the acrAB operon deleted and 
these fluoresce at a concentration of 0.6 µg/ml of EB. 
 
The results presented in Figure 5 show that the colonies of MRSA HPV107 growing 
right up to the disks containing the OXA, ERY, and CIP begin to show evidence of 
fluorescence at 1.8 µg/ml of EB, whereas those present in the areas that are far from 
these disks begin to show fluorescence at 0.4 µg/ml. Removal of single white colonies 
from the areas around the antibiotic-containing disks and fluorescent colonies from the 
EB plates containing 0.4 µg/ml of EB with subsequent culture and testing for 
susceptibility confirmed that the white colonies were of the HPV107 MDR strain and 
those that fluoresced were the ATCC strain. Transfer of these plates to 4ºC reduced the 
minimal concentration of EB needed to produce fluorescence of the colonies 
surrounding the disks (data not shown). 
 
 
 
 
0.4 µg/mL 1.0 µg/mL 
1.8 µg/mL 
37ºC 
CIP ERY 
OXA 
CIP 
ERY 
OXA 
CIP 
ERY 
OXA 
 
Figure 5. The ability of the method to distinguish the antibiotic-susceptible S. 
aureus ATCC25923 strain from the antibiotic-resistant MRSA HPV107 strain. 
Aliquots of 10 µl of S. aureus ATCC25923 and 40 µl of MRSA HPV107 strains from overnight cultures 
were added to 10 ml of saline and from this 10 µl were diluted 100-fold with saline. The mixture was 
swabbed onto EB-containing plates and antibiotic susceptibility disks containing CIP, ERY and OXA 
applied, and the plates incubated overnight at 37ºC. Colonies growing right up to the disks of CIP begin 
to show evidence of fluorescence at 1.8 µg/ml. The zone of inhibition noted is devoid of colonies that 
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fluoresce. Isolation of non-fluorescent colonies and fluorescent colonies were later shown by 
susceptibility assay to be MRSA HPV107 and S. aureus ATCC strains, respectively.  
 
DISCUSSION  
 
The extrusion or retention of the common efflux pump substrate, EB, has been the 
primary means by which the activity of bacterial efflux pumps has been assessed by 
most studies (Beyer et al., 2000; Bolhuis et al., 1996; Giraud et al., 2000; Kaatz et al., 
2002, 2003; Kern et al., 2006; Paulsen et al., 1996). Because efflux pumps are 
temperature dependent one could predict that the extrusion of EB would be reduced by 
decreasing the temperature in which a stationary culture is maintained. The results 
obtained in this study show exactly this – namely, that the fluorescence manifested by 
this agent, associated with a colony or confluent bacterial mass maintained at 37ºC, is 
evident at a given concentration of EB. The simple transfer to 4ºC will markedly reduce 
the concentration of EB that produces similar fluorescence. The manifestation of 
fluorescence at a lower concentration of EB produced at 4ºC must be the result of 
retention of this compound as opposed to an increase in the diffusion into the bacterial 
cell, since the rate of diffusion at 4ºC would be much lower than that taking place at 
37ºC. The viability of cells cultured on agar containing concentrations of EB associated 
with the onset of fluorescence has been evaluated with the aid of colony forming units 
(CFU) when colonies showing fluorescence at minimal concentrations of EB were 
transferred to saline, diluted and aliquots then cultured in TSB or LB, depending on the 
species of bacteria under study, and evaluated at intervals by the use of the CFU 
method, they were found to have growth rates indistinguishable from those of controls 
pre-grown in EB-free broth (data not shown).  
 
The results presented in this study demonstrate that the degree of efflux pump activity 
between strains of bacteria, as well as species, can easily be assessed by the use of the 
EB-agar method requiring no specialized instrumentation.  The method affords a level 
of precision that may, after extensive study, provide the means by which efflux pump 
activity can be evaluated by a consortium of clinical laboratories. If the method 
progresses to that point, it may find its way into the clinical laboratory and provide the 
clinician with an additional laboratory tool that identifies the source of MDR of a given 
bacterial clinical isolate.   
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The method may prove extremely useful when introducing plasmids that contain 
individual genes that code for distinct components of efflux pumps into bacteria. It 
would be expected that when these genes are expressed, the colonies on the agar surface 
would exhibit fluorescence at significantly higher concentrations of EB than those 
colonies not having the plasmid-carrying gene (uninfected colonies). If the resolution of 
this discrimination is sufficiently high, then one may expect that the method may allow 
the use of plasmids that do not contain antibiotic-resistant genes, required by other 
methods for the selection of plasmid-carrying efflux pump colonies. The ability to use 
plasmids that are free from antibiotic resistant marker genes means that larger genes 
may be introduced without having to increase the size of the plasmid. Moreover, the 
smaller the plasmid used, the greater its retention by the bacterium, hence, the higher 
the efficiency of recovery.  
 
The advantages provided by the method transcend its simplicity. Firstly, an agar culture 
containing a mixture of colonies that differ with respect to the degree of efflux pumps 
expressed can be replicate plated to agars containing increasing amounts of EB. This 
affords easy identification, quantification and isolation of the phenotypes exhibited. 
Secondly, the replicate cultures themselves can then be transferred to agar containing a 
more limited range of EB concentrations in combination with concentrations of an agent 
that is being examined for the inhibition or activation of efflux pump(s). The 
applications of this method can be further extended to the rapid characterization of 
bacteria harboring plasmids containing genes that code for distinct components of 
specific efflux pumps, their regulators and sensors. Variations of the replicate plating 
can also be tested, in order to evaluate the possible automation of the method, adapting 
it to microwell-plate technology. The method is currently being used by members of the 
Unit of Mycobacteriology for the assessment of over-expressed efflux pump systems of 
mycobacteria as well as those of S. aureus that have been made extremely resistant to 
EB (MIC increased from 5 to over 100 mg/L of EB) (Couto et al., 2008, submitted).   
 
Lastly, this method can be easily adapted for hightroughput screening of compounds 
with inhibitory activity againt efflux pumps of bacteria. These can later be tested for the 
enhancement of the killing activity of the infected macrophage, along the same lines 
previously described, in order to detect new antimicrobial agents. 
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CHAPTER OUTLINE 
 
This review chapter is divided into two parts: 
 
The first part of this chapter is focused on the discovery of new anti-
microbial/mycobacterial agents that are known efflux pump inhibitors, and that can be 
used in the therapy of MDR bacteria, namely, MDR-TB. A new approach that uses 
these agents in conjunction with the classical antibiotics is analysed and described. 
These now termed “helper compounds” could provide the basis for a novel strategy 
implemented in the management and control of MDR and XDR-TB. This chapter also 
summarises much of my published work that has been jointly conducted with 
colleagues from Ireland, Denmark, Germany, Hungary, France, India and the USA, all 
of whom are identified in the Acknowledgement section of this Thesis.  
 
The second part of this chapter provides: a) The rationale for my thesis and future work; 
b) Results from my research that are relevant to the therapy of XDR-TB and MDR-TB 
and, c) alternative therapy supported by my studies.  
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VIII.1 The future of chemotherapy: From where will new antimicrobial agents 
come from? 
 
SUMMARY  
 
Multidrug resistance in Gram-negative bacteria is now known to be primarily caused by 
overexpression of efflux pumps that extrude unrelated antibiotics from the periplasm or 
cytoplasm of the bacterium prior to their reaching their intended target. This review 
chapter focuses on a variety of agents that have been shown to be efflux pump inhibitors 
(EPIs) and which, if used as ‘helper compounds’ in combination with antibiotics to 
which the organism is initially resistant, may produce the required cure. Although not 
all of the EPIs may serve a helper role owing to their toxicity, they may nevertheless 
serve as lead compounds. 
 
Antibiotics or Non-antibiotics 
 
An antibiotic as defined by Webster’s dictionary is a substance produced by a 
microorganism that destroys or inhibits the growth of another microorganism. In 
contrast to an antibiotic, there are medicinal compounds that are used for the therapy of 
non-infectious pathology and that have antimicrobial properties (Haug et al., 2007). For 
lack of a better name, these latter compounds are termed ‘non-antibiotics’ (Nishimura, 
1986) and given their potential for the therapy of some problematic infections (Amaral 
et al., 2006; Kristiansen and Amaral, 1997), they may eventually achieve antimicrobial 
status. The group of ‘non-antibiotics’ consists of two subgroups, each with activities 
that are distinctly different. Those non-antibiotics that have direct antimicrobial activity 
make up the first group (antimicrobial non-antibiotics) (Kristiansen and Amaral, 1997). 
The second group consists of two subclasses, one of which alters the permeability of the 
microorganism to a given antibiotic (Amaral and Lorian, 1991; Dutta et al., 2007; 
Viveiros and Amaral, 2001), termed ‘helper compounds’, whilst the second subgroup 
enhances the killing activity of macrophages that have phagocytosed the microorganism 
(Amaral et al., 2007b) and may be termed ‘macrophage modulators’. The purpose of 
this review of ‘non-antibiotics as helper compounds’ is to discuss the mechanisms by 
which some non-antibiotics have direct antibacterial activity, some assist the penetration 
of antibiotics by their ability to inhibit efflux of the antibiotic prior to it reaching its 
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intended target, others directly transform non-killer cells into effective killers of bacteria 
which cause infections that are problematic to manage, and lastly some of which have 
the ability to cure bacteria of plasmids and hence may have potential in the area of 
animal husbandry. 
History of ‘non-antibiotics’ 
 
Prior to end of the 19th century, the work of Paul Ehrlich demonstrated the antimicrobial 
activity of methylene blue, a dye that is the ‘poster child’ for a group of heterocyclic 
compounds, the phenothiazines. Methylene blue was also shown to obviate the mobility 
of microorganisms and this finding quickly spurred studies by others to see whether the 
dye would also affect the mobility of a mammal and indeed it did, inasmuch as 
intravenous (i.v.) administration of this dye produced lethargy in humans (Amaral and 
Kristiansen, 2001). Because the dye turned the patient blue, it could not be used for 
therapy of neurological disease that required restraining the patient from overactive 
activity. Nevertheless, interest in the dye as a potential neuroleptic was maintained for 
the next 50 years, ultimately resulting in the first neuroleptic non-coloured 
phenothiazine, CPZ (Lopez-Munoz et al., 2005). Interest in the antimicrobial properties 
of methylene blue was not sufficient to motivate its exploitation as an antimicrobial 
agent. However, with global use of CPZ, anecdotal reports demonstrated that patients 
receiving CPZ therapy could be cured of bacterial infections (Amaral and Kristiansen, 
2000). Nevertheless, because the appearance of these reports took place during the 
‘golden age of antibiotics’ (1950s to 1970s), there was little need for the use of CPZ as 
another antibiotic, especially since the serious side effects produced by this agent were 
rather frequent (Amaral et al., 2004). However, because antibiotic resistance, especially 
multidrug resistance, has become common (WHO/IUATLD, 2004), a number of 
investigators turned their interest to CPZ and other derived phenothiazines as potential 
agents against MDR organisms. 
Antimicrobial activity of non-antibiotics 
 
The in vitro antimicrobial activities of non-antibiotics have been widely described. 
However, with few exceptions the concentrations of these agents needed to inhibit in 
vitro growths are well beyond those that can be achieved clinically (Amaral and 
Kristiansen, 2000). Nevertheless, phenothiazines such as trimethoprim and 
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trimeprazine, at concentrations that are tolerated by the mouse, protect the animal from 
developing Salmonella infections (Guha et al., 2000). Similar protection of the mouse 
against infection by highly virulent Salmonella strains is afforded by diclofenac sodium 
(Dutta et al., 2004, 2007). Non-antibiotic phenothiazines and their derivatives have been 
shown to protect mice against Escherichia coli infection (Komatsu et al., 1997). 
However, although the above non-antibiotics protect the mouse against a Gram-negative 
infection, they have not yet been shown to cure a Salmonella-infected mouse. 
Nevertheless, children who present with recurrent pyelonephritis due to E. coli can be 
cured with CPZ and gentamicin, whereas therapy with the antibiotic alone results in 
failure (Gunics et al., 2000; Molnar et al., 1990). 
 
Although the use of phenothiazines for therapy of Gram-negative infections is still very 
far from being seriously considered, phenothiazines appear to have great potential for 
the therapy of MDR-TB (Amaral and Kristiansen, 2000; Amaral et al., 2006, 2007b; 
Kristiansen and Amaral, 1997; Viveiros and Amaral, 2001). As is the case for in vitro 
activity against Gram-negative bacteria, a large number of phenothiazines have been 
shown to have in vitro activity against Mycobacterium tuberculosis (Amaral et al., 
1996; Bate et al., 2007; Bettencourt et al., 2000; Chakrabarty et al., 1993; Gadre et al., 
1998, 1999; Madrid et al., 2007; Ratnakar and Murthy, 1992, 1993; Ratnakar et al., 
1995; Reddy et al., 1996; Yano et al., 2006). However, the concentrations of 
phenothiazines that inhibit in vitro growth cannot be achieved clinically (Amaral et al., 
2004). Nevertheless, because phenothiazines are concentrated as much as 100-fold by 
macrophages (Daniel and Wojcikowski, 1999b; Ordway et al., 2003b) and M. 
tuberculosis is an intracellular infection of the human macrophage (Saunders and 
Britton, 2007); phenothiazines have been studied for activity against intracellular 
mycobacteria. These studies have shown that killing of phagocytosed M. tuberculosis 
by non-killing macrophages is enhanced by concentrations of the phenothiazine that are 
well below those employed for the therapy of psychoses (Crowle et al., 1992; Martins et 
al., 2007b; Ordway et al., 2003b; Reddy et al., 1996) (discussed on Chapter IV). It is 
important to note that whereas many compounds have been shown to have in vitro 
activity, few of these penetrate the macrophage and retain activity against intracellular 
mycobacteria. With respect to the phenothiazines, because these compounds are 
concentrated many-fold by the macrophage, it is probable that any phenothiazine will 
have intracellular antimycobacterial activity. In line with the demonstration that 
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phenothiazines promote the killing of intracellular mycobacteria, mice infected with M. 
tuberculosis have been cured of this infection when treated with thioridazine (Martins et 
al., 2007a) (Chapter V) and with analogues of CPZ (Weinstein et al., 2005). Because a 
given phenothiazine has the same activity against M. tuberculosis regardless of its 
resistance to one, two or more antibiotics (Amaral et al., 1996), phenothiazines should 
be seriously considered for the therapy of MDR-TB (Amaral and Kristiansen, 2000; 
Amaral et al., 2006, 2007b) and extensively drug-resistant (XDR)-TB (Amaral et al., 
2007c). However, because some phenothiazines such as CPZ produce a plethora of 
serious side effects, only those phenothiazines that are relatively free of serious effects 
are to be considered as candidates for the therapy of MDR-TB (Amaral and Kristiansen, 
2000; Amaral et al., 1996, 2006, 2007b; Kristiansen and Amaral, 1997). 
Mechanism of action by which phenothiazines express in vitro and ex vivo activity 
In vitro 
 
Phenothiazines inhibit transport of calcium (Ca2+) by preventing its binding to Ca2+-
binding proteins such as calmodulin (CaM) (Weiss et al., 1980). This means that 
enzyme systems which are dependent upon Ca2+, such as those involved in generating 
cellular energy from hydrolysis of ATP, are inhibited (Francis et al., 2002; Garcia et al., 
1995). Among these phenothiazine-sensitive systems are transporters that extrude from 
the cell a variety of noxious agents and hence protect the cell from these agents. All 
bacteria studied to date contain a variety of transporters that intrinsically recognise 
noxious agents, such as antimicrobial agents and detergents, and extrude these agents 
from the periplasmic space of the cell envelope (Piddock, 2006b). When these 
transporters are overexpressed, the bacterium becomes resistant to a variety of unrelated 
antibiotics, hence their MDR phenotypes. Phenothiazines have been shown to reverse 
MDR phenotypes of bacteria and therefore render these bacteria susceptible to 
antibiotics to which they were initially resistant (Amaral et al., 2000; Kawase and 
Motohashi, 2003; Kristiansen et al., 2003, 2006; Kristiansen et al., 2007; Michalak et 
al., 2006). Because multidrug resistance is due to the overexpression of efflux pumps 
that are the cause of MDR bacteria (Piddock, 2006a) and these efflux systems are driven 
by energy provided by the proton-motive force which is dependent upon Ca2+-
dependent enzyme systems (Molnar et al., 1997; Plishker, 1984), the inhibition of Ca2+ 
binding to Ca2+-dependent enzymes will render the bacterium susceptible to that which 
Chapter VIII 
 184
they were initially resistant (Bhatnagar and Singh, 2003). Therefore, it is not surprising 
to note that phenothiazines reverse MDR phenotypes of bacteria. Inhibition of intrinsic 
efflux of a noxious agent such as a phenothiazine is believed to result in greater 
permeability to other noxious agents, including the phenothiazine itself. Increased 
permeability ensures that phenothiazine molecules eventually reach the DNA, 
intercalate between the bases (Rohs and Sklenar, 2004), inhibit all DNA-based 
processes (Dastidar et al., 2000; Ratnakar and Murthy, 1993) and hence inhibit 
replication. The in vitro concentrations of the phenothiazine that inhibit replication of 
the bacterium are generally many hundred-fold greater than that which can be achieved 
in the patient (Mengozzi et al., 1994). 
Ex vivo 
 
In contrast to the in vitro activity, the enhancement of killing of intracellular bacteria 
promoted by a phenothiazine has generally been considered to be due to concentration 
of the phenothiazine to a level that is compatible with the in vitro concentration that 
inhibits replication of the bacterium (Amaral et al., 2007b; Crowle et al., 1992; Ordway 
et al., 2003b). However, because phenothiazines can inhibit any transport process, 
including those for K+ and Ca2+ (Chukhlova et al., 1984; Kim and Kim, 2005), and 
these ions are essential for acidification of the phagolysosome and subsequent activation 
of its hydrolases (Pillay et al., 2002), the possibility that enhanced killing is not due to a 
concentration effect but is related to the inhibition of K+ and Ca2+ transport processes 
has been considered and investigated (Wittekindt et al., 2006) (Chapter VI). Although 
the concentrating effect cannot be ruled out, recent experiments have shown that 
common inhibitors of K+ and Ca2+ transport enhance the killing of intracellular bacteria 
and support the contention that phenothiazines enhance killing by the same mechanism 
(Ahluwalia et al., 2004). 
Efflux pump inhibitors (EPIs) of MDR bacteria 
 
Antibiotic-sensitive bacteria that are gradually exposed to increasing concentrations of a 
given antibiotic develop increasing resistance to that antibiotic (Martins A et al., 2007; 
Viveiros et al., 2005a). Accompanying this induced resistance are increases in 
resistance to other unrelated antibiotics (Martins A et al., 2007; Viveiros et al., 2007). 
This induced resistance can be reversed with the transfer of the bacterium to a drug-free 
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medium or by exposure of the bacterium to an EPI such as phenylalanine arginyl β-
naphthylamide (PAβN), phenothiazines such as thioridazine and CPZ, carbonyl cyanide 
m-chlorophenylhydrazone (CCCP) and reserpine (Guillier et al., 2006; Kristiansen et 
al., 2006). These studies suggest that exposure to an antibiotic at concentrations that do 
not completely inhibit replication of the bacterium serve to induce the bacterium to 
withstand the action of the antibiotic even though its concentration has been increased 
(Bamberger et al., 1997). Development of a MDR phenotype suggests that the 
development of multidrug resistance in Gram-negative bacteria in patients treated with 
subinhibitory doses of the antibiotic occurs via the same mechanism.  
 
Nevertheless, the above studies only demonstrate an association of induced MDR 
phenotypes with the development of an overexpressed putative efflux pump system. 
Recent studies (Viveiros et al., 2007) have demonstrated that exposure of E. coli to 
increasing concentrations of tetracycline (TET) results in significantly increased activity 
of genes that regulate genes coding for transporters of the resistance-nodulation-cell 
division (RND) superfamily efflux pumps (Elkins and Nikaido, 2003). The stress genes 
soxS and rob are increased when the organism is first exposed to TET. This is followed 
by increased activity of marA, marB and marR, which remain increased in activity 
during prolonged exposure to increasing concentrations of TET, whereas those of soxS 
and rob decrease to levels that approximate to that of unexposed controls. Together with 
the increased activity of regulator genes, there are increases in the activity of genes that 
code for the two main transporters, AcrB and YhiV, which remain at their highest level 
while the organism remains cultured in the presence of high concentrations of TET. 
Interestingly, the response to an antibiotic is not limited to the activation of efflux pump 
genes. micF, a gene that downregulates the post-transcription of porins (Guillier et al., 
2006), is increased, as well as ompX, a gene that is considered to be a downregulator of 
porins by interfering with their assembly (Viveiros et al., 2007). Although inducement 
of TET resistance does not significantly alter the activity of ompF and ompC genes, the 
amounts of the outer membrane proteins OmpF and OmpC are decreased, possibly due 
to the increased activity of genes that code for proteases which degrade these outer 
membrane proteins prior to their assembly into the tri-barrel porin (Viveiros et al., 
2005a). However, we cannot at this time rule out the possibility that downregulation of 
type F porin is due to the increased activity of the micF gene as noted (Viveiros et al., 
2007). This gene produces a short anti-sense mRNA that binds to the tail end of the 
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OmpF mRNA, thereby preventing translation of OmpF mRNA. Hence, increase of 
micF activity results in less OmpF protein (Chen et al., 2004). It may be concluded that 
MDR phenotypic resistance of a Gram-negative bacterium results from treatment of a 
patient with subinhibitory doses of an antibiotic and that this MDR phenotype involves 
overexpression of efflux pumps and downregulation of porins, both systems working 
together to reduce the permeability of the organism to that antibiotic as well as to other 
unrelated antibiotics. Because the MDR efflux pump can be inhibited by a variety of 
agents, the use of EPIs as helper compounds to antibiotics to which the bacterium is 
initially resistant has become a focus of investigation. 
The search for EPIs 
 
Enterobacter aerogenes and Klebsiella pneumoniae are among the commonest Gram-
negative bacteria involved in nosocomial respiratory and urinary tract infections. These 
bacteria exhibit a marked decrease in antibiotic susceptibility. In various clinical 
isolates, the MDR phenotype is strongly associated with a marked decrease in the 
synthesis of non-specific porins and the overproduction of active drug efflux systems. 
These modifications of envelope permeability contribute to a high level of resistance for 
structurally unrelated molecules such as β-lactams, quinolones, macrolides, 
tetracyclines and chloramphenicol (Piddock, 2006a; Poole, 2005). 
 
Today, one challenge is to synthesise and characterise new molecules that are capable of 
circumventing efflux activity and restoring the internal concentration of common 
antibiotics that are substrates of efflux pumps. In addition, these compounds must be 
devoid of any intrinsic antibacterial activity at the concentration used (Viveiros et al., 
2007). Enterobacter aerogenes and K. pneumoniae clinical isolates that exhibit a MDR 
phenotype and active efflux mechanisms have been used to test several quinoline 
derivative molecules as chemosensitisers or EPIs. This group of molecules has been 
selected due to their structural homology with the quinolones and with attention to 
previous results obtained with resistant microbes (Mahamoud et al., 2006). The 
respective minimum inhibitory concentrations (MICs) of these quinoline compounds are 
quite similar to those obtained with the commercially available EPI PAβN (MC-207, 
110), which is the first inhibitor previously developed against Pseudomonas aeruginosa 
(Lomovskaya and Bostian, 2006). PAβN is currently used to detect efflux pump 
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activities in various Gram-negative bacteria, including resistant E. aerogenes and K. 
pneumoniae strains (Lomovskaya and Bostian, 2006; Pagès et al., 2005). Of the 
quinoline derivatives that have been tested for their capability to decrease resistance, 
certain of them (belonging to alkoxyquinoline, alkylaminoquinoline, 
thioalkoxyquinoline and chloroquinoline subclasses) are efficient chemosensitisers of 
chloramphenicol activity, with an 8- and 32-fold decrease in the chloramphenicol MIC 
in resistant strains. In addition, they significantly increase the intracellular accumulation 
of chloramphenicol or norfloxacin in resistant bacteria that exhibit an overproduction of 
efflux pumps, especially the AcrB pump in E. aerogenes and K. pneumoniae. The 
subsequent increase of intracellular drug concentration reached a level similar to that 
obtained with an energy poison which disrupts the inner membrane proton gradient 
required for the activity of the efflux pump, indicating a clear effect on the efflux 
mechanism (Pagès et al., 2005). Moreover, some of these compounds were also able to 
restore partially norfloxacin and tetracycline susceptibility of resistant clinical isolates 
and of a resistant variant strain (Mahamoud et al., 2006, 2007). 
 
The variation obtained in the level of restoration of susceptibility conferred by the 
quinoline derivatives to antibiotic classes could be attributed to the differences in the 
pump sites involved in drug transport. It is possible that EPIs may have specific effects 
on drug transport mechanisms depending on their own affinity for specific residues 
located inside the pump cavity (affinity site). There are two possibilities that generate a 
collapse in drug transport. First, interactions resulting in the pump–inhibitor complex 
may saturate all the drug affinity sites if the antibiotic and the inhibitor have equal 
affinity for the same sites. Alternatively, inhibitor–pump interactions may induce steric 
hindrance if the respective binding sites for antibiotic and inhibitor on the pump are in 
close proximity (Mahamoud et al., 2007). It has been hypothesised previously that 
quinoline molecules may act as competitive inhibitors of the antibiotic flux that takes 
place inside the transporter, e.g. AcrB pump (Pagès et al., 2005). This proposal has been 
supported by some preliminary results showing a relationship between the dose of 
quinoline compound and the level of intracellular drug concentration reached during the 
incubation time. However, at the moment no direct and clear assay is available to 
measure and characterise the extrusion of intracellular antibiotic through transporter 
channels present in resistant isolates. Owing to the presence of active efflux 
mechanisms in various bacteria and the increase of resistant phenotypes, it is necessary 
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to develop an efficient assay to decipher the molecular parameters of transporters (Pagès 
et al., 2005) (Chapter VII). This assay will be very useful for the determination of 
specificity, kinetic constants for various drugs and efficiency of EPIs. In conjunction 
with molecular modelling using crystallisation data (Higgins, 2007; Lomovskaya et al., 
2007), these kinetic data will yield great improvement in the design of future efflux 
inhibitors. With the recent determination of several three-dimensional (3D) structures of 
efflux transporters (Higgins, 2007; Murakami et al., 2006; Seeger et al., 2006), various 
models proposed for efflux activity and results obtained with current inhibitors, it seems 
reasonable to propose that this approach regarding ‘pump–antibiotic–inhibitor’ 
interactions (Mahamoud et al., 2007) will be used to improve the design of the new 
generation of EPIs. 
Anti-plasmid activities of non-antibiotics 
 
Antibiotic resistance is based on a complex of multifactorial processes in which the 
transfer of mobile genetic elements encoding resistance further aggravates the spread of 
resistant bacterial strains. Moreover, the use of antimicrobial drugs in clinical and 
veterinary medicine is a recognised driving force for the selection of resistant bacteria. 
This selective pressure is a major contributor to the emergence and evolution of MDR 
phenotypic bacteria. Bacterial plasmids play a major role in these processes with their 
ability to be replicated independently from the chromosome and be transferred by 
conjugation from a host cell to a recipient bacterium. Bacterial resistance constitutes a 
considerable therapeutic and economic burden, requiring new therapeutic approaches to 
overcome. Plasmid-mediated bacterial resistance may be tackled by curing of these 
resistance-carrying genetic elements (Spengler et al., 2003). 
 
For plasmid curing, replication should be inhibited at three different levels 
simultaneously: the intracellular replication of plasmid DNA; partition; and intercellular 
transconjugal transfer. Various methods involving chemical and physical agents have 
been tested for this purpose and have revealed that super-optimal temperature, DNA 
intercalators (ethidium bromide, acridine orange, acriflavine or surface-active 
compounds, e.g. sodium dodecyl sulphate) are potent plasmid eliminators (Mándi et al., 
1976). Based on these findings, Molnar and colleagues carried out a systematic assay to 
determine the structure–activity relationship among tricyclic antipsychotic drugs that 
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interfere with the genetic elements encoding resistance (Mándi et al., 1976; Molnár et 
al., 1975, 1980, 2003). Several members of this drug group and their derivatives, 
synthesised according to computer-aided drug design, exerted anti-plasmid activity. The 
antidepressants possessing a secondary amine side chain are more effective in inhibiting 
bacterial growth and in eliminating plasmids than are the drugs with tertiary amine side 
chains, whereas the plasmid-eliminating potency of quaternary amines is weaker as they 
are probably unable to penetrate the cell membrane. Inhibition of plasmid replication 
resulted in a single nick outside the replication origin of the superhelical structure. The 
process leads to further relaxation of the plasmid DNA. Intercalation of the compounds 
was proved by the increase in the melting point of DNA and by circular dichroism 
measurements (Barabas and Molnar, 1980; Nikaido, 2001). When the native plasmid 
DNA and its promethazine complex were analysed by agarose gel electrophoresis, the 
superhelical form was missing from the promethazine-treated plasmid DNA. The ratio 
of open circular and linear forms of plasmid DNA increased in promethazine-treated 
samples. 
 
It has been proposed that the HOMO orbital energy, the conjugated pi-electron system of 
the tricyclic skeleton, the symmetric pi-electron distribution to the L-molecular region, 
and the superdelocalisability of the pi-electron system on 10, 12, 13 atoms have special 
importance in anti-plasmid activity. In a computer-aided structure–activity relationship 
study, some correlations were found between anti-plasmid effect and the symmetry of 
the HOMO orbitals of phenothiazines and related compounds. The correlation 
coefficient was as high as 0.97 when the electrophilic superdelocalisability of the heavy 
atoms of the tricyclics on atoms C8, C9b and N10 were taken into consideration. In this 
way, the anti-plasmid and carcinogenic molecular orbitals were clearly differentiated 
(Amaral et al., 2004; Molnar et al., 1992b; Motohashi et al., 1992, 1999; Spengler et 
al., 2006; Tanaka et al., 1997). A possible mechanism of action is a complex formation 
of tricyclics with the guanine–cytosine-rich regions of the plasmid DNA, which are 
necessary for normal plasmid replication in an uncomplexed form (Miskolci et al., 
2000). The use of phenothiazine drugs as resistance modifiers is restricted owing to 
their toxicity, because the concentrations required for anti-plasmid effects are beyond 
that which may be clinically achievable; therefore, only limited data are available 
regarding their resistance-modifying activity in vivo. Promethazine was studied in 
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children with frequently recurring pyelonephritis, in combination with gentamicin. 
Results were positive; the combination reduced the number of recurrences of urinary 
tract infections compared with the control group (Molnar et al., 1990). In another in 
vivo study, some patients recovered from urogenital infections despite the fact that 
plasmid elimination in the urine did not occur and the causative agents were resistant to 
gentamicin. These findings suggest that promethazine may affect the specific pili-
mediated and plasmid-encoded adhesion or multiplication of bacteria on epithelial cells 
(Kásler et al., 1982). Promethazine and imipramine were investigated in the inhibition 
of adhesion of nephropathogenic E. coli strains in tissue culture using scanning electron 
microscopy. It was found that in addition to the direct antibacterial effect, it can be 
presumed that a low concentration of promethazine and imipramine can inhibit the 
reversible and irreversible attachment of bacteria to epithelial cells, since both drugs 
interfere with the function of the microfilaments of cells and bacteria via membrane 
effects (Hirota, 1960; Molnár et al., 1983, 1992b). 
 
VIII.2 MDR- and XDR-TB; Rationale for alternative therapy; Recommended 
therapy based on the results obtained from Thesis Research 
 
Global rates of pulmonary tuberculosis (TB) continue to increase.  Moreover, resistance 
of the causative organism Mycobacterium tuberculosis to the two most effective anti-
TB medications continue to rise. Now, multi-drug resistant TB (MDR-TB) has 
progressed to extensively drug resistant TB (XDR-TB) - a M. tuberculosis organism 
that is resistant the most effective second line drugs, and most commonly resistant to all 
of the antibiotics available. This work provides detailed, significant evidence that 
supports the use of an old neuroleptic compound, thioridazine (TZ), for the management 
of MDR-TB and XDR-TB infections (Chapters IV, V and VI). The argument has been 
previously presented but no one seems to be listening - and the disease continues 
unabated when there is a very good probability that the suggested drug will prove to be 
effective. When the prognosis is poor, available therapy predictably ineffective and 
death is inevitable, compassionate therapy with TZ should be contemplated. The risks 
are small and the rewards great. 
 
Tuberculosis causes of morbidity and mortality worldwide and was declared by the 
World Health Organization a global emergency: over 2 billion infections worldwide, 9 
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million new cases and over 2 million TB deaths in 2004 (WHO, 2007a). Multidrug 
resistant TB (MDR-TB) is caused by Mycobacterium tuberculosis resistant to the two 
most potent first-line drugs; Rifampin (RIF) and Isoniazid (INH). MDR-TB not 
detected or managed properly can develop extensively drug-resistant TB (XDR-TB-
resistant to RIF, INH, any fluoroquinolone and 1 of 3 injectable second line drugs 
(capreomycin, kanamycin and amikacin) (WHO, 2006b, 2007a). The danger from MDR 
and XDR-TB cannot be overstressed. XDR-TB represents a major threat to public 
health worldwide, as many of these strains may become virtually untreatable by any 
drug available. For that reason the WHO Global Task Force on XDR-TB stressed the 
need for research in the development of new anti-TB drugs and therapeutic strategies 
(WHO, 2006b). 
 
Phenothiazines 
 
Phenothiazines are heterocyclic compounds from which over 95% of all medicinal 
compounds ever used have been derived (Mosnaim et al., 2006). With respect to their 
antimicrobial properties, phenothiazines have been shown to have direct and indirect 
activities against a large gamut of bacteria (Amaral et al., 2006; Kristiansen and 
Amaral, 1997).  Direct activity has been shown to be due to their reaching a large 
number of targets (Amaral and Kristiansen, 2001). Phenothiazines such as thioridazine 
(TZ) inhibit the binding of calcium to calcium binding proteins, and therefore indirectly 
inhibit calcium dependent enzymes that are involved in the hydrolysis of ATP (Amaral 
et al., 2007a). Phenothiazines also inhibit efflux pumps of multi-drug resistant (MDR) 
bacteria that extrude diverse and unrelated antibiotics prior to their reaching their targets 
(Viveiros et al., 2005a).  However, because these in vitro activities take place with 
concentrations of the agent that are clinically irrelevant - that is, at concentrations that 
are many fold higher than those that can be achieved clinically, the use of these agents 
for the therapy of bacterial infections is not recommended. However, with respect to 
TB, the situation is quite different. 
 
Tuberculosis - the disease 
 
Pulmonary TB is an intracellular infection caused by the steadfast human bacterial 
pathogen Mycobacterium tuberculosis. Because infection is almost always silent, that is, 
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if symptoms are present they are sub-clinical, the infection goes unnoticed. 
Nevertheless, only about 5 to 10 % of all infections progress to active disease - that is, 
the organism has broken free of its intracellular prison (the alveolar macrophage) and 
can now be retrieved in the sputum of the patient. Interestingly, the distinction of 
infection from active disease is not always understood by physicians and hence there is 
some confusion between infection and active disease. Active disease is the infectious 
phase of TB and it is the phase of the disease which is recognised symptomatically.  It is 
recognised symptomatically because a good part of the world’s people are immunised 
with the Bacilli of Calmétte-Guérin (BCG) and therefore the diagnostic power of the 
simple purified protein derivative (PPD) test (also known as Mantoux test) that can 
readily, in the absence of BCG vaccination, detect a M. tuberculosis infection is 
obviated by the immune response due to vaccination alone. The quantitative Mantoux 
test that was once thought to distinguish by the size of induration a new M. tuberculosis 
infection from the immune response due to BCG vaccination has been shown to be 
unreliable and significantly affected by underlying pathology (Nagelkerke et al., 2001; 
Ponce de León et al., 2005).  
 
Therapy of Active Disease 
 
The therapy of antibiotic susceptible active disease with the two most effective anti-TB 
antibiotics isoniazid (INH) and rifampin (RIF) is highly effective when therapy is 
conducted at the correct dose, interval and duration. However, when the guidelines for 
therapy are not followed or when the patient is non-compliant, that is, fails to take the 
medication as instructed, the opportunity for the selection of a spontaneous mutation 
that renders one of the antibiotics totally ineffective, takes place. This patient can, as a 
consequence of the infectious nature of active TB disease, infect others. In turn, and by 
chance, if the newly infected patient progresses to active disease, is treated ineffectively 
with INH and RIF, or is non-compliant, the opportunity for the selection of a second 
mutation against the other antibiotic arises. The strain of M. tuberculosis is now 
considered to be MDR and it is known as MDR-TB. But the story does not end here 
since the resistance of MDR-TB has progressed to 5 or more antibiotics, and some of 
these strains are so highly virulent, extensively drug resistant TB (XDR-TB), that they 
have caused a panic to the extent that when such an XDR-TB infection is recognised, 
therapy with second line of defence drugs has been recommended world-wide (WHO, 
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2006b). Unfortunately, the frequency of resistance to each of these second lines of 
defence drugs is many folds higher than that for INH and RIF (Balabanova et al., 2005). 
Given the fact that when a patient that is infected with MDR-TB and co-infected with 
HIV and has progressed to advanced HIV infection or presents with full-blown AIDS, 
mortality within one year of diagnosis is certain regardless of therapy (Amaral et al., 
2007c), some consideration for an alternative form of therapy should be made, if only 
along the lines of compassionate therapy (Amaral et al., 2004). 
 
The Basis for Recommended Alternative Therapy of XDR-TB/MDR-TB  
 
The activity of phenothiazines against antibiotic susceptible M. tuberculosis was first 
noticed soon after the first neuroleptic chlorpromazine (CPZ) was employed for the 
therapy of psychosis and patients infected with this organism were cured of the 
infection (Amaral et al., 2001b). However, because these anecdotal reports took place 
during the Golden Age of antibiotics, and because the therapy of active TB had been so 
successful that many believed the infection would eventually be eliminated, much as 
was believed to be the case for polio, there was no interest in developing CPZ for anti-
TB use. Moreover, the global use of CPZ demonstrated that this compound produced 
very serious and frequent side effects (Amaral et al., 2001a). However, with the advent 
of the 1990’s, a resurgence of pulmonary TB was noticed, at first quite slowly as was 
the case for New York City in 1992 when it was discovered that the rates of new cases 
of pulmonary TB had more than doubled during the previous decade (Munsiff et al., 
2006) and of greater significance and importance, the large majority of these cases were 
resistant to one or more antibiotics (Munsiff et al., 2003). However late, this terrible 
news promoted the United States Centres for Disease Control and Prevention (CDC) in 
conjunction with the American Thoracic Society to establish a set of therapeutic 
guidelines, which when fully implemented and monitored by the City and State of New 
York, quickly reduced the rate of new cases to an all-time low (Munsiff et al., 2002).  
The TB and MDR-TB situation for most of the globe, however, continued to escalate 
although there are indications that the problem has begun to level off (WHO, 2007a). 
The once thought effective armamentarium of anti-TB drugs was and is inadequate for 
the management of XDR-TB/MDR-TB. Moreover, because much of TB and antibiotic 
resistant infections take place in disadvantaged countries that cannot even afford 
conventional drugs, there is little incentive for the development of new and effective 
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anti-TB compounds (Millet, 2006). As of this time, there are no new effective anti-TB 
drugs. And this will remain for the foreseeable future given the almost total absence of 
clinical trials with new agents. And all of this is understandable given the fact that the 
cost of delivering an anti-TB drug from the bench to the bedside exceeds half a billion 
US dollars (Wishart, 2007). Although, as previously stated, CPZ was not considered for 
the development of anti-TB drugs, interest in this compound remained. CPZ was shown 
to have in vitro activity against antibiotic susceptible M. tuberculosis (Amaral et al., 
1996; Bettencourt et al., 2000; Kristiansen and Vergmann, 1986; Molnar et al., 1977; 
Ratnakar et al., 1995; Viveiros and Amaral, 2001) and against antibiotic mono and poly 
resistant strains (Amaral et al., 1996; Bettencourt et al., 2000; Viveiros and Amaral, 
2001), against MDR-TB and XDR-TB (Amaral et al., 1996; Viveiros and Amaral, 
2001). Because CPZ has many serious and frequent side effects, other phenothiazines 
were studied for activity against antibiotic susceptible (Amaral et al., 1996; Bettencourt 
et al., 2000; Viveiros and Amaral, 2001) and antibiotic resistant strains, including 
MDR-TB (Viveiros and Amaral, 2001). Among these phenothiazines, thioridazine (TZ), 
a derivative of CPZ, was shown to be as effective as CPZ in vitro (Amaral et al., 1996; 
Bettencourt et al., 2000; Viveiros and Amaral, 2001) and because TZ had fewer serious 
side effects than CPZ, TZ was intensively studied for its potential as an anti-XDR-
TB/MDR-TB agent. 
 
Pulmonary TB is an intracellular infection. This means that if a drug is to be effective 
against this bacterium it must have activity where the bacterium resides-namely, the 
macrophage component of the alveolus of the lung. Hundreds of compounds have been 
shown to have in vitro activity against M. tuberculosis but only a precious few are 
active against intracellular M. tuberculosis. Among the most active compounds is CPZ, 
first shown to have activity against intracellular M. tuberculosis by Crowle and his 
group in 1992 (Crowle et al., 1992). The significance of this finding was that the 
intracellular concentration of the medium that was required to promote complete killing 
was within clinical reach. This finding was confirmed 10 years later by Amaral and his 
international group (Ordway et al., 2002b) with the demonstration that a concentration 
of CPZ that is lower than that clinically employed for chronic therapy of psychosis 
promoted complete killing of M. tuberculosis and MDR-TB within 3 days of culture 
(Chapter IV). Moreover, TZ, the much milder drug (Ordway et al., 2003b) as well as 
three of its derivatives (Martins et al., 2007b), had intracellular activities that were equal 
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to or even greater than that promoted by CPZ (Chapter IV).  Finally, TZ was shown to 
cure the mouse of a TB infection caused by the intraperitoneal introduction of over 1 
million M. tuberculosis colony forming units (Martins et al., 2007a) - a massive dose 
compared to one that causes infection in man (Chapter V).   
 
Mechanism of action of TZ enhanced intracellular killing of M. tuberculosis by 
non-killing human macrophages 
 
Phenothiazines are concentrated by tissues rich in macrophages that contain lysosomes 
(Amaral et al., 2004, 2007c; Viveiros et al., 2005c). At first, the ability of the 
macrophage to concentrate CPZ or TZ to levels compatible with the in vitro inhibition 
of replication of M. tuberculosis was considered to be the mechanism by which 
enhanced killing of intracellular M. tuberculosis by non-killing macrophages took place 
(Ordway et al., 2003b). This assumption was further strengthened with electron 
microscopy studies that showed that the in vitro effects of TZ on the ultrastructure of S. 
aureus could be reproduced when the organism had been phagocytosed by non-killing 
human macrophages (Martins et al., 2004) (Chapter III). However, i) killing of 
intracellular bacteria has been shown to be dependent upon the availability of K+ needed 
for the acidification of the phagolysosome and subsequent activation of hydrolases that 
degrade the bacterium and cause its death (Ahluwalia et al., 2004; Reeves et al., 2002); 
ii) TZ is an inhibitor of Ca2+ and K+ transport (Eilam, 1983; Landmark et al., 1972) and 
hence enhanced killing could be due to the ability of TZ to insure adequate levels of K+, 
within the phagolysosome, required for the killing. Because common inhibitors of K+ 
transport that do not have in vitro activity against M. tuberculosis have been shown to 
enhance the killing of intracellular M. tuberculosis (Martins et al., 2008), it seems 
highly plausible that enhanced killing by TZ takes place by the same K+ dependent 
mechanism (Amaral et al., 2007b) (Chapter VI). Further studies are needed for 
complete elucidation of the role of TZ and K+ in enhanced killing of intracellular M. 
tuberculosis.     
 
The Fly in the ointment - TZ cause arrhythmia/increase of QTc interval            
 
Neuroleptics, typical or atypical, have been shown to cause QTc prolongation in 
humans (Pacher and Kecskemeti, 2004) that is augmented with metabolic inhibitors 
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(Harrigan et al., 2004). However, due to the association of sudden death-torsade de 
pointes with chronic administration of TZ, caution has been recommended, and in the 
United Kingdom, special legislation governing the use of TZ has been implemented. 
Given this information, it is quite natural to resist the use of TZ even for the therapy of 
psychosis. However, by far, TZ has been for the past 40 years the most used 
neuroleptic, and the most serious side effect of sudden death is quite rare. Moreover, 
recent evidence has been provided that QTc prolongation takes place only in patients 
with a CYP2D6 genotype (LLerena et al., 2002). Moreover, the dosages administered to 
patients whose QTc is prolonged is quite high (300 mg) and not related to dosages 
employed for the early management of psychosis. However, QTc prolongation with a 
single dose of 50 mg of TZ has been reported (Thanacoody et al., 2007). Nevertheless, 
there is no data available that supports QTc prolongation with early management doses 
and the single dose study may not reflect patient adjustment to the drug during chronic 
administration. Evidence that TZ does not produce significant danger to the vast 
majority of patients who are free of cardiopathy has recently been put forth by 
Thanacoody (Thanacoody, 2007).  
 
The essential question - to use or not to use TZ for the therapy of XDR-TB/MDR-
TB infections with poor prognosis 
 
When faced with a patient who is infected with MDR-TB or XDR-TB, and is co-
infected with HIV or presents with advanced HIV or full blown AIDS, the question that 
the physician must answer is: What can I do for the patient that will extend his life, 
improve the quality of life, or perhaps even cure the patient of this deadly infection? 
Given the limitations of what is available to the physician, it is clear that an alternative 
form of therapy which is solidly based on science and which will do no harm may be 
preferred to the use of therapy that will yield predictable ineffectiveness. The question is 
a tough one?  Perhaps, the question may be asked to the physician - given the same 
conditions, how he would treat himself. If the physician can answer this question, his 
selection of alternative therapy with TZ, if only for compassionate reasons, may be 
reached.   
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
CHAPTER IX. 
 
The Tuberculosis laboratory of the Future: The role of the 
macrophage in the selection of agents that can be used for the 
successful therapy of an XDR-TB infection 
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infection. Future Medicine: In press.  
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CHAPTER OUTLINE 
 
The results from my Thesis Research up to this point have been focused on the 
development of new drugs that provide a potentially effective alternative for the therapy 
of XDR-TB/MDR-TB.  As a consequence of the methods developed and applied for the 
study of mode of action of some of the compounds studied, the consistency of the data 
and its relevance to the clinical Mycobacteriology laboratory, have together provided 
the basis for the creation of the Tuberculosis laboratory of the future. Because of the 
nature of this Chapter, some of the data presented earlier will again be presented in 
order to facilitate the concepts that are being developed.  Therefore, this chapter is 
focused on the Multi- and Extensively-drug resistance and the rapid identification of 
these strains. MDR-TB has progressed to extensively drug resistant M. tuberculosis 
(XDR-TB), defined by resistance to INH, RIF, any fluoroquinolone and at least 1 of the 
3 injectable second line drugs. The TB laboratory of the future must identify rapidly 
antibiotic resistant TB (MDR-TB/XDR-TB). The identification of an MDR-TB 
infection could be accomplished within one day of receiving the clinical specimen by 
the application of The Faster TB Track Programme, as previously reported. However, 
the rationale for evaluating the intracellular killing activity of anti-tubercular agents 
against M. tuberculosis isolated from the patient’s sputum and its subsequent 
phagocytosis by macrophages isolated from that same patient is an important subject 
that deserves attention. By this manner, the pulmonary TB laboratory is essential if 
control of TB is to be achieved. The TB laboratory of the future must assess second line 
of defence drugs for activity against the MDR-TB/XDR-TB strain isolate after it is 
phagocytosed by the patients own macrophage. The human non-killing macrophage can 
be easily prepared from the MDR-TB/XDR-TB infected patient’s peripheral blood prior 
to the patient receiving any form of therapy. This is important in the evaluation of drugs 
for enhanced killing of intracellular S. aureus, which can be used as a model. Therefore, 
compounds that enhance the killing of intracellular S. aureus are usually effective 
against intracellular mycobacteria. The demonstration of degrees of killing activity 
promoted by drugs against S. aureus and M. tuberculosis involve drugs that enhance 
killing of intracellular S. aureus to a greater extent than TZ (and that can then be 
selected for study against intracellular M. tuberculosis). TZ can be used as the positive 
control for the demonstration of enhanced killing of intracellular bacteria. Drugs which 
are therefore shown to enhance killing of the phagocytosed MDR-TB/XDR-TB strain 
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have a high probability of achieving therapeutic success. This therapeutic strategy will 
be focused on the patient itself involving an individualized approach. If these 
approaches are to be implemented the TB laboratory of the future can be a reality today. 
 
SUMMARY  
 
Therapy of MDR-TB is highly problematic; that of XDR-TB even more so. Both 
infections result in high mortality, especially if the patient is co-infected with HIV or 
presents with AIDS. Selection of therapy for these infections is limited, and for most 
situations, it is blind. But there is a solution for the selection of effective therapy and 
this is presented herein. Ideal therapy of the patient infected with MDR-TB or XDR-TB 
can be determined a priori by the Mycobacteriology laboratory. This would involve the 
isolation of the patient’s macrophages, the phagocytosis of the mycobacterial isolate 
and the presentation of the anti-tubercular agent to the macrophage-bacterium complex. 
This system is reviewed in its entirety and its potential and feasibility are supported by 
hard experimental demonstrations.  
 
Multi- and Extensively-drug resistance 
 
Multi-drug resistant Mycobacterium tuberculosis (MDR-TB) is resistant to the two most 
effective anti-tubercular drugs isoniazid (INH) and rifampin (RIF) and even under the 
best of circumstances, that is, under appropriate therapy, patient compliance and under 
direct observable therapy (DOT), it produces significant mortality (WHO, 2007a). 
When the infection takes place in a patient that is co-infected with HIV and has 
advanced to AIDS, mortality is almost always certain within a year, regardless of 
therapy (CDC, 2007; WHO, 2006b, 2007a). To make matters worse, MDR-TB has 
progressed to extensively-drug resistant M. tuberculosis (XDR-TB), defined by 
resistance to INH, RIF, any fluoroquinolone and at least 1 of the 3 injectable second line 
drugs (capreomycin, kanamycin and amikacin) (CDC, 2007; Shah et al., 2007; WHO, 
2006b). Even though, individual resistance of wild type M. tuberculosis to these drugs 
exceeds the frequency of individual resistance to INH and RIF (Shah et al., 2007; 
WHO, 2006b) these drugs in combination have been recommended for the therapy of 
XDR-TB (Goldman et al., 2007).  
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Pulmonary tuberculosis (TB) is an intracellular infection of the alveolar macrophage. 
Because this cell has little killing activity of its own, the M. tuberculosis exists in situ 
for decades without causing any overt symptoms of infection. In fact, in the absence of 
immuno-incompetence, less than 10% of all infections progress to active disease 
(Goldman et al., 2007; WHO, 2007a), the phase characterized by the release of the 
organism from its macrophage prison which is now extracellular and eventually 
manifested in patient sputum. Because of the intracellular nature of the infection, in 
order for a given drug to be therapeutically effective it must be able to penetrate the 
macrophage and have activity against the in situ localized organism. Consequently, 
although literally thousands of compounds have been shown to have in vitro activity 
against M. tuberculosis (Spigelman, 2007) only a very few have activity against the 
organism at its intracellular location (Amaral et al., 2006, 2007c). This simple fact 
means that if an agent is to be therapeutically active against antibiotic susceptible M. 
tuberculosis, MDR-TB and even XDR-TB it must first be shown to be active where 
these strains of M. tuberculosis are to be found, namely, the human macrophage 
(Amaral et al., 2006, 2007b, 2007c). 
 
It is the purpose of this chapter to present cogent support for the use of the human 
macrophage model in the clinical TB laboratory as the only realistic means by which 
effective anti-MDR-TB/XDR-TB compounds can be a priori selected for the therapy of 
the MDR-TB/XDR-TB infected patient. Moreover, because time is of essence for the 
identification and antibiotic susceptibility of MDR-TB/XDR-TB if this infection is to be 
curtailed, the system in place at our laboratory for close to five years which identifies 
MDR-TB within one day of receiving the specimen will also be discussed in detail. 
 
Identification of an MDR-TB infection within one day of receiving the clinical 
specimen: The Faster TB Track Programme 
 
As a consequence of the resurgence of TB and MDR-TB in the city of New York during 
the early 1990’s, New York State Department of Health instituted the TB Fast Track 
Programme (Frieden et al., 1993; Hale et al., 2001; Parsons et al., 2004). This 
programme required that the clinical specimen be accompanied by a positive acid fast 
stained sputum after which its reception resulted in the shunting of the specimen along 
the most rapid manner (Fast Track) for the identification of the organism and the 
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determination of antibiotic susceptibilities, namely, the use of molecular probes for 
identification of M. tuberculosis complex from positive cultures and the BACTEC 460 
system for determination of antibiotic susceptibility. Because the rates of new cases of 
pulmonary TB in Portugal in 2000 were the highest in Western Europe (Antunes et al., 
2000; Shah et al., 2007) our Mycobacteriology laboratory at the Institute of Hygiene 
and Tropical Medicine, Universidade Nova de Lisboa, Lisbon, Portugal, adopted and 
modified the TB Fast Track programme to yield the required data within 12 days of 
receiving the specimen. Although this rapid turn-around time for complete analysis of 
the specimen was considered a major advancement, it was still, in our opinion, not good 
enough. Discussions with Max Salfinger (Hale et al., 2001; Parsons et al., 2004), then 
Director of Tuberculosis Laboratory of the New York Department of Health during 
2003, resulted in the development and implementation of the Faster Track Programme 
in our Mycobacteriology laboratory. This Faster Track Programme consisted of 
employing the INNO-LiPA Rif.TB Line Probe Assay (Innogenetics, Zwijndrecht, 
Belgium) for the simultaneous identification of M. tuberculosis complex and detection 
of RIF resistance directly on the sputum specimen that was accepted into the 
programme due to it being accompanied by a positive acid fast stained sputum. Because 
resistance to RIF is almost always accompanied by resistance to INH (Hale et al., 2001; 
Viveiros et al., 2005b), identification of the mutated rpoB gene provided the 
identification of an MDR-TB strain. This TB Faster Track programme enabled the 
identification of MDR-TB strains within 8 hours of receiving the specimen, and hence, 
within that same day, the patient could be isolated and treated aggressively (Viveiros et 
al., 2005b). This programme, unique in Europe, has now been adopted in the USA and 
United Kingdom (CDC, 2007; Goldman et al., 2007; Sam et al., 2006). The 
employment of the TB Faster Track programme for patients presenting with clinical and 
radiological symptoms of pulmonary TB in Lisbon has contributed to the reduction of 
rates of new cases of MDR-TB from an excess of 28 per cent of all M. tuberculosis 
isolates to less than 8 per cent within a 3 year period (Antunes et al., 2000; DGS, 2007).  
 
 
 
 
Chapter IX 
 
 
203 
The rationale for evaluating the intracellular killing activity of anti-tubercular 
agents against M. tuberculosis isolated from the patient’s sputum and its 
subsequent phagocytosis by macrophages isolated from that same patient  
 
As previously stated, pulmonary TB is an intracellular infection of the pulmonary 
macrophage. Because this pulmonary macrophage has little killing of its own (Amaral 
et al., 2004, 2006, 2007c) M. tuberculosis can reside in a viable state within its 
phagosome prison for many decades (Saunders and Britton, 2007). If a compound is to 
be effective for the therapy of pulmonary TB it must be able to penetrate the 
macrophage and have activity against the organism at the intracellular site of the 
macrophage where it resides (Amaral et al., 2004, 2007b). If the compound is to be 
effective for the therapy of a specific patient that is presenting with pulmonary TB, the 
activity of the compound against the M. tuberculosis strain isolated from the patient 
would best shown if the macrophage that is to phagocytose the organism is obtained 
from that same patient. Employing this approach should result in the best predictive 
situation for the selection of effective anti-tubercular agents. With this consideration in 
mind, it is important therefore, that the assay that is to provide the means by which 
effective therapy can be a priori selected be fully mastered.  
  
The human non-killing macrophage and its preparation from human peripheral 
blood  
 
Human non-killing macrophages can be easily prepared from the MDR-TB/XDR-TB 
infected patient’s peripheral blood prior to the patient receiving any form of therapy. 
The process involves obtaining peripheral blood with a syringe containing heparin, the 
mixing of the blood with Hank’s Balanced Salt Solution (HBSS) or tissue culture 
medium such as RPMI 1640 (Sigma-Aldrich Química, S.A., Madrid, Spain), followed 
by the overlay of the diluted blood on top of Ficoll-Hypaque 1.077 (Sigma-Aldrich 
Química, S.A., Madrid, Spain), and subsequent centrifugation for the isolation of the 
layer containing the mononuclear cells. The isolated layer is washed twice with HBSS 
and the mononuclear cells suspended in medium and transferred to a tissue culture 
bottle (Leighton flask) and incubated at 37ºC for five days during which time the 
monocytes adhere to the bottom of the flask; the medium containing the non-adhered 
lymphocytes is then removed by pouring directly into a waste receptacle, and replaced 
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with fresh medium. The adhered monocytes are gently suspended into the medium with 
the aid of a sterile rubber policeman, an aliquot removed for counting the cells and 
aliquots of 0.8 mL containing approximately 100,000 monocytes are transferred to 1 ml 
wells of a 24-well microplate. The microplates are incubated at 37ºC and 5% of CO2 
until further use. During this last incubation the macrophages settle and adhere to the 
bottom of the wells. Details of this method have been completely described (Ordway et 
al., 2002b, 2003b) (Chapters III and IV).  
  
Evaluation of drugs for enhanced killing of intracellular Staphylococcus aureus 
and Mycobacterium tuberculosis 
  
We have found that compounds that enhance the killing of intracellular Staphylococcus 
aureus ATCC25923 are usually effective against intracellular mycobacteria (Amaral et 
al., 2006; Ordway et al., 2002a) and because the killing of intracellular S. aureus 
promoted by these drugs can be defined within two days as opposed to three or four 
weeks when M. tuberculosis is used, S. aureus is used for the screening of drugs that 
enhance intracellular killing. Drugs that enhance killing of intracellular S. aureus to a 
greater extent than our positive control (thioridazine - TZ) are then selected for study 
against intracellular M. tuberculosis. The assay for the evaluation of intracellular 
activity of drugs is performed as follows: To each well of the 24 wells of an duplicate 
microplate containing 105 macrophages adhered to the bottom of the well in a volume of 
0.9 mL of medium, 106 S. aureus/mL in 0.1 mL of medium are added and the plates 
incubated at 37ºC for 30 minutes. During this time the bacteria are effectively 
phagocytosed. Nevertheless, to insure that no free bacteria remain in the well, each well 
is washed 3 times with medium to remove non-phagocytosed bacteria after the 
incubation period. After the replacement of the medium with 0.9 mL of fresh medium 
the agents to be evaluated for intracellular killing activity are to be added in a volume of 
0.1 mL of medium to sets of triplicate wells. The triplicate set of absolute control wells 
receives an equal volume of drug free-medium (Chapter III). The selection of 
concentrations of each drug is arbitrary and may be guided as follows: Three 
concentrations of each compound should be empirically used: concentration #1 to be 
added should be equal to the in vitro minimum inhibitory concentration (MIC) of that 
drug against S. aureus; concentrations #2 and 3 should be 1/10 and 1/100 of the MIC, 
respectively. Because the macrophage has the ability to concentrate many drugs once 
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they penetrate into the cell (Daniel and Wojcikowski, 1999b), if the agent is effective 
against intracellular S. aureus ATCC25923, concentrations below the MIC should prove 
effective especially if shown to be active at 1/100 of its MIC (Ordway et al., 2002a, 
2002b, 2003b) (Chapter III). The second duplicate microplate containing 105 adhered 
macrophages per well is to be used for the addition of 106 M. tuberculosis/mL obtained 
from the liquid BACTEC 460 cultures used for the isolation of the strain (Ordway et al., 
2003b) (Chapter IV), the addition of three concentrations of the agents under 
investigation and processed as that containing the staphylococci as described above. The 
microplate containing the phagocytosed staphylococci and phagocytosed M. 
tuberculosis are to be incubated for up to 6 hours and 3 days, respectively (Ordway et 
al., 2002a, 2002b, 2003b) (Chapter IV). At hourly intervals of the 3 hour incubation 
period of the microplate containing the phagocytosed staphylococci 0.01 mL of 0.01% 
SDS are added to lyse the macrophage and release the intracellular bacteria and aliquots 
of the medium are processed for colony forming units (CFU) on plates containing a 
suitable solid medium. An identical approach is to be used for the microplates 
containing the macrophage/M. tuberculosis except that the intervals should be 24 hours 
for the duration of the incubation (Ordway et al., 2002a, 2002 b, 2003b). Using the two 
microorganisms in a combined macrophage assay allows the rapid screening of new 
anti-TB drugs, the evaluation of effectiveness of combined therapies and patient 
directed selection of effective therapies. For the latter, the macrophage-S. aureus assay 
is of lesser importance since our attention will be focused in the intelligent selection of 
the most effective therapy against TB and/or XDR/MDR-TB.  
 
Demonstration of degrees of killing activity promoted by drugs against S. aureus 
and M. tuberculosis - Thioridazine: the positive control for the demonstration of 
enhanced killing of intracellular bacteria  
 
The in vitro activity of TZ against S. aureus and M. tuberculosis strains has been 
extensively studied by us and has been shown to be consistent (Ordway et al., 2002a; 
2003b). Briefly, the MIC of TZ against S. aureus and M. tuberculosis strains is 20-30 
and 15 mg/L, respectively (Ordway et al., 2002a, 2003b) (Chapter III). At 
concentrations just below the MIC, TZ produces major alterations of the bacterium’s 
ultrastructure such as: blebbing and thickening of the cell wall; bizarre cross-walls; 
marked vacuolization of the cytoplasm and destruction of the internal compartments of 
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the cell (Amaral et al., 2007b; Martins et al., 2004) (Chapter III). Figure 1 is an 
example where all of these alterations can be found in a single S. aureus cell that has 
been exposed in vitro to TZ for 18 hours. Although these alterations can be considered 
to be severe-they do not cause cell death inasmuch as the minimal bactericidal 
concentration of TZ exceeds 60 mg/L (Ordway et al., 2002a, 2002b).  
 
 
 
 
 
 
 
Figure 1.  In vitro effect of TZ on the ultra-structure of MRSA after 18 hours of 
culture. The alterations on the ultra-structure of MRSA are: blebbing of the cell wall (a); thickening of 
the cell wall and cross-walls (b); partial separation of the internal portion of the cell wall (c); continued 
production of cross-walls without subsequent separation of the replicated cells (d); asymmetrical cross-
wall formation (e); partial loss of cell wall (f) and evidence of lysis (g) (Martins et al., 2004). 
 
The concentrations of TZ that inhibit the growth of M. tuberculosis or S. aureus exceed 
that which produces toxicity to the macrophage (Ordway et al., 2002a). However, 
because the human macrophage concentrates the phenothiazine at least 100 fold over 
that non-toxic concentration-i.e. below 0.5 mg/L, exposure of macrophages containing 
phagocytosed bacteria to concentrations of TZ as small as 0.1 mg/L reproduces in situ 
all of those alterations of the ultrastructure produced in vitro at a concentration near the 
MIC (Ordway et al., 2002a, 2002b, 2003b) (Chapter IV). An example of this is 
presented by Figure 2.  
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Figure 2. Ex vivo effect of TZ (0.1 mg/L) in phagocytosed S. aureus exposed for 6 
hours.  Control (A) and cells treated with 0.1 mg/L of TZ after 6 hours of phagocytosis (Martins et al., 
2004). 
 
The ultrastructural changes produced by TZ after the bacterium has been phagocytosed 
are accompanied by an enhanced killing activity of the non-killing human macrophage. 
As shown by Figure 3 exposure of the macrophage containing the phagocytosed 
bacterium to a concentration of TZ as low as 0.1 mg/L enhances the killing of 
Methicillin-Resistant S. aureus (Fig 3A) and Multi-Drug Resistant M. tuberculosis (Fig 
3B).  
 
These assays have been repeated at least 25 times and the results have been consistent 
when one donor serves as the source of peripheral blood employed for the derivation of 
human macrophages (Ordway et al., 2002a, 2002b, 2003b). When peripheral blood 
comes from a different donor source, although the results are similar, the degree of 
killing varies. This variability is to be expected due to age and sex of the donor as well 
to underlying pathology and is therefore the reason why the patient’s own peripheral 
blood is to serve as the source for the preparation of macrophages. 
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Figure 3. Effect of TZ in the killing activity of macrophages infected with MRSA 
(A) and MDR-TB (B). The effect of TZ on the intracellular growth of MRSA (A) and MDR-TB (B) 
strains was evaluated. TZ (0.1 mg/L) was separately added to human macrophages cultures. Control 
cultures received no drug. Control and TZ containing cultures were infected for 30 and 60 minutes with 
MRSA and MDR-TB strains, respectively, at concentrations of 10 CFU per macrophage (10:1). Results 
are expressed as the mean CFU of the strains tested in three independent experiments. MRSA – 
Methicillin-Resistant S. aureus; MDR-TB – Multi-Drug Resistant M. tuberculosis; TZ – Thioridazine 
(Martins et al., 2004; Ordway et al., 2003b). 
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The enhanced intracellular killing activity promoted by TZ resulted in studies that 
evaluated the ability of TZ to cure the mouse infected with M. tuberculosis (Martins et 
al., 2007a) (Chapter V). As shown by Figure 4 mice that have been infected with a 
massive dose of M. tuberculosis (excess of one million cells) can be cured of this 
infection with daily TZ injections (1200 mg/Kg mouse body weight) (Chapter V). 
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Figure 4. Effect of TZ treatment of Balb/C mice infected with M. tuberculosis. Four 
groups of eight mice were infected with approx. 106 CFU of M. tuberculosis H37Rv ATCC 27294 and 
treated with daily doses of TZ (1200 mg/kg). The control group received no drug. At monthly intervals 
animals from each group were sacrificed, their lungs removed and mycobacteria released from the 
cellular debris and plated; TZ – Thioridazine; CFU - Colony Forming Units (Amaral et al., JAC 2007b; 
Martins et al., 2007a). 
 
The macrophage assay has been extended for the evaluation of many compounds 
(Martins et al., 2005; Ordway et al., 2003a), other phenothiazines (Ordway et al., 
2002a, 2002b) and derivatives of TZ (Martins et al., 2007b) for activity against 
intracellular bacteria. The data obtained have provided direction for the selection of 
which compounds should be further studied for their curative activity (Chapters IV.2, 
VI and VII).  
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The Macrophage Model 
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CHAPTER OUTLINE 
 
In sequence with the previous chapters, this chapter is now focused on the 
characteristics of MDR-TB and identifies a variety of compounds that address these 
characteristics and that show potential for managing these infections. The enhanced 
killing of intracellular multi-drug resistant M. tuberculosis by compounds that affect the 
activity of MDR efflux pumps was assayed. The mechanism by which these agents 
enhance the killing of intracellular bacteria is extremely important for the design of new 
anti-tubercular agents. From the results obtained, a hypothetical model was constructed. 
This model describes the mechanisms by which efflux pumps of the phagosome-
lysosome complex are inhibited by agents known to inhibit the K+ flux. 
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X.1 Phenothiazines as Anti-Multi-Drug Resistant Tubercular Agents 
 
SUMMARY  
 
Pulmonary tuberculosis (TB) has again become a global problem: it infects 2.2 billion 
people world-wide, caused the deaths of over 3 million last year and will produce over 8 
million new cases of TB this coming year. Although effective therapy is widely 
available for antibiotic susceptible strains of Mycobacterium tuberculosis, current drugs 
are relatively useless against multi-drug resistant infections (MDR-TB). Mortality is 
almost complete within two years regardless of therapy, and in the case of co-infection 
with HIV/AIDS, mortality is 100% within a few months of diagnosis especially the M. 
tuberculosis strain is XDR-TB. As of the time of this writing no new effective anti-TB 
drugs have been made available by the pharmaceutical industry and XDR-TB. Because 
TB is an intracellular infection of the non-killing macrophage of the lung, any agent that 
is to prove effective must have activity against MDR-TB and XDR-TB strains that have 
been phagocytosed by the human macrophage. This chapter intents to provide cogent in 
vitro, ex vivo and in vivo evidence that supports the use of a variety of commonly 
available phenothiazines for the therapy of MDR-TB and XDR-TB, especially when the 
prognosis of the infection is poor and the use of the recommend agents can take place 
along lines of “compassionate therapy”. In addition, it will describe the macrophage 
assay as indispensable if an agent is to be further studied for its effectiveness as an anti-
TB drug. In vitro studies if not pursued by ex vivo studies will for the most be dead-
ended since few agents that have activity in vitro have any activity against 
phagocytosed M. tuberculosis.       
 
If hundreds of antibiotics are available for therapy of bacterial infections why are 
there none for the therapy of MDR-TB? 
 
The last effective anti-TB drug was RIF and this drug came into use in the early 1960’s. 
Since TB has remained a serious medical problem in Africa, South-East Asia and South 
America (WHO, 1997, 2000) why are there no new anti-TB drugs available? Monetary 
incentive is a major cause for the lack of new anti-TB drugs inasmuch as the infection is 
most frequent in countries that are economically disadvantaged (Amaral et al., 2004). 
However, resurgence of TB in Western urban centers, and more importantly, the 
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appearance and escalation of MDR-TB and XDR-TB worldwide has caused sufficient 
concern to the extent that a number of international programs have been created which 
make funds available for the development of new anti-TB drugs (WHO, 2007b). 
Although these programs may in time alleviate the problem, it should be understood 
that the creation of new and effective anti-TB drugs is far more difficult than that for the 
therapy of other bacterial infections, inasmuch as the drug must not only penetrate the 
cell housing the trapped mycobacterium but it must be active at that site when non-toxic 
concentrations of the drug are administered to the patient. Consequently, although 
literally thousands of compounds can inhibit the replication of mycobacteria in vitro, 
very few are effective at the intracellular site where the mycobacterium resides.  
 
What is meant by an “effective” anti-TB drug?  The answer is simple-it must kill the 
bacterium in situ. Remarkably, neither INH nor RIF alone can readily accomplish this 
task and hence the need to use these two agents in tandem. Why are they effective when 
administered together? Firstly, both penetrate the macrophage and retain their activity at 
the site where mycobacterium resides (Amaral et al., 2007b; Martins et al., 2007b). 
Secondly, whereas RIF inhibits the replication of the organism by binding to the RNA 
polymerase sub-unit β (Vattanaviboon et al., 1995), INH kills by interfering with the 
physical chemistry of the cell wall after its is converted to an active form (i.e. INH is a 
pro-drug) (Cappelletty, 2007). The separate action of each drug, inhibition of replication 
and killing is highly effective if, and only if, the organism is susceptible to both 
compounds (Chauca et al., 2007).   
 
Will future therapies for MDR-TB involve the use of two or more compounds? Most 
would agree that the use of two or more effective drugs would be more effective than 
the use of only one, if only because the latter would be rendered ineffective within a 
short period of time due to the advent of spontaneous mutation whereas the 
simultaneous development of two separate mutations would be less probable.  It would 
be ideal if only one compound were to be required that would not be subject to eventual 
mutation-based resistance. Is the ideal possible?   
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Phenothiazines as anti-MDR-TB agents  
 
The antimicrobial activity of phenothiazines has been known since the time Paul 
Ehrlich studied the effects of methylene blue on the mobility of bacteria (Amaral et al., 
2004; Kristiansen and Amaral, 1997). However, because the dye was shown to cause 
cats to become lethargic (McMahon and Kadowitz, 1992), the evolution of this first 
phenothiazine progressed towards the development of the first neuroleptic, CPZ in 1953 
(Amaral and Kristiansen, 2001; Amaral et al., 2001b) and little attention was paid to its 
potential as an antimicrobial agent (Kristiansen and Amaral, 1997). Nevertheless, 
because of worldwide use of CPZ for therapy of psychoses and severe neuroses, 
clinicians noted that patients treated with this agent were cured of a variety of infections 
(Amaral and Kristiansen, 2000; Amaral et al., 2001b). Regardless, because these 
observations were made during the Golden Age of Antibiotics (1950s-1970s) there was 
no need for another antibiotic, especially for one that produced a high frequency of 
serious side-effects (Amaral and Kristiansen, 2000). However, as antibiotic use became 
more and more common, the opportunity for misuse increased, and misuse resulted in 
the appearance of bacterial strains that were resistant to one or more antibiotics (Amaral 
and Kristiansen, 2001; Amaral et al., 2004, 2007b; Kristiansen and Amaral, 1997). The 
appearance of MDR strains of bacteria provided the impetus for a search for non-
antibiotic compounds, i.e., drugs that were used for the therapy of non-infectious 
pathology, that could either be used directly (Kristiansen and Amaral, 1997), or as 
possible adjuncts with conventional antibiotics, or, serve as lead compounds for the 
syntheses of new agents (Martins et al., 2007b) (Chapter IV). Consequently, 
phenothiazines were shown to inhibit the replication of Gram-negative (Amaral and 
Lorian, 1991) and Gram-positive bacteria (Kristiansen et al., 2003, 2006; Martins et al., 
2004; Ordway et al., 2002a, 2002b), mycobacteria (Amaral and Kristiansen, 2000; 
Amaral et al., 2001b, 2007b; Martins et al., 2007b; Viveiros et al., 2005c) (Chapters 
III and IV), a large variety of microorganisms (Amaral et al., 2004, 2006, 2007a; 
Grácio et al., 2003; Viveiros et al., 2003; Wainwright and Amaral, 2005), parasites that 
cause malaria (Amaral et al., 2001b; Wainwright and Amaral, 2005), sleeping sickness 
(Boda et al., 2006; Khan et al., 2000; Page and Lagnado, 1995; Wainwright and 
Amaral, 2005), and leishmania (Amaral et al., 2004; Kristiansen and Amaral, 1997; 
Leandro and Campino, 2003; Wainwright and Amaral, 2005) and even parasitic worms 
(Grácio et al., 2003). However, because all of these activities were shown to take place 
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in vitro at concentrations that were well beyond any that could be achieved in the 
patient, their use as direct antimicrobial agents was out of the question (Amaral and 
Kristiansen, 2000; Amaral and Lorian, 1991; Amaral et al., 2001a, 2001b, Kristiansen 
and Amaral, 1997; Kristiansen et al., 2003, 2006; Martins et al., 2004, 2007b; Ordway 
et al., 2002a, 2002b, 2003b) even though some reports showed their in vivo 
effectiveness (Amaral et al., 2001a, 2001b). Furthermore, because some phenothiazines 
were shown to enhance the activity of antibiotics to which the bacterium was 
susceptible and could also render antibiotic resistant bacteria susceptible to the 
antibiotic to which they were initially resistant (Amaral et al., 1992; Bettencourt et al., 
2000), interest in phenothiazines continued (Amaral et al., 2006, 2007b). This interest 
would rise dramatically when Crowle and his group demonstrated that a concentration 
of CPZ in the medium that corresponded to one that would be expected in the plasma of 
a patient chronically managed with this phenothiazine would enhance the killing of 
intracellular M. tuberculosis (Crowle et al., 1992). However, because CPZ produces so 
many serious side-effects this demonstration remained limited to academic interest until 
a similar demonstration of enhanced killing of intracellular M. tuberculosis by the far 
less noxious phenothiazine, TZ, was reported (Amaral et al., 2001a). Killing of 
phagocytosed M. tuberculosis is enhanced by concentrations of TZ that are below those 
found in the plasma of patients chronically treated with this neuroleptic. Because TZ 
may on rare occasions can even cause sudden death (1 sudden death per ten thousand 
man years of use (Crowle et al., 1992), its use for the therapy of MDR-TB has not been 
seriously considered, despite its potential for the therapy of terminal MDR-TB, if only 
for compassionate reasons (Amaral et al., 2006). Regardless, because TZ is very 
effective in enhancing the killing of intracellular MDR-TB (Amaral et al., 2001a; 
Martins et al., 2005, 2007b; Ordway et al., 2003b; Viveiros et al., 2005c) (Chapter IV, 
Section IV.1) the opportunity for the syntheses of TZ derivatives was pursued and the 
derivatives studied for their intracellular effectiveness (Martins et al., 2007b; Yano et 
al., 2006) (Chapter IV, Section IV.2). The derivatives that were proven to have 
significant in vitro activity against M. tuberculosis were selected for potential 
enhancement of killing of phagocytosed M. tuberculosis. It is important to note that 
these derivatives produced no cytotoxicity as per trypan blue exclusion criteria (Ordway 
et al., 2002a, 2003b) (Chapter IV, Section IV.2). During the time that the derivatives 
were being made, TZ was studied for its ability to cure the mouse of a severe pulmonary 
TB infection (Amaral et al., 2007a, 2007b). Although normally the study of an agent 
Chapter X 
 
218 
with the use of a mouse model requires doses of the agent to be at least 10 fold higher 
than those used in the human (Amaral et al., 2007b; Jia et al., 2005; Wieland et al., 
2006), the highest dose of TZ used in the mouse study was 0.5 mg/day and is equivalent 
to about twice that given to a human who is chronically treated with this drug. A dose of 
0.5 mg/day practically eliminated within 30 days all traces of M. tuberculosis that could 
be retrieved from the lungs of the infected mouse (Chapter V). During the time of this 
study, others have reported that derivatives of CPZ can also cure the mouse of 
pulmonary TB (Weinstein et al., 2005).     
 
How do phenothiazines inhibit the in vitro growth of bacteria? 
 
All phenothiazines studied to date have the ability to inhibit the binding of Ca2+ to 
specific proteins (Amaral et al., 2007a), such as calmodulin (Mayur et al., 2006), 
calmodulin-like proteins of bacteria (Fry et al., 1986) and Ca2+-dependent ATPases 
(Bhatnagar and Singh, 2004). Because of these effects they can also inhibit a variety of 
processes which are dependent upon Ca2+-dependent ATPase derived energy 
(Wieczorek et al., 1999; Zakharov et al., 1996). Therefore, the motility of flagellate-
bacteria (Molnar et al., 1992a), parasites (Boda et al., 2006; Jori, 2006) and cells in 
tissue cultures (Gil-Ad et al., 2004), processes of endocytosis (phagocytosis and 
pinocytosis), processes that activate the entrance of viruses (Hewlett et al., 1997) and 
bacteria (Molnar et al., 1982) into a eukaryotic cell are all inhibited by phenothiazines. 
However, these processes are not significantly affected at concentrations of the 
phenothiazine which correspond to those that are clinically achievable.  
 
The in vitro inhibitory activity of phenothiazines against bacteria and mycobacteria 
(Kristiansen et al., 2003, 2006; Martins et al., 2007b; Viveiros et al., 2005c) at the 
lowest concentrations, i.e., at their MIC is always bacteriostatic (Amaral et al., 2004; 
Kristiansen et al., 2006). At substantially higher concentrations, phenothiazines are 
bactericidal (Amaral and Lorian, 1991; Amaral et al., 1992; Kristiansen et al., 2003). 
The means by which the inhibitory effects are produced are the result of the effects of 
the agent on Ca2+-dependent ATPase processes which when affected reduce the amount 
of cellular energy needed to maintain active transport processes over an extended period 
of time (Amaral et al., 2007a). Most of these processes are of an ABC transporter type 
and hence, the transport of vital substances from the medium into the bacterium is 
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reduced or inhibited (Marquez, 2005). In addition, specialized transport processes that 
extrude metabolic-toxic compounds to the environment are also affected (Langton et al., 
2005). These latter export processes are efflux pumps, named Multidrug And Toxic 
Extrusion (MATE) and which recognize a wide number of unrelated metabolic products 
and extrude them to the environment (Cattoir, 2004). In a manner of speaking, MATE 
efflux pumps serve as the “renal system” of the bacterium. The third grouping of active 
transport processes that may be affected by phenothiazines at concentrations equivalent 
to those that inhibit the replication of bacteria in vitro are clinically relevant, inasmuch 
as these are energy dependent processes (efflux pumps) and are responsible for MDR 
phenotypes of Gram-negative (Viveiros et al., 2005a, 2007) and Gram-positive 
pathogenic bacteria (Kristiansen et al., 2003, 2006; Martins A et al., 2007; Martins et 
al., 2006a). Recently, Rubin and his team have proposed another mechanism by which 
phenothiazines exert their anti-tubercular activity (Yano et al., 2006). These studies 
demonstrate that the activity of Type-II NADH-menaquinone oxidoreductase which is 
an essential respiratory enzyme of M. tuberculosis is significantly inhibited by 
analogues of phenothiazines. The ability of the phenothiazine to reduce or reverse the 
resistance of the bacterium to a given antibiotic means that the phenothiazine could be 
used as an adjuvant with the conventional antibiotic to which the bacterium was initially 
resistant. This remarkable ability suggests that if these phenothiazine agents reach 
clinical use, many antibiotics that have fallen by the wayside due to MDR phenotypes 
of clinically relevant bacteria may again be used. The need for new antibiotics, which 
will in time, encounter efflux-mediated resistance may be highly reduced or even 
obviated. The mechanism by which phenothiazines exert bactericidal activity is not 
entirely understood.  However, at concentrations greater than the MIC, the agent 
reaches the DNA and via intercalation (Cremieux et al., 1995) binds to sites of the DNA 
that are rich in guanosine and cytosine bases (Rohs et al., 2001). When intercalation 
takes place, it is irreversible and therefore inhibits all DNA based processes (Amaral et 
al., 2007a). This alone may be the cause for the bactericidal effects of the 
phenothiazine. 
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How do phenothiazines enhance the killing of intracellular Mycobacterium avium 
and Mycobacterium tuberculosis?  
 
Macrophages are cells rich in lysosomes that concentrate phenothiazines as much as 
one-hundred fold over the concentration in the medium (Amaral et al., 2007a; 
Wojcikowski and Daniel, 2002). It was at first believed that the concentration of the 
phenothiazine by the lysosome would be at least equal to that required to kill the 
bacterium in vitro (Ordway et al., 2002a, 2002b, 2003b) (Chapter IV).  However, 
recent studies have shown that the killing of intracellular bacteria by neutrophils is 
dependent upon ATP (Matsumoto et al., 1991), K+ (Reeves et al., 2002) and Ca2+ 
(Ahluwalia et al., 2004) and that these substances are required for the acidification of 
the lysosome which in turn activates lysosomal hydrolases (Pillay et al., 2002). Because 
phenothiazines inhibit directly or indirectly the transport of K+ (Mazumder et al., 1990) 
and Ca2+ (Williams et al., 1997), the possibility that killing of intracellular bacteria was 
not due to the phenothiazine being concentrated by the lysosome but due to the 
inhibition of the transport of K+ and Ca2+ was considered (Chapter VI).   
  
Agents which inhibit the transport of Ca2+ and K+ directly or indirectly, and which have 
no activity against bacteria at the concentrations used in the study (Amaral et al., 2007b; 
Martins et al., 2007b) cause non-killing macrophages to kill S. aureus (Ordway et al., 
2002a) (Chapter III) and M. tuberculosis (Martins et al., 2007b) (Chapter IV). The 
results obtained in these studies suggest the following: Bacteria bind to receptors 
present at the surface of the plasma membrane of the macrophage (Sharon et al., 1981). 
Binding activates invagination of the plasma membrane thereby forming the phagosome 
(Amaral et al., 2007b). The Ca2+ and K+ transporting pumps, which are present in the 
plasma membrane and which prior to the formation of the phagosome pumped Ca2+ and 
K+ into the cell against a concentration gradient, will now pump these cations from the 
phagosome to the cytoplasm of the cell (Amaral et al., 2007b). The penetration of the 
phenothiazine, ouabain, verapamil and reserpine, all inhibitors of Ca2+ and K+ transport, 
takes place via pinocytosis. The pinocytic vesicles fuse with the lysosome that had 
fused with the phagosome creating the phagolysosome. The cation pumps at its surface 
are inhibited by phenothiazines, ouabain, reserpine or verapamil, and Ca2+ and K+ are 
retained inside the phagolysosome (Chapter VI). This Ca2+ and K+ retention will 
induce a raise in the intracellular concentrations of these cations that in turn will activate 
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other ATP-driven membrane pumps, namely, vacuolar-type proton ATPases (V-
ATPases). The V-ATPases are enzymes responsible for the import of H+ to the 
phagolysosome. This import is accomplished by the exchange of cations from the inside 
of the phagolysossome for H+ from the cytoplasm. Therefore, the acidification of the 
phagolysosome will activate the hydrolases to destroy the bacterium (Amaral et al., 
2007b). The enhanced killing of M. avium by phenothiazines (Viveiros et al., 2005c) as 
well as by substances extracted from plants (Martins et al., 2005; Ordway et al., 2003a) 
is most probably due to the same mechanism (Chapter VI). 
 
What are the clinical implications for enhanced killing of intracellular bacteria? 
 
It is generally accepted that with time resistance to any given antibiotic will take place 
(Poole, 2007). Agents that enhance the killing of intracellular bacteria by non-killing 
macrophages afford the advantage over conventional antibiotics inasmuch as the 
problem of bacterial resistance is by-passed. Therefore, perhaps it may be prudent to 
design agents which have the ability to inhibit K+ transport and evaluate their ability to 
kill intracellular bacteria. If this is to be taken, there would be the need to establish a 
routine working macrophage-bacterium model that would yield the type of data needed 
for establishing the potential of a given compound for the therapy of MDR-TB. 
 
The monocyte-derived macrophage/Staphylococcus aureus model for the 
evaluation of enhanced killing by agents that inhibit Ca2+ and K+ transport 
 
The enhancement of killing of intracellular S. aureus by agents which we have studied 
provided a reliable prediction of whether that same agent would also enhance the killing 
of intracellular M. tuberculosis (Ordway et al., 2003b). Because the results can be 
obtained within a few days when S. aureus is used, as opposed to 3 or more weeks when 
M. tuberculosis is used, we recommend that the former bacterium be employed as a 
“screening” tool for the selection of agents that are to be evaluated for similar activity 
against intracellular M. tuberculosis. The assay is identical whether staphylococci or 
mycobacteria are employed-and differs with respect to media, to the period of 
incubation post-phagocytosis and of course, the time needed for CFU to form and be 
counted is about 1 day with S. aureus (Ordway et al., 2002a) and at least 3 weeks for 
mycobacteria (Ordway et al., 2003b) (Chapters III and IX). 
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X.2 Enhanced killing of intracellular pathogenic bacteria by phenothiazines and 
the role of K+ efflux pumps of the bacterium and the killing macrophage 
 
SUMMARY 
 
Pulmonary tuberculosis is an intracellular infection caused by Mycobacterium 
tuberculosis. Because its intracellular site is commonly the macrophage of the 
pulmonary system, and that cell has little killing action of its own, an antibiotic that is to 
be effective against this organism must be able to penetrate the macrophage and exert its 
action at the intracellular site where the organism resides. The anti-tubercular drugs 
which are most effective against this intracellular infection and which constitute the 
“first line of defence” are isoniazid and rifampin, both of which have activity against 
phagocytosed M. tuberculosis. Unfortunately, resistance to both of these agents (MDR-
TB) continues to increase in frequency, and regardless of therapy, mortality is very 
high, nearing 100% within one year if the patient is co-infected with HIV or presents 
with AIDS. Since no new effective drugs have been made available for almost 40 years, 
compounds that enhance the killing activity of monocytes against MDR-TB are 
obviously needed. As previously shown, monocytes can be transformed into effective 
killers of intracellular bacteria when exposed to clinical concentrations of a 
phenothiazine or to inhibitors of efflux pumps, such as reserpine and verapamil, or to 
the inhibitor of K+ transport, ouabain. This section discusses the in vitro and ex vivo 
activity of phenothiazines, their derivatives and the mechanism by which these agents 
manifest their antibacterial activity. It also identifies a variety of other efflux pump 
inhibitors that address these characteristics and therefore have potential for managing 
MDR-TB. Lastly, a model describing the mechanisms by which distinct efflux pumps 
of the phagosome-lysosome complex are inhibited by agents that are known to inhibit 
K+ flux is presented. The model also predicts the existence of a K+ activated exchange 
(pump) that is probably located in the membrane that delineates the lysosome. It is this 
putative pump, immune to the inhibitors of K+ flux which is identified as being the 
cause for the acidification of the lysosome thereby activating its hydrolytic enzymes. 
Because the non-killer macrophage can be transformed into an effective killer by a 
variety of compounds that inhibit K+ transport, perhaps it would be wiser to develop 
drugs that enhance the killing activity of these cells inasmuch as this approach would 
not be subject to any resistance as is the eventual case for conventional antibiotics.       
Chapter X 
 
 
223 
The macrophage and why it does not kill intracellular M. tuberculosis 
 
The killing activity of the alveolar macrophage, as compared to that of the neutrophils is 
quite nominal (Amaral and Lorian V, 1988; Appelberg, 2007). Nevertheless, this 
nominal killing activity involves the initiation of a cascade of biochemical and cellular 
events all of which lead to the recruitment of other cells involved in cellular immunity 
(Akagawa et al., 2006; Appelberg, R. 2007; Kwiatkowska and Sobota, 1999; 
Riethmüller et al., 2006). The initial event subsequent to the phagocytosis of a 
bacterium by the macrophage is the release of cytokines IL-6 and IL-12 that attract T 
helper lymphocytes to the site of infection. At the site of infection T helper cells release 
IFN-gamma, a very potent macrophage-activating cytokine, that eventually results in 
the acidification of the phagolysosome and the subsequent activation of hydrolases 
which afford the complete destruction of the bacterium (Ordway et al., 2004; Russell, 
2007). However, mycobacteria have evolved strategies that control the ability of the 
macrophage to kill the bacterium (Nguyen and Pieters, 2005). Firstly, unlike the events 
that follow the phagocytosis of a bacterium, phagocytosis of M. tuberculosis does not 
result in the fusion of the phagosome with the lysosome (Vergne et al., 2003). Although 
the mechanism by which this inhibition takes place is not fully understood, because 
fusion of the phagosome with the lysosome requires Ca2+ (Vergne et al., 2003) and ATP 
(Wittekindt et al., 2006), presumably for the energy provided from the activity of a 
Ca2+-dependent ATPase (Martins et al., 2006a), it is most probable that the entrapped 
mycobacterium secretes a substance that inhibits access to Ca2+ by binding all of the 
available Ca2+ within its phagosome trap. This is supported by studies that demonstrate 
that M. tuberculosis contains a Ca2+-binding type protein with similar properties of the 
Ca2+ binding protein calmodulin (Méndez-Samperio et al., 2006; Ratnakar and Murthy, 
1993; Salih et al., 1991). The inhibition of phagolysosome-lysosome fusion obviates the 
destruction of the mycobacterium allowing the existence of the bacterium within its 
phagosomal trap for decades. Although this period has been termed to be one of latency, 
the reality is that the bacterium is actually undergoing replication, albeit slowly, and 
after an unknown number of such replications, the bacterium breaks out of its 
phagosomal trap and is subsequently phagocytosed by neighbouring macrophages of the 
alveolar structure.  The repeat of the above processes results in the development of a 
granuloma that is large enough to be seen with the naked eye (in histological sections of 
affected lung and or radiographs) and may be considered the earliest evidence of TB 
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(Russell, 2007). Although this treatise may suggest that the infection will proceed until 
death, only 5 to 10% of all such infections actually result in active disease (Kamholz, 
2002; Russell, 2007). The activity of the immune system has long been suspected to in 
some way restrict or limit the progression of infection to active disease status (Ordway 
et al., 2004, 2005a). This restriction apparently involves the creation of a “cellular 
block” that is formed by T lymphocytes that have responded to the secretions of IL-6 
and IL-12 from the infected macrophages (Ordway et al., 2005a; Russell, 2007). This 
“cellular wall” inhibits dissemination of the mycobacteria to further sites of the lung via 
the capillaries or lymphatics (Ordway et al., 2005b; Russell, 2007). In addition, the 
“cellular wall” also restricts access of the bacterium to sputum thereby reducing or 
completely inhibiting transmission of the bacterium to others (Flynn and Chan, 2005; 
Russell, 2007). However, as a consequence of external factors such advanced age, 
malnutrition, stress, co-infections (ex: HIV), the loss of the “cellular wall” may result 
and the granuloma structure could caseate, i.e., disrupt, therefore releasing large 
numbers of mycobacteria that can infect more of the lung (Nguyen and Pieters, 2005; 
Ordway et al., 2005b; Russell, 2007). The release of mycobacteria due to caseation also 
results in discharge of large numbers of the organism to the environment via sputum, 
and now renders the subject as a serious source of infection to others (Kamholz, 2002; 
Russell, 2007). The need to develop agents that are effective against M. tuberculosis, 
especially MDR-TB strains, is obvious and significant to the reduction of new 
infections.  
 
Limitations of drugs 
 
Although hundreds of compounds are reported each year that have activity against TB, 
with few exceptions, activities are restricted to in vitro only-and the need to evaluate 
these compounds for ex vivo activity is essential if a compound is to be used for therapy.  
We have been studying phenothiazines and their derivatives for in vitro activity first 
(Amaral and Kristiansen, 2000, 2001; Amaral and Lorian, 1991; Amaral et al., 1992, 
2000, 2001a, 2001b, 2004, 2006; Bettencourt et al., 2000), and when amply present, 
evaluated their activity against bacteria that were phagocytosed by monocyte-derived 
macrophages (MDM) (Amaral et al., 2001a, 2006, 2007b; Amaral and Kristiansen, 
2000; Martins et al., 2006b, 2007b; Ordway et al., 2002a, 2002b, 2003b) which have 
little killing activity of their own (Ordway et al., 2002b, 2003b; Smith et al., 2000; 
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Theus et al., 2004). These studies, carried over a period of 15 years were based on the 
observations of Crowle et al who demonstrated that the in vitro activity of CPZ against 
M. tuberculosis could be reproduced against the phagocytosed organism at 
concentrations of the agent that were far below those needed for in vitro activity 
(Crowle et al., 1992). Although the in vitro activity of CPZ against mycobacteria had 
been known for many years (Amaral and Kristiansen, 2000, 2001; Amaral et al., 2001a, 
2001b, 2004, 2006), its use as an anti-TB agent was never seriously considered due to 
the wide availability of effective anti-TB compounds (Amaral and Kristiansen, 2000, 
2001; Amaral et al., 2001a, 2001b, 2004, 2006; Radhakrishnan et al., 1999) and, 
perhaps of greater significance, three decades of global experience with the use of CPZ 
for the therapy of psychosis indicated a large number of serious side effects (Amaral 
and Kristiansen, 2000, 2001; Amaral et al., 1996, 2001a; 2006). However, TZ, a 
specific derivative of CPZ and the equal of CPZ for the effective control of psychoses, 
is a much milder drug, producing as its major side effect somnia although it is now 
known to produce Torsades de Pointes (Amaral and Kristiansen, 2000, 2001), albeit, at 
a very low frequency (1 sudden death over 10,000) man years of use (Amaral and 
Kristiansen, 2000; Amaral et al., 2001b). Because of these facts, we have studied the in 
vitro activity of TZ against antibiotic susceptible strains as well as against strains that 
were mono, poly-drug and MDR, including strains that were resistant to all five of the 
drugs used as the “first line of defence” (Amaral and Kristiansen, 2000; Amaral et al., 
1996, 2001a, 2004; Bettencourt et al., 2000; Martins et al., 2007b; Ordway et al., 
2003b; Viveiros and Amaral, 2001) (Chapter IV).  In addition, the results of other 
investigators are similarly presented in order to demonstrate that phenothiazines, in 
general, have in vitro activity against antibiotic susceptible and, more importantly, 
antibiotic resistant strains. Nevertheless, the activity of TZ takes place at concentrations 
which are clinically irrelevant, inasmuch as the highest plasma concentration that can be 
safely achieved in a patient that is chronically treated with the agent is about 0.4 mg/L 
and the lowest in vitro active concentration is of the order of 15 mg/L.   
 
Ex vivo activity of phenothiazines 
 
Agents which have in vitro activity against MDR-TB, if they are to be effective anti-TB 
compounds, must also have activity against these bacteria at their intracellular sites 
within the non-killing macrophage (Amaral and Kristiansen, 2000; Amaral et al., 1996, 
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2001a, 2004, 2006, 2007b; Martins et al., 2005, 2006b, 2007b; Ordway et al., 2002a, 
2002b, 2003b; van den Broek et al., 1999; Viveiros and Amaral, 2001). In addition, 
they must be essentially non-toxic (Kristiansen and Amaral, 1997; Wainwright and 
Amaral, 2005). Our studies and those conducted by Crowle et al demonstrate that 
phenothiazines enhance the killing of M. tuberculosis that has been phagocytosed by 
macrophages at concentrations well below those that have activity in vitro (Bettencourt 
et al., 2000; Crowle et al., 1992; Martins et al., 2004; Ordway et al., 2002a, 2002b, 
2003b) (Chapter V). These concentrations are clinically acceptable in as much as they 
are within the ranges anticipated in the plasma of patients treated with these agents 
(Ordway et al., 2002a, 2002b, 2003b). Because CPZ and to a far lesser extent, TZ, 
produce undesirable  side effects (express levels of toxicity), we have studied newly 
synthesised derivatives of  TZ for in vitro activity, and when present, studied those that 
were significantly active relative to TZ for activity against antibiotic susceptible and 
antibiotic resistant strains of M. tuberculosis. Whereas in vitro active derivatives of TZ 
are also active against phagocytosed mycobacteria, derivatives #1867, #1870 and #1875 
present higher activity than the parent compound (TZ) (Chapter IV). Evaluation of 
these compounds for cellular toxicity indicate that substantially higher concentrations 
than those which have intracellular activity are devoid of any cellular toxicity. The 
agents are good candidates for the therapy of MDR infections of TB. However, animal 
studies are still needed prior to clinical trials.     
 
How does a Phenothiazine enhance the killing of intracellular bacteria including 
mycobacteria? 
 
Phenothiazines have been shown to inhibit the transport of K+ from external to internal 
cellular compartments such as transport channels of cardiac Kir2.1 cells and red blood 
cells (Kim and Kim, 2005; Plishker, 1984; Sun et al., 2006;) and between intracellular 
compartments (ex. diencephalic neurons; rat liver mitochondria) (Chukhlova et al., 
1984; Tolón et al., 2000;). They also inhibit the binding of calcium to calmodulin, the 
calcium binding protein of mammalian cells (Weiss et al., 1980). The binding of 
calcium to calmodulin-like proteins of bacteria has been amply demonstrated (Dhople, 
1999; Fry et al., 1986; Nagai et al., 1994, 1997; Reddy et al., 2003; Rigden et al., 2003; 
Salih et al., 1991; Sarma et al., 1998; Sarkisova et al., 2005; Yonekawa et al., 2005). 
The inhibition of calcium access to Ca2+ dependent-ATPase inhibits transport processes 
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such as those performed by influx and efflux pumps (Kaatz et al., 2003; Molnar et al., 
1997; Nacsa et al., 1998). Because phenothiazines inhibit access to calcium, they inhibit 
the activity of calcium-dependent ATPase and hence, the transport processes (Kaatz et 
al., 2003; Kristiansen et al., 2003, 2006; Molnar et al., 1997; Nacsa et al., 1998; 
Viveiros et al., 2002, 2003, 2005a). 
 
Bacteria as well as mammalian cells contain efflux pumps that extrude noxious agents 
from the periplasm and cytoplasm of the former (Piddock, 2006a) and from the 
cytoplasm of the latter (Hoffmann and Kroemer, 2004). Understanding the effects of a 
phenothiazine on calcium dependent transport processes of the bacterium or the 
mammalian cell predict that efflux pumps of the bacterial or mammalian cell will be 
affected by a phenothiazine. This prediction has been shown to be correct whenever 
studied (Kaatz et al., 2003; Kristiansen et al., 2003, 2006; Molnar et al., 1997; Nacsa et 
al., 1998; Viveiros et al., 2002, 2003, 2005a). Since the first contact of the 
phenothiazine with the bacterium takes place at the surface of the cell envelope, it 
would be expected that although the phenothiazine could penetrate this structure as a 
consequence of a concentration gradient and its amphipathic structure, one of the many 
efflux pumps of the bacterium would recognize this molecule and extrude it once it 
reached the periplasm of the bacterium. Although this expectation has yet to be fully 
studied, the effect of the phenothiazine on the efflux system of the bacterial cell has 
been shown to one of inhibition (Kristiansen et al., 2003, 2006; Molnar et al., 1997; 
Viveiros et al., 2002, 2003, 2005a). Phenothiazines readily intercalate between nucleic 
bases of the DNA helix (de Mol et al., 1983; Rohs and Sklenar, 2004; Sinha et al., 
2006; Webb et al., 1979, 1984). The degree of intercalation is dependent upon the 
number of guanosine-cytosine residues (Rohs and Sklenar, 2004). When phenothiazines 
intercalate into DNA they inhibit all DNA based processes as well as the degree of 
coiling and uncoiling of DNA promoted by gyrases (Boshoff et al., 2004). The 
inhibition of the efflux pump by a phenothiazine would result in large numbers of 
phenothiazine molecules entering the cell, reaching their intercalative sites of the DNA 
and thereby inhibiting the replication of the bacterium. The concentrations of the 
phenothiazine in the medium required for the inhibition of bacterial replication vary 
greatly with respect to the bacterium: the MIC for Gram-negative bacteria ranges from 
100 to 200 mg/L whereas for Gram-positive bacilli or cocci the MIC ranges from 10 to 
40 mg/L (Kristiansen and Amaral, 1997). Although not proven, there seems to be a 
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strong correlation between bacteria that contain a highly effective system of efflux 
pumps and the concentration of the phenothiazine required for the in vitro inhibition of 
replication. As an example, as much as 35% of the genome of Gram-negative bacteria 
codes for influx/efflux pumps (transporters) and with respect to E. coli, as many as 
twenty mdr efflux pumps have been genetically characterized (Piddock, 2006a). 
Although this organism has an obvious redundancy of efflux pumps-the major efflux 
pump that accounts for multi-drug resistance in this organism is coded by the acrAB-
TolC operon (Viveiros et al., 2005a; Yu et al., 2003). When this operon is deleted, the 
organism becomes extremely sensitive to antibiotics and the phenothiazines CPZ and 
TZ (Viveiros et al., 2005a). When both the acrAB intact and acrAB deleted strains are 
induced to high level of resistance to tetracycline, the genetic expression of the acrAB 
efflux pump of the former has been increased six-fold whereas the acrEF efflux pump of 
the latter strain has been increased eighty-fold (Viveiros et al., 2005a). The increased 
genetic expression of these pumps renders both strains significantly more resistant to 
chlorpromazine and thioridazine as opposed to their parents. These results support the 
contention that the phenothiazines chlorpromazine and thioridazine are substrates of the 
AcrAB and AcrEF efflux pump systems and that when the ability of the pumps to 
extrude the agents is exceeded, the agents reach their intercalative targets and bacterial 
replication is inhibited. Because the concentration of either phenothiazine in the 
medium that enhances the killing of intracellular bacterium is about one hundredth of 
that needed to kill the bacterium in vitro (Ordway et al., 2003b, 2002a, 2002b; 
Weinstein et al., 2005; Yano et al., 2006), the killing activity appears to be related to the 
phenothiazine being concentrated by the non-killing macrophage to levels comparable 
to those required for killing in vitro (Crowle et al., 1992). Electron microscopy studies 
of the effects of phenothazines on phagocytosed Staphylococcus aureus demonstrate 
that the in vitro effect of these agents on the bacterium’s morphology is reproduced 
when the bacterium is phagocytosed by macrophages that are subsequently exposed to 
concentrations of the agent (see Figure 1) that produce neither an inhibition of 
replication nor a change in the morphology of the organism (Martins et al., 2004) 
(Chapter III).   
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Figure 1. The ex vivo effects of Thioridazine on the ultrastructure of 
Staphylococcus aureus phagocytosed by monocyte derived macrophages. Control 
(A) and Thioridazine treated (B) 6 hours post phagocytosis. Thioridazine (0.1 mg/L) 
added to the medium 30 minutes after phagocytosis (Martins et al., 2004). 
 
The requirement of K+ for intracellular killing 
 
The killing activity of neutrophils, although highly complex, has been shown by a series 
of elegant studies conducted by Segal’s group (Reeves et al., 2002) to depend upon the 
availability of K+ (Ahluwalia et al., 2004) to the phago-lysosome and the dependence of 
this process on active Ca2+ channels of the phago-lysosome unit.  The essential need for 
Ca2+ required for the availability of K+ involves a Ca2+ dependent ATPase that is 
employed for the generation of energy required in K+ transport. Because the K+ 
concentration needed to trigger the acidification process required for the activation of 
hydrolases (Pillay et al., 2002) is higher than that present in the cytoplasm (Ahluwalia 
et al., 2004; Munsiff et al., 2003) one would have to assume that the membrane of the 
phago-lysosome complex would contain the required energy driven efflux pumps. 
Because phenothiazines do transform non-killing macrophages into effective killers 
(Crowle et al., 1992; Ordway et al., 2002a, 2002b, 2003b) and because phenothiazines 
are potent inhibitors of K+ transport processes that are dependent upon Ca2+ dependent 
ATPase, it seems probable that killing is enhanced due to the inhibition of efflux of K+ 
from the phago-lysosome by the phenothiazine. If this hypothesis is correct, then one 
would predict that inhibitors of K+ transport would also enhance the killing activity of 
non-killing macrophages. As is evident from Figure 2 ouabain, verapamil and reserpine, 
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inhibitors of K+ transport processes, also enhance the killing activity of non-killer 
macrophages (Martins et al., 2006b) (Chapter VI).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Effects of ouabain, verapamil and reserpine in the killing activity of 
human monocyte-derived macrophages (Martins et al., 2006b). 
 
The question of whether the K+ efflux pump units pre-exist in the lysosome or are part 
of the phagosome unit and hence have their origins in the plasma membrane of the 
macrophage has not yet been addressed.  Nevertheless, with the exception of smooth 
muscle (Aydemir-Koksoy and Allen, 2001) the plasma membrane of most mammalian 
cells has a plethora of K+ transport units (Terreros and Tiedemann, 1991), in all 
likelihood the plasma membrane that delineates the phagosome probably contains many 
K+ transport units whose origins are from the plasma membrane of the macrophage and 
which due to the invagination process that results in the phagosome, would  pump K+ 
from the lumen of the phagosome to the cytoplasm, a region of the cell that is known to 
have a high concentration of the ion (Gribble et al., 2000) (Figure 3A – I to III). It is at 
these K+ transport sites of the phagosome where ouabain, verapamil, reserpine and 
phenothiazines inhibit K+ efflux and thereby the concentration of K+ within the 
phagosome would be maintained to levels needed for the acidification of the phago-
lysosome, and ensuing activation of the hydrolases (Ahluwalia et al., 2004; Reeves et 
al., 2002) (Figure 3A – IV). However, recent studies have shown that the killing activity 
of monocyte-derived macrophages which are identical to those used in the experiments 
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described by Figure 2, is dependent upon extracellular Ca2+ and extracellular ATP 
(Fairbairn et al., 2001; Kusner and Barton, 2001) both of which are under transport 
control mediated by Ca2+ dependent ATPase. As is the case for the K+ transport 
systems, the transport process for Ca2+ would be reversed in the phagosome if this 
system were to be retained in the plasma membrane that delineates the phagosome unit. 
Phagocytosis of the bacterium by macrophages should result in a phagosome that 
contains K+ and Ca2+ transport systems that pump out these ions to the cytoplasm of the 
cell.  It is hypothesized that failure to kill bacteria present in the phagosome-lysosome is 
due to the low concentration of these ions in the complex that results from their 
extrusion to the cytoplasm.  The inhibition of either one or both of these processes by a 
phenothiazine may establish conditions by which the concentration of these ions can be 
increased to a point where other ATP driven membrane exchange systems involved in 
the cytosolic homeostasis are activated leading to an intense hydrolytic activity of the 
phagosome-lysosome ATPases, in particular the V-ATPases (Fairbairn et al., 2001; 
Kusner and Barton, 2001; Pillay et al., 2002) (Figure 3B - I to VII). The import of H+ 
thereby creating the acidification of the lysosome component that had fused with the 
phagosome and the activation of the hydrolases needed for the killing of the bacterium. 
These ATP driven membrane exchange systems must also be immune to ouabain, 
phenothiazines, etc. Figures 3A and B summarizes the hypothetical model which 
describes the aforementioned events that ultimately transform non-killer macrophages 
into effective killers. The phagocytosis of the bacterium (Figure 3A) results in a 
phagolysosome whose pumps extrude K+ and Ca2+ from the vacuole to the cytoplasm 
(IV). When a phenothiazine is presented to the macrophage that has phagocytosed the 
mycobacterium (Figure 3B), the efflux of K+ and Ca2+ from the phagolysosome is 
prevented, the build up of H+ protons takes place, the hydrolases are now activated and  
the bacterium is digested (Figure 3B-VII). 
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Figure 3. Hypothetical model suggested for the enhancement of killing of human 
monocyte-derived macrophages by phenothiazines and other efflux pumps. (A) 
Infected and untreated macrophage and (B) Infected and treated macrophage.  
K+
H+
Ca2+
Ca2+
H+
K+
ATP
K+
ATP
Ca2+ Ca2+
ATP
Na+
K+
Ca2+ Ca2+
ATP
H+ K+
ATP
Ca2+
Ca2+
Ca2+
Ca2+
Ca2+
Ca2+
Na+I
II
H+
ATP K+
Ca2+
Ca2+
Ca2+
ATP
K+
Ca2+
K+
H+ATP
A
ATP
ATP
ATP
ATP
ATP ATP
III
IV
H+
H+
K+ H+
ATP
Ca2+
Ca2+
Ca2+
K+
Ca2+
K+
H+
Ca2+
Ca2+
H+
K+
ATP
K+
ATP
Ca2+ Ca2+
ATP
Na+
K+
Ca2+ Ca2+
ATP
H+ K+
ATP
Ca2+
Ca2+
Ca2+
Ca2+
Ca2+
Ca2+
Na+I
II
H+
H+
K+H+
H+
H+
H+
H+
ATP
Ca2+
Ca2+
Ca2+
K+
Ca2+
Ca2+
H+
IV
V
VI
VII
K+
Ca2+
K+
Ca2+
K+
Ca2+
Ca2+
Ca2+
ATP
K+
Ca2+
H+
Ca2+
K+
H+
Ca2+
ATP
K+Ca2+
ATP
H+
Ca2+ K+
H+ATP
III
B ATP
ATP
ATP
ATP
ATP
ATP
ATP
H+ H+
H+
H+
Chapter X 
 
 
233 
Legend: I: Binding of bacteria (    ) to plasma membrane. II: Invagination and formation of phagosome. 
III and IV:  Maturation of phagosome and fusion of the lysosome with the phagosome. V: Binding of 
inhibitor of efflux pump (    ) and formation of vesicle. VI:  Fusion of vesicle containing the inhibitor of 
efflux pumps with matured phago-lysosome. VII:  Inhibition of Ca2+ and K+ efflux by inhibitor of efflux 
pump; K+ leaks into phago-lysosome with cytosolic homeostasis mechanisms activated leading to an 
increased activity of the ATPases; acidification; activation of  hydrolases; killing of bacteria.        
 
Key:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The search for inhibitors of efflux pumps which may also enhance the killing 
activity of non-killing macrophages 
 
Our previous studies demonstrated unusual properties of an extract made from the 
nuisance plant Carpobrotus edulis (Martins et al., 2005; Ordway et al., 2003a). Among 
these were: 1) the ability to invoke Th1 responses of a variety of T cell subsets as well 
as to stimulate the production of cytokines that are involved in the immune response to 
an infectious agent; 2) the ability to render highly resistant mouse lymphoma cells that 
contain the mdr efflux pump transport pg1 completely susceptible to cytotoxic agents; 
3) the ability to inhibit the mdr efflux pump of these mouse lymphoma cells as evident 
from the increased retention of the efflux pump substrate rhodamine 1,2,3; and 4) the 
ability to enhance the killing of intracellular (phagocytosed) M. tuberculosis as well as 
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Mycobacterium avium (Viveiros et al., 2005c) whereas the highest concentration of the 
extract was devoid of any in vitro activity against these mycobacteria. Although it is not 
yet known whether the activities noted for the C. edulis extract are due to one or more 
substances, because the extract and the inhibitors of K+ transport (ouabain, reserpine 
and verapamil) enhance the killing of intracellular bacteria by non-killing macrophages 
whereas they do not have any in vitro activity against these bacteria, it seems possible 
that the activity noted for the extract is due to one agent, and that this agent manifests its 
effects via the inhibition of K+ transport (Chapter VII). Other plant extracts as well as 
plant derived compounds that have been shown to inhibit efflux pumps of cancer cells 
also have activity against phagocytosed bacteria. The suggestion that inhibitors of the 
paraglycoprotein of mammalian cells may also inhibit the efflux pump of bacteria 
receives support from the studies that used piperidine, an alkaloid isolated from the 
fruits of Piper longum (Lee et al., 2005) and its derivative piperine, to inhibit the 
paraglycoprotein of Caco-2 cells (Bhardwaj et al., 2002) as well to increase the retention 
of ethidium bromide by S. aureus by the inhibition of efflux activity (Khan et al., 2006). 
Polyphenols obtained from plant sources have been shown to inhibit efflux pumps of 
Caco-2 cells (Sergent et al., 2005) and have been shown to enhance the killing of 
intracellular M. tuberculosis (Anand et al., 2006).  
 
Other plant derived agents that have activity against efflux pumps of cancer cells may 
also enhance the killing activity of macrophages against bacteria, perhaps even 
mycobacteria. Voacamine, a bisindolic alkaloid from Peschiera fuchsiaefolia, induces a 
significant increase of drug retention of cancer cells by its ability to inhibit the mdr 
transporter protein P-glycoprotein (Meschini et al., 2005). Irofulven, a novel anticancer 
agent derived from the mushroom reverses the resistance of cancer cells to cytotoxic 
agents by inhibiting the mdr efflux pump responsible for this resistance (Poindessous et 
al., 2003). Curcumin mixture and three major curcuminoids purified from turmeric 
(curcumin I, II, and III) have been shown to modulate the function of MRP1, the mdr 
protein 1 (MRP1) of HEK293 cells stably transfected with MRP1-pcDNA3.1 
(Chearwae et al., 2006). These and many other plant derived compounds that are active 
against efflux pumps of cancer cells may serve as lead compounds for the synthesis of 
new agents that have activity against intracellular bacteria, and will be explored in the 
continuation of this work as important sources of new antimicrobial agents. 
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Tuberculosis continues to be considered the major cause for worldwide morbidity and 
mortality caused by an infective organism. Since TB remains a serious medical problem 
around the world, the need for new anti-TB drugs is more and more prominent. The 
resurgence of TB in some urban centers, allied to the appearance and escalation of 
MDR-TB and XDR-TB worldwide has become the cause of increased medical and 
political concern. Since these intracellular infections target the alveolar macrophage, 
compounds presenting activity against these bacteria have to reach its intracellular site. 
However, most of the compounds reported to have activity against these infections, are 
most of the time restricted to in vitro activity and by this manner, ineffective. In order to 
obtain new compounds for the treatment of these infections, a novel approach in the 
drug design should be considered. It would be wiser to develop compounds that 
enhance the killing activity of the infected macrophages instead of the traditional 
approach implemented until the present time. If we design drugs that target and activate 
the phagocytic cells instead of acting on the bacteria itself, then the problem of 
resistance could also be avoided.  
 
Phenothiazines are a group of tricyclic compounds whose antimicrobial activity has 
been known for over a century. The resistance associated to its clinical use is mainly 
due to the side-effects associated with its long-term use. However, toxic side-effects 
occur infrequently with new phenothiazine neuroleptics, such as TZ, that is less toxic 
than CPZ and that is also used for the treatment of psychosis. In fact, the major side 
effect is somnia although it is now known to produce torsades de pointes (Vieweg and 
Wood, 2004), but at a very low frequency (1 sudden death over 10,000) man years of 
use (Glassman and Bigger, 2001). TZ has in vitro antimycobacterial properties, being 
effective against clinical strains of M. tuberculosis regardless of their antibiotic 
susceptibility status (Amaral et al., 1996). Based on this evidence, TZ might be useful 
as an adjuvant to current regimens used for the management of freshly diagnosed TB 
(Viveiros and Amaral, 2001). The chemical manipulation of the parent phenothiazine 
sometimes yields a molecule that is more active than the parent compound (Csiszar and 
Molnar 1992; Molnar et al., 1991). Based on this, alternative strategies such as TZ 
derivatives should be considered. This could constitute a good approach to obtain more 
efficient compounds that lack the problems previously stated for the parental molecule.  
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Clinical Concentrations of Thioridazine Enhance the Killing of Intracellular 
Methicillin-resistant Staphylococcus aureus: an In Vivo, Ex Vivo and Electron 
Microscopy Study (detailed in Chapter III) 
 
The results presented in this study showed that TZ kills intracellular MRSA at 
concentrations that are well within those clinically achieved for the management of 
psychosis. MRSA exposed to in vitro concentrations of TZ just below its MIC showed 
ultrastructural changes of the bacterial cells. TZ inhibited the replication of 
phagocytosed MRSA, affecting the structure of the cell envelope that resulted in the 
lysis of the bacterium 6 hours post-phagocytosis. The effects of this agent on the 
ultrastructure of phagocytosed MRSA parallels that observed in vitro.  
 
Macrophages are cells rich in lysosomes and these organelles are known to concentrate 
compounds. When the bacteria are phagocytosed by the macrophage it resides within 
phagosomes and when this organelle fuses with the lysosome the bacteria is killed. 
Furthermore, because lysosomes are known to concentrate the phenothiazine and the 
phagocytosed organisms are clearly within cell organelles that have the characteristics 
of lysosome-phagosomes, it was postulated that it is in the lysosomal-phagosome 
structure that the microbe is killed. Support was provided for the contention that TZ has 
potential for the management of MRSA intracellular infections that are difficult to treat 
due to the privileged site offered by the macrophage, which can serve as sources for 
subsequent recurrent infections. By this manner, TZ, as well as other phenothiazines, 
has potential for the management of MRSA intracellular infections that are difficult to 
treat.  
 
In vitro and ex vivo activity of TZ and its derivatives against Mycobacterium 
tuberculosis and M. avium (detailed in Chapter IV) 
 
Clinical concentrations of thioridazine kill intracellular multidrug-resistant 
Mycobacterium tuberculosis 
 
TZ has equal in vitro activity against antibiotic-sensitive and -resistant M. tuberculosis. 
However, it has not been used as anti-M. tuberculosis agent because its in vitro activity 
takes place at concentrations that are beyond those clinically achievable. We have 
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performed studies to evaluate if TZ kills M. tuberculosis that has been phagocytosed by 
human macrophages. The results obtained demonstrated that when TZ was used at 
concentration in the medium well below that present in the plasma of patients treated 
with this agent, it killed intracellular antibiotic-sensitive and -resistant M. tuberculosis. 
This in vitro concentration was not toxic to the macrophage and complete killing was 
obtained after 3 days post-infection at a concentration of 0.1 mg/L of TZ. When M. 
tuberculosis strains were exposed to in vitro concentrations of TZ, the minimum 
concentration required to completely inhibiting growth ranged from 8 to over 30 mg/L 
and the MBC ranged from 20 to 50 mg/L. The concentration of these compounds 
required to kill M. tuberculosis in vitro can be achieved inside the macrophage since 
these cells have the ability to concentrate compounds inside their lysosomes and 
phagosomes (structures were the entrapped phagocytosed bacterium is located). It was 
also demonstrated that clinically relevant concentrations of TZ kill phagocytosed 
mycobacteria. These results support the use of TZ in the management of intracellular M. 
tuberculosis infections. However, its use has some risks associated such as the case of 
cardiac failure or episodes of torsade de pointes that might result in sudden deaths (10 to 
15 such events in 10,000 person-years of observation (Glassman and Bigger, 2001). 
However, these episodes are rare and usually associated with prolonged therapy. In this 
sense, the use of TZ for the management of an active pulmonary TB infection caused by 
antibiotic-susceptible M. tuberculosis strains provides no advantage over the use of 
present therapies. However, due to the severity of MDR M. tuberculosis in some parts 
of the world where effective therapy is not possible, the use of TZ deserves 
consideration. Therefore, TZ can be used as an adjunct to conventional therapy during 
initial management of the patient, until the susceptibility data for the causative organism 
are available.  
 
In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium 
tuberculosis 
 
TZ has been shown by us to have in vitro and ex vivo activity against antibiotic-
susceptible and MDR-TB. The current therapy of MDR-TB is highly problematic even 
when all the ‘first line of defence’ drugs are employed. Therefore, the need for effective 
antituberculosis drugs is obvious. Twenty-two new derivatives of TZ were synthesised 
and their in vitro activity against a reference strain of M. tuberculosis evaluated. The 
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results obtained showed that all of the TZ derivatives tested had activity against the M. 
tuberculosis reference strain H37Rv and derivatives #1867, #1870 and #1875 had 
similar activity to that of TZ. Toxicity of the derivatives, assayed by the Trypan Blue 
exclusion method, showed that at concentrations equivalent to that associated with TZ, 
no significant toxicity was detected. Derivatives that showed significant in vitro activity 
were then evaluated by ex vivo studies and were shown to enhance the killing of 
intracellular M. tuberculosis at a concentration of 0.1 mg/L. Some of the derivatives 
tested even demonstrated higher ex vivo activity than TZ, since after one day no 
phagocytosed M. tuberculosis could be retrieve from the cultures. These results 
demonstrate the ex vivo potential of TZ derivatives against M. tuberculosis strains.  
 
The in vitro activity of phenothiazines against Mycobacterium avium: potential of 
thioridazine for therapy of the co-infected AIDS patient 
 
Patients presenting with AIDS are predisposed to co-infection with M. avium. In order 
to manage these infections there is the need for effective and non-toxic compounds. 
Since M. avium presents a very high resistance to most of the available compounds, we 
evaluated the effect that phenothiazines have on these strains. Therefore, we assessed 
the in vitro activity of CPZ, TZ, promazine, promethazine and desipramine against M. 
avium strains. The results obtained showed that CPZ, TZ, PMZ, PMTZ and DSP have 
in vitro activity against M. avium, showing MICs that ranged from ca. 10 to >50 mg/L. 
These results had previously been obtained with M. tuberculosis. TZ was the most 
active against M. avium, having an MIC of 10 mg/L. These results highlight the 
importance of TZ to treat these infections. However, at the present time it is not 
recommended for the management of AIDS patients co-infected with M. avium since 
more studies are needed, namely with infected macrophages. 
 
The Curative Activity of Thioridazine on Mice Infected With Mycobacterium 
tuberculosis (detailed in Chapter V) 
 
Animal studies were initiated to establish the effectiveness of TZ. BALB/C mice were 
infected with M. tuberculosis ATCC H37Rv strain. After thirty days, treatment with TZ 
was initiated, except for the control group. Animals were then treated with different 
concentrations of TZ ranging from 0.05 to 0.5 mg/day (at equivalent concentrations to 
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that used in the humans). The results showed that a daily dose of 0.5 mg/day of TZ 
reduced the number of CFU retrieved from the lungs of the infected mice within one 
month in comparison to the control group. These results reflect the effectiveness of TZ. 
However, by the end of the 300 days of therapy, mycobacteria could still be recovered 
from the organs of the infected animals. Hence, the infection persisted, albeit at a very 
low level. This could be explained by the increase in the number of CFU obtained from 
the liver and spleen of the infected animals that could be a continuous source of 
mycobacteria. However, considering the massive dose of infection, it is important to 
stress the effectiveness of TZ therapy. Nevertheless, it is important to note that although 
TZ is effective for the therapy of pulmonary TB of the mouse, other than anecdotal 
evidence and laboratory studies that support the use of TZ, its effectiveness for therapy 
of human pulmonary TB remains to be performed. More studies are needed not only 
using TZ but also the TZ derivatives that demonstrated a higher activity than TZ on the 
infected macrophages.       
 
Inhibition of the Carpobrotus edulis methanol extract on the growth of 
phagocytosed multidrug-resistant Mycobacterium tuberculosis and methicillin-
resistant Staphylococcus aureus (detailed in Chapter VI) 
 
We tested a methanolic extract of C. edulis against MRSA and MDR-TB strains. 
Because fivefold concentrations of the plant extract which produce toxicity against 
monocyte-derived macrophages does not inhibit the growth of methicillin-resistant S. 
aureus or multidrug-resistant M. tuberculosis, we conclude that the effectiveness of the 
highly diluted extract (tenfold) on the growth of phagocytosed methicillin-resistant S. 
aureus and multidrug-resistant M. tuberculosis may be due to the ability of the 
monocyte derived macrophages to concentrate the extract beyond the highest 
concentration employed in vitro. Our results correlate with the antimicrobial effects 
observed with the traditional uses of C. edulis described (Van Wyk et al., 1997) and 
suggest that this plant may serve as a source of new antimicrobial agents that are 
effective against problematic drug-resistant intracellular infections. 
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Reserpine, ouabain and the calcium channel blocker verapamil, cause intracellular 
killing of Staphylococcus aureus (detailed in Chapters VI and X) 
 
Monocyte-derived macrophages obtained from the peripheral blood have little killing 
activity of their own. However, these cells can be transformed into effective killers of 
intracellular bacteria by in vitro exposure of the cells to clinically relevant 
concentrations of TZ and other phenothiazines. Some studies had also reported that the 
neutrophils killing activity is highly dependent upon the availability of K+. Because 
mechanisms dependent upon the availability of Ca2+ are inhibited by phenothiazines, we 
investigated the possibility if that these and other compounds presenting similar activity 
also have the ability to enhance the killing of bacteria by the macrophage derived 
monocytes. The compounds selected were inhibitors of Ca2+ and K+ flux, namely, 
ouabain, reserpine and verapamil. In this study we showed that the presence of 
increasing concentrations of ouabain, reserpine or verapamil in the medium have the 
capacity to enhance the killing of S. aureus that have been phagocytosed by monocyte 
derived macrophages. From our previous studies (Ordway et al., 2002a, 2003b) the 
enhancement of the macrophage killing activity in the presence of phenothiazines was 
suggested to be due to the concentration of the compounds inside the macrophage. If 
this takes place, the compounds could reach concentrations comparable to those 
achieved in vitro and presenting bactericidal activity. However, these concentrations of 
ouabain, verapamil and reserpine had no activity on the replication or killing of the S. 
aureus, and by this manner, the killing was deemed to be due to the macrophage itself. 
The results obtained suggest that these agents have similar activity to phenothiazines 
and we attribute their intracellular activity with respect to their effects on the inhibition 
of the transport of K+ and Ca2+. A model was developed describing the mechanism by 
which these agents and phenothiazines indirectly activate lysosomal enzymes as a result 
of the inhibition of K+ efflux pumps. However, more studies were also conducted on 
macrophages infected with S. aureus and M. tuberculosis strains in order to clarify the 
enhancement of the macrophage killing activity by these K+ and Ca2+ inhibitors.  
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Inhibitors of Ca2+ and K+ Transport Enhance Intracellular Killing of M. 
tuberculosis by Non-Killing Macrophages (detailed in Chapters VI and X) 
 
Our previous studies demonstrated that monocyte derived macrophages kill intracellular 
S. aureus when cultured in the presence of inhibitors of Ca2+ and K+ efflux pumps. The 
aim of this study was to evaluate the effect of ouabain, reserpine and verapamil in the 
killing activity of macrophages infected with M. tuberculosis. After three days post-
infection, macrophages treated with the inhibitors demonstrated an enhancement of the 
killing activity destroying the phagocytosed mycobacteria.  
 
These results suggest a different approach for the therapy of TB, and especially, MDR-
TB and XDR-TB. This approach involves the design of compounds that target the 
macrophage and transform it into an effective bacterial killer. Compounds which target 
the bacterium are predicted to become ineffective due to mutations of the bacterial 
target, however, agents that enhance the killing activity of the infected macrophage will 
not present this disadvantage. By this manner, these compounds that enhance killing by 
macrophages but that normally do not kill mycobacteria may yield a more effective 
form of therapy of infections caused by MDR and XDR-TB. This is a viable and 
innovative approach that could be applied for the therapy of other intracellular 
infections such as malaria, leishmaniasis, among others. These results highlight the 
effectiveness of inhibitors of Ca2+ and K+ transport processes that could be applied for 
the therapy of intracellular infections. 
 
SILA compound 421, an inhibitor of efflux pumps of cancer cells, enhances the 
killing of intracellular MDR-TB (detailed in Chapter VII) 
 
As already mentioned Multi-Drug Resistant (MDR) and Extensively-Drug Resistant 
(XDR) Tuberculosis (TB) infections are problematic to manage. Therefore, there is a 
dire need for effective anti-TB agents. From the studies conducted by our team, we have 
shown that agents that inhibit efflux pumps of MDR bacteria and cancer cells also 
enhance the killing of intracellular mycobacteria. This killing is possibly associated 
with the increasing of K+ and Ca2+ needed for the activation of lysosomal enzymes. We 
have evaluated a newly synthesized and recently patented SILA compound 421 for its in 
vitro and ex vivo activity against an XDR-TB strain. The minimum in vitro 
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concentration that inhibits the growth of the strain was determined, as well as the effect 
of this compound on the killing activity of human monocyte-derived macrophages 
infected with the XDR-TB strain. SILA compound 421 was shown to have in vitro 
activity against XDR-TB, with an MIC below 3.5 mg/L, and also to transform non-
killing macrophages into effective killers of phagocytosed XDR-TB. From the toxicity 
studies performed no toxicity was demonstrated at the concentrations used on the 
studies. The fact that this compound is devoid of any cytotoxic activity makes it a very 
good candidate for the treatment of XDR-TB and MDR-TB infections.   
 
An instrument-free method for the demonstration of efflux pump activity of 
bacteria (detailed in Chapter VII) 
 
The search for new compounds that present activity against MDR infections is one main 
goal of all the work developed during this Thesis. However, most of the times, this 
search is associated with methods that are expensive and non-reproducible. With this in 
mind, we have developed a simple, inexpensive and reproducible method – the ethidium 
bromide (EB)-agar based method. This method requires no specialized instrumentation 
and allows the demonstration of efflux pump activity, responsible for antibiotic 
resistance of bacteria. Since EB is a well known substrate for efflux pumps, the method 
is based on a series of agar plates containing varying concentrations of EB. The plates 
are then swabbed with the bacterial strains that are to be studied and the plates 
incubated at different temperatures and time-points. The fluorescence obtained from the 
strains is then used to evaluate the efflux activity of each culture. From the results 
obtained we where able to identify the efflux of EB in different bacteria, namely E. coli 
and S. aureus strains. The minimal concentration of EB that produced fluorescence was 
significantly greater at 37ºC than at 4ºC, suggesting the presence of an energy-
dependent pump. It was also possible to identify strains of a mixed culture that differed 
from each other with respect to the activity of their efflux pumps. This is a simple, 
inexpensive and reproducible method that may be employed for inter-laboratory 
standardization of efflux pump activity of MDR clinical isolates, allowing the fast 
screening of a large collection of bacteria. A new improved version of this method 
(Carthweel-agar EB method) is being currently developed and tested at the Unit of 
Mycobacteriology and the results are currently the subject of a manuscript to be 
submitted to an International Peer-reviewed journal. 
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The future of chemotherapy (detailed in Chapter VIII) 
 
The discovery of new anti-microbial agents that are known inhibitors of efflux pumps is 
determinant in the therapy of MDR bacteria, such as, MDR-TB. To treat these 
infections, new approaches are urgently needed. The use of these agents in conjunction 
with the classical antibiotics could provide the basis for a novel strategy implemented in 
the management and control of MDR infections. The group of compounds termed ‘non-
antibiotics’ exhibit properties that render them important for the therapy of MDR 
infections. However, with the exception of infections caused by MDR-TB and XDR-TB 
where some of these have promise, non-antibiotics are at this time best considered as 
‘helper compounds’ to be co-administered with conventional antibiotics to which the 
MDR organism was initially resistant. Nevertheless, regardless of how certain we may 
feel regarding their use, it still remains for clinical trials to demonstrate their importance 
in the therapy of some of the most serious bacterial infections. Because TZ has in vitro 
and ex vivo activity against XDR-TB and MDR-TB and cures the mouse of a pulmonary 
infection produced by M. tuberculosis, it is recommended that this phenothiazine be 
considered for the management of XDR-TB and MDR-TB infections with poor 
prognosis if only for compassionate reasons. Taking into account the certainty of 
mortality produced by XDR-TB infections that are immune to available antibiotics, the 
risks associated with TZ are minimal. 
 
The Tuberculosis laboratory of the Future: The role of the macrophage in the 
selection of agents that can be used for the successful therapy of an XDR-TB 
infection (detailed in Chapter IX) 
 
The global resurgence of pulmonary TB, the resulting development of MDR-TB, and 
now, the progression of antibiotic resistance to practically any available antibiotic as is 
the case for XDR-TB strains, is due in large part to the failure to recognize laboratories 
as a corner-stone of TB control policy (Goldman et al., 2007; WHO, 2006b). Newly 
developed molecular methods for the direct screening of TB from smear-positive 
samples, which also detect the mutations most frequently associated with RIF and INH 
resistance, are now referred by the WHO, in order to early detect MDR-TB cases. The 
guidelines recently proposed at the WHO Laboratory Strengthening Task Force 
recommend rapid molecular methods for detection as an essential tool for TB and 
Chapter XI 
 
246 
MDR/XDR-TB control (WHO, 2006a). Rapid identification of pulmonary TB and 
XDR/MDR-TB makes it possible to provide effective therapy and hence interfere with 
the cycle of transmission from patient to patient that is currently experienced. Hence, 
there is a need for new and effective biotechnological strategies to detect TB and 
XDR/MDR-TB as well as develop alternative therapies (Pai et al., 2006; Palomino, 
2006). The biotechnological approach presented in this Thesis aimed to identify 
XDR/MDR-TB rapidly and predict the most effective therapeutic combination to 
maximize a favorable outcome in the patient that is being treated. However, given the 
fact that resistance of antibiotic sensitive M. tuberculosis to each of the compounds of 
the “second line of defence” exceeds resistance to INH and RIF; and, given the fact that 
XDR-TB strains are far more resistant to these compounds (Hamilton et al., 2007; 
Migliori et al., 2007), it is obvious that there is a dire need for new and effective anti-
tubercular compounds. It is therefore strongly suggested that the macrophage model be 
used during drug development phase. Moreover, and of more immediate importance, we 
recommend that the model as described be used for the evaluation of “second-line of 
defence” drugs for activity against intracellular mycobacteria (Martins et al., 2008). 
This latter recommendation will, we believe, provide the eventual basis for the 
intelligent selection of drugs to be used for the therapy of MDR-TB/XDR-TB 
infections.  
 
Enhanced killing of intracellular pathogenic bacteria by phenothiazines and the 
role of K+ efflux pumps of the bacterium and the killing macrophage (detailed in 
Chapter X) 
 
The determination of anti-TB properties of any given agent must be proven by the use 
of the macrophage model presented regardless of its in vitro activity. Although few 
published studies have made the leap from in vitro activity to a successful 
demonstration of the effectiveness of an agent in an M. tuberculosis infected mouse, 
most studies that have gone directly from an in vitro to an in vivo model fail, and are 
therefore not published. These failed studies are expensive and time consuming. Hence, 
we recommend the use of the staphylococcus-macrophage model, and if successful, 
proceed with mycobacteria, and only if the agent is significantly effective and produces 
no cytotoxicity, proceed to the M. tuberculosis infected mouse model. 
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The demonstration that inhibitors of Ca2+ and K+ transport cause the killing of 
phagocytosed mycobacteria significantly alters the approach employed for the design of 
anti-TB agents. Because phenothiazines enhance the killing of intracellular 
mycobacteria, they should be seriously considered as sources for new anti-TB agents. 
Because these agents by-pass the possibility of mutation of a mycobacterial target, they 
have the potential to be used for considerable periods of time. Nevertheless, it remains 
for future studies to determine whether these considerations are to be realised.    
    
Phenothiazines as Anti-Multi-Drug Resistant Tubercular Agents (detailed in 
Chapter X) 
 
The in vitro activity of phenothiazines against M. tuberculosis is now well known.  
Nevertheless, these activities take place at concentrations which are beyond clinical 
relevance. The effectiveness of any compound against pulmonary TB, regardless of its 
in vitro activity, is dependent upon the ability of the agent to kill the bacterium where it 
normally resides post-infection. That phenothiazines have activity in situ against 
intracellular mycobacterium at concentrations that are comparable to those expected in 
the plasma of subjects treated with these agents provide a degree of prediction of its 
effectiveness when the agent is to be used for the therapy of active disease. That this 
prediction is probable is supported by recent studies that employed TZ successfully for 
the therapy of mice presenting with active pulmonary TB (Weinstein et al., 2005; Yano 
et al., 2006). Although we do not recommend that TZ of any other phenothiazine be 
used for therapy of antibiotic susceptible active TB, inasmuch as existing antibiotics are 
effective, we do recommend that this agent be considered for the therapy of MDR-TB if 
and when all other agents have failed and mortality is certain.  In other words, to be 
used as “compassionate therapy” (Amaral and Kristiansen, 2000; Amaral et al., 2001a; 
2001b; 2006). When employed as compassionate therapy, we recommend that the dose 
and schedule employed for the therapy of psychoses be used. Because therapy would be 
limited to months as opposed to years, rare but serious side effects associated with 
chronic use are not anticipated (Amaral and Kristiansen, 2000; Amaral et al., 2006). 
Lastly, we cannot stress enough the need for studies that evaluate the effectiveness of an 
active in vitro agent via ex vivo methods. The use of the macrophage-Mycobacterium 
assay provides distinctive advantages that are not evident with in vitro assays alone.  
Because the ex vivo assay is very inexpensive and yields results quickly as compared to 
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the use of in vivo (mice studies), we urge that they be employed prior to the use of in 
vivo assays.   
 
Enhanced killing of intracellular multi-drug resistant Mycobacterium tuberculosis 
by compounds that affect the activity of MDR efflux pumps: a review.  
 
The global rise of MDR-TB continues and the need for new effective agents is obvious.  
Because MDR-TB is an intracellular infection of the non-killing macrophage of the 
lung, any drug that is to be effective must have activity at this site. Conventionally, anti-
tubercular drugs are designed to have direct activity against intracellular MDR-TB.  
And as has been the case for all other antibiotics, resistance would ensue with usage of 
the compound. Because the non-killer macrophage can be transformed into an effective 
killer by a variety of compounds that inhibit K+ transport, perhaps it would be wiser to 
develop drugs that enhance the killing activity of these cells inasmuch as this approach 
would not be subject to any resistance as is the eventual case for conventional 
antibiotics. A model describing the mechanisms, by which distinct efflux pumps of the 
phagosome-lysosome complex are inhibited by agents that are known to inhibit K+ flux, 
was developed and presented. This macrophage model predicts the existence of a K+ 
activated exchange putative pump, probably located in the membrane that delineates the 
lysosome and that is immune to the inhibitors of K+ flux which is identified as being the 
cause for the acidification of the lysosome thereby activating its hydrolytic enzymes. 
Since those non-killer macrophages could be transformed into effective killers by a 
variety of compounds that inhibit K+ transport, it would be wiser to develop drugs that 
enhance the killing activity of these cells inasmuch as this approach would not be 
subject to any resistance as is the eventual case for conventional antibiotics.  
 
The data obtained in this Thesis, have provided direction for the selection of which 
compounds should be further studied for the curative activity of MDR infections. It is 
therefore strongly suggested that the macrophage model be used during drug 
development phase. Moreover, and of more immediate importance, we strongly 
recommend that the model described be used for the evaluation of “second-line of 
defence” drugs for activity against intracellular mycobacteria. We believe that this latter 
recommendation will provide the eventual basis for the intelligent selection of drugs to 
be used for the therapy of MDR-TB and XDR-TB infections. 
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